Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Nucleic acid based assay involving a hybridization step with a nucleic acid probe, involving a single nucleotide polymorphism (SNP), involving pharmacogenetics, involving genotyping, involving haplotyping, or involving detection of DNA methylation gene expression

Subclass of:

435 - Chemistry: molecular biology and microbiology

435004000 - MEASURING OR TESTING PROCESS INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITION OR TEST STRIP THEREFORE; PROCESSES OF FORMING SUCH COMPOSITION OR TEST STRIP

435600100 - Involving nucleic acid

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20130045479METHODS FOR EVALUATING THE STAGE OF OVARIAN CANCER OR THE SURVIVAL RATE OF AN OVARIAN CANCER PATIENT - An object of the present invention is to provide a method for detecting cancer through identification of genes exhibiting characteristic behavior in the cases of cancer such as ovarian cancer, and a cell growth inhibitor. The present invention provides a method for detecting cancer, which comprises detecting canceration including malignancy of a specimen through detection of at least one alteration of a gene existing in a chromosomal region 2q14. 2, 3p24. 1, 3q26. 2, 3q29, 4q34. 2, 6q23, 9p21. 3, 11q13. 3, 13q22.1, 13q33. 1, 13q33. 3, 15q12, 15q15. 1, 17p12, 17p13. 1, 17p13. 3, 18q21. 1, 18q21. 2, 18q21. 31, 18q21. 32, 18q21. 33, 18q23, 20q13. 13, 20q13. 2, 20q13. 31, 20q13. 33, Xp11. 23, Xp13.1, Xp13. 3, Xp26. 2, Xp26. 3, or Xq28 in the specimen.02-21-2013
20130045478NOVEL METHOD FOR ANALYZING DNA METHYLATION - This invention provides a method for efficiently detecting DNA methylation. The method for detecting DNA methylation comprises subjecting DNA to bisulfite treatment, subjecting DNA after bisulfite treatment to a first PCR, subjecting the resultant to nested PCR, and subjecting amplified DNA to denaturing gradient gel electrophoresis.02-21-2013
20130045477DIRECT NUCLEIC ACID ANALYSIS - Methods and apparatus are described for nucleic acid analysis of swab samples without the need for purification.02-21-2013
20110177506AMPLIFICATION OF TRP1 FOR SPECIFIC DETECTION OF PHYTOPHTHORA RAMORUM - is currently a devastating disease for many plant species and infection presents significant economic problems, and in particular has lead to devastating effects on many specie of oak trees. The present invention provides methods and kits for selective detection of 07-21-2011
20110177503CARDIAC RISK STRATIFICATION BY NOS1AP GENOTYPING - A risk-conferring genetic modifier is found in a large LQTS cohort. A NOS1AP tag SNP genotype provides an additional clinical assessment, which helps assess risk and choice of therapeutic strategies in LQTS as well as other conditions such as Brugada Syndrome, and catecholaminergic polymorphic ventricular tachycardia (CPTV).07-21-2011
20120202201DEVICE AND METHOD FOR ANALYSIS OF KIDNEY FAILURE - The invention provides a method for analysis of the status of kidney function in a sample of body fluid obtained from a patient who has not been diagnosed with acute kidney injury (AKI, also referred to as acute kidney failure) or in a sample of body fluid obtained from a patient who has been diagnosed with AKI, which analysis is suitable for evaluating the prospects for long-term survival, which method for analysis comprises or consists of determining the concentration of the microRNA-21008-09-2012
20120202199METHOD FOR ADJUSTING AMPLIFICATION EFFICIENCY OF TARGET POLYNUCLEOTIDE - Disclosed is a method for adjusting the amplification efficiency of a target polynucleotide in the amplification of the target polynucleotide by PCR using primers (i) to (iii) below, the method comprising adjusting the amplification efficiency of the target polynucleotide by changing the quantity ratio of the primers (i) to (iii) below: 08-09-2012
20110207129METHODS OF DIAGNOSING NON-URINARY TRACT DISEASES BY DETECTING ABERRANT METHYLATION - Provided are methods of diagnosing and/or determining treatment of non-urinary tract cancers by detecting biomarkers, and aberrant methylation in said biomarkers, in human urine samples08-25-2011
20110207127MARKERS FOR DETECTION OF LEGIONELLA PNEUMOPHILA STRAINS - The invention relates to a method of detecting 08-25-2011
20120171677COMPENSATION FOR SPECTRAL CROSSTALK IN MULTIPLEX NUCLEIC ACID AMPLIFICATION - A method includes performing a nucleic acid amplification of a nucleic acid sample using a detection probe, wherein the nucleic acid amplification occurs over one or more interrogation periods, and, from the nucleic acid amplification, acquiring amplification data that indicates an amount of nucleic acid present for each of the one or more interrogation periods. The method also includes, based on the amplification data, determining a crosstalk correction value associated with a spectral neighbor to the probe to reduce spectral crosstalk from the spectral neighbor; and applying the crosstalk correction value to amplification data collected from multiplex nucleic acid amplifications of nucleic acid samples.07-05-2012
20120171671CHK2 POLYMORPHISM AS A CANCER MARKER - The invention relates to the use of gene modifications in the human gene CHK2 (CHEK2), which encodes the checkpoint kinase 2, for predicting the risk and progression of cancer diseases, for predicting the response to pharmacological or non-pharmacological therapeutic measures for treating cancer diseases, and for predicting undesired effects of drugs. The invention further relates to the provision of individual gene variants with the help of which further gene modifications that can be used for the aforementioned purposes can be detected and validated. Such gene modifications can comprise a substitution of adenine for guanine in position -7161 in the promoter of CHK2, a substitution of guanine for cytosine in position -7235, a substitution of adenine for guanine in position -10532, or a deletion of 29 base pairs in positions -10621 to -10649.07-05-2012
20130045476METHOD FOR COMBINED MONITORING OF DETECTION OF AT LEAST TWO MOLECULAR TARGETS AND TO A KIT THEREFOR - The invention relates to methods for combined monitoring of detection of at least two molecular targets.02-21-2013
20120183960METHOD FOR IDENTIFYING E. COLI M-17 - A method of identifying an M17 strain of 07-19-2012
20120183959SELECTIVE DETECTION OF BORDETELLA SPECIES - A process for detecting 07-19-2012
20120183958METHODS FOR PREDICTING FAT AND LEAN PHENOTYPES IN CHICKENS - The invention provides molecular methods for predicting chickens that are more likely to have a lean phenotype, comprising detecting in samples of genetic material obtained from the chickens for the presence of paired single nucleotide polymorphisms (SNPs) in the beta-defensin 9 (DEFB9) gene.07-19-2012
20120183964MAMMALIAN CYTOKINE; RELATED REAGENTS - Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.07-19-2012
20120183963DETERMINATION OF FETAL ANEUPLOIDY BY QUANTIFICATION OF GENOMIC DNA FROM MIXED SAMPLES - The present invention provides systems, apparatuses, and methods to detect the presence of fetal cells when mixed with a population of maternal cells in a sample and to test fetal abnormalities, i.e. aneuploidy. In addition, the present invention provides methods to determine when there are insufficient fetal cells for a determination and report a non-informative case. The present invention involves quantifying regions of genomic DNA from a mixed sample. More particularly the invention involves quantifying DNA polymorphisms from the mixed sample.07-19-2012
20120183962CRUDE BIOLOGICAL DERIVATIVES COMPETENT FOR NUCLEIC ACID DETECTION - The invention relates generally to the fields of making biological unit lysates or admixtures of body fluids and of RNA analysis. More specifically, it relates to direct methods for the detection of a specific sequence of RNA in a biological unit, for example a virus, cell or tissue sample, or a body fluid, for example saliva, sputum, blood plasma, etc. More generally, the invention may be used to enzymatically manipulate and protect the RNA in lysate or bodily fluids for a number of applications.07-19-2012
20120183961METHOD FOR FUNCTIONAL TESTING OF SITE-SPECIFIC DNA METHYLATION - Methods and kits are provided for testing the functional effect of methylating different cytosine residues or testing patterns of DNA methylation on gene expression. Methods are also provided for site-specific methylation, as well as methylated DNA constructs.07-19-2012
20110195413Integrated Method for Enriching and Detecting Rare Cells from Biological Body Fluid Sample - The present invention relates to an integrated method for enriching and detecting rare cells in biological body fluid sample. The enriching method comprises: (a) removing plasma protein by centrifugation; (b) optionally adding a red cell lysis solution to carry out red cell lysis so as to remove the red blood cells; (c) adding immunomicrospheres or immunoadsorbent to incubate; and (d) carrying out density centrifugation based on a special cell separation medium for separating the circulating rare cells, residual red blood cells after removing red blood cells and the white blood cells combined on the immunomicrospheres. The method for detecting the enriched rare cells according to the present invention comprises combining immunohistochemistry based staining with immunofluorescence, or bicolor, tricolor or multicolor staining based on immunohistochemistry, and observing and identifying by fluorescence or ordinary optical microscope or a scanner based on microscope principle. The novel and unique method for enriching and staining has been proved to have low cost and can rapidly, effectively and high specifically enrich and quantitatively detect the rare cells in blood.08-11-2011
20110195412Predictive Biomarkers for Response to Exercise - A set of biomarkers have been identified that allows one to predict subjects who will respond to an exercise regime in term of cardiorespiratory fitness as assessed by maximal oxygen uptake. These predictions may be used, for example, to predict risk of cardiovascular disease, to design a more effective program for cardiac rehabilitation, to predict capacity for athletic performance or physically demanding occupation, and to predict ability to maintain functional capacity with aging using exercise.08-11-2011
20110195411ARL-1 SPECIFIC ANTIBODIES AND USES THEREOF - This invention provides antibodies immunologically specific for human ARL-1 (also referred to AKR1B10), a species of the aldo-keto reductase superfamily of proteins. The invention also provides methods of making and methods of using said antibodies.08-11-2011
20110195410Compositions and methods related to solid phase sequence detection and genotyping - The present invention provides improved compositions and methods of sequence detection and single nucleotide (“SNP”) genotyping. The methods of the present invention are related to combining sequence or allelic specific ligation on a solid phase platform with specific and efficient solid phase signal amplification. The methods for sequence detection include a first, second and third oligonucleotide. The methods of SNP genotyping include four oligonucleotides for SNPs associated with two alleles and additional oligonucleotides may be added for SNPs associated with more than two alleles. The usefulness of the present method is that it results in the determination of thousands of genotypes simply, rapidly and inexpensively on a solid support from a single genomic DNA sample.08-11-2011
20110195409STREPTOCOCCUS PYOGENES CLASSIFICATION - The difference Lancefield T-serotypes correlate with the sequence of the pilus backbone protein (Pbp) in 08-11-2011
20110195408Labeling Dye for Detecting Biomolecule, Labeling Kit, and Method for Detecting Biomolecule - A labeling dye of the present invention includes a coloring portion comprising an organic EL-dye, a bonding portion to be bonded with a biomolecule and a spacer portion for linking the coloring portion and the bonding portion. The present invention provides a high incorporation ratio and also high fluorescence intensity in solid state.08-11-2011
20130078636METHOD FOR DETECTING AND QUANTITATING MULTIPLE SUBCELLULAR COMPONENTS - A method for detecting and quantitating multiple and unique fluorescent signals from a cell sample is provided. The method combines immunohistochemistry and a fluorescent-labeled in situ hybridization techniques. The method is useful for identifying specific subcellular components of cells such as chromosomes and proteins.03-28-2013
20130078635RAPID METHOD FOR IDENTIFYING DRUG-RESISTANT GENE USING ARTIFICIAL CHROMOSOME OF PLASMODIUM, AND METHOD FOR PREPARING RECOMBINANT PLASMODIUM - The present invention relates to a rapid method for identifying a drug-resistant gene using an artificial chromosome of a protozoa. Specifically, it relates to a method for screening for a drug-resistant gene, which involves preparing a recombinant 03-28-2013
20130078632MATERIALS AND METHODS FOR PROGNOSIS OF PROGRESSION OF BARRETT'S ESOPHAGUS - A method of prognosticating progression of Barrett's esophagus in a patient comprising detecting in a sample of esophageal cells from the patient at least one abnormality selected from the group consisting of p16 loss, p53 loss, chromosome 7 aneuploidy, and chromosome 17 aneuploidy, which method can further comprise detecting at least one abnormality selected from the group consisting of 20q gain, C-myc gain, and Her2 gain; and a kit comprising (a) a set of probes comprising a probe for p16, a probe for p53, a probe for chromosome 7, and a probe for chromosome 17 and (b) instructions comprising determining at least one abnormality selected from the group consisting of p16 loss, p53 loss, chromosome 7 aneuploidy, and chromosome 17 aneuploidy, which kit can further comprise at least one additional probe selected from the group consisting of a probe for 20q, a probe for C-myc, and a probe for Her2 and additional instructions comprising determining at least one additional abnormality selected from the group consisting of 20q gain, C-myc gain, and Her2 gain.03-28-2013
20130078631Probe, and polymorphism detection method using the same - The present disclosure relates to a probe for detecting a polymorphism, a method of detecting a polymorphism, a method of evaluating the efficacy of a drug, and a reagent kit for detecting a polymorphism.03-28-2013
20130078630Use of G-Clamp for Improved Allele-SpecificPCR - The present invention includes a method of allele-specific amplification, utilizing an allele-specific oligonucleotide, at least partially complementary to more than one variant of the target sequence, but having at least one selective nucleotide complementary to only one variant of the target sequence and incorporating at least one “G-clamp” nucleotide.03-28-2013
20130078625FLUID HANDLING APPARATUS AND CONFIGURATIONS - Systems and methods are provided for sample processing. A device may be provided, capable of receiving the sample, and performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing multiple assays. The device may comprise one or more modules that may be capable of performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing the steps using a small volume of sample.03-28-2013
20120244540Probe for Detecting Polymorphism in Disease-Related Gene and Use of the Probe - The present invention provides a polymorphism detection probe that can identify a different polymorphism in a K-ras gene easily with high reliability and use of the polymorphism detection probe.09-27-2012
20120244528Susceptibility Genes for Age-Related Maculopathy (ARM) on Chromosome 10q26 - Allelic variations in the genes PLEKHA1 and LOC387715 are identified herein as risk factor for Age Related Maculopathy (ARM). A method is therefore provided for identifying a risk of development of ARM in an individual that comprises identification of allelic variations in PLEKHA1 and/or LOC387715. Related apparatus, such as an array, are identified as being useful in implementing those methods.09-27-2012
20130078626CATEGORIZATION OF DNA SAMPLES - The present application describes methods for accurate and cost-effective categorization of DNA samples into different types of in vitro generated DNA or different types of natural DNA such as from different tissues and/or physiological/pathological states. The invention achieves categorization by comparing “signal ratios” that are correlated to ratios of methylation levels at specific genomic loci, but does not rely on calculation of actual methylation levels at any genomic locus. Therefore the disclosed inventive method eliminates the requirement for external DNA species and controls, thereby simplifying and increasing the accuracy of the assay. The described inventive technology also enables performing the categorization of DNA together with DNA profiling in the same reaction, thereby allowing for concomitant categorization and determination of identity of the samples.03-28-2013
20130078628Single nucleotide polymorphisms of human chromosome 4 in the inositol polyphosphate-4-phosphatase type II gene (INPP4b gene) for the diagnosis or pre-diagnosis of multiple sclerosis - The invention relates to a single nucleotide polymorphism (SNP) of the nucleobase at base position 143470133 (rs13102150) of human chromosome 4 in the inositol polyphosphate 4-phosphatase type II gene (INPP4b gene) for the diagnosis or pre-diagnosis of multiple sclerosis or for determining the risk of contracting multiple sclerosis.03-28-2013
20130078629METHOD FOR DETECTING NUCLEIC ACIDS BY PROMOTING BRANCHED DNA COMPLEX FORMATION - Disclosed is a method for detecting nucleic acids by promoting branched DNA complex formation. The target nucleic acid detection signal and sensitivity can be dramatically increased by promoting self assembly of branched DNA between a plurality of amplified DNA targets and a single-chain oligonucleotide probe, by means of the integrated implementation of PCR, thermal denaturation and hybridization in a single reaction mixture.03-28-2013
20130078633Detection of Isotype Profiles as Signatures for Disease - The invention provides a non-invasive technique for the detection and quantification of immunoglobulin isotypes, in a biological sample containing a plurality of distinct cell populations. Methods are conducted using sequencing technology to detect and enumerate immunoglobulin isotype profiles within a heterogeneous biological sample.03-28-2013
20130078637ANTIPSYCHOTIC-INDUCED PARKINSONISM GENOTYPES AND METHODS OF USING SAME - The present invention relates to genotypes associated with resistance to antipsychotic-induced parkinsonism and other extrapyramidal symptoms induced by antipsychotics, and use of said genotypes for assessment of patient populations. The methods and kits of the invention are based on identifying in a sample obtained from a subject, specific SNPs in the ZFPM2 and RGS2 genes.03-28-2013
20130078634SEQUENCES AND THEIR USE FOR DETECTION AND CHARACTERIZATION OF STEC BACTERIA - This invention relates to a rapid method for detection and characterization of STEC bacteria based on the presence of nucleic acid sequences, in particular, to a PCR-based method for detection, and to oligonucleotide molecules and reagents and kits useful therefore. This method is preferably employed to detect STEC bacteria in a food or water sample, such as a beef enrichment. The present invention further relates to isolated polynucleotides, replication compositions, kits, and reagent tablets for carrying out the method of the present invention.03-28-2013
20130034851DETECTION OF METHYLATED DNA - The use of ion sensitive field effect transistor (ISFET) to detect methylated nucleotides in a DNA sample is described. A method of detecting methylated nucleotides in a DNA sample may include the steps of treating a sample of DNA with a reagent which discriminates between methylated and non-methylated nucleotides to provide treated DNA, amplifying the treated DNA and optionally sequencing the amplified DNA. An ISFET is used to monitor the addition of one or more dNTPs in the strand extension reactions during the amplification and/or sequencing step. Suitable apparatus is also provided.02-07-2013
20130034849DIAGNOSIS OF HEREDITARY SPASTIC PARAPLEGIAS (HSP) BY DETECTION OF A MUTATION IN THE KIAA1840 GENE OR PROTEIN - The invention relates to an ex vivo method of diagnosing or predicting an hereditary spastic paraplegias (HSP), in a subject, which method comprises detecting a mutation in the KIAA1840 gene or protein (spatacsin), wherein said mutation is indicative of an hereditary spastic paraplegias (HSP).02-07-2013
20130034852METHOD FOR THE SELECTION OF A LONG-TERM PRODUCING CELL - Herein is reported a method for determining methylation of a promoter nucleic acid operably linked to a nucleic acid encoding a polypeptide and thereby determining the long-term productivity of a cell. Also an aspect is a method for selecting a cell for producing a polypeptide by determining the methylation of the promoter nucleic acid operably linked to the structural gene encoding the polypeptide.02-07-2013
20130034854Antibody-Nanoparticle Conjugates and Methods for Making and Using Such Conjugates - Disclosed herein are antibody-nanoparticle conjugates that include two or more nanoparticles (such as gold, palladium, platinum, silver, copper, nickel, cobalt, iridium, or an alloy of two or more thereof) directly linked to an antibody or fragment thereof through a metal-thiol bond. Methods of making the antibody-nanoparticle conjugates disclosed herein include reacting an arylphosphine-nanoparticle composite with a reduced antibody to produce an antibody-nanoparticle conjugate. Also disclosed herein are methods for detecting a target molecule in a sample that include using an antibody-nanoparticle conjugate (such as the antibody-nanoparticle conjugates described herein) and kits for detecting target molecules utilizing the methods disclosed herein.02-07-2013
20130034853TWO-COLOR CHROMOGENIC IN SITU HYBRIDIZATION - The present invention relates to systems and processes for chromogenic in situ hybridization (CISH), and in particular to methods that prevent interference between two or more color detection systems in a single assay. The present invention also relates to processes for scoring assays utilizing break-apart probes.02-07-2013
20130034848TUMOR SUPPRESSOR GENE P33ING2 - The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods of diagnosing and treating tumors with such nucleic acids and proteins.02-07-2013
20130034850MARKER FOR DETECTING MYOGENIC DISEASE AND DETECTION METHOD USING THE SAME - A marker for myogenic disease and a non-invasive, highly sensitive method for detecting the marker are presented. Analysis of blood levels of miR-1, miR-133a, miR-133b, and miR-206 in a subject is used to detect levels of the marker indicating myogenic disease. The method is independent of exercise-induced stress.02-07-2013
20130078627GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS, METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.03-28-2013
20130084571METHYLATION PROFILING OF DNA SAMPLES - The present disclosure relates to methodology for fast and cost-effective identification of the source of DNA samples. DNA samples obtained from unknown or unrecognized tissues or cell types are analyzed according to the methodology described herein, yielding an identification of the tissue and/or cell type source. Identification is based on sequential biochemical procedures including methylation sensitive/dependent restriction and polymerase chain reaction, followed by analysis of the data. All biochemical steps are performed in a single test tube. The disclosure has immediate applications in forensic science for identification of the tissue source of DNA obtained from biological stains. The disclosure also has immediate applications in cancer diagnosis for identification.04-04-2013
20130084570METHODS OF EVALUATING RESPONSE TO CANCER THERAPY - A method of evaluating a cancer patient comprising evaluating gene expression levels in a patient sample, calculating a predictor score using the gene expression levels, and assessing the likelihood of a therapeutic outcome using the predictor score is disclosed.04-04-2013
20130084569NANOMOTORS AND MOTION-BASED DETECTION OF BIOMOLECULAR INTERACTIONS - Techniques and systems are disclosed for detecting biomolecular interactions based on the motion of nanomotors. In one aspect, a method of detecting biomolecular interactions based on a motion of a nanomachine includes functionalizing a nanomachine with a capture probe adapted to interact with biological targets; and detecting a presence of the biological targets in an environment based on a motion of the nanomachine.04-04-2013
20130084568Probe, and polymorphism detection method using the same - The present disclosure relates to a probe for detecting a polymorphism, a method of detecting a polymorphism, a method of evaluating the efficacy of a drug, and a reagent kit for detecting a polymorphism.04-04-2013
20130084567Systems and Methods of Sample Processing and Temperature Control - Systems and methods of sample processing and temperature control are disclosed. The invention may especially relate to temperature control, and may in some embodiments be methods of temperature control of an automated sample processing system and methods of automated sample processing. Specifically, the present invention provides temperature control in relation to sample processing systems and methods of processing samples, and in some embodiments provides temperature control in relation to sample carriers and processing materials such as reagents. Corresponding systems and devices are disclosed, including sample processing systems (04-04-2013
20130084566FETAL METHYLATION MARKERS - This application describes the discovery that, in a pregnant woman, certain genes (such as RASSF1A, APC, CASP8, RARB, SCGB3A1, DAB2IP, PTPN6, THY1, TMEFF2, and PYCARD) originated from a fetus are highly methylated, whereas the same genes of maternal origin are unmethylated. This discovery allows the easy detection of one or more of these methylated fetal genes in a biological sample from a pregnant woman, serving as a universal indicator of the presence of fetal DNA in the sample. These fetal methylation markers are particularly useful as positive controls for a non-invasive analytical process during which the quality and quantity of fetal DNA are monitored. These newly identified fetal markers can also be measured directly for diagnosis of certain pregnancy-related conditions.04-04-2013
20130084565VERSATILE, VISIBLE METHOD FOR DETECTING POLYMERIC ANALYTES - The invention provides methods to detect or determine the presence or amount of a polymeric analyte in a sample, which employ magnetic substrates and subjects the sample and the magnetic substrate to forms of energy so as to induce aggregate formation.04-04-2013
20130084564ASSESSMENT OF CANCER RISK BASED ON RNU2 CNV AND INTERPLAY BETWEEN RNU2 CNV AND BRCA1 - Polynucleotides useful for detecting copy number variation of RNU2 sequences and methods of assessing risk of developing breast or ovarian cancer using molecular combing and/or detection or quantification of BRCA1 expression.04-04-2013
20130040299METHOD FOR DETECTING OR MONITORING SEPSIS BY ANALYSING CYTOKINE MRNA EXPRESSION LEVELS - The present invention relates to a method for identifying patients who are likely to develop sepsis in response to infection, a method for monitoring the progress of sepsis in a patient and to an assay kit for identifying patients who are likely to develop sepsis and/or monitoring the progress of sepsis.02-14-2013
20130040297PROCESS FOR THE PRODUCTION OF CELLS WHICH ARE CAPABLE OF CONVERTING ARABINOSE - The invention relates to a process for the production of cells which are capable of converting arabinose, comprising the following steps: 02-14-2013
20130040294COMPOSITIONS AND METHODS FOR PERFORMING HYBRIDIZATIONS WITH NO DENATURATION - This disclosure is directed to, inter alia, methods and compositions for hybridizing at least one molecule to a target. The invention may, for example, eliminate the use of, or reduce the dependence on formamide in hybridization. Compositions for use in the invention include an aqueous composition comprising at least one nucleic acid sequence and at least one polar aprotic solvent in an amount effective to denature double-stranded nucleotide sequences.02-14-2013
20130040296METHOD AND RAPID TEST DEVICE FOR DETECTION OF TARGET MOLECULE - Method and rapid test device for detection of target molecule from sample with which is performed purification and preprocessing of sample, preparation and modification, amplification, detection and capturing of target molecule, producing, of signal, amplification and visualization of read 02-14-2013
20130040298Two-pore channels as regulators of proliferation in cancer - The present invention relates to the discovery that two pore K02-14-2013
20130040295METHOD TO INCREASE DETECTION EFFICIENCY OF REAL TIME PCR MICROARRAY BY QUARTZ MATERIAL - A reactor for the quantitative analysis of target nucleic acids using an evanescent wave detection technique and a method for the quantitative analysis of target nucleic acids are provided. The reactor includes a substrate with a cavity, a buffer layer arranged over the substrate, a quartz cover plate arranged over the buffer layer, and inlet and outlet ports. The reactor is thermally and chemically stable for PCR processing and suitable for an evanescent wave detection technique.02-14-2013
20130040293METHODS FOR GENETIC ANALYSIS OF DNA TO DETECT SEQUENCE VARIANCES - Methods for determining genotypes and haplotypes of genes are described. Also described are single nucleotide polymorphisms and haplotypes in the ApoE gene and methods of using that information.02-14-2013
20130040292NANOPARTICLE BIOSENSOR, METHOD OF PREPARING SAME AND USES THEREOF - The invention relates to the field of biosensors and, more specifically, to nanoparticle biosensors comprising: a magnetic core, a silica layer, one or more outer metal layers which can be of different types and deposited in an alternating manner and immobilized on the outer surface, and a layer of synthetic or natural organic or inorganic biosensor molecules that can bind to biomolecules. The invention also relates to a method of obtaining the nanoparticle biosensors as well as to the different uses thereof.02-14-2013
20130210012METHOD FOR ASSESSING BREAST CANCER SUSCEPTIBILITY - The present invention aims to provide a method for determining breast cancer susceptibility, in which a DNA copy number polymorphism associated with breast cancer susceptibility is identified and determination is made based on an increase or decrease in the DNA copy number polymorphism. The present invention attempts to achieve this by performing microarray assay using the peripheral blood of sporadic breast cancer patients, identifying a DNA copy number polymorphism associated with breast cancer susceptibility in a chromosomal region, detecting the number of copies of the above DNA copy number polymorphism by quantitative PCR, and then determining breast cancer susceptibility based on an increase or decrease in the DNA copy number polymorphism. Furthermore, the precision of the determination of breast cancer susceptibility can be improved by detecting a DNA copy number polymorphism by the aforementioned quantitative PCR by selecting two or more chromosomal regions and then performing a discriminant analysis based on the results thus obtained.08-15-2013
20130210009CONJUGATE BETWEEN A THIOPHILIC SOLID PHASE AND AN OLIGONUCLEOTIDE COMPRISING A THIOOXONUCLEOTIDE - An oligonucleotide-solid phase conjugate, wherein the solid phase is thiophilic and the oligonucleotide comprises at least one thiooxonucleobase according to Formula I,08-15-2013
20130034855DETECTION OF MUTATIONS IN A GENE ENCODING IKB KINASE-COMPLEX-ASSOCIATED PROTEIN TO DIAGNOSE FAMILIAL DYSAUTONOMIA - A method for detecting the presence in a subject of a polymorphism linked to a gene associated with familial dysautonomia, said method comprising detecting a disruptive mutation in a gene of said subject encoding the IκB kinase-complex-associated protein, and, preferably, detecting a T→C change in position 6 of the donor splice site of intron 20 and/or a G→C transversion of nucleotide 2390 in exon 19 of the gene encoding the IκB kinase-complex-associated protein which is present on chromosome 9q31. Also disclosed are oligonucleotide primers useful in the detection method. This abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to ascertain quickly the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.02-07-2013
20120264130CORN EVENT MIR162 - A novel transgenic corn event designated MIR162 is disclosed. The invention relates to nucleic acids that are unique to event MIR162 and to methods for detecting the presence of the MIR162 event based on DNA sequences of the recombinant constructs inserted into the corn genome that resulted in the MIR162 event and of genomic sequences flanking the insertion site. The invention further relates to corn plants comprising the transgenic genotype of MIR162 and to methods for producing a corn plant by crossing a corn plant comprising the MIR162 genotype with itself or another corn variety. Seeds of corn plants comprising the MIR162 genotype are also objects of the present invention. The invention also relates to methods of controlling insects using MIR162 corn plants.10-18-2012
20130029336KRAS Primers and Probes - The present invention provides oligonucleotide primers or probes for the detection of a mutation of the KRAS gene. The invention also provides a method for detecting a mutation in the KRAS gene using the oligonucleotide primers or probes disclosed therein. Furthermore, the present invention encompasses a method for predicting the sensitivity of a tumor in a patient to epidermal growth factor receptor-directed chemotherapy, comprising obtaining DNA from the tumor; and determining whether there is a mutation in codon 12 and/or a mutation in codon 13 in exon 2 of the KRAS gene in the DNA using a method utilizing at least one of the oligonucleotide primers and/or probes of the present invention.01-31-2013
20130029337METHODS AND USES INVOLVING GENETIC ABNORMALITIES AT CHROMOSOME 12 - The present invention relates to the fields of genetics and oncology and provides methods for predicting and identifying tumors of epithelial origin. Specifically, the present invention relates to a novel method of predicting tumor initiation, tumor progression and/or carcinomas, the method comprising detecting genetic abnormality associated with tumors of epithelial origin. The present invention further relates to a novel method of identifying an individual with potential for developing carcinoma, the method comprising detection of genetic abnormalities. The present invention also relates to a method of predicting the progression of carcinomas and the transformation thereof to an aggressive variant, the method comprising detection of genetic abnormalities, which indicate the probability to develop carcinoma. The present invention also relates to a use of specific chromosomal region, a gene or a fragment thereof, and/or genetic markers for predicting tumor initiation, tumor progression and/or carcinoma. The present invention also relates to a use of specific chromosomal region or a gene or a fragment thereof in therapy, for the development of therapy, and for the preparation of a medicament for treating tumors of epithelial origin.01-31-2013
20130029332COMPOSITIONS AND METHODS FOR DETECTING NOONAN SYNDROME - Diagnostic and therapeutic applications for Noonan Syndrome are described. The diagnostic and therapeutic applications are based on certain mutations in a RAS-specific guanine nucleotide exchange factor gene SOS1 or its expression product. The diagnostic and therapeutic applications are also based on certain mutations in a serine/threonine protein kinase gen RAF1 or its expression product thereof. Also described are nucleotide sequences, amino acid sequences, probes, and primers related to RAF1 or SOS1, and variants thereof, as well as host cells expressing such variants.01-31-2013
20130029331NOVEL FLUORESCENCE-BASED ASSAY FOR THE RAPID DETECTION AND QUANTIFICATION OF DEOXYRIBONUCLEOSIDE TRIPHOSPHATES - The inventors have developed a rapid and sensitive fluorescence-based assay to quantify dNTPs. This assay relies on the principle that incorporation of a limiting dNTP is required for primer-extension and polymerase-mediated 5-3′ exonuclease hydrolysis of a quenched fluorophore-labeled probe resulting in fluorescence. The concentration of limiting dNTPs is directly proportional to the fluorescence generated. This assay has important applications in research that investigates the influence of pathological conditions or pharmacological agents on dNTP biosynthesis and regulation.01-31-2013
20130029335SPINOCEREBELLAR ATAXIA TYPE 8 AND METHODS OF DETECTION - The present invention provides an isolated nucleic acid molecule containing a repeat region of an isolated spinocerebellar ataxia type 8 (SCA8) coding sequence, the coding sequence located within the long arm of chromosome 13, and the complement of the nucleic acid molecule. Diagnostic methods based on identification of this repeat region are also provided.01-31-2013
20130029334mRNA As Biomarkers For Liver Injury or Other Liver Perturbations - The present invention provides a method for assessing the likelihood or for detecting the presence of liver perturbation in an individual. The method is particularly useful for detecting drug-induced liver injury (DILI) or other forms of hepatotoxicity or hepatic perturbation. The method comprises measuring the level of at least one RNA biomarker comprising mRNA and comparing the measured level to an appropriate reference value for the sample type and RNA biomarker type, and wherein a significant difference between the measured level and the reference value is indicative of liver perturbation.01-31-2013
20130029333Magnetic Bead Quantum Dot Nanoparticle Assay - The present disclosure includes a magnetic bead (MB) quantum dot (QD) nanoparticle assay for detecting, capturing, separating, and/or quantifying a target in a sample.01-31-2013
20130029329DETECTION OF AAD-12 SOYBEAN EVENT 416 - The invention relates in part to methods of detecting an AAD-12 soybean event. The subject invention provides assays for detecting the presence of the subject event in a sample (of soybeans, for example). Kits and conditions useful in conducting the assays are also provided. More specifically, the present invention relates in part to an endpoint TaqMan PCR assay for the AAD-12 soybean event. Some embodiments are directed to assays that are capable of high throughput zygosity analysis. The subject invention further relates, in part, to the discovery of a preferred reference gene for use in determining zygosity. This invention also relates in part to plant breeding using any of the subject methods. In some embodiments, said event/polynucleotide sequence can be “stacked” with other traits. The subject procedures can be used to uniquely identify soybean lines comprising the event of the subject invention.01-31-2013
20130029328METHODS AND KITS FOR THE IDENTIFICATION OF ANIMALS HAVING A GREATER POTENTIAL FOR DESIRABLE CHARACTERISTICS, AND FOR THE EARLY IDENTIFICATION OF FAT DEPOSITS IN BOVINES - The present invention relates to a method and a kit for the identification of animals having greater potential for desirable characteristics of meat quality, rib eye area (REA), weaning weight and 18-month weight by means of the analysis of specific markers.01-31-2013
20130029327GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS, METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.01-31-2013
20130029330MUTANT LDL RECEPTOR GENE - There is disclosed a method of identifying individuals susceptible to familial hypercholesterolemia and which method comprises identifying in a sample from said individual at least one polymorphism at position 1706-2 of the coding region (41902 of the genomic DNA) in the low density lipoprotein receptor gene, and wherein the presence of at least one said polymorphism is indicative of said individual being of a higher susceptibility to familial hypercholesterolemia.01-31-2013
20120164639METHODS FOR DETECTING LOW GRADE INFLAMMATION - The present invention relates to methods for detecting the presence of low grade inflammation in a patient.06-28-2012
20120164637SUSCEPTIBILITY TO BONE DAMAGE - In one aspect, the present invention provides methods for determining susceptibility to bone damage in a subject. In some embodiments, the methods comprise screening for polymorphisms in the MTHFR and collagen Iα1 genes that are associated with susceptibility to bone damage. In some embodiments, the methods comprise screening for elevated levels of homocysteine in a subject, wherein elevated levels of homocysteine are associated with an increased risk of bone damage. The methods of the invention may be used in predicting the response of a patient to treatment. Also provided are methods for prevention or reducing the risk of bone damage in a subject.06-28-2012
20130052645METHOD FOR IDENTIFYING BACTERIA IN A SAMPLE - This invention describes a method for identifying bacteria. In particular, this invention relates to a method for identifying and quantifying mycobacteria from a sputum sample taken from a subject using flow cytometry. Further described is the use of flow cytometry to identify and quantify 02-28-2013
20130089862Genetic Lesion Associated With Cancer - The invention comprises methods for identifying mutations within the 3′UTR of genes that lead to increased risk or probability of developing cancer.04-11-2013
20130089860COMPARATIVE TRANSCRIPT ANALYSIS - One example embodiment includes a method of comparative transcript analysis. The method includes providing an antisense DNA probe. The method also includes linking a blocking adapter to the antisense DNA probe.04-11-2013
20130071836COLON CANCER BIOMARKER DISCOVERY - The present application discloses an epigenetic marker for colon cancer.03-21-2013
20130089863RISK CALCULATION FOR EVALUATION OF FETAL ANEUPLOIDY - The present invention provides processes for determining accurate risk probabilities for fetal aneuploidies. Specifically, the invention provides non-invasive evaluation of genomic variations through chromosome-selective sequencing and non-host fraction data analysis of maternal samples.04-11-2013
20130089864METHODS FOR CHARACTERIZING KIDNEY FUNCTION - Embodiments of the invention relate generally to methods of characterizing kidney function. In particular, several embodiments quantify kidney-associated marker RNA isolated from vesicles contained in patient urine samples. In some embodiments, the quantified RNA from urine vesicles is compared to a normal population and in some embodiments is compared to the patient to evaluate kidney function over time04-11-2013
20130089859COMPOSITIONS, METHODS AND KITS TO DETECT ADENOVIRUS NUCLEIC ACIDS - The disclosed invention is related to methods, compositions, kits and isolated nucleic acid sequences for targeting Adenovirus nucleic acid. Compositions include amplification oligomers and/or detection probe oligomers. Kits and methods comprise at least one of these oligomers.04-11-2013
20130089861Detection of Immune Cells, In Particular T Cells Through DNA-Methylation Analysis of the Genes CCR6 and BLR1 - The present invention relates to a method, in particular an in vitro method, for identifying certain immune cells of a mammal, comprising analysing the methylation status of at least one CpG position in the gene CCR6 and/or BLR1 or an orthologous or paralogous gene thereof, and the use of DNA-methylation analysis of the genes of the proteins CCR6 and/or BLR1 for a detection and quality assurance and control of certain immune cells. In particular, the present invention relates to analysing the methylation status of at least one CpG position in the gene CCR6 in T cells. Furthermore, the present invention relates to a kit for performing the above methods, as well as to respective uses.04-11-2013
20130071845IDENTIFICATION OF HUMAN MOUSE DOUBLE MINUTE 2 HOMOLOG NUCLEOTIDE SEQUENCES - The invention is directed to isolated genomic polynucleotide fragments that encode human carboxypeptidase M and human mouse double minute 2 homolog, vectors and hosts containing these fragments and fragments hybridizing to noncoding regions as well as antisense oligonucleotides to these fragments. The invention is further directed to methods of using these fragments to obtain human carboxypeptidase M and human mouse double minute 2 homolog and to diagnose, treat, prevent and/or ameliorate a pathological disorder.03-21-2013
20130071843METHODS, PROBE SETS, AND KITS FOR DETECTION OF DELETION OF TUMOR SUPPRESSOR GENES BY FLUORESCENCE IN SITU HYBRIDIZATION - Methods, probe sets, kits, and compositions for gene deletion assays are disclosed. In some embodiments, the methods relate to preparing probes for a deletion assay, performing a deletion assay, or optimizing a deletion assay. In some embodiments, the methods and probe sets can provide reduced artifactual deletion frequency, for example, when analyzing samples subject to truncation artifacts. In some embodiments, the methods and probe sets can distinguish between small and large deletions.03-21-2013
20130071842Hypermethylation Biomarkers for Detection of Head and Neck Squamous Cell Cancer - Differentially methylated oral squamous cell carcinoma (OSCC) biomarkers, identified in-vitro and validated in well-characterized surgical specimens, have shown poor clinical correlation in cohorts with different risk profiles. To overcome this lack of relevance we used the HumanMethylation27 BeadChip, publicly available methylation and expression array data, and Quantitative Methylation Specific PCR to uncover differential methylation in OSCC clinical samples with heterogeneous risk profiles. A two stage-design consisting of Discovery and Prevalence screens was used to identify differential promoter methylation and deregulated pathways in patients diagnosed with OSCC and head and neck squamous cell carcinoma. This Phase I Biomarker Development Trial identified a panel of differentially methylated genes in normal and OSCC clinical samples from patients with heterogeneous risk profiles. This panel may be useful for early detection and cancer prevention studies.03-21-2013
20130071846KIT AND METHOD - The present invention relates to a kit comprising a DNA-dependant DNA polymerase and at least one natural deoxynucleoside and to a kit comprising a DNA-dependent DNA polymerase and a detection system comprising a DNA template molecule, a DNA primer molecule, and a fluorescent moiety capable of being displaced from,or bound to, dsDNA synthesized by said DNA-dependent polymerase. It further relates to A method for measuring deoxynucleoside kinase activity in a sample characterized by; (i) contacting the sample, in a container, with a reaction mix comprising a DNA-dependent DNA polymerase, at least one deoxynucleoside and a detection system comprising a DNA template molecule, a DNA primer molecule, and a fluorescent moiety capable of being incorporated in, displaced from,or bound to dsDNA synthesized by said DNA dependent polymerase; (ii) incubating said container; (iii) measuring the signal from the fluorescent moiety;and correlating the signal from the fluorescent moietyto the deoxynucleoside kinase activity in the sample.03-21-2013
20130071844METHOD FOR DETECTING TARGET BASE SEQUENCE USING COMPETITIVE PRIMER - Disclosed is a method of detecting a target base sequence having a polymorphic base, the method including: (a) a step of adding to a nucleic acid sample having a target nucleic acid that includes a base sequence including the target base sequence: at least one type of detection primer, at least one type of competitive primer, and at least one type of common primer; (b) a step of annealing the detection primer and the competitive primer to the target nucleic acid in a competitive manner, thereby synthesizing an extension product A; (c) a step of annealing the common primer to the extension product A obtained in the step (b) or in the following step (d), thereby synthesizing an extension product B; (d) a step of annealing the detection primer or the competitive primer to the extension product B obtained in the previous step (c), thereby synthesizing the extension product A; and (e) a step of detecting the extension product A or the extension product B.03-21-2013
20130071841TRANSLOCATION AND MUTANT ROS KINASE IN HUMAN NON-SMALL CELL LUNG CARCINOMA - In accordance with the invention, a novel gene translocation, (4p15, 6q22), in human non-small cell lung carcinoma (NSCLC) that results in a fusion proteins combining part of Sodium-dependent Phosphate Transporter Isoform NaPi-3b protein (SLC34A2) with Proto-oncogene Tyrosine Protein Kinase ROS Precursor (ROS) kinase has now been identified. The SLC34A2-ROS fusion protein is anticipated to drive the proliferation and survival of a subgroup of NSCLC tumors. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of the new fusion protein enables new methods for determining the presence of these mutant ROS kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.03-21-2013
20130071837Method and System for Characterizing or Identifying Molecules and Molecular Mixtures - A system and method for identifying a material passing through a nanopore filter wherein an electrical signal is detected as a result of the passage and that signal is processed in real-time using mathematical and statistical tools to identify the molecule. A carrier molecule is preferably attached to one or more molecule(s) under consideration using a non-covalent bond and the pore in the nanopore filter is sized so that the molecule rattles around in the pore before being discharged without passing through the filter pore. The present invention includes not only a method and system for identifying the molecule(s) under consideration but also a kit for setting up the filter as well as mathematical tools for analyzing the signals from the sensing circuitry for the molecule(s) under consideration.03-21-2013
20130071839SYSTEMS AND METHODS FOR DETECTING BIOMARKERS OF INTEREST - In some embodiments, a strand displacement system is provided. Such a system may include a first nucleic acid catalyst molecule; a nucleic acid gate molecule, wherein the first nucleic acid catalyst molecule binds the nucleic acid gate molecule forming a nucleic acid gate-catalyst complex and releases an output molecule; and a nucleic acid sink molecule. The nucleic acid sink molecule sequesters a putative second nucleic acid catalyst, wherein the second nucleic acid catalyst differs from the first nucleic acid catalyst molecule by at least one nucleotide. In some aspects, the first nucleic acid catalyst may include a biomarker of interest or a nucleic acid aptamer which binds an amino acid-based biomarker of interest.03-21-2013
20130071838PEPTIDE NUCLEIC ACID PROBES FOR ANALYSIS OF CERTAIN STAPHYLOCOCCUS SPECIES - The present invention relates to peptide nucleic acid (PNA) probes, PNA probe sets and methods for the analysis of certain 03-21-2013
20130071840ENHANCED DETECTION OF NON-SOMATIC CIRCULATING NUCLEIC ACIDS - Methods, equipment and software for the detection of abnormal nucleic acid or fetal nucleic acid sequences circulating in the subject's blood or other body fluids. A scan of a subject's circulating nucleic acid (CNA) is compared to the CNA Data On Normal Healthy Population or to a scan of the subject's own Somatic Nucleic Acid (SNA). Abnormal peaks are identified by subtracting out the “normal” or somatic peaks. The resultant anomalous peaks are compared to anomalous CNA data to identify the abnormalities, or the anomalous peaks of the subject's CNA are isolated, amplified, and sequenced or probed to determine the nature of the anomaly.03-21-2013
20130164742Droplet-Based Pyrosequencing - The present invention relates to droplet-based pyrosequencing including a method of identifying a base at a target position in a sample nucleic acid. The method includes: (a) providing a droplet microactuator including a first droplet including a sample nucleic acid immobilized on a bead; and (b) on the droplet microactuator: (i) contacting the first droplet with one or more reagent droplets to yield a second droplet, wherein the one or more reagent droplets include reagents for extending a double stranded portion of the sample nucleic acid by incorporating a nucleotide at the target position; (ii) splitting the second droplet to yield a third droplet including the bead and a fourth droplet lacking the bead; and (iii) assaying the third droplet to determine whether the nucleotide was incorporated at the target position.06-27-2013
20130164753DIAGNOSTIC METHODS FOR COLITIS - A method of screening for, diagnosing or detecting the presence of 06-27-2013
20130059308POLYMER MICROFILTERS AND METHODS OF MANUFACTURING THE SAME - A microfilter comprising a polymer layer formed from epoxy-based photo-definable dry film, and a plurality of apertures each extending through the polymer layer. A method of forming a microfilter is also disclosed. The method includes providing a first layer of epoxy-based photo-definable dry film disposed on a substrate, exposing the first layer to energy through a mask to form a pattern, defmed by the mask, in the first layer of dry film, forming, from the exposed first layer of dry film, a polymer layer having a plurality of apertures extending therethrough, the plurality of apertures having a distribution defined by the pattern, and removing the polymer layer from the substrate.03-07-2013
20130059307Methods And Compositions For Detecting Fungi And Mycotoxins - The invention relates to a method of identifying a specific fungal species in patient tissue or body fluid. The method comprises the steps of extracting and recovering DNA of the fungal species from the patient tissue or body fluid, amplifying the DNA, hybridizing a probe to the DNA to specifically identify the fungal species, and specifically identifying the fungal species. The invention also relates to a method of identifying a mycotoxin in patient tissue or body fluid. The method comprises the steps of extracting and recovering the mycotoxin from the patient tissue or body fluid, contacting the mycotoxin with an antibody directed against the mycotoxin, and identifying the myocotoxin. Both of these methods can be used to determine if a patient is at risk for or has developed a disease state related to a fungal infection, and to develop an effective treatment regimen for the patient.03-07-2013
20130059306PRIMER AND PROBE FOR DETECTING CHLAMYDIA TRACHOMATIS, AND METHOD FOR DETECTING CHLAMYDIA TRACHOMATIS USING SAME - The present invention relates to an oligonucleotide which is designed on the basis of a nucleotide sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 and hybridizes with the endogenous plasmid gene of 03-07-2013
20130059305TRANSLOCATION AND MUTANT ROS KINASE IN HUMAN NON-SMALL CELL LUNG CARCINOMA - In accordance with the invention, a novel gene translocation, (4p15, 6q22), in human non-small cell lung carcinoma (NSCLC) that results in a fusion proteins combining part of Sodium-dependent Phosphate Transporter Isoform NaPi-3b protein (SLC34A2) with Proto-oncogene Tyrosine Protein Kinase ROS Precursor (ROS) kinase has now been identified. The SLC34A2-ROS fusion protein is anticipated to drive the proliferation and survival of a subgroup of NSCLC tumors. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of the new fusion protein enables new methods for determining the presence of these mutant ROS kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.03-07-2013
20130059304TRANSLOCATION AND MUTANT ROS KINASE IN HUMAN NON-SMALL CELL LUNG CARCINOMA - In accordance with the invention, a novel gene translocation, (4p15, 6q22), in human non-small cell lung carcinoma (NSCLC) that results in a fusion proteins combining part of Sodium-dependent Phosphate Transporter Isoform NaPi-3b protein (SLC34A2) with Proto-oncogene Tyrosine Protein Kinase ROS Precursor (ROS) kinase has now been identified. The SLC34A2-ROS fusion protein is anticipated to drive the proliferation and survival of a subgroup of NSCLC tumors. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of the new fusion protein enables new methods for determining the presence of these mutant ROS kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.03-07-2013
20130059303CDKN2A AS A PROGNOSTIC MARKER IN BLADDER CANCER - The present invention provides methods for predicting clinical outcome and for providing information for determining follow-up strategy of a subject affected with a non-muscle invasive bladder cancer, as well as a method for selecting a subject affected with a non-muscle invasive bladder cancer for an anti-tumoral therapy. The present invention also provides kits for implementing these methods.03-07-2013
20130059302NUCLEIC ACID DETECTION APPARATUS, METHOD AND COMPUTER READABLE RECORDING MEDIUM - A light reception section receives fluorescence emitted according to the amount of target nucleic acid that has been amplified by PCR due to a light source illuminating excitation light onto a reaction liquid. Electrical signals from the light reception section whose level depends on the received fluorescence intensity are amplified by plural amplification circuits having different amplification factors. A multiplexor selects an electrical signal amplified with an amplification factor in an initial stage of an amplification reaction and detects a fluorescence value for that cycle. A CPU acquires the largest fluorescence value in the initial stage and determines the amplification factor for a corrected stage and inputs a selection signal to the multiplexor to select the electrical signal amplified by the determined amplification factor. In the corrected stage the electrical signal amplified with the determined amplification factor is selected and fluorescence values detected.03-07-2013
20130059301ASXL1 AS A NEW DIAGNOSTIC MARKER OF MYELOID NEOPLASMS - A method for diagnosing a myeloid cancer in a subject, includes the step of analyzing a biological sample from the subject by determining the presence or the absence of a mutation in the ASXL1 (additional sex combs like 1) gene coding for the polypeptide having the sequence SEQ ID N°2. A kit for diagnosing myeloid cancer in a subject including at least one nucleic acid probe or oligonucleotide or at least one antibody, which can be used in a such a method is also described.03-07-2013
20130059300Insect Resistant Cotton Plants And Methods For Identifying Same - The invention provides specific transgenic cotton plants, plant material and seeds, characterized in that these products harbor a specific transformation event at a specific location in the cotton genome. Tools are also provided which allow rapid and unequivocal identification of the event in biological samples.03-07-2013
20130059299ABERRANT MITOCHONDRIAL DNA, ASSOCIATED FUSION TRANSCRIPTS AND TRANSLATION PRODUCTS AND HYBRIDIZATION PROBES THEREFORE - The present invention provides novel mitochondrial fusion transcripts, the parent mutated mtDNA molecules, and the resulting translation products (proteins) for predicting, diagnosing and/or monitoring cancer. Hybridization probes complementary thereto for use in the methods of the invention are also provided.03-07-2013
20120309006SPECIFIC METHOD OF PROSTATE CANCER DETECTION BASED ON PCA3 GENE, AND KITS THEREFOR - The invention relates to a method to diagnose prostate cancer by detecting a PCA3 sequence. In one embodiment the method and kit enables amplification of PCA3 RNA through an exon-exon junction of a spliced PCA3 mRNA, and methods and kits to detect an amplified PCA3 RNA, using a probe which spans the amplified exon-exon junction. The methods and kits can detect a PCA3 RNA lacking one intron or more. Also provided are methods of detecting PCA3 RNA expressed in non-prostate tissue or cells of the urinary tract, which comprises PCA3 intron 3. In addition, methods are provided to determine whether a sample from a subject contains or lacks prostate cells, by performing a hybridization and/or amplification reaction on RNA from the sample to detect the presence or level of PCA3 RNA that lacks at least one intron and distinguishing a prostate cell from a non-prostate cell.12-06-2012
20120308999DETECTION OF SHORT RNA SEQUENCES - An assay for detection of short sequences of RNA in a synthetic or clinically isolated sample is presented herein. Particular reference is made to detecting RNA based pathogens, such as H5 influenza.12-06-2012
20120190025ENTEROCOCCUS AND FECAL BACTEROIDES FOR RAPID WATER QUALITY ASSESSMENT - The present invention is drawn to methods and compositions for the rapid assessment of fecal indicator bacteria in a sample. Provided herein are novel primer and probe compositions for use in detecting the presence of these organisms in a sample, particularly using quantitative PCR methods. Provided herein are novel oligonucleotide primers and probes, including the primers set forth in SEQ ID NOS: 1-4, 7 and 8, the novel oligonucleotide probe sequences set forth in SEQ ID NOS:5, 6, and 9, and methods for using these primers and probes for the detection and/or quantification of fecal indicator bacteria, particularly 07-26-2012
20120190022METHOD FOR DETERMINATION OF THE LENGTH OF THE G-TAIL SEQUENCE AND KIT FOR THE METHOD - A method of measuring the length of a G tail sequence, characterized by hybridizing the G tail of an nondenatured chromosomal DNA in a sample with a labeled DNA probe having a sequence complementary to the telomere repeat sequence, measuring chemiluminescence from the hybridized DNA probe, and determining the length of the G tail sequence from the measured value, and a kit used for use in such a method.07-26-2012
20120225429METHODS, COMPOSITIONS AND KITS FOR DETECTION AND ANALYSIS OF ANTIBIOTIC-RESISTANT BACTERIA - The present invention relates generally to detection of antibiotic-resistant bacteria in a sample. In particular, the invention provides methods, compositions and kits for detecting and analyzing methicillin-resistant 09-06-2012
20120225425Cathepsin E as a Marker of Colon Cancer - Elevated levels of cathepsin E (catE) are demonstrated to be diagnostic of intestinal forms of cancer, such as colorectal cancer. Elevated levels of cathepsin E (catE, monomeric forms) are demonstrated to be detectable in the urine of animals having colorectal cancer, and a diagnostic/screening method for identifying and/or detecting colorectal cancer in an animal from a urine sample is provided. Specific tissue immunohistochemcial staining for catE (monomeric forms) in dysplastic tissue is also disclosed, and is shown to correlate with the level of dysplastic lesion severity. Hence, a method for identifying and determining the level of dysplastic lesion severity is provided. Cathepsin E mRNA transcription and expression levels are also demonstrated to be upregulated in dysplastic tissue, relative to non-dysplastic tissue. Hence, a method for transcriptionally profiling an animal to monitor the progression of colorectal disease is provided.09-06-2012
20130065236METHOD FOR REAL-TIME NUCLEIC ACID AMPLIFICATION BY DROPLET MANIPULATION - The present invention provides a real-time nucleic acid amplification method capable of quickly and accurately detecting fluorescence obtained by a nucleic acid amplification method performed in a droplet in a perfect closed system. A real-time nucleic acid amplification reaction method for performing a nucleic acid amplification reaction in a droplet present in a container, wherein the droplet is composed of a nucleic acid amplification reaction liquid including a nucleic acid to be amplified and magnetic particles; the container holds a droplet encapsulating medium immiscible with the nucleic acid amplification reaction liquid forming the droplet, and has a transport surface having a temperature gradient; and at least the droplet encapsulating medium out of the droplet and the droplet encapsulating medium includes a fluorochrome at start of the nucleic acid amplification reaction, the method comprising transporting the droplet together with the magnetic particles by generating a magnetic field by means for applying a magnetic field to start and maintain a nucleic acid amplification reaction so that the droplet is placed on the transport surface at a temperature point at which the nucleic acid synthesis reaction is started and maintained, thereby controlling a temperature of the reaction liquid.03-14-2013
20130065238SYNGAP1 DYSFUNCTIONS AND USES THEREOF IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS FOR MENTAL RETARDATION - The invention identifies Syngap1 dysfunctions as causative of mental retardation. Described are methods of detecting mental retardation and methods of detecting non-syndromic mental retardation (NSMR) in a human subject. Particular methods comprise sequencing a human subject's genomic DNA for comparison with a control sequence from an unaffected individual. Also described are probes, kits, antibodies and isolated mutated Syngap1 proteins.03-14-2013
20130065237NOVEL MIXTURES FOR ASSAYING NUCLEIC ACID, NOVEL METHOD OF ASSAYING NUCLEIC ACID WITH THE USE OF THE SAME AND NUCLEIC ACID PROBE TO BE USED THEREFOR - [Problems] To provide a novel mixture for assaying a target nucleic acid, characterized by enabling a nucleic acid assay while: 1) requiring no step of diluting the target nucleic acid; 2) requiring no procedure of changing a probe concentration depending on a concentration of the target nucleic acid.03-14-2013
20130065235BINDING AND FUNCTIONAL ASSAYS THAT USE THE T1R3 RECEPTOR TO SCREEN FOR TASTE MODULATORY COMPOUNDS - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed.03-14-2013
20130065234METHOD FOR DIAGNOSING BONE AND JOINT DISEASE BASED ON SINGLE NUCLEOTIDE POLYMORPHISM IN CHROMOSOME 10Q24 - Provided is a method for diagnosing a bone and joint is disease such as scoliosis. A single nucleotide polymorphism present in region 24 on the long arm of chromosome 10 (region 10q24) is analyzed and the risk of onset of a bone and joint disease and/or the presence or absence of onset of the same are diagnosed on the basis of a result of the analysis.03-14-2013
20130065231Primer and Probe for Use In Detection of Mycobacterium Kansasii and Method for Detection of Mycobacterium Kansasii Using The Same - The present invention discloses an oligonucleotide which comprises a part or the entire sequence of the nucleotide sequence depicted in SEQ ID NOS: 1-4, or a part or the entire sequence of a nucleotide sequence complementary to SEQ ID NOS: 1-4, wherein the oligonucleotide is capable of hybridizing with the nucleotide sequence of 03-14-2013
20130065232ASSAYS AND KITS FOR SEROTYPING PSEUDOMONAS AERUGINOSA AND OLIGONUCLEOTIDE SEQUENCES USEFUL IN SUCH METHODS AND KITS - The present invention relates to assays, kits and oligonucleotides for the detection of 03-14-2013
20130065233DETECTION OF DNA METHYLATION - In a first aspect, the invention concerns a method for detecting or quantifying DNA methylation at a locus. In one embodiment, a methylation-sensitive endonuclease is formulated together with a polymerase enzyme in an appropriate reaction mixture such that amplification of DNA occurs in a methylation specific manor. Quantitative DNA amplification at selected loci can be used to determine the level of methylation. Kits and reagents for performing such methods are also provided.03-14-2013
20130065230SOYBEAN EVENT pDAB9582.814.19.1 DETECTION METHOD - Soybean Event pDAB9582.814.19.1 comprises genes encoding Cry1F, Cry1Ac (synpro), and PAT, affording insect resistance and herbicide tolerance to soybean crops containing the event, and enabling methods for crop protection and protection of stored products. The invention provides PCR event detection methods.03-14-2013
20130065228GENOME-SCALE ANALYSIS OF ABERRANT DNA METHYLATION IN COLORECTAL CANCER - Particular aspects provide methods and compositions (e.g., gene marker panels) having substantial utility for at least one of diagnosis, identification and classification of colorectal cancer (CRC) (e.g., tumors) relating to distinctive DNA methylation-based subgroups of CRC including CpG island methylator phenotype (CIMP) groups (e.g., CIMP-H and CIMP-L) and non-CIMP groups. Exemplary marker panels include: B3GAT2, FOXL2, KCNK13, RAB31 and SLIT1 (CIMP marker panel); and FAM78A, FSTL1, KCNC1, MYOCD, and SLC6A4 (CIMP-H marker panel). Further aspects relate to genetic mutations, and other epigenetic markers relating to said CRC subgroups that can be used in combination with the gene marker panels for at least one of diagnosis, identification and classification of colorectal cancer (CRC) (e.g., tumors) relating to distinctive CIMP and non-CIMP groups.03-14-2013
20130065229BIOMARKERS FOR SYSTEMIC LUPUS ERYTHEMATOSUS - The present invention provides methods and reagents for diagnosing system lupus erythematosus and for monitoring system lupus erythematosus disease activity in a subject.03-14-2013
20120196283Qualitative and Quantitative Detection of Microbial Nucleic Acids - The present invention relates to new methods and uses for the qualitative and quantitative detection of microbial nucleic acids using at least a first control nucleic acid, or a first and a second control nucleic acid in different concentrations. The method is based on amplification of nucleic acids, for example the polymerase chain reaction. Further provided are kits comprising components for performing said methods and uses.08-02-2012
20130164749DELETED SEQUENCES IN M. BOVIS BCG/M. BOVIS OR M. TUBERCULOSIS, METHOD FOR DETECTING MYCOBACTERIA USING SAID SEQUENCES AND VACCINES - The invention concerns the isolation of nucleotide and peptide sequences in particular for differentiating, in diagnostic terms, an immunisation resulting from BCG vaccination of an infection by 06-27-2013
20120115152Screening Method - The present invention relates to clinical diagnosis of Alzheimer's disease or early-stage Alzheimer's disease in the live patient. In particular, the invention provides a screening method which can be used to assist with diagnosis of Alzheimer's disease in live human subjects, or to identify human subjects with a predisposition to Alzheimer's disease.05-10-2012
20120115151METHOD FOR TESTING A SUBJECT THOUGHT TO BE PREDISPOSED TO HAVING METASTATIC CANCER USING DELTA133P53BETA - The present invention concerns a method of testing a subject thought to be predisposed to having a metastatic cancer which comprises: analyzing a biological sample from said subject for detecting the presence of a p53 isoform selected from the group consisting of Δ133p53, Δ133p53γ and Δ133p53β, the presence of said p53 isoform being indicative of a metastatic cancer.05-10-2012
20120115150miRNA BIOMARKERS FOR THE DIAGNOSIS OF DUCHENNE MUSCULAR DYSTROPHY, ITS PROGRESSION AND FOR MONITORING THERAPEUTIC INTERVENTIONS - The invention refers to diagnosis and therapy of muscle degenerative disorders, as Duchenne Muscular Dystrophy (DMD) by means of a class of specific miRNAs.05-10-2012
20120115149SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM - The gene (SLC6A4) responsible for encoding the serotonin transporter (SERT) has a functional polymorphism at the 5′-regulatory promoter region, which results in two forms, long (L) and short (S). The LL-genotype is hypothesized to play a key role in the early onset of alcohol use. The present invention discloses the differences in treatment and diagnosis based on the L or short genotypes as well as on a single nucleotide polymorphism of the SERT gene, the 3′ UTR SNP rs1042173. The present invention demonstrates the efficacy of using the drug ondansetron and similar drugs for treatment based on diagnosing variations in the polymorphisms of the SERT gene and expression and activity of the SERT gene, as well as methods for diagnosing susceptibility to abuse of alcohol and other addiction-related diseases and disorders, for monitoring treatment and/or abuse (addictive behavior), and for determining which treatment should be used.05-10-2012
20120115148Reagents and Methods for Detecting Neisseria Gonorrhoeae - This invention provides compositions and methods for detecting 05-10-2012
20120115147NEUROPSYCHIATRIC TEST REPORTS - Methods and reports for presenting genetic information that is patient-specific and relevant to treatment of neuropsychiatric disorders, including treatment resistant depression. The methods and reports described include genotype information for each of six specific genetic loci and allow patient-specific therapy for the effective treatment of treatment resistant disorders (TRD).05-10-2012
20120115146METHOD OF ANALYZING GENETICALLY ABNORMAL CELLS - The present invention relates to a method for analyzing genetically abnormal cells including (a) preparing a cell sample containing eukaryotic cells, (b) conducting an antigen-antibody reaction to cells contained in the cell sample using antibodies which specifically bind to a molecule existing on the cell surface of eukaryotic cells after (a), (c) subjecting the cells contained in the cell sample to a permeation treatment after (b), (d) subjecting the cells contained in the cell sample to an immobilization treatment after (b), (e) conducting FISH to the cells contained in the cell sample using nucleic acid probes after (d), (f) analyzing fluorescence signals from the nucleic acid probes in the cells contained in the cell sample using a three-dimensional image analysis method after (e), and (g) determining whether the cells contained in the cell sample are genetically abnormal cells or not based on the results of (b) and (f).05-10-2012
20120115145STRAND DISPLACEMENT ACTIVITY OF MODIFIED POLYMERASES AND USES THEREOF - The present invention is directed to the use of the strand displacement activity of a modified polymerase. The present invention is more specifically directed to a modified Taq DNA polymerase, which exhibits strand displacement activity, whereas the native polymerase does not possess the strand displacement activity.05-10-2012
20120115144Detection of Extracellular Tumor-Associated Nucleic Acid in Blood Plasma or Serum - This invention relates to detection of specific extracellular DNA in plasma or serum fractions of human or animal blood associated with neoplastic, pre-malignant or proliferative disease. Specifically, the invention relates to detection tumor-associated DNA, and to those methods of detecting and monitoring tumor-associated DNA found in the plasma or serum fraction of blood by using DNA extraction and amplification with or without enrichment for DNA. The invention allows the selection and monitoring of patients for various cancer therapies including receptor tyrosine kinase inhibitor therapies.05-10-2012
20120115143Universal Probe Assay Methods - Reagents and methods are provided for detecting the presence of a target polynucleotide in a sample are disclosed. In one aspect, a method for producing a labeled amplification product by amplifying a target nucleic acid sequence to produce an amplification product comprising the target sequence, a first probe-binding sequence 5′ to the target sequence, and a second probe-binding sequence 3′ to the target sequence, thereby producing an amplification product; and hybridizing a first detection probe to the amplification product, said first detection probe comprising a first segment that hybridizes to the first probe-binding sequence and a second segment that hybridizes to the second probe-binding sequence, thereby producing a labeled amplification product is disclosed.05-10-2012
20120115139METHOD FOR EVALUATING CANCER - Provided is a cancer evaluation method using a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject. At least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as the novel cancer marker in cancer evaluation. The cancer marker in a sample of a cell or a tissue is detected, and the possibility of a cancer in the sample is evaluated based on the expression level of the cancer marker. According to this evaluation method, by detecting the miRNA as the cancer marker, it becomes possible to evaluate the possibility of a cancer in the sample with excellent reliability. As a method for detecting the cancer marker, it is preferable to perform an in situ hybridization method using a labeled probe with respect to the sample that has been immobilized, for example.05-10-2012
20120115138METHOD FOR IN VITRO DIAGNOSING A COMPLEX DISEASE - The present invention relates to a method and kit for in vitro diagnosing a complex disease such as cancer, in particular, acute myeloid leukemia (AML), colon cancer, kidney cancer, prostate cancer; transient ischemic attack (TIA), ischemia, in particular stroke, hypoxia, hypoxic-ischemic encephalopathy, perinatal brain damage, hypoxic-ischemic encephalopathy of neotatals asphyxia; demyelinating disease, in particular, white-matter disease, periventricular leukoencephalopathy, multiple sclerosis, Alzheimer and Parkinson's disease; in a biological sample. For the diagnosis, use is made of measuring at least two different species of biomolecules and classifying the results by means of suitable classifier algorithms and other statistical procedures. With the present invention, a significant improvement of the reliability of e.g. expression profiles alone, are achieved. In other words, in a defined collective, an up to 100% accurate positive diagnosis could be achieved, which renders the method of the present invention superior over the prior art.05-10-2012
20120115137Methods of Predicting Osteoarthritis - The present invention relates generally to methods for predicting progression, initiation and susceptibility of osteoarthritis in human subjects using their genotype test results.05-10-2012
20120115136PNA DIAGNOSTIC USE - The present invention pertains to certain nucleic acid analogs and related kits that are useful for the capture, recognition, detection, identification, or quantification of certain chemical or biological entities.05-10-2012
20120115135METHOD FOR DETECTION OF ACTIVE PERIODONTAL DISEASE AT THE LOCAL TOOTH SITE - A method for site-specific detection and early diagnosis of periodontal disease using periodontal pocket fluid biomarkers is disclosed.05-10-2012
20120115134METHODS FOR DIAGNOSIS AND PROGNOSIS OF CANCER - We have discovered a protein in humans, herein referred to as collagen like gene (CLG) product (SEQ ID NOS: 12 and 13), that is expressed in human prostate cancer and breast cancer cell lines but not in normal adult, placenta, lung, liver, skeletal muscle, kidney or pancreas tissues. We have also discovered that the level of CLG mRNA expression correlates positively with the metastatic potential of the cancer cell lines tested.05-10-2012
20120115133CYANINE DYES - The invention provides a novel class of cyanine dyes that are functionalized with a linker moiety that facilitates their conjugation to other species. Also provided are conjugates of the dyes, methods of using the dyes and their conjugates and kits including the dyes and their conjugates.05-10-2012
20120115132IDENTIFICATION OF CENTROMERE SEQUENCES USING CENTROMERE ASSOCIATED PROTEINS AND USES THEREOF - The present invention is directed to methods of centromere discovery using centromere-associated proteins in a variety of experimental formats. The methods of the invention can be used on any organism, and include using Cal1, Cbf1, Cbf3, Cbf5, CenH3 (Cenp-A), Cenp-B, Cenp-C, Cenp-D, Cenp-E, Cenp-F, Cenp-G, Cenp-H, Cenp-I, Cenp-K, Cenp-L, Cenp-M, Cenp-N, Cenp-O, Cenp-P, Cenp-Q, Cenp-R, Cenp-S, Cenp-T, Cenp-U, Cenp-V, Cenp-W, Chd1, Chp1, cohesin, condensin, Dnmt3b, Fact, Gcn5p, H2A.Z, Haspin, Hjurp, HP1, Hst4, Ima1, Incep, Ino80, Kms2, Knl-2, Mif2, Mis6, Np95, Pich, Sad1, Scm3, Shugoshin, Sim3, Skp1, Sororin, Survivin, Tas3, ZW10, and homologs thereof to identify centromere sequences. The invention is also directed to artificial chromosomes comprising centromeres made according to the methods of the invention, as well as to cells comprising such artificial chromosomes.05-10-2012
20120115131GENETIC LESION ASSOCIATED WITH CANCER - The invention comprises methods for identifying mutations within the 3′ UTRs of genes that lead to increased risk or probability of developing cancer.05-10-2012
20130164750In Situ Hybridization Method And Buffer - An improved method of in situ hybridization which relies on an improved formulation of the in situ hybridization buffer is described. In at least some formulations the buffer are non-toxic. The combination of Locked Nucleic Acid (LNA) comprising ISH probes and the improved ISH buffer are useful for detection of small non-coding RNA as well as in the manufacturing of ISH kits directed to the detection of such small non-coding RNA. Further disclosed is a method of semi-quantitative ISH and demonstration of the semi-quantitative ISHs diagnostic potential.06-27-2013
20120231463Primer Set for Amplification of MTHFR Gene, MTHFR Gene Amplification Reagent Containing the Same, and Use of the Same - The present invention provides a primer set for specifically amplifying a target region in a MTHFR gene by a nucleic acid amplification method, a MTHFR gene amplification reagent containing the primer set, and use of the primer set.09-13-2012
20130164748Detection of nucleic acid amplification - Methods for detecting a target polynucleotide sequences are provided that utilize a probe having a target-complementary segment and a detectable tag. By cleaving the detectable tab and associating the tag with a tag complement coupled to an electrode, an electrochemical signal can be detected that is related to the presence of the tag:tag complement complex.06-27-2013
20130164743METHOD FOR DIAGNOSING AND MONITORING SCHIZOPHRENIA AND TAUOPATHIES - The present invention provides methods and kits for diagnosing or monitoring conditions such as schizophrenia and tauopathies in a patient by determining the level of ADNP1 or ADNP2 in a sample from the patient.06-27-2013
20130164744Methods for Genetic Analysis of DNA to Detect Sequence Variances - Methods for determining genotypes and haplotypes of genes are described. Also described are single nucleotide polymorphisms and haplotypes in the ApoE gene and methods of using that information.06-27-2013
20130164745Methods for Assessing Risk for Cardiac Dysrythmia in a Human Subject - The present invention relates to methods for assessing the risk of a patient for developing a potentially fatal cardiac dysrhythmia and for diagnosing Andersen's Syndrome. A tissue sample from a patient is obtained and the DNA or proteins of the sample isolated. From the DNA and protein isolates the sequence of the KCNJ2 gene or the Kir2.1 polypeptide can be obtained. The KCNJ2 gene or the Kir2.1 can be screened for alteration as compared to the wile-type sequence. An alteration in a copy of the KCNJ2 gene or a Kir2.1 polypeptide indicates that the patient has a high risk for developing a cardiac dysrhythmia and can be diagnosed with Andersen's Syndrome. The invention also related to isolated nucleic acid molecules with one or more alterations as compared to the wild-type sequence.06-27-2013
20130164746Mutations in SF3B1 and Chronic Lymphocytic Leukemia - The disclosure provides methods of prognosing a subject with CLL and determining the response of the subject to treatment with fludarabine by determining the presence or absence of mutations within the SF3B1 gene.06-27-2013
20130164747Predicting Treatment Response in Cancer Subjects - The invention relates to methods of determining an appropriate cancer therapy for a subject based on intratumoral expression levels of a gene, such as the RRM1 or ERCC1 gene. Compositions and kits useful for the methods are also provided.06-27-2013
20130164751CARCINOMA DIAGNOSIS AND TREATMENT, BASED ON ODC1 GENOTYPE - The present invention provides methods and kits a) for predicting colorectal cancer patient survival, as well as the survival of patients harboring other invasive cancers where cellular proliferation and carcinogenesis is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and b) for selecting the corresponding treatment options for such patients based on the allelic nucleotide sequence or SNP at position +316 of the ODC1 promoter gene as well as cancer treatment methods, in each case, which include the determination of the ODC1 promoter +316 position genotype, as a means to guide treatment selection.06-27-2013
20130164752Detection of mecA Variant Strains of Methicillin-Resistant Staphylococcus Aureus - The present invention provides improved tests for the detection of methicillin-resistant 06-27-2013
20120237936METHODS AND RELATED DEVICES FOR SINGLE MOLECULE WHOLE GENOME ANALYSIS - Provided are methods of labeling and analyzing features along at least one macro molecule such as a linear biopolymer, including methods of mapping the distribution and frequency of specific sequence motifs or the chemical or proteomic modification state of such sequence motifs along individual unfolded nucleic acid molecules. The present invention also provides methods of identifying signature patterns of sequence or epigenetic variations along such labeled macro molecules for direct massive parallel single molecule level analysis. The present invention also provides systems suitable for high throughput analysis of such labeled macro mo lecules.09-20-2012
20120237935REAGENT KIT FOR QUANTITATIVELY DETECTING THE MUTATIONS OF EPIDERMAL GROWTH FACTOR RECEPTOR(EGFR) - The present invention relates to a detection method and a detection kit for EGFR gene mutations, which relates to the therapeutic efficacy of molecular-targeted anti-cancer drugs. Particularly, the present invention relates to a fluorescent quantitative PCR method and kit for detecting mutations at hotspots of EGFR gene, together with the use thereof. The present invention detects the mutations at specific sites of EGFR gene, and can predict the therapeutic efficacy of EGFR tyrosine kinase inhibitors. Therefore, it can provide a guidance to individualize treatments for cancer patients.09-20-2012
20120237934METHODS OF DETECTING MUTATIONS ASSOCIATED WITH ATAXIA-OCULAR APRAXIA 2 (AOA2) - Methods of identifying polymorphisms associated with ataxia-ocular apraxia 2 (AOA2), are described. The polymorphisms associated with AOA2 include specific mutations in the senataxin (SETX) gene. Also described are methods of diagnosis of AOA2, as well as methods of assessing an individual for carrier status for AOA2.09-20-2012
20120237933METHOD FOR SCREENING ACTIVE AGENTS FOR TREATING AT LEAST ONE CUTANEOUS SIGN OF AGING BY DETERMING THE ABILITY TO STIMULATE FN3K AND/OR FN3KP EXPRESSION - A method for screening active agents capable of treating at least one cutaneous sign of aging. The agents are identified based on their ability to stimulate fructosamine-3-kinase (FN3K) and/or fructosamine-3-kinase-related protein (FN3K RP) expression.09-20-2012
20120237932METHODS AND MATERIALS FOR ASSESSING THE CIS/TRANS NATURE OF HUMANS HAVING CYP2C19*2 AND CYP2C19*17 ALLELES - This document provides methods and materials involved in determining if a human heterozygous for CYP2C19*2 and heterozygous for CYP2C19*17 contains one CYP2C19 allele with both CYP2C19*2 and CYP2C19*17 (e.g., a cis relationship) or contains one CYP2C19 allele with CYP2C19*2 and one CYP2C19 allele with CYP2C19*17 (e.g., a trans relationship).09-20-2012
20120237931IDENTIFICATION AND MONITORING OF CIRCULATING CANCER STEM CELLS - The present invention comprises a method of detecting circular tumor cells and methods of detecting, evaluating, or staging cancer in a patient, as well as a method of monitoring treatment of cancer in a patient using the claimed method. The method comprises contacting a sample with a ALDH1 binding agent; selecting the cells based on positive or negative ALDH1 staining; contacting the selected cells with a labeled nucleic acid probe, and detecting hybridized cells by fluorescence in situ hybridization; and analyzing a signal produced by the labels on the hybridized cells to detect the CTCs. In other embodiments, the method provides for directed to a method of determining the level of CTCs in a sample having blood cells from a patient by contacting a sample having blood cells from a patient, wherein the sample has not been pre-sorted into ALDH1-positive and ALDH1-negative cells.09-20-2012
20120237930METHOD OF ANALYZING CHROMOSOMAL TRANSLOCATIONS AND A SYSTEM THEREFORE - The present disclosure relates to systems and methods for analyzing chromosomal translocations, and in particular to analysis of chromosomal translocation by in situ hybridization.09-20-2012
20120237929LONG INTERSPERSED NUCLEAR ELEMENTS (LINE-1) AND ALU HYPOMETHYLATION AS BIOMARKERS FOR COLORECTAL CANCER METASTASIS - A method for determining a colorectal cancer metastasis in a human subject suffering from a primary colorectal cancer (CRC) is described herein. The method of the present invention comprises the steps of: i) identifying the human subject suffering from the primary CRC, ii) obtaining one or more biological samples from the human subject, iii) detecting a methylation level of Alu, LINE-1, or both in the one or more biological samples, and iv) increasing the level of the colorectal metastatic stage in the human subject when the methylation level of Alu, LINE-1 is lower compared to a corresponding control methylation level of Alu, LINE-1.09-20-2012
20120237928METHOD FOR DETERMINING COPY NUMBER VARIATIONS - The invention provides a method for determining copy number variations (CNV) of a sequence of interest in a test sample that comprises a mixture of nucleic acids that are known or are suspected to differ in the amount of one or more sequence of interest. The method comprises a statistical approach that accounts for accrued variability stemming from process-related, interchromosomal and inter-sequencing variability. The method is applicable to determining CNV of any fetal aneuploidy, and CNVs known or suspected to be associated with a variety of medical conditions. CNV that can be determined according to the method include trisomies and monosomies of any one or more of chromosomes 1-22, X and Y, other chromosomal polysomies, and deletions and/or duplications of segments of any one or more of the chromosomes, which can be detected by sequencing only once the nucleic acids of a test sample.09-20-2012
20120237927Method of Mapping of mRNA Distribution With Atomic Force Microscopy Comprising Dendron - The present invention relates to a method of mapping of mRNA distribution, comprising the steps of a preparing a probe DNA attached to a apical liner region of the dendron on AFM cantilever where the probe DNA can specifically hybridize a target mRNA and measuring specific adhesive force between the probe DNA and the target mRNA on sectioned tissue at nanometer resolution.09-20-2012
20120237926RAPID SCREENING OF BIOLOGICALLY ACTIVE NUCLEASES AND ISOLATION OF NUCLEASE-MODIFIED CELLS - Disclosed herein are methods and compositions for rapidly identifying active nucleases and cells having nuclease-mediated genomic modifications.09-20-2012
20120270220DETECTION OF NUCLEIC ACID SEQUENCE DIFFERENCES USING COUPLED LIGASE DETECTION AND POLYMERASE CHAIN REACTIONS - The present invention relates to a method for identifying a target nucleotide sequence. This method involves forming a ligation product on a target nucleotide sequence in a ligation detection reaction mixture, amplifying the ligation product to form an amplified ligation product in a polymerase chain reaction (PCR) mixture, detecting the amplified ligation product, and identifying the target nucleotide sequence. Such coupling of the ligase detection reaction and the polymerase chain reaction permits multiplex detection of nucleic acid sequence difference.10-25-2012
20120270217RESTRICTION ENDONUCLEASE ENHANCED POLYMORPHIC SEQUENCE DETECTION - Provided in part herein is an improved method for the detection of specific polymorphic alleles in a mixed DNA population. The method comprises enriching the relative percentage of a given polymorphic allele that is exponentially amplifiable by PCR. Provided also are methods for selectively enriching target nucleic acid, for example, fetal nucleic acid in a maternal sample. In the case of detecting fetal nucleic acid in a maternal sample, a restriction enzyme is introduced that can discriminate between the alleles of a polymorphic site. In some embodiments, the maternal allele is digested and nucleic acid comprising the paternal allele is relatively enriched.10-25-2012
20120244537Nanowire-Based System for Analysis of Nucleic Acids - System for detection and/or analysis of nucleic acids using nanowires to detect covalent modification of nucleic acids.09-27-2012
20110159493DIAGNOSTIC POLYMORPHISMS FOR CARDIAC DISEASE - One or more polymorphisms, including single nucleotide polymorphisms (SNPs), or combinations thereof, for diagnosis of cardiac disease, such as heart failure and atrial fibrillation.06-30-2011
20110183330Analysis for Nucleic Acids by Digital PCR - The present invention provides a method for analyzing nucleic acids for their lengths and relative abundance in a sample, based on digital amplification of individual template molecules. This invention has many applications, including those in noninvasive prenatal diagnosis, transplantation monitoring, and the detection and monitoring of cancers and virus-associated diseases.07-28-2011
20120322066Development of Novel Detergents for Use in PCR Systems - This disclosure relates to novel detergents for use in various procedures including, for example, nucleic acid amplification reactions such as polymerase chain reaction (PCR). Methods for preparing the modified detergents are also described.12-20-2012
20130017541Methods and Compositions for Segregating Target Nucleic Acid from Mixed Nucleic Acid Samples - The invention provides methods, compositions and kits for segregating a target nucleic acid from a mixed nucleic acid sample. The methods, compositions and kits comprise a non-processive endonuclease (e.g., a restriction enzyme) or an antibody that binds the target nucleic acid (e.g., has methylation specificity). The mixed nucleic acid sample can comprise prokaryotic and eukaryotic nucleic acid and/or nucleic acid from more than one prokaryotic or eukaryotic organisms.01-17-2013
20120088239Detection of Chromosomal Inversions - A method and a kit for the identification of chromosomal inversions are described. Chromosomal inversions are difficult to detect unless they are quite large. The improved ability to detect chromosomal inversions is important to a number of medical applications, such as cancer and birth defects, as examples. Reporter species are attached to oligonucleotide strands designed such that they may hybridize to portions of only one of a pair of single-stranded sister chromatids prepared by the CO-FISH procedure, as an example. If an inversion has occurred, these marker probes will be detected on the sister chromatid at the same location as the inversion on the first chromatid.04-12-2012
20110281266Identification of Nucleic Acids - This disclosure relates to methods for identifying target nucleic acids in a sample by detecting an amplified sequence corresponding to the target using a detectable probe and by monitoring its melting temperature (T11-17-2011
20110281267FUNCTIONALIZED MICROFLUIDIC DEVICE FOR IMMUNOFLUORESCENCE - It is described a microfluidic device, for use in the field of analytical fluorescence based assays and, in particular, in FISH assays.11-17-2011
20110281262DETECTION OF GERMS ASSOCIATED WITH PERIODONTITIS - The invention relates to a method for detecting and/or determining bacteria associated with periodontitis from a biological sample with at least one of the oligonucleotides SEQ ID No. 1 to SEQ ID No. 5 as well as a microfluidic device for detecting and/or determining at least one germ associated with periodontitis from a biological sample comprising a carrier consisting of at least one base part with a surface and at least one oligonucleotide bound to the carrier surface or nucleic acid molecule, in which the oligonucleotide represents at least one sequence of SEQ ID No. 1 to SEQ ID No. 5.11-17-2011
20110281265Primer set for amplifying UGT1A1 gene, reagent for amplifying UGT1A1 gene containing the same, and the uses thereof - Primer sets for amplifying target regions containing sites to be detected in the UGT1A1 gene by a gene amplification method are provided, wherein the primer sets can amplify the regions specifically Three pairs of primer sets are used including forward primers consisting of the base sequences of SEQ ID NOs: 4 or 81, 21, and 42 as well as reverse primers consisting of the base sequences of SEQ ID NOs: 13 or 91, 29 and 48, respectively. The use of these primer sets makes it possible to amplify three target regions including parts where three types of polymorphisms (UGT1A1*6, UGT1A1*27, and UGT1A1*28) of the UGT1A1 gene are generated, respectively, in the same reaction solution at the same time.11-17-2011
20110281263Compositions and Methods for Detection of Chromosomal Aberrations with Novel Hybridization Buffers - The present invention provides compositions and methods for the detection of nucleic acid sequences associated with chromosomal aberrations. The invention may, for example, eliminate the use of or reduce the dependence on formamide in hybridization. Compositions for use in the invention include an aqueous composition comprising at least one nucleic acid sequence and at least one polar aprotic solvent in an amount effective to denature double-stranded nucleotide sequences.11-17-2011
20110129835METHODS AND COMPOSITIONS FOR DETECTING METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS - Provided are methods of detecting the presence and/or amount of methicillin-resistant 06-02-2011
20120288858ASSESSING SMALL CELL LUNG CANCER OUTCOMES - This document provides methods and materials involved in assessing lung cancer (e.g., SCLC). For example, methods and materials for identifying a mammal having lung cancer (e.g., SCLC) as being susceptible to a poor outcome are provided.11-15-2012
20120288862KITS FOR QUANTITATIVE DETECTION OF K-RAS MUTATIONS - The present invention relates to an assay kit for quantitatively detecting k-ras gene mutations. Particularly, the present invention relates to detection method and a detection kit for K-ras gene mutations, which relates to the therapeutic efficacy of targeted molecular anti-cancer drugs. More particularly, the present invention relates to a fluorescent quantitative PCR method and kit for detecting mutations at hotspots of K-ras gene, together with the use thereof. The present invention detects the mutations at specific sites of K-ras gene, and can predict the therapeutic efficacy of anti-EGFR tyrosine kinase inhibitors. Therefore, it can provide a guidance to individualized treatments for cancer patients.11-15-2012
20120288860DIFFERENTIAL GENE EXPRESSION FOR DETECTING AND/OR DIFFERENTIATING LUNG DISEASE - Disclosed herein are methods, constructs, kits, and the like, which can be used for detecting and/or differentiating interstitial lung disease. For example, idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP) can be detected and/or differentiated using at least one biomarker.11-15-2012
20120288859Probe for Detecting Poly A Repeat Number Polymorphism of HGF Gene and Uses Thereof - The present disclosure relates to probes for detecting a polymorphism of HGF gene.11-15-2012
20110262919METHOD FOR PRETREATING SPECIMEN AND METHOD FOR ASSAYING BIOLOGICAL SUBSTANCE - On magnetic particles serving as a first support, an antibody against a nonspecific reaction factor is immobilized. These magnetic particles are mixed with a specimen and suspended therein. After suspending, the suspension is sucked up into a pipette chip and a magnet comes close to the pipette chip. While remotely constraining with the magnet the magnetic particles carrying the nonspecific reaction factor bonded thereto, the residual liquid is discharged into a well. Thus, the removal of a contaminant contained in the specimen is completed. The thus treated specimen discharged into the well is subjected to an immunoassay. The magnetic particles carrying the antibody immobilized thereon are mixed with the treated specimen and suspended therein. The suspension is sucked up into a pipette chip and the magnetic particles carrying an antigen bonded thereto are separated by use of the magnet. The magnetic particles carrying the antigen bonded thereto are washed, mixed with an enzyme-labeling solution, which contains a second support, and suspended therein. After suspending, the magnetic particles being labeled and carrying the antigen bonded thereto are mixed with a substrate solution and subjected to the measurement of emission intensity, etc.10-27-2011
20110262918IMPROVED NANOPARTICULATE COMPOSITIONS OF POORLY SOLUBLE COMPOUNDS - The present invention is related to a method for the quantification of one or more target ribonucleic acids in a sample comprising the steps of, (i) providing a sample comprising said one or more target ribonucleic acids, (ii) contacting said sample with a ribonucleic acid specific fluorescence dye under conditions allowing for binding of said dye to the one or more ribonucleic acids in said sample, (iii) measuring fluorescence of said RNA-bound dye in said sample, (iv) correlating said measured fluorescence to the total amount of RNA in the sample, (v) reverse transcribing said one or more ribonucleic acids, thereby creating double-stranded nucleic acids, (vi) amplifying said one or more created double-stranded nucleic acids, wherein one or more fluorescence probes specific for said one or more amplification products are present during and/or after amplification under conditions allowing for binding of said one or more probes to said one or more created double-stranded deoxyribonucleic acids in the sample, (vii) measuring fluorescence of said one or more probes bound to said one or more amplification products during and/or after the amplification reaction and correlating said measured fluorescence to the amount of target RNA sequence in the sample and (viii) normalizing the amount of target RNA sequence in the sample to the total amount of RNA in the sample.10-27-2011
20120288857MULTIFUNCTIONAL PROBE-PRIMERS - Methods and reagents for detection and analysis of nucleic acids are provided. Certain methods involves an encoding amplification in which a target sequence is associated with probe-binding sequences and optionally with indexing sequences, (2) an optional distribution step in which the product of the encoding amplification is split into multiple aliquots, and (3) a decoding and detection step in which the presence, absence, quantity, or relative amount of the target sequence in the aliquots is determined. The detection step makes use of a multifunctional “self-digesting” molecular probe comprising a primer polynucleotide and a probe oligonucleotide, linked in a 5′-5′ orientation.11-15-2012
20120288861GERMLINE POLYMORPHISMS IN THE SPARC GENE ASSOCIATED WITH CLINICAL OUTCOME IN GASTRIC CANCER - This disclosure provides compositions and methods for determining the likely tumor recurrence of gastric cancer patients based on genomic polymorphisms of the SPARC gene. The disclosure also provides compositions and methods for selecting gastric cancer patients for appropriate treatments and methods of treating them.11-15-2012
20130022977METHODS FOR DETECTING FETAL NUCLEIC ACIDS AND DIAGNOSING FETAL ABNORMALITIES - The invention generally relates to methods for detecting fetal nucleic acids and methods for diagnosing fetal abnormalities. In certain embodiments, the invention provides methods for determining whether fetal nucleic acid is present in a maternal sample including obtaining a maternal sample suspected to include fetal nucleic acids, and performing a sequencing reaction on the sample to determine presence of at least a portion of a Y chromosome in the sample, thereby determining that fetal nucleic acid is present in the sample. In other embodiments, the invention provides methods for quantitative or qualitative analysis to detect fetal nucleic acid in a maternal sample, regardless of the ability to detect the Y chromosome, particularly for samples including normal nucleic acids from a female fetus.01-24-2013
20130022976HYPERTHERMOSTABLE ENDONUCLEASE IV SUBSTRATE PROBE - The present invention relates to a hyperthermostable endonuclease IV substrate probe to be used in nucleic acid assay methods which can be carried out using hyperthermostable enzymes, including detection of target nucleic acids, and detection of nucleic acid polymorphism.01-24-2013
20130022975METHOD FOR DETECTING ARTERIOSCLEROTIC DISEASES ON THE BASIS OF SINGLE NUCLEOTIDE POLYMORPHISM AT HUMAN CHROMOSOME 5P15.3 - An atherosclerotic disease such as myocardial infarction or angina pectoris is detected by analyzing a single nucleotide polymorphism on human chromosome 5p15.3, and by associating results of the analysis with the risk of the onset thereof. Examples of the single nucleotide polymorphism on human chromosome 5p15.3 include a nucleotide corresponding to the nucleotide at position 61 in the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, and a polymorphism at a nucleotide which is in linkage disequilibrium with the above nucleotide.01-24-2013
20110300538BIFIDOBACTERIA CRISPR SEQUENCES - The invention relates to CRISPR sequences found in bifidobacteria and their uses.12-08-2011
20130022974DNA METHYLATION PROFILES IN CANCER - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to methylation levels of genes (e.g., in CGI islands of the promoter regions) as diagnostic markers and clinical targets for prostate cancer.01-24-2013
20130022973Multiplex Amplification for the Detection of Nucleic Acid Variations - Kits, primers, and methods are provided herein for detecting relative target source to reference source ratios in a biological sample, by distributing the biological sample into discrete subsamples, wherein the biological sample includes, a plurality of target molecules on a target source; and a plurality of reference molecules on a reference source; providing target primers directed to one or more of the plurality of target molecules and reference primers directed to one or more of the plurality of reference molecules; performing digital amplification with the target primers and the reference primers; and detecting the presence or absence of amplified target products with target probes and detecting the presence or absence of amplified reference products with reference probes, wherein the ratio of amplified target products to amplified reference products is indicative of a relative amount of target source to reference source in a biological sample.01-24-2013
20130022972OLIGONUCLEOTIDES AND METHODS FOR DETECTING LAVENDER FOAL SYNDROME - A method for detecting a genetic polymorphism associated with Lavender Foal Syndrome or a predisposition thereto in a subject, the method including screening a genomic material sample from the subject for the presence of at least one polymorphism in a MYO5A gene.01-24-2013
20130022971NON-THIOPURINE METHYLTRANSFERASE RELATED EFFECTS IN 6-MERCAPTOPURINE THERAPY - The present invention provides methods for predicting tolerance associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. In particular, the present invention provides methods for predicting a patient's risk of an adverse drug reaction (or tolerance) to a 6-mercaptopurine drug by genotyping a patient at a polymorphic site in at least one gene selected from the group consisting of a xanthine dehydrogenase (XDH) gene, molybdenum cofactor sulfurase (MOCOS) gene, and aldehyde oxidase (AOX) gene. The present invention further provides methods for optimizing therapeutic efficacy in a patient receiving a 6-mercaptopurine drug by determining whether the patient should be given an alternative drug based on the presence or absence of a polymorphism in at least one of the XDH, MOCOS, and AOX genes.01-24-2013
20130022970Methods Of Classifying Biological Samples For Predicting Response To Tyrosine Kinase Inhibitor Treatment - Gene copy numbers of signaling components downstream of EGFR identify non-small cell lung cancer (NSCLC) patients with poor outcomes on 2nd/3rd line gefitinib therapy.01-24-2013
20110136115METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL PROLIFERATIVE DISORDERS - The invention provides methods, nucleic acids and kits for detecting prostate cell proliferative disorders. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of said disorder, thereby enabling the improved diagnosis and treatment of patients.06-09-2011
20110318732PREDICTION OF CHEMOTHERAPEUTIC RESPONSE VIA SINGLE-CELL PROFILING OF TRANSCRIPTION SITE ACTIVATION - The present invention generally relates to methods for determining tumor resistance or sensitivity to chemotherapeutic agents and the likelihood of tumor reoccurrence based on the expression levels of genes known to correlate to the chemotherapeutic agent. In particular, the expression levels of TYMS, MRGX, ATP7B and/or BAK in tumor cells, as measured by the number of active transcription sites detected by fluorescence in situ hybridization (FISH), are predictive of resistance and sensitivity to chemotherapy and the likelihood of reoccurrence following chemotherapy treatment.12-29-2011
20120003646METHOD AND APPARATUS FOR IDENTIFYING ANALYTE-CONTAINING SAMPLES USING SINGLE-READ DETERMINATION OF ANALYTE AND PROCESS CONTROL SIGNALS - Apparatus and method for detecting analyte in a reaction mixture comprising an internal control. The invention is illustrated using amplification and detection of nucleic acids, where the amplification reaction comprises an exogenous internal control. Magnitude of the detection signal serves as the variable for identifying invalid trials, identifying valid trials that are negative for analyte, and identifying trials that are positive for analyte. Detection of a signal indicating probe hybridization can be used for assigning the presence or absence of analyte nucleic acid in validated reactions using only a single detectable label, and without distinguishing the proportion of signal contributed by internal control probe binding, and analyte probe binding.01-05-2012
20120003635DIAGNOSING FETAL CHROMOSOMAL ANEUPLOIDY USING MASSIVELY PARALLEL GENOMIC SEQUENCING - Embodiments of this invention provide methods, systems, and apparatus for determining whether a fetal chromosomal aneuploidy exists from a biological sample obtained from a pregnant female. Nucleic acid molecules of the biological sample are sequenced, such that a fraction of the genome is sequenced. Respective amounts of a clinically-relevant chromosome and of background chromosomes are determined from results of the sequencing. The determination of the relative amounts may count sequences of only certain length. A parameter derived from these amounts (e.g. a ratio) is compared to one or more cutoff values, thereby determining a classification of whether a fetal chromosomal aneuploidy exists. Prior to sequencing, the biological sample may be enriched for DNA fragments of a particular sizes.01-05-2012
20120107820Multiplexed Quantitative PCR End Point Analysis of Nucleic Acid Targets - Certain embodiments of the present invention are directed to one pot multiplexed quantitative PCR methods for end point analysis of a plurality of nucleic acid targets in a complex sample without user intervention, and to various encoded particles on which are immobilized one or more probes that hybridize with the plurality of targets. Certain other embodiments are directed to a new “multiple-color genetic variation detection method” that can detect SNPs and kit using one chamber multiplexed endpoint PCR and differentially labeled allele-specific primers (one recognizing only the wild type allele and one only the mutant allele).05-03-2012
20120107813QUANTIFICATION OF NUCLEIC ACIDS - The invention relates to a method for the quantification of one or more nucleic acids in a sample. The method comprises the following steps: making a sample available which contains at least one nucleic acid to be quantified, adding an oligonucleotide probe to the sample, the oligonucleotide probe comprising a sequence which can specifically hybridize to the nucleic acid to be quantified or to a common sequence of the nucleic acids to be quantified, incubating the sample under conditions which allow the hybridization of the oligonucleotide probe to the nucleic acid(s) to be quantified, incubating the sample under conditions which allow the extension of hybridized probes, the nucleic acid(s) serving as a template in each case, removing the non-hybridized probes from the sample and quantifying the hybridized oligonucleotide probes to measure the quantity of the nucleic acid(s) to be quantified. The invention also relates to a kit for carrying out said method.05-03-2012
20120107811BURSTABLE LIQUID PACKAGING AND USES THEREOF - The present invention relates to systems, devices, and methods for performing biological and chemical reactions. In particular, the present invention relates to the use of burstable liquid packaging for delivery of reagents to biological and chemical assays.05-03-2012
20120107807Highly sensitive method for the detection of cytosine methylation patterns - The present invention concerns a method for the detection of cytosine methylation in DNA samples, wherein the following steps are conducted: (a) a genomic DNA sample, which comprises the DNA to be investigated and background DNA, is chemically treated in such a way that all of the unmethylated cytosine bases are converted to uracil, whereas the 5-methylcytosine bases remain unchanged; (b) the chemically treated DNA sample is amplified with the use of at least 1 primer oligonucleotide as well as a polymerase, whereby the DNA to be investigated is preferred as the template over the background DNA, and (c) the amplified products are analyzed and the methylation status in the DNA to be investigated is concluded from the presence of an amplified product and/or from the analysis of additional positions.05-03-2012
20110300536GENE MARKER AND METHOD FOR DETECTION OF ORAL CANCER - A gene marker for the detection of oral cancer, comprising methylated CpG sites in target genes, is provided. The CpG sites in the target genes are selected from a group consisting of the following CpG sites: FLT4_E206_F, ASCL1_E24_F, KDR_E79_F, TFPI2_P9_F, TERT_E20_F, ADCYAP1_P455_R, MT1A_P49_R, and combinations thereof. A method for the detection of oral cancer, comprising the following steps is also provided: a) providing a sample to be examined from an individual; b) detecting a methylation state of at least one CpG site in a target gene on the genomic DNA from cells of the sample, wherein the CpG site in the target gene is selected from a group consisting of the following CpG sites: FLT4_E206_F, ASCL1_E24_F, KDR_E79_F, TFPI2_P9_F, TERT_E20_F, ADCYAP1_P12-08-2011
20110300540METHODS AND PROBE COMBINATIONS FOR DETECTING MELANOMA - The present invention is based on the discovery of methods and combinations of probes to chromosomal regions that are gained or lost or imbalanced in melanoma that provide highly specific and sensitive assays for the detection of melanoma cells.12-08-2011
20110300539Method for Detecting Polymorphism at Nucleotide Position -1639 of VKORC1 Gene, and Nucleic Acid Probe and Kit Therefor - A probe for detecting a polymorphism at position −1639 of the VKORC1 gene, the probe comprising an oligonucleotide having a nucleotide sequence having a length of 10 to 50 nucleotides, which nucleotide sequence comprises the nucleotides 80 to 89 of SEQ ID NO:1 or 2 and has a homology to SEQ ID NO:1 or 2 except that the nucleotide corresponding to the nucleotide at position 80 in SEQ ID NO:1 or 2 is cytosine, which nucleotide corresponding to the nucleotide at position 80 is labeled with a fluorescent dye.12-08-2011
20110300537METHODS OF DETECTING SEQUENCE DIFFERENCES - The invention relates to methods of genotyping single nucleotide differences in a nucleic acid sample. More particularly, the invention provides methods of identifying the nucleotide at a polymorphic site or a group of polymorphic sites in a sample of genomic DNA. The method uses tagged primer extension in which a set of tag sequences correspond to the identity of the nucleotides at the polymorphic sites. Primer extension products are PCR amplified using a common set of tag-specific primers, the downstream primers bearing distinguishable labels. Following separation by size and/or charge, the detection of distinguishable label in a product of the anticipated size determines the identity of the nucleotide at the polymorphic site. The method is well-suited for the genotyping of multiple single-nucleotide differences in one series of reactions.12-08-2011
20110300535METHOD OF IDENTIFYING INDIVIDUALS AT RISK OF THIOPURINE DRUG RESISTANCE AND INTOLERANCE - The invention relates to methods and kits for identifying individuals at risk of thiopurine drug intolerance based on detecting the presence of mutations in the TPMT gene promoter associated with thiopurine drug resistance or intolerance.12-08-2011
20110287428NEISSERIA GONORRHOEAE DETECTION - A method for determining whether a human individual is or has been infected with 11-24-2011
20110287416METHYLATION DETECTION - A real-time method of detecting the presence and/or amount of a methylated or unmethylated gene of interest in a DNA-containing sample, comprises the steps of: (a) contacting the DNA-containing sample with a reagent which selectively modifies unmethylated cytosine residues in the DNA to produce detectable modified residues but which does not modify methylated cytosine residues (b) amplifying at least a portion of the methylated or unmethylated gene of interest using at least one primer pair, at least one primer of which is designed to bind only to the sequence of methylated or unmethylated DNA following treatment with the reagent, wherein at least one primer in the primer pair is a primer containing a step loop structure carrying a donor and an acceptor moiety of a molecular energy transfer pair arranged such that in the absence of amplification, the acceptor moiety quenches fluorescence emitted by the donor moiety upon excitation and during amplification, the stem loop structure is disrupted so as to separate the donor and acceptor moieties sufficiently to produce a detectable fluorescence signal which is detected in real-time to provide an indication of the gene copy number of the methylated or unmethylated gene of interest (c) quantifying the results of the real-time detection against a standard curve for the methylated or unmethylated gene of interest to produce an output of gene copy number. The method may be characterized in that the amplification is considered valid where the cycle threshold value is less than (40). Alternatively the method, which may be carried out in real-time or at end point, is characterized in that the portion of the gene which is amplified is between approximately (50) and 250 bp, especially for plasma and serum samples.11-24-2011
201102874273'OH-UNBLOCKED, NUCLEOTIDES AND NUCLEOSIDES BASE MODIFIED WITH LABELS AND PHOTOCLEAVABLE, TERMINATING GROUPS AND METHODS FOR THEIR USE IN DNA SEQUENCING - Provided are novel nucleotides, nucleoside, and their derivatives described herein, that can be used in DNA sequencing technology and other types of DNA analysis. In one embodiment, the nucleotide or nucleoside with an unprotected 3′-OH group is derivatized at the nucleobase to include a fluorescent dye attached via a linker to a photocleavable terminating group. The photocleavable-fluorescent group is designed to terminate DNA synthesis as well as be cleaved so that DNA oligomers can be sequenced efficiently in a parallel format. The design of such rapidly cleavable fluorescent groups on nucleotides and nucleosides can enhance the speed and accuracy of sequencing of large oligomers of DNA in parallel, to allow rapid whole genome sequencing, and the identification of polymorphisms and other valuable genetic information, as well as allowing further manipulation and analysis of nucleic acid molecules in their native state following cleavage of the fluorescent group.11-24-2011
20110287426Apparatus and Methods for Analyzing Samples - The present invention relates to apparatus, systems, and methods for analyzing biological samples. The apparatus, systems, and methods can involve using a vacuum source to pull microfluidic volumes through analytical equipment, such as flow cells and the like. Additionally, the invention involves using optical equipment in conjunction with the analytical equipment to analyze samples and control the operation thereof.11-24-2011
20110287425Assays to Detect Small-Scale Mutations in Individual Cells - Methods, compositions, and assays are described which are useful in identifying point mutations, identifying cancer cells, and diagnosing cancer.11-24-2011
20110287424METHYLATION-SPECIFIC COMPETITIVE ALLELE-SPECIFIC TAQMAN POLYMERASE CHAIN REACTION (CAST-PCR) - In some embodiments, the present inventions relates generally to compositions, methods and kits for use in discriminating between different methylated and/or unmethylated nucleic acid loci. In certain embodiments, the inventions provides for detecting or quantitating undifferentiated embryonic stem cells in a population of differentiated cells. The invention is also useful for discriminating between fetal versus maternal cells, or healthy versus infected cells, or normal versus cancerous cells, or detecting reduction in viral load or measuring therapeutic efficiency in a patient, and more.11-24-2011
20110287423DIAGNOSIS OF VIRAL INFECTIONS BY DETECTION OF GENOMIC AND INFECTIOUS VIRAL DNA BY MOLECULAR COMBING - A method for detecting in vitro the presence of a genome of a DNA virus or a viral derived DNA in an infected eukaryotic cell, tissue or biological fluid using Molecular Combing or other nucleic acid stretching methods together with probes, especially nucleic acid probes, having a special design. A method for monitoring in vitro the effects of anti-viral treatment by following the presence of genomic viral or viral derived DNA polynucleotides in a virus-infected cell, tissue or biological fluid. Detection of an infectious form of a virus using Molecular Combing and DNA hybridization. A kit comprising probes used to carry out these methods and a composition comprising the probes.11-24-2011
20110287414Systems and methods for identifying a portion of a molecule - Techniques for identifying a portion of a molecule are described herein. In one example, multiple electrical measurements associated with a molecule are acquired, wherein each of the multiple electrical measurements corresponds to a discrete position of the molecule within a nanopore. The multiple electrical measurements are correlated with one or more sequences of electrical measurements corresponding to a possible structure of the molecule. The portion of molecule is determined to include the possible structure of the molecule based on the correlation.11-24-2011
20110287422NUCLEIC ACID PROBES AND METHODS FOR DETECTING PLASMODIUM PARASITES - This invention relates to novel nucleic acid probes and methods for detecting 11-24-2011
20110287421Probes for Detection of NAT2 Gene, Reagent Containing the Same, and The Uses Thereof - Primer sets for amplifying target regions containing sites to be detected in the NAT2 gene by a gene amplification method are provided, wherein the primer sets can amplify the regions specifically. Three pairs of primer sets are used including forward primers consisting of the base sequences of SEQ ID NOs: 7, 33, and 60 as well as reverse primers consisting of the base sequences of SEQ ID NOs: 18, 48 and 81, respectively. The use of these primer sets makes it possible to amplify three target regions including parts where three types of polymorphisms (NAT2*5, NAT2*6, and NAT2*7) of the NAT2 gene are generated, respectively, in the same reaction solution at the same time.11-24-2011
20110287420Compositions for diagnosis and therapy of diseases associated with aberrant expression of kremen and/or WNT - The present invention relates to a composition useful for the diagnosis and therapy of diseases associated with aberrant expression of the gene encoding the receptor Kremen 1 and/or Kremen 2 e.g. tumors or diseases of the kidneys, bones and eyes, lipid and glucose metabolism and obesity. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Kremen 1 and/or Kremen 2 or (b) the activity of the Kremen 1 and/or Kremen 2 receptor.11-24-2011
20110287419Method For Genetic Analysis Of DNA To Detect Sequence Variances - Methods for determining genotypes and haplotypes of genes are described. Also described are single nucleotide polymorphisms and haplotypes in the ApoE gene and methods of using that information.11-24-2011
20110287418Compositions and Methods for Diagnosis and Treatment of Epilepsy - Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1, EFHC1 agonists, or EFHC1 analogs are provided. Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC111-24-2011
20110143342NEW FETAL METHYLATION MARKERS - This application describes the discovery that, in a pregnant woman, certain genes (such as RASSF1A, APC, CASP8, RARB, SCGB3A1, DAB2IP, PTPN6, THY1, TMEFF2, and PYCARD) originated from a fetus are highly methylated, whereas the same genes of maternal origin are unmethylated. This discovery allows the easy detection of one or more of these methylated fetal genes in a biological sample from a pregnant woman, serving as a universal indicator of the presence of fetal DNA in the sample. These fetal methylation markers are particularly useful as positive controls for a non-invasive analytical process during which the quality and quantity of fetal DNA are monitored. These newly identified fetal markers can also be measured directly for diagnosis of certain pregnancy-related conditions.06-16-2011
20110143349METHODS AND COMPOSITIONS FOR DETECTING BK VIRUS - The invention provides methods and compositions for rapid, sensitive, and highly specific nucleic acid-based (e.g., DNA based) detection of a BK virus in a sample. In general, the methods involve detecting a target nucleic acid having a target sequence of a conserved region of BK viral genomes. The invention also features compositions, including primers, probes, and kits, for use in the methods of the invention.06-16-2011
20110143348METHOD FOR QUANTIFYING OR DETECTING DNA - The present invention relates to a method for quantifying or detecting DNA having a target DNA region, and so on.06-16-2011
20110143344GENETIC POLYMORPHISMS AND SUBSTANCE DEPENDENCE - The invention encompasses methods for identifying subjects at risk for substance dependence by detecting the presence of polymorphism in the CHRNA5-CHRNA3-CHRNB4 gene cluster and the CHRNA4 gene. The invention also encompasses determining the response of a subject to a therapeutic substance, treating substance dependence in a subject, and evaluating the response of a subject to a substance cessation treatment.06-16-2011
20110294126KITS AND METHODS FOR ASSESSING OXIDATIVE STRESS - The invention relates to kits and methods for assessing the susceptibility of a human to oxidative stress or damage. The methods involve assessing occurrence in the human's genome of one or more polymorphisms (e.g., single nucleotide polymorphisms) that occur in one or more genes associated with oxidative stress and that are associated with a disorder in humans. Preferred assessment and scoring methods are disclosed, as are kit for performing the methods.12-01-2011
20110294123METHODS FOR DIAGNOSING OR TREATING PROSTATE CANCER - The present invention provides methods for detecting and/or diagnosing cancer through the determination of the expression level of the STC2 gene. The gene was discovered to discriminate cancer cells from normal cells. Furthermore, the present invention provides methods of screening for therapeutic agents useful in the treatment of cancer, methods for treating cancer. Moreover, the present invention provides double-stranded molecules targeting the STC2 gene, which are suggested to be useful in the treatment of cancer. The compositions and methods of the present invention find particular applicability to prostate cancer, more specifically, castration-resistant prostate cancer and aggressive prostate cancer.12-01-2011
20110294125COLORIMETRIC BIOSENSOR WITH ALLOSTERIC DNAZYME ACTIVATION AND ROLLING CIRCLE SIGNAL AMPLIFICATION - The present disclosure includes a method of determining the presence of a target in a sample comprising an allosteric DNAzyme; rolling circle amplification dependent on the activity of the allosteric DNAzyme in the presence of target and a detection system. The methods further comprise quantifying the amount of target in the sample by comparing the detection with a control. Also included herein are kits for practicing the methods described herein and methods of designing biosensor systems.12-01-2011
20110294124METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS - Described herein are methods of syntheses of phosphorous atom-modified nucleic acids comprising chiral X-phosphonate moieties. The methods described herein provide backbone-modified nucleic acids in high diasteteomeric purity via an asymmetric reaction of an achiral molecule comprising a chemically stable H-phophonate moiety with a nucleoside/nucleotide.12-01-2011
20110294121METHODS AND COMPOSITIONS FOR PROGNOSING, DETECTING, AND TREATING AGE-RELATED MACULAR DEGENERATION - The invention provides methods and compositions for determining whether a subject is at risk of developing age-related macular degeneration, for example, the wet or neovascular form of age-related macular degeneration. The method involves determining whether the subject has a protective variant and/or a risk variant at a polymorphic site in the HTRA1 gene. In addition, the invention provides a method of treating or slowing the progression of age-related macular degeneration by reducing the expression of the HTRA1 gene, or reducing the biological activity of the HTRA1 gene product.12-01-2011
20110294120Probes for Detection of SULT1A1 Gene, Reagent Containing the Same, and the Uses Thereof - A primer set for amplifying a region including sites to be detected of SULT1A1*2 and SULT1A1*3 in the SULT1A1 gene by a gene amplification method is provided, wherein the primer set can amplify the region specifically. A pair of primer set is used including a forward primer consisting of the base sequence of SEQ ID NO: 7 as well as a reverse primer consisting of the base sequence of SEQ ID NO: 18. The use of this primer set makes it possible to specifically and efficiently amplify a region including both sites where two types of polymorphisms (SULT1A1*2 and SULT1A1*3) of the SULT1A1 gene are generated.12-01-2011
20110294119NOVEL METHODS OF DIFFERENTIATING YEAST STRAINS AND/OR DETERMINING GENETIC STABILITY OF YEAST STRAINS, AND USES THEREOF - The invention relates to a method of determining the strain or strains of yeast in a sample, comprising: obtaining and screening nucleic acid from yeast for target sequences comprises all or part of a gene, or a flanking region associated with a gene, in the yeast mitochondrial DNA; and determining from the results of the screen the yeast strain or strains in the sample. Also provided is a method of determining the genetic stability of a yeast strain in a sample, wherein one target sequences in the nucleic acid comprises all or part of a gene, or a flanking region associated with a gene, in the yeast mitochondrial DNA or all or part of a gene, or a flanking region associated with a gene, located in the subtelomeric region of a chromosome; and determining from the results of the screen if the yeast strain is genetically stable.12-01-2011
20110207122METHOD FOR DETERMINATION OF PROGRESSION RISK OF GLAUCOMA - A method of determining the presence or the absence of a glaucoma risk, including the steps of detecting in vitro an allele and/or a genotype of a single nucleotide polymorphism which is located on a 31st base of a base sequence, in a sample from a subject, wherein the base sequence is at least one base sequence selected from the group consisting of base sequences shown in SEQ ID NOs: 203 to 752 or a complementary sequence thereto (step A), and comparing the allele and/or the genotype detected in the step A with at least one of an allele and/or a genotype, containing a high-risk allele, in the base sequences shown in SEQ ID NOs: 203 to 752 (step B). According to the method of the present invention, the level of a progressive risk of glaucoma in a sample donor can be determined by analyzing an allele or a genotype of a single nucleotide polymorphism in the present invention in the sample, so that the sample donor can take a preventive measure of glaucoma, or can receive appropriate treatments, on the basis of this risk.08-25-2011
20110269123MARKER FOR GASTRIC CANCER AND METHOD FOR DETECTING GASTRIC CANCER - In embodiments the expression or methylation of the PAX5 gene is used as a marker for the diagnosis and prognosis of gastric cancer. In further embodiments methods for detecting gastric cancer are disclosed as are methods for inhibiting the growth of gastric cancer.11-03-2011
20120190024METHOD FOR DETERMINING PRESENCE OR ABSENCE OF EPITHELIAL CANCER-ORIGIN CELL IN BIOLOGICAL SAMPLE, AND MOLECULAR MARKER AND KIT THEREFOR - The present invention provides a method for determination of presence or absence of an epithelial cancer-derived cell in a biological sample obtained from a subject comprising the steps of: extracting DNA from the biological sample, analyzing methylation status of a CpG site located in at least one region represented by base sequences SEQ ID NOs: 1, 2, 3 and 4 in the DNA obtained from the step of extracting, and determining presence or absence of the epithelial cancer-derived cell in the biological sample based on an analysis result obtained from the step of analyzing.07-26-2012
20110217708METHODS AND COMPOSITIONS FOR DETECTING COLON CANCERS - This application describes methods and compositions for detecting and treating vimentin-associated neoplasia. Differential methylation of the vimentin nucleotide sequences has been observed in vimentin-associated neoplasia such as colon neoplasia.09-08-2011
20110217707EVALUATION/SCREENING METHOD FOR DISEASES ASSOCIATED WITH D-AMINO ACID UTILIZING DA01-/-MOUSE - Disclosed is an evaluation method which can rapidly discriminate a Dao09-08-2011
20110217705METHODS AND COMPOSITIONS FOR SEQUENCE-SPECIFIC PURIFICATION AND MULTIPLEX ANALYSIS OF NUCLEIC ACIDS - Methods and materials for determining the presence of at least one nucleic acid in a sample are provided, said methods comprising (1) a purification step using sequence specific hybrid capture; (2) an amplification step; and (3) a detection step using two separate sequence-specific polynucleotide probes. Also provided are nucleic acids comprising SEQ ID NO: 1 to SEQ ID NO: 727 and nucleic acid probes and probe sets comprising the same.09-08-2011
20110217704LEPA/GUF1 GENE SEQUENCES AS A DIAGNOSTIC TARGET FOR THE IDENTIFICATION OF BACTERIAL SPECIES - The current invention relates to a diagnostic kit for a bacterial species and/or fungal and/or yeast species comprising at least one oligonucleotide probe capable of binding to at least a portion of the LepA and/or Guf1 genes or its corresponding mRNA.09-08-2011
20110217703P2/P2A/P2B GENE SEQUENCES AS DIAGNOSTIC TARGETS FOR THE IDENTIFICATION OF FUNGAL AND YEAST SPECIES - The present invention relates to nucleic acid primers and probes to detect one or more fungal and yeast species. More specifically the invention relates to the P2, P2A and P2B gene sequences (also known as 60S acidic ribosomal protein P2, RLA-2-ASPFU, Allergen ASP f8 or Afp2), the corresponding RNA, specific probes, primers and oligonucleotides related thereto and their use in diagnostic assays to detect and/or discriminate fungal and yeast species.09-08-2011
20110217701Prognostic Marker for Endometrial Carcinoma - The present invention relates to a method for diagnosis of different stages of endometrial cancer in an individual. Further, the present invention relates to a method for evaluating the probability of survival for an individual suffering from endometrial carcinoma. In another aspect, the present invention relates to the stratification of therapy regimen of endometrial tumor, ovarian cancer, breast cancer, non-small lung cancer or hormone refractory prostate cancer therapy in an individual or monitoring therapeutic efficacy in an individual suffering from the same based on the expression status of STMN1 gene or protein. Moreover, the present invention relates to a kit for use in any of the above referenced methods comprising a means for determining amplifications and deletions of chromosomal regions 3q26.32 and 12p12.1, determining alterations of the gene expression profile of the genes (gene signature): upregulation of the genes PLEKHK1, ATP10B, NMU, MMP1, ATAD2, NETO2, TNNI3, PHLDA2, OVOL1 and down-regulation of the genes: NDP, KIAA1434, MME, CFH, MOXD1, SLC47A1, RBP1, PDE8B, ASRGL1, ADAMTS19, EFHD1, ABCA5, NPAS3, SCML1, TNXB, ENTPD3, AMY1A, ENPP, RASL11B, PDZK3, or the expression status of the STMN1 gene or protein, respectively. Finally, the present invention provides a method for predicting the response to taxanes in an individual suffering from a disease treated with the taxanes based on the expression status of the STMN1 gene or protein.09-08-2011
20110217706GENE METHYLATION IN CANCER DIAGNOSIS - DNA biomarker sequences that are differentially methylated in samples from normal individuals and individuals with cancer are provided Additionally, methods of identifying differentially methylated DNA biomarker sequences and their use for the detection and diagnosis of cancer are provided.09-08-2011
20110195414Method and Markers for Determining the Genotype of Horned/Polled Cattle - Provided herein are methods to discover and use single nucleotide polymorphisms (SNP) for determining the genotype of a horned/polled ruminant subject. The present invention further provides specific nucleic acid sequences, SNPs, and SNP patterns that can be used for determining the genotype of a horned/polled ruminant subject.08-11-2011
20130189687METHOD FOR MEASURING PYROPHOSPHORIC ACID AND SNP TYPING METHOD - One general aspect provides a method for detecting pyrophosphoric acid in a sample solution with high sensitivity and high accuracy by a small sensor element, and an SNP typing method. In the general aspect, a sample solution having a volume of more than that of a measurement cavity is supplied to the measurement cavity through a flow path, so as to expose a droplet from the opening. The droplet has a shape of sphere. The shape of the sphere is maintained by surface tension generated on a surface of the droplet. At least part of the sample solution contained in the droplet is evaporated so as to increase a concentration of pyrophosphoric acid in the sample solution included in the measurement cavity.07-25-2013
20130189685Method for Improved Diagnosis of Dysplasias - The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK4a gene products and at least one marker for cell proliferation. Particularly the present invention provides a method for discriminating dysplastic cells over-expressing INK4a gene products from cells over-expressing INK4a gene products without being dysplastic by detection of a marker suitable for characterising the proliferation properties of the respective cell. The characterisation of the proliferation properties may comprise the detection of a marker or a set of markers characteristic for active cell proliferation and/or a marker or a set of markers characteristic for retarded or ceased cell proliferation. The method presented herein thus enables for a specific diagnosis of dysplasias in histological and cytological specimens.07-25-2013
20130189686Method for Improved Diagnosis of Dysplasias - The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK07-25-2013
20110171648METHOD OF DETECTING AND QUANTIFYING HEPATITIS C VIRUS - Methods, reagents, and kits for detecting hepatitis C virus (HCV) in biological samples.07-14-2011
20110171640Method for isolating cell free apoptotic or fetal nucleic acids - The present invention provides methods for isolating cell free nucleic acid, e.g., apoptotic or fetal nucleic acids and methods of detecting neoplastic cells or identifying the genetic composition of a fetus. The invention also provides magnetic particles comprising an anti-DNA antibody, and kits comprising the magnetic particles.07-14-2011
20110262917MODIFIED NUCLEOTIDES - Modified nucleotides, and methods to modify nucleotides with a moiety or label, such as biotin, that permits their detection and results in a modified nucleotide, and methods of use of the modified nucleotide in quantitative and qualitative assays.10-27-2011
20110262910MARKER FOR COLON CANCER AND METHOD FOR DETECTING COLON CANCER - In embodiments the expression or methylation of the TBX5 gene is used as a marker for the presence and prognosis of colon cancer. In further embodiments methods for detecting colon cancer are disclosed as are methods for inhibiting the growth of colon cancer cells.10-27-2011
20110262908ISOLATION OF PROTEIN FACTORS THAT ASSOCIATE DIRECTLY OR INDIRECTLY WITH NUCLEIC ACIDS - Methods for isolating polypeptides and polypeptide complexes that are associated with a target nucleic acid sequence are provided. The methods comprise the steps of obtaining a sample that comprises a target nucleic acid sequence and one or more polypeptides or proteins associated with that target nucleic acid sequence; contacting the sample with at least one oligonucleotide probe that comprises a sequence that is complimentary to and capable of hybridising with at least a portion of the target nucleic acid sequence, wherein the oligonucleotide probe comprises at least one locked nucleic acid (LNA) nucleotide and wherein the oligonucleotide probe further comprises at least one affinity label (e.g. biotin); allowing the at least one oligonucleotide probe and the target nucleic acid sequence to hybridise with each other so as to form a probe-target hybrid; isolating the probe-target hybrid from the sample by immobilizing the probe-target hybrid through a molecule that binds to the at least one affinity label (e.g. using streptavidin-coated magnetic beads); and eluting the one or more polypeptides that are associated with the target nucleic acid sequence. Probes (e.g. with long spacer) for use in the methods of screening are also provided.10-27-2011
20110171639POLYMER FOR DETECTION OF TARGET SUBSTANCE, AND METHOD FOR DETECTION OF TARGET SUBSTANCE - Provided is a method of detecting a target substance by which the target substance can be detected with efficiency and a high sensitivity, and in a simple manner, a target substance detection polymer used in the method, and a method of forming the polymer. The method of detecting a target substance includes the steps of: (A) forming a target substance detection polymer by causing multiple kinds of nucleic acid probes for forming a polymer to react with a binding probe having a region capable of binding to the target substance and a region capable of binding to at least one of the nucleic acid probes in a solution; (B) binding the target substance detection polymer and the target substance; and (C) detecting the target substance detection polymer to which the target substance is bound.07-14-2011
20110151452DETECTION OF STAPHYLOCOCCUS AUREUS AND IDENTIFICATION OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS - Aspects of the present invention relate to methods and compositions for the detection and/or quantification of 06-23-2011
201201220875-Hydroxymethylcytosine as a biomarker for early detection, treatment and prognostic monitoring of cancer - The present invention is related to the use of 5-hydroxymethylcytosine or a biomolecule having general structure of 5-hydroxymethycytosine as a biomarker for the detection, treatment monitoring, and prognostic prediction of cancer.05-17-2012
20110123995TREATMENT OF DISEASE - The invention relates to the use of angiogenin, or a fragment or variant thereof, to treat diseases or conditions characterised by neuronal injury or death, or axonal degeneration, especially neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). The invention also describes a plurality of mutations of the human angiogenin gene which are associated with a neurodegenerative disease phenotype, and particularly a ALS phenotype. Also described is a method of assessing whether an individual is afflicted with, or generically predisposed to develop, a disease or condition characterised by neuronal injury or death, or axonal degeneration.05-26-2011
20120141987METHOD AND PROBES FOR THE DETECTION OF CANCER - Probe sets and methods of using probes and probe sets for the detection of cancer are described. Methods for detecting cancer that include hybridizing a set of chromosomal probes to a biological sample obtained from a patient, and identifying if cancer cells are present the sample. Also included are methods of selecting a combination of probes for the detection of cancer.06-07-2012
20110183331RNA IN SITU HYBRIDIZATION - Disclosed is a method for identifying the presence of a target gene mRNA, which comprises hybridizing one or more oligonucleic acid probes with the target gene mRNA expressed in a tissue sample, and detecting a low-molecular-weight compound label added to at least one of the bases of the oligonucleic acid probes, 07-28-2011
20110189676COMPOSITIONS FOR USE IN IDENTIFICATION OF FUNGI - The present invention relates generally to identification of fungi pathogens, and provides methods, compositions, systems and kits useful for this purpose when combined, for example, with molecular mass or base composition analysis.08-04-2011
20110201004Digital Amplification - The identification of pre-defined mutations expected to be present in a minor fraction of a cell population is important for a variety of basic research and clinical applications. The exponential, analog nature of the polymerase chain reaction is transformed into a linear, digital signal suitable for this purpose. Single molecules can be isolated by dilution and individually amplified; each product is then separately analyzed for the presence of pre-defined mutations. The process provides a reliable and quantitative measure of the proportion of variant sequences within a DNA sample.08-18-2011
20110200993NEW TREATMENT OF AUTOIMMUNE CONDITIONS - The invention relates to methods and materials involved in diagnosing and treating autoimmune conditions. In particular, the invention relates to methods and materials involved in identifying agent suitable for the prophylaxis, prevention and/or treatment of an autoimmune condition. The invention further relates to methods and materials involved in diagnosing autoimmune diseases like arthritis, multiple sclerosis and inflammatory bowels disease accompanied by decreased cellular uptake of amino acids caused by defects in cellular amino acid transporters like Slc38A1 (Solute carrier family 38, member 1). The invention also relates to methods and materials involved in diagnosing, treating, preventing, or delaying the onset and ameliorating the symptoms of autoimmune conditions that are accompanied by defects in cellular amino acid transporters.08-18-2011
20110201006Oligonucleotide Detection Method - The invention relates to a method for the detection of oligonucleotides using anion exchange high performance liquid chromatography. Fluorescently labelled peptide nucleic acid oligomers, complementary to the oligonucleotide are hybridized to the oligonucleotides. Anion exchange high performance liquid chromatography is then performed and the hybridized moieties detected and quantitated. The invention also relates to a method for the simultaneous detection of both strands of an oligonucleotide in parallel from one sample, and a kit for use in qualitative and quantitative detection of one or two strands of an oligonucleotide08-18-2011
20120107819Detection of Clostridium difficile - The invention provides methods to detect 05-03-2012
20120107817Probe for Detection of Polymorphism in EGFR Gene, Amplification Primer, and Use Thereof - A polymorphism-detecting probe, an amplification primer and the use thereof are provided to enable simple and highly reliable determination of different polymorphisms in an EGFR gene.05-03-2012
20120107816Primer Set for Detecting EGFR Exon 21 Polymorphism and Application Thereof - The invention provides a primer set for detecting a polymorphism in EGFR exon 21 L858R. The primer set has a P1 oligonucleotide and a P2 oligonucleotide and can performing amplification by using a region including the 172792nd base of SEQ ID NO: 1 as a template. As a base that is complementary to the 172792nd base of SEQ ID NO: 1, the P1 oligonucleotide has cytosine and the P2 oligonucleotide has adenine. The melting temperature of the P1 oligonucleotide is higher than the melting temperature of the P2 oligonucleotide, and/or the P1 oligonucleotide is one or more bases longer than the P2 oligonucleotide. The invention further provides a polymorphism detection primer, a polymorphism detection method using the primer set, a method of evaluating a EGFR tyrosine kinase inhibitor using the primer set, a primer used in the polymorphism detection method, and a kit including the primer set.05-03-2012
20120107815Polymorphism Detection Probe, Polymorphism Detection Method, Evaluation of Drug Efficacy, and Polymorphism Detection Kit - The invention provides a probe which detects a polymorphism in the MDR1 gene. The probe has a P1 and/or a P2 oligonucleotide. The P1 oligonucleotide has a sequence that is complementary to a first base sequence, in which the first base sequence is a partial sequence of SEQ ID NO: 2 having a length of from 13 bases to 68 bases and including the 288th to 300th bases of SEQ ID NO: 2. The base complementary to the 288th base is labeled with a fluorescent dye. The P2 oligonucleotide has a sequence that is complementary to a second base sequence, in which the second base sequence is a partial sequence of SEQ ID NO: 2 having a length of from 6 bases to 93 bases and including the 300th to 305th bases of SEQ ID NO: 2. The base complementary to the 305th base is labeled with a fluorescent dye.05-03-2012
20120107814Method for Determining the Predisposition of a Patient to Changed Biotransformation and to the Development of Undesired Drug Effects in a Treatment of the Patient with Atrovastatin - A method for determining a predisposition of a patient to the development of muscular diseases and/or to changed biotransformation in a treatment of the patient with atorvastatin is disclosed. The presence of at least one single nucleotide polymorphism (SNP) in the UGT1A3 gene (uridine diphosphate glucuronosyltransferase gene 1A3) and/or an increased UGT1A3 gene expression is determined in a biological sample of the patient. The disclosure further relates to oligonucleotides that can be used in the method and to diagnostic kits that use the oligonucleotides.05-03-2012
20120107812Means and methods for investigating nucleic acid sequences - The invention provides improved methods for investigating nucleic acid sequences, wherein at least one additional probe is used which is specific for a (pseudo)gene variant of a target nucleic acid. The invention further provides improved calibrators which are particularly suitable for determining (pseudo)gene variants and copy number variation.05-03-2012
20120107810Epigenetic Markers for the Identification of Blood Sub-Cells of Type 1 - The present invention relates to a method, in particular an in vitro method, for identifying CD3CD4 positive T lymphocytes of a mammal, wherein said method comprises analysing the methylation status of at least one CpG position in the CD3a/b/c/d/g genes, in particular their “upstream” regulatory regions, and in particular the promoter and other conserved regions of the gene cd3, wherein a demethylation of at least one CpG in the analyzed sample to at least 90% is indicative for memory and naive CD4 or/and memory and/or native T lymphocytes. Furthermore, the present invention is directed at the use of DNA-methylation analysis of the genes CD3a/b/c/d for the detection and quality assurance and control of T lymphocytes. Furthermore, the present invention relates to a kit for performing the above methods as well as respective uses thereof. In a preferred embodiment, the present invention furthermore provides an improved method for analysing the methylation status of at least one CpG position in the gene CD3, allowing for a precise analysis even from sub-optimal quality samples, such as non-freshly obtained blood or serum samples.05-03-2012
20120107809METHOD FOR SIMULTANEOUSLY DETECTING HISTOPLASMA CAPSULATUM AND PARACOCCIDIOIDES BRASILIENSIS - The present invention relates to a method for simultaneously detecting DNA of 05-03-2012
20120107808High throughput detection of gene-specific hydroxymethylation - This invention provides a method for the detection of hydroxymethylation patterns in a DNA sample, especially in genetic regions. A test sample containing hydroxymethylated DNA is hybridized to capture oligonucleotides immobilized on a solid phase. The hydroxymethylated DNA in hybrid is detected using an antibody which specifically recognizes hydroxymethylcytosine structure the marker of DNA hydroxymethylation-followed by immuno-signal amplification. The present invention provides a method to detect gene-specific hydroxymethylation in a simple, rapid and high throughput format with high specificity and sensitivity.05-03-2012
20130217009METHODS OF IDENTIFYING AN ORGANISM - This disclosure features methods of identifying an organism. In certain embodiments, the invention provides methods of distinguishing virulent and non-virulent strains of 08-22-2013
20130217012C-CBL MUTATIONS AND USES THEREOF - The present invention relates generally to the fields of molecular biology and growth factor regulation. The invention concerns methods and compositions useful for diagnosing and treating human lung cancer associated with mutated c-CBL.08-22-2013
20130217014METHODS OF USING CDK8 ANTAGONISTS - Provided herein are CDK8 antagonists and methods of using the same.08-22-2013
20110201003METHOD FOR OBTAINING PURKINJE PROGENITOR CELL BY USING NEPH3(65B13) AND E-CADHERIN - 65B13 was discovered to be a useful marker for isolating GABA neuron progenitor cells including Purkinje cells. Furthermore, E-cadherin was revealed to be a useful marker for isolating Purkinje progenitor cells from a 65B13-positive cell population. Specifically, when used in combination with 65B13, E-cadherin was found to be a useful marker for isolating Purkinje progenitor cells.08-18-2011
20110201007DIAGNOSTIC TEST FOR STREPTOCOCCUS EQUI - The invention relates generally to methods and materials concerning diseases caused by 08-18-2011
20110201005Methods and Nucleic Acids for the Detection of Metastasis of Colon Cell Proliferative Disorders - The invention provides methods, nucleic acids and kits for detecting metastasis of colon cell proliferative disorders. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of metastasis of colon cell proliferative disorders, thereby enabling the improved diagnosis and treatment of patients.08-18-2011
201102010022'-Terminator Nucleotide-Related Methods and Systems - The present invention provides methods of extending primer nucleic acids and sequencing target nucleic acids. The methods include the use of 2′-terminator nucleotides to effect chain termination. In addition to related reaction mixtures and kits, the invention also provides computers and computer readable media.08-18-2011
20110201001METHODS AND MATERIALS FOR ASSESSING RNA EXPRESSION - This document provides methods and materials for assessing RNA expression. For example, methods and materials for detecting the presence, absence, or amount of target nucleic acid (e.g., target RNA or target cDNA produced from target RNA), kits for detecting the presence, absence, or amount of target nucleic acid (e.g., target RNA or target cDNA produced from target RNA), and methods for making such kits are provided.08-18-2011
20110201000METHODS AND MATERIALS FOR DETECTING GENETIC OR EPIGENETIC ELEMENTS - This document provides methods and materials for detecting genetic and/or epigenetic elements. For example, methods and materials for detecting the presence or absence of target nucleic acid containing a genetic or epigenetic element, methods and materials for detecting the amount of target nucleic acid containing a genetic or epigenetic element within a sample, kits for detecting the presence or absence of target nucleic acid containing a genetic or epigenetic element, kits for detecting the amount of target nucleic acid containing a genetic or epigenetic element present within a sample, and methods for making such kits are provided.08-18-2011
20110200999NOVEL DEVICE AND METHOD FOR RAPID DETECTION OF MICROORGANISMS - The present invention is directed to a platform technology for quick and easy detection and identification of single or multiple microorganisms in a sample using peptide labeled oligonucleotides (PLONs). The PLONs are specifically designed to be complementary to certain nucleic acid sequences on a target microorganism. When the PLONs of the present invention are added to nucleic acids extracted from a sample (both biological and/or non-biological), they hybridize to the specific target nucleic acids of the microorganisms, and the PLONs are then detected with one or more specific enzymes coupled to antibodies that are specific to the conjugated peptides attached to the PLONs. The hybridized PLON-enzyme coupled antibody complex is further localized to a test region on a solid matrix or support by the presence of a composition comprising a secondary antibody to enzyme coupled antibody and provides a specific, sensitive, easy to use tool for the detection and identification that does not require any amplification step and any equipment for the final read out. A kit and methods of use of the invention are also provided.08-18-2011
20110200998Prognosis and Therapy Predictive Markers and Methods of Use - Disclosed is a set of genes differentially expressed in chemotherapy and radiation resistant tumors useful in predicting response to therapy and assessing risk of local-regional failure, survival and metastasis in cancer patients. Also disclosed are methods for characterizing tumors according to gene expression and kits for use in the methods of the invention.08-18-2011
20110200997COMPOSITIONS FOR USE IN IDENTIFICATION OF ENTERIC BACTERIAL PATHOGENS - The present invention relates generally to identification of enteric bacterial pathogens, and provides methods, compositions and kits useful for this purpose when combined, for example, with molecular mass or base composition analysis.08-18-2011
20110200996COMPOSITIONS AND METHODS FOR DETECTION OF COLORECTAL CANCER - We have identified a new variant of ileal bile acid binding protein (IBABP), designated IBABP-L, which is a biomarker for colorectal cancer. The transcript for IBABP-L arises from an alternative start site and includes three exons that are absent in IBABP. IBABP-L also shares part of a fourth exon with IBABP. The protein encoded by IBABP-L contains a deduced 49 residue N-terminal sequence that is not found in the IBABP protein. The present invention provides methods for diagnosing colorectal cancer and other compositions and methods based on this discovery.08-18-2011
20110171638DIAGNOSIS OF FETAL ABNORMALITIES USING POLYMORPHISMS INCLUDING SHORT TANDEM REPEATS - The present invention provides systems, apparatuses, and methods to detect the presence of fetal cells when mixed with a population of maternal cells in a sample and to test fetal abnormalities, i.e. aneuploidy. In addition, the present invention provides methods to determine when there are insufficient fetal cells for a determination and report a non-informative case. The present invention involves quantifying regions of genomic DNA from a mixed sample. More particularly the invention involves quantifying DNA polymorphisms from the mixed sample.07-14-2011
20120295262MULTIBASE DELIVERY FOR LONG READS IN SEQUENCING BY SYNTHESIS PROTOCOLS - The present technology relates to molecular sciences, such as genomics. More particularly, the present technology relates to methods for obtaining long lengths of sequencing data.11-22-2012
20120295257METHOD, MICROCHIP AND MIXED REAGENT FOR ANALYSIS OF NUCLEIC ACID BASE SEQUENCE - A technology is provided for achieving high efficiency of nucleic acid amplification reaction and high precision of melting curve analysis when performing melting curve analysis in a nucleic acid amplification process of obtaining an amplification product in which the target nucleic acids are continuously arranged via a loop. A method for analysis of nucleic acid base sequence is provided, and includes: performing amplification reaction of target nucleic acid which is targeted for amplification, in presence of a probe nucleic acid that is capable of hybridizing with the target nucleic acid, to obtain an amplification product in which the target nucleic acids are continuously arranged via a loop site and employing as the probe nucleic acid, a probe nucleic acid having a melting temperature which is lower than the reaction temperature of the amplification reaction; and performing melting curve analysis of the amplification product and the probe nucleic acid.11-22-2012
20120295261METHOD FOR THE IN VITRO DIAGNOSIS OF BRONCHOPULMONARY CARCINOMA BY DETECTION OF MAJOR ALTERNATIVE TRANSCRIPTS OF THE KLK8 GENE ENCODING KALLICREIN 8 AND USE THEREOF FOR PROGNOSTICATING SURVIVAL - A method for the in vitro diagnosis of bronchopulmonary carcinoma, in particular of non-small cell bronchial carcinoma, that includes a stage of detecting, in a biological sample derived from a patient suspected to be suffering from bronchopulmonary carcinoma, at least one of the major alternative transcripts of the KLK8 gene encoding kallikrein 8. This method is particularly useful for the survival prognostication of patients suffering from bronchopulmonary carcinoma.11-22-2012
20120295258UTILITY OF B-RAF DNA MUTATION IN DIAGNOSIS AND TREATMENT OF CANCER - The present invention discloses a method of detecting a wild-type or mutant B-RAF gene in a body fluid sample from a subject. Also disclosed are methods of using B-RAF as a biomarker for detecting cancer, predicting the outcome of cancer, and monitoring the treatment of cancer or the status of cancer. Furthermore, the invention discloses methods and compositions for detecting a mutant gene with a peptide nucleic acid clamp capable of hybridizing to a wild-type gene and a locked nucleic acid probe capable of hybridizing to a mutant of the gene.11-22-2012
20120295259Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients - The present invention relates generally to methods of accurately quantifying HER2 and/or p95 expression in subjects with a HER2 positive cancer and indicating the risk of brain relapse in such patients.11-22-2012
20110171645METHODS OF DIAGNOSING ACUTE CARDIAC ALLOGRAFT REJECTION - The present invention relates to methods of diagnosing acute rejection of a cardiac allograft using genomic expression profiling, proteomic expression profiling, metabolite profiling, or alloreactive T-cell genomic expression profiling,07-14-2011
20110171641Gene Expression Markers of Recurrence Risk in Cancer Patients After Chemotherapy - The present invention relates to genes, the expression levels of which are correlated with likelihood of breast cancer recurrence in patients after tumor resection and chemotherapy.07-14-2011
20130217019CORN EVENT MZDT09Y - A novel transgenic corn event designated MZDT09Y is disclosed. The invention relates to nucleic acids that are unique to event MZDT09Y and to methods of detecting the presence of event MZDT09Y based on DNA sequences of the recombinant constructs inserted into the corn genome that resulted in the MZDT09Y event and of genomic sequences flanking the insertion site. The invention further relates to corn plants comprising the transgenic genotype of event MZDT09Y and to methods for producing a corn plant by crossing a corn plant comprising the MZDT09Y genotype with itself or another corn variety. Seeds of corn plants comprising the MZDT09Y genotype are also objects of the invention.08-22-2013
20110171644Multiplex capture of nucleic acids - Methods of capturing two or more nucleic acids simultaneously from a single sample are provided. Different nucleic acids are captured through cooperative hybridization events on different subsets of particles or at different selected positions on a spatially addressable solid support. Methods of capturing one or more long nucleic acids and methods of capturing one or more nucleic acid for sequencing are also provided. Compositions, kits, and systems related to the methods are also described.07-14-2011
20110171649DETECTION OF NUCLEIC ACIDS BY OLIGONUCLEOTIDE PROBES CLEAVED IN PRESENCE OF ENDONUCLEASE V - Particular aspects provide nucleic acid detection methods comprising contacting a test sample having a nucleic acid target sequence with at least one endo-V-cleavable oligonucleotide probe complementary to the target sequence in the presence of an endonuclease V, incubating the reaction mixture under conditions suitable to support hybridization of the endo-V-cleavable oligonucleotide probe with the target nucleic acid and endonuclease V-mediated cleavage of the target-hybridized probe, and detecting at least one endonuclease V-mediated cleavage product of the target-hybridized probe wherein the presence of the cleavage products is indicative of the presence of the target nucleic acid sequence in the sample. Particular aspects comprise amplification of the target nucleic acid sequence before and/or during the incubating and/or detecting, wherein detecting is post-amplification and/or real-time. Additional aspects provide suitable kits. Further aspects comprise use of at least one nick-directing modification or other structural modification of the at least one endo-V-cleavable oligonucleotide probe.07-14-2011
20110171647METHOD FOR QUANTIFYING OR DETECTING DNA - The present invention relates to a method for quantifying or detecting DNA having a target DNA region, and so on.07-14-2011
20110171637METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS - The invention provides methods, nucleic acids and kits for detecting, or for detecting and distinguishing between or among prostate cell proliferative disorders or for detecting, or for detecting and distinguishing between or among colorectal cell proliferative disorders. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of and differentiation between said class of disorders, thereby enabling the improved diagnosis and treatment of patients.07-14-2011
20110200994Method for Diagnosing a Genetic Predisposition for Vascular Disease - The invention relates to a method for diagnosing a genetic predisposition for a vascular disease, in particular for a coronary artery disease (CAD). According to the invention, the method has the following steps: Providing a sample containing a nucleic acid derived from the gene GCH1; and determining the presence or absence of a nucleotide polymorphism (SNP) of the gene GCH1 in the nucleic acid, wherein the SNP is selected from the group consisting of rs8007267 G>A, rs3783641 A>T, and rs10483639 C>G, wherein the presence of at least one of said SNPs indicates a genetic predisposition for a vascular disease.08-18-2011
20110171650GENE EXPRESSION RELATED TO PREECLAMPSIA - Gene expression patterns contemporaneous with early placental development in the first trimester of preeclamptic versus unaffected pregnancies have been obtained. Observation of differences in these gene expression patterns has allowed the identification of biomarkers that are useful in predicting and monitoring preeclampsia. These biomarkers are also useful in screening potential therapeutics for efficacy in the prevention or treatment of preeclampsia.07-14-2011
20110171646MICRORNA EXPRESSION PROFILE ASSOCIATED WITH PANCREATIC CANCER - Methods are provided for diagnosing whether a subject has, or is at risk of developing, pancreatic cancer. The methods include measuring the level of at least one miR gene product in a biological sample derived from the subject's pancreas. An alteration in the level of the miR gene product in the biological sample as compared to the level of a corresponding miR gene product in a control sample, is indicative of the subject either having, or being at risk for developing, pancreatic cancer07-14-2011
20120295256WEIGHT MANAGEMENT GENETIC TEST SYSTEMS AND METHODS - Disclosed herein is a nutritional genomic weight management algorithm running on a computer system, and more specifically, a nutritional genomic weight management algorithm where an analysis of a customer's unique DNA results in individualized diet and exercise plans, in accordance with the present invention. Methods of weight management, weight management business methods, and panels of alleles for nutritional genomics are also disclosed.11-22-2012
20120295254PNA PROBES, MIXTURES, METHODS AND KITS PERTAINING TO THE DETERMINATION OF MYCOPLASMA AND RELATED MOLLICUTES - This invention is related to PNA probes, probe sets, mixtures, methods and kits pertaining to the determination of 11-22-2012
20120295255METHOD FOR HIGH RESOLUTION MELT GENOTYPING - Various methods are described that provide for high resolution melt (HRM) genotyping. The embodiments include providing a locus specific primer and two allele specific primers each having a 5′ end with a short tail, providing a nucleic acid having a single nucleotide polymorphism (SNP) base located within 1-20 base pairs of the 3′ end of nucleic acid, hybridizing the locus specific primer and the allele specific primers to the nucleic acid, amplifying the sample using pyrophosphorolysis activated polymerization (PAP) PCR enzyme, and determining the Tm of the amplicons using HRM. In other embodiments, reactions mixtures and kits for HRM genotyping are provided and disclosed. These kits comprise a locus specific primer, one or more allele specific primers each having a 5′ end with a short tail, a nucleic acid, and a pyrophosphorolysis activate polymerization (PAP) PCR enzyme.11-22-2012
20120295263Haplotype Analysis - The present invention provides an efficient way for high throughput haplotype analysis. Several polymorphic nucleic acid markers, such as SNPs, can be simultaneously and reliably determined through multiplex PCR of single nucleic acid molecules in several parallel single molecule dilutions and the consequent statistical analysis of the results from these parallel single molecule multiplex PCR reactions results in reliable determination of haplotypes present in the subject. The nucleic acid markers can be of any distance to each other on the chromosome. In addition, an approach wherein overlapping DNA markers are analyzed can be used to link smaller haplotypes into larger haplotypes. Consequently, the invention provides a powerful new tool for diagnostic haplotyping and identifying novel haplotypes.11-22-2012
20130217015HMGA2 AS A BIOMARKER FOR DIAGNOSIS AND PROGNOSIS OF OVARIAN CANCER - The subject invention pertains to uses of HMGA2 as a diagnostic biomarker for ovarian cancer and for prediction of a subject's resistance to cancer therapy. The methods of the subject invention are particular useful for early detection of epithelial ovarian cancer.08-22-2013
20110207124Genetic Alterations Associated with Autism and the Autistic Phenotype and Methods of Use Thereof for the Diagnosis and Treatment of Autism - Compositions and methods for the detection and treatment of autism and autistic spectrum disorder are provided.08-25-2011
20110207123METHOD FOR DETECTING CHROMOSOMAL ABNORMALITIES - The invention relates to an in vitro method for detecting chromosomal abnormalities in a mammal, comprising the in situ hybridization of n chromosomes from a metaphase chromosome preparation with sets of a plurality of nucleic acids, each set hybridizing, over a length of 700 000 to 3 000 000 contiguous bp, specifically to the subtelomeric ends specific to said chromosomes, each set being detectably labeled with a fluorochrome, such that each chromosome is distinguishable by a particular fluorochrome or a particular fluorochrome combination.08-25-2011
20110223600Method For Predicting Athletic Performance Potential - A method and assay for predicting athletic performance potential of a subject, such as a thoroughbred race horse, comprising the steps of assaying a biological sample from a subject for the presence of a single nucleotide polymorphism in one or more genes associated with athletic performance. The athletic performance genes may be selected from one or more of MSTN, COX4I2, PDK4, CKM and COX4I1.09-15-2011
20110223601Method for pairwise sequencing of target polynucleotides - The invention relates to methods for pairwise sequencing of a double-stranded polynucleotide template, which methods result in the sequential determination of nucleotide sequences in two distinct and separate regions of the polynucleotide template. Using the methods of the invention it is possible to obtain two linked or paired reads of sequence information from each double-stranded template on a clustered array, rather than just a single sequencing read from one strand of the template.09-15-2011
20110200995OPTIMIZED PROBES AND PRIMERS AND METHODS OF USING SAME FOR THE DETECTION, SCREENING, ISOLATION AND SEQUENCING OF VANCOMYCIN RESISTANCE GENES AND VANCOMYCIN RESISTANT ENTEROCOCCI - Described herein are primers and probes useful for detecting, screening, isolating, and sequencing of the vancomycin resistance genes and vancomycin resistant Enterococci and methods of using the described primers and probes.08-18-2011
20120288863Oligonucleotides and methods for detecting KRAS and PIK3CA mutations - Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.11-15-2012
20120288864DETECTION OF SALMONELLA BY REAL-TIME MULTIPLEX PCR - The invention relates to the detection of 11-15-2012
20110269130Antibiotice Susceptibility Profiling Methods - The invention provides methods for the rapid determination of the antibiotic susceptibility of a microorganism, such as, an infectious microorganism in a biological sample, using fluorescence in situ hybridization (“FISH”). Methods of the invention may be applied to the rapid identification, typing, antibiotic susceptibility determination, and/or antibiotic minimum inhibitory concentration (MIC) determination for any infectious microorganism, such as a Gram positive bacteria, a Gram negative bacteria, or a yeast.11-03-2011
20110207134MONITORING HEALTH AND DISEASE STATUS USING CLONOTYPE PROFILES - There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using DNA sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions. Identified biomarkers can be used to determine and/or monitor the disease state for a subject with an associated lymphoid disorder or autoimmune disease or other condition. In particular, the invention provides a sensitive method for monitoring lymphoid neoplasms that undergo clonal evolutions without the need to development alternative assays for the evolved or mutated clones serving as patient-specific biomarkers.08-25-2011
20110207135METHODS OF MONITORING CONDITIONS BY SEQUENCE ANALYSIS - The invention is directed to methods of generating sequence profiles of populations of nucleic acids, whose member nucleic acids contain regions of high variability, such as populations of nucleic acids encoding T cell receptors or B cell receptors. In one aspect, the invention provides pluralities of sets of primers for generating nested sets of templates from nucleic acids in such populations, thereby insuring the production of at least one template from which sequence reads are generated, despite such variability, or dispite limited lenghs or quality of sequence reads. In another aspect, members of such populations are bidirectionally sequenced so that further sequence information is obtained by analyzing overlapping sequence reads in the zones of highest variability.08-25-2011
20110269133Compositions and Methods For Detecting The Presence Of Cryptosporidium Parvum In A Test Sample - The present invention describes novel oligonucleotides targeted to nucleic acid sequences derived from 11-03-2011
20110269128FORENSIC IDENTIFICATION - The invention provides allelic ladder mixtures and individual alleles suitable for use in such mixtures. The allelic ladder mixtures give improved identification and distinguishing capabilities, particularly suitable in forensic investigations.11-03-2011
20110207131MULTIPLEX AMPLIFICATION AND DETECTION - The invention relates to the field of multiplex amplification. In particular, the invention relates to methods for assaying a sample for one or more nucleic acid targets in a single reaction based on the distinct melting temperatures or melting profiles of primers and/or probes. The invention also provides probes and kits for use in such methods.08-25-2011
20110269127MEANS AND METHOD FOR DETERMINING TUMOR CELL PERCENTAGE IN A SAMPLE - The invention provides a method for determining the percentage of tumor cells in a sample of an individual, preferably a breast sample. More specifically, the invention provides one or more genes than can be used to determine the percentage of tumor cells. The invention further provides a set of probes, a set of primers, and uses thereof for detection of said one or more genes.11-03-2011
20110269126EPIGENETIC METHODS AND NUCLEIC ACIDS FOR THE DETECTION OF BREAST CELL PROLIFERATIVE DISORDERS - The present application provides methods and nucleic acids for the detection and differentiation of breast cell proliferative disorders. This is achieved by the analysis of the methylation of a panel of genes, or subsets thereof. The invention may be used for the detection and/or differentiation of a variety of tissue types including breast cancer and benign breast disorders as well as other cancers and tissue types.11-03-2011
20120064521DETECTION OF DNA HYDROXYMETHYLATION - Reagents and methods for analysis of DNA hydroxymethylation are provided. Methods comprise modification of hydroxymethylated cytosine residues with a bulky moiety to protect hydroxymethylated positions from cleavage with a DNA endonuclease. For example, methods may comprise contacting DNA with a glucosyltransferase to glucosylate hydroxymethylated DNA positions and digesting the DNA with a DNA endonuclease to cleave DNA in positions lacking hydroxymethylation. Reagents and kits for hydroxymethylated DNA analysis are also provided.03-15-2012
20110207132PROBES AND METHODS FOR DETECTING ANALYTES - Embodiments disclosed herein relate generally to probes, methods, and kits for detecting the presence of a target analyte. The probe generally comprises two strands that have regions of complementarity and do not associate with each other at the reaction temperature. In the presence of an analyte, the two strands of the probe can hybridize to each other, and the analyte can hybridize to both strands of the probe in a juxtapose manner to form a tripartite structure (probe-analyte complex). If the region of complementarity between the two probe strands contain cognate restriction endonuclease (REN) sequences, then the formation of the tripartite structure will lead to the generation of a REN site that can be cleaved by a REN, and the cleavage can then be detected by a variety of methods to signal the presence of the analyte.08-25-2011
20110207133BINDING AND FUNCTIONAL ASSAYS THAT USE THE T1R3 RECEPTOR TO SCREEN FOR TASTE MODULATORY COMPOUNDS - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed.08-25-2011
20110207130Method of detecting tumor-associated hypermethylated DNA in plasma or serum - This invention relates to detection of specific extracellular nucleic acid in human or animal blood plasma or serum associated with disease. Specifically, the invention relates to detection of nucleic acid derived from mutant oncogenes or other tumor-associated DNA including non-mutated hypermethylated DNA, and to methods of detecting and monitoring extracellular mutant oncogenes or tumor-associated DNA including non-mutated hypermethylated DNA found in blood plasma or serum. In particular, the invention relates to the detection, identification, or monitoring of the existence, progression or clinical status of neoplasia in humans or other animals that contain a mutation that is associated with the neoplasm through detection of the non-mutated hypermethylated nucleic acid of the neoplasm in plasma or serum fractions.08-25-2011
20110207128METHODS AND KITS FOR DETERMINING BIOLOGICAL AGE AND LONGEVITY BASED ON GENE EXPRESSION PROFILES - Described herein are methods of predicting the likelihood of survival in a subject. Additionally, described herein are methods of modulating survival in a subject.08-25-2011
20110212442UNIVERSAL NUCLEIC ACID PROBE SET AND METHOD FOR UTILIZATION THEREOF - A nucleic acid probe set includes (A) a fluorescent probe and (B) a binding probe. The fluorescent probe (A) is formed of an oligonucleotide, which includes (a) a nucleotide unit labeled with (d) a fluorescent substance. The binding probe (B) is formed of an oligonucleotide having (b09-01-2011
20110269132Methods for Determining Dysregulation of Methylation of Brain Expressed Genes on the X Chromosome to Diagnose Autism Spectrum Disorders - The discovery that alterations in methylation, which can cause one or more genes on the single X chromosome in males to be partially silenced or overexpressed, constitute a predisposition to autism spectrum disorders is generally disclosed herein. These alterations provide the rationale and basis for methods to diagnose autism spectrum disorders.11-03-2011
20110207125METHOD FOR LABELLING A PRODUCT USING A PLURALITY OF POLYNUCLEOTIDES, METHOD FOR IDENTIFYING THE LABELLING AND LABELLED PRODUCT - A method for labeling a product includes a step of adding on or in the product a plurality of single-stranded polynucleotides, which plurality of polynucleotides includes at least one target polynucleotide constituted of a single-stranded polynucleotide of predetermined length and sequence, and decoy polynucleotides which have identical or different predetermined lengths and identical or different predetermined sequence, which decoy polynucleotides have a length or lengths identical to or different from and sequences different from the sequence of the at least one target polynucleotide, wherein each of the target and decoy polynucleotides does not hybridize with any of the other polynucleotides of the plurality of polynucleotides and wherein the polynucleotides of the plurality of polynucleotides are deoxyribonucleic or ribonucleic acid sequences, respectively having the same proportion of the four, natural or modified, bases A, C, G, and T, or A, C, G and U.08-25-2011
20110207126CELL-BASED SCREEN FOR AGENTS USEFUL FOR REDUCING NEURONAL DEMYELINATION OR PROMOTING NEURONAL REMYELINATION - This invention is in the field of neurology. Specifically, the invention relates to the discovery and characterization of molecular components that play a role in neuronal demyelination or remyelination. In addition, the invention relates to the generation of an animal model that exhibits hypomyelination. The compositions and methods embodied in the present invention are particularly useful for drug screening and/or treatment of demyelination disorders.08-25-2011
20110223603DIAGNOSING AND MONITORING RESPONSE TO TREATMENT OF NON-INCONTINENT UROLOGICAL AND RELATED DISEASES - Techniques for diagnosing and monitoring response to treatment of non-incontinent urological disorders (NIUD) in a patient are provided. For example, a technique for diagnosing NIUD in a patient includes obtaining peripheral blood-derived nucleic acid containing nucleated acellular components such as serum and/or plasma and/or nucleated cellular components from the patient to provide a reporter function in the patient. Also, a technique for monitoring response to treatment of NIUD in a patient includes obtaining peripheral blood-derived nucleic acid containing nucleated acellular components such as serum and/or plasma and/or nucleated cellular components from the patient to provide a reporter function in the patient.09-15-2011
20110223598METHOD FOR REAL-TIME DETECTION OF SALMONELLA IN FOOD USING A CLEAVABLE CHIMERIC PROBE - A method is described for the real-time detection of 09-15-2011
20130217010CONTAINERS FOR AGITATION OF LIQUID SAMPLES AND METHODS OF USE THEREOF - The present invention relates to containers for holding liquid samples. The containers may be useful for mixing a liquid sample or lysing cells in a liquid sample. The invention also relates to methods of using the containers of the invention.08-22-2013
20120070832SE33 MUTATIONS IMPACTING GENOTYPE CONCORDANCE - Disclosed are primer set compositions, methods and kits for human identification using the highly complex sequence locus, SE33 (ACTBP2) in single and multiplex PCR reactions. Additionally, disclosed are three newly discovered single nucleotide polymorphisms (SNPs) within the SE33 locus that can cause discordance seen as mobility shift or allelic dropout. Also disclosed are kits useful in human identification.03-22-2012
20120070827DETECTION OF FETAL CELLS FROM MATERNAL BLOOD - The present application relates to methods for identification of foetal cells and generation and isolation of binding members recognising foetal cells. Said methods may further be used for other purposes relating to characterisation of biological samples and biological antigens. The methods are characterised by the applicability in situations where the interesting objects are present in a limited amount, or where the interesting objects are intermixed with other material, thus the methods are suitable for use in situations where the ratio of the interesting material compared to other material is low. The application discloses methods for use of detecting foetal cells and method of generating/isolating binding members towards antigenic material of low abundancy.03-22-2012
20110223594METHODS, KITS AND COMPOSITIONS FOR DETERMINING SEVERITY AND SURVIVAL OF HEART FAILURE IN A SUBJECT - The application provides a method of determining a severity of heart failure in a human test subject, by determining a level of RNA encoded by one or more heart failure marker genes in blood of the test subject compared to controls. The application also provides a method of determining survival outcome and allows the ranking of test subjects based on the level of RNA encoded by one or more survival associated genes.09-15-2011
20110229893METHOD OF MEASURING CYTOKERATIN 19 mRNA - Disclosed is a method of amplifying and detecting cytokeratin 19 mRNA in RNA amplification process, comprising: a step for forming a double-stranded DNA containing a promoter sequence with a reverse transcriptase by use of a combination of oligonucleotides consisting of a first primer having a sequence homologous to a portion of cytokeratin 19 mRNA and a second primer having a complementary sequence, wherein the promoter sequence is added to the 5′-end of either the first primer or the second primer, forming an RNA transcription product by use of an RNA polymerase with using the double-stranded DNA as template, and forming the double-stranded DNA by use of a reverse transcriptase by continuing to use the RNA transcription product as a template of DNA synthesis, by measuring an amount of amplified RNA produced over time with an oligonucleotide probe designed so that signal properties change with the formation of a complementary double strand with the amplified RNA.09-22-2011
20110229894METHODS FOR DETECTING AN INCREASED SUSCEPTIBILITY TO CANCER - The invention relates to methods for detecting an altered susceptibility to breast and ovarian cancer in a subject carrying a BRCA mutation, comprising determining the nucleic acid sequence of a polymorphism of a microRNA-related gene.09-22-2011
20110229892METHOD FOR PREDICTING A PATIENT'S RESPONSIVENESS TO ANTI-FOLATE THERAPY - A method of predicting responsiveness of a subject to a folylpolyglutamate synthetase (FPGS) dependent anti-folate is provided. The method comprises analyzing for a presence or absence of a splice variant of FPGS or a polypeptide encoded thereby, in a sample of the subject, wherein the presence of the splice variant or the polypeptide encoded thereby is indicative of a negative response to a FPGS-dependent anti-folate. Kits for prediction responsiveness of a subject to FPGS-dependent anti-folate are also disclosed. Antibodies specific for splice variants, the splice variant nucleic acids and polypeptides encoded by the splice variants are also claimed. In particular splice variants missing exons selected from the group of exon 3, exon 7, exon 10 and exon 12 are disclosed.09-22-2011
20110229885Methods and Compositions for Determining Predisposition to Inflammation-Mediated Cardiovascular Disease - The present invention provides methods and compositions for detecting a predisposition to an inflammation-mediated cardiovascular disease in a human subject by detecting a level of leukotriene C4 synthase (LTC4S) gene product in a sample from a human subject indicative of a predisposition to an inflammation-mediated cardiovascular disease or detecting the presence or absence of an allele of LTC4S indicative of a predisposition to an inflammation-mediated cardiovascular disease. In addition, the present invention also provides kits for practicing the methods.09-22-2011
20110229884METHOD OF GENOME-WIDE NUCLEIC ACID FINGERPRINTING OF FUNCTIONAL REGIONS - A method of specifically amplifying desired regions of nucleic acid from a sample is provided. The method uses a plurality of first and second PCR primers, each having a region of fixed nucleotide sequence identical or complementary to a consensus sequence of interest and a region of randomized nucleotide sequence located 5′ to, 3′ to, anywhere within, or flanking the region of fixed nucleotide sequence; and then amplifying the nucleic acid present in the sample via PCR using the plurality of first and second PCR primers; whereby a subset of the first primers binds to the consensus sequence of interest wherever it occurs in the sample, and a subset of the second primers binds to the sample at locations removed from the first primers such that DNA regions flanked by the first primer and the second primer are specifically amplified.09-22-2011
20110223596Multiplex Detection Compositions, Methods, and Kits - The present invention generally relates to the detection of analytes, particularly biomolecules in samples. The invention also relates to compositions, methods, and kits for detecting the presence of analytes, typically in multiplex detection formats. The invention also relates to methods for determining the presence of at least one analyte in a sample, the methods employing employ single molecule detection techniques to individually detect at least one molecular complex or at least part of a molecular complex.09-15-2011
20110229888Compositions and Methods for the Detection of Genomic Features - The invention provides compositions and methods for the detection of gene copy number and/or chromosome copy number in a multiplexed reaction. The assays and kits described herein are applicable for the identification, diagnosing, and monitoring of disorders including, but not limited to cancer, developmental and degenerative disease, neurological disorders, and stem cell disorders.09-22-2011
20110229891SYNGAP1 DYSFUNCTIONS AND USES THEREOF IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS FOR MENTAL RETARDATION - The invention identifies Syngap1 dysfunctions as causative of mental retardation. Described are methods of detecting mental retardation and methods of detecting non-syndromic mental retardation (NSMR) in a human subject. Particular methods comprise sequencing a human subject's genomic DNA for comparison with a control sequence from an unaffected individual. Also described are probes, kits, antibodies and isolated mutated Syngap1 proteins.09-22-2011
20110223595STANDARDIZED AND OPTIMIZED REAL-TIME QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION METHOD FOR DETECTION OF MRD IN LEUKEMIA - The invention relates to in a real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) method for minimal residual disease detection in leukemic patients through amplification of a fusion gene transcript, the improvement comprising: (i) selecting amplifiable and qualified patient samples for subsequent analysis; (ii) defining optimal conditions for performing the RT reaction; (iii) defining optimal conditions RQ-PCR protocol; and (iv) establishing a standardized procedure for data analysis.09-15-2011
20110223597METHODS RELATING TO OLANZAPINE PHARMACOGENETICS - There is significant variability in subject clearance, half-life and side-effects from treatment with olanzapine (OLZ) in subjects. Methods for aiding in determining therapeutic efficacy of olanzapine in a subject are provided according to embodiments of the present invention which include identifying in a subject sample whether UDP-glucuronosyltransferase 2B10 (UGT2B10) and/or UDP-glucuronosyltransferase 1A4 (UGT1A4) is “wild-type” or a variant associated with altered glucuronidation of an olanzapine metabolite compared to wild-type.09-15-2011
20110223593Predicting a response to olanzapine - The invention relates generally to the relative effect of specific genetic polymorphisms in predicting the clinical outcome of olanzapine therapy in patients suffering from a psychiatric disease such as schizophrenia.09-15-2011
20110223599PARASITE DETECTION VIA ENDOSYMBIONT DETECTION - The present invention provides systems, methods, and compositions for identifying a subject as infected with a parasite by detecting nucleic acid from an endosymbiont of the parasite in a sample from the subject. In certain embodiments, the parasite is a nematode that infects humans or dogs (e.g., 09-15-2011
20120141994METHODS AND COMPOSITIONS FOR PROGNOSING AND DETECTING AGE-RELATED MACULAR DEGENERATION - The invention provides methods and compositions for determining whether a subject is at risk of developing age-related macular degeneration, for example, the wet or neovascular form of age-related macular degeneration. The method involves determining whether the subject has a protective variant and/or a risk variant at a polymorphic site in the RORA gene. A protective or risk variant may be defined by a haplotype in the RORA gene.06-07-2012
20120196287Tmsb4 as a Biomarker for IgA Nephropathy - The present invention provides a method for diagnosis or prognosis of IgA nephropathy in a subject based on detection of the expression level of one or more biomarker genes selected from the group consisting of thymosin β4 (Tmsb4), serine or cysteine proteinase inhibitor clade E member 2 (Serpine2), secreted phosphoprotein 1 (OPN), butyrophilin-like-2 (BTNL2), S100 calcium binding protein A8 (S100A8), Cystatin C (CysC), and any combination thereof.08-02-2012
20120196282METHOD OF REGENERATING ELASTIC FIBER AND SCREENING METHOD - A method of regenerating an elastic fiber according in the present invention is characterized in that the method comprises bringing an elastic fiber regenerating agent containing LTBP-4 into contact with a cell having the fiber regenerating ability. Preferably, the elastic fiber regenerating agent further contains DANCE and/or LTBP-4 expression potentiating factor. According to the present invention, the elastic fiber regenerating ability is further enhanced than so far.08-02-2012
20110143347SUBSTANCES AND METHODS FOR A DNA BASED PROFILING ASSAY - The present invention relates to a DNA profiling assay comprising the following steps, providing a sample to be analyzed, providing reagents, enzyme and primer oligonucleotides which are necessary for simultaneous polymerase chain reaction amplification of at least 20 loci, amplifying the loci, detecting the amplification products, wherein the amplification products and the loci to be amplified are characterized by the following features, each locus to be amplified is characterized by at least one deletion-insertion polymorphism known to be present in the population, wherein the two alleles from each locus differ in size by more than 2 nucleotides and less than 100 nucleotides, a first set of at least two amplification products ranging in size from about 20 nucleotides to about 300 nucleotides stemming from at least two different loci carries a first label, a second set of at least two amplification products ranging in size from about 20 nucleotides to about 300 nucleotides stemming from at least two different loci carries a second label, a third set of at least two amplification products ranging in size from about 20 nucleotides to about 300 nucleotides stemming from at least two different loci carries a third label, label one, label two and label three are each different fluorescent labels which can he differentiated and simultaneously detected by a multi-colour detector in combination with, e.g. a DNA sequencing device.06-16-2011
20110143346COTTON EVENT MON15985 AND COMPOSITIONS AND METHODS FOR DETECTION THEREOF - The present invention provides cotton plants, cotton tissues, and cotton seeds that include the MON15985 event, which confers resistance to Lepidopteran insect damage. Also provided are assays for detecting the presence of the MON15985 event based on the DNA sequence of the recombinant construct inserted into the cotton genome that resulted in the MON15985 event and/or the genomic sequences flanking the insertion site.06-16-2011
20110143345Genetic Markers for SCD or SCA Therapy Selection - Variations in certain genomic sequences useful as genetic markers of Sudden Cardiac Death (“SCD”) or Sudden Cardiac Arrest (“SCA”) risk are described. Novel genetic markers useful in assessing the risk of SCD or SCA and compositions containing the same are provided herein. Methods of distinguishing patients having an increased susceptibility to SCD or SCA, through use of these markers, alone or in combination with other markers, are also provided. Further, methods of detecting a polymorphism associated with SCD or SCA are taught.06-16-2011
20120141998ANTIGEN-PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS FOR ENHANCING OR REDUCING IMMUNE TOLERANCE - The present invention is based on the discovery antigen-presenting cells (APCs) may be generated to have predetermined levels of expression of the intracellular enzyme, indoleamine 2,3-dioxygenase (IDO). Because expression of high levels of IDO is correlated with a reduced ability to stimulate T cell responses and an enhanced ability to induce immunologic tolerance, APCs having high levels of IDO may be used to increase tolerance in the immune system, as for example in transplant therapy or treatment of autoimmune disorders. For example, APCs having high levels of IDO, and expressing or loaded with at least one antigen from a donor tissue may be used to increase tolerance of the recipient to the donor's tissue. Alternatively, APCs having reduced levels of IDO expression and expressing or loaded with at least one antigen from a cancer or infectious pathogen may be used as vaccines to promote T cell responses and increase immunity.06-07-2012
20120141997Compositions And Methods For Free-Solution Conjugate Nucleic Acid Analysis - The present invention provides compositions and methods for performing free-solution conjugate analysis of nucleic acid molecules. For example, the present invention provides multiplexed single-base extension assays for genotyping. In particular, the present invention provides a series of disperse polyamide “drag tags” for use in achieving high-resolution separation of nucleic acid reaction products.06-07-2012
20120141993COMPOSITIONS AND METHODS FOR NEISSERIA GONORRHOEAE DIAGNOSTIC TESTING - The invention provides methods, reagent, and kits for detecting the presence of 06-07-2012
20120141990METHODS, COMPOSITIONS AND KITS FOR DETECTION AND ANALYSIS OF ANTIBIOTIC-RESISTANT BACTERIA - The present invention relates generally to detection of antibiotic-resistant bacteria in a sample. In particular, the invention provides methods, compositions and kits for detecting and analyzing methicillin-resistant 06-07-2012
20110229889DOPAMINERGIC NEURON PROLIFERATIVE PROGENITOR CELL MARKER Msx1/2 - The present invention is a probe, a primer, and an antibody, for detecting a dopaminergic neuron proliferative progenitor cell. According to the present invention, there is provided a polynucleotide probe and a polynucleotide primer for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell, which can hybridize with a polynucleotide consisting of a nucleotide sequence of an Msx1 gene or an Msx2 gene, or a complementary sequence thereto, and an antibody against an Msx1 protein or an Msx2 protein, or a part thereof for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell.09-22-2011
20130122495DIAGNOSIS KIT AND CHIP FOR BLADDER CANCER USING BLADDER CANCER SPECIFIC METHYLATION MARKER GENE - The present invention relates to a kit and nucleic acid chip for diagnosing bladder cancer using a bladder cancer-specific marker gene. More particularly, the invention relates to a kit and nucleic acid chip for diagnosing bladder cancer, which can detect the promoter methylation of a bladder cancer-specific gene, the promoter or exon region of which is methylated specifically in transformed cells of bladder cancer. The use of the diagnostic kit or nucleic acid chip of the invention enables diagnosis of bladder cancer at an early stage of transformation, thus enabling early diagnosis of bladder cancer, and can diagnose bladder cancer in a more accurate and rapid manner compared to a conventional method.05-16-2013
20130122499SYSTEM AND METHOD OF DETECTING LOCAL COPY NUMBER VARIATION IN DNA SAMPLES - Systems and methods for measuring local copy number variation in DNA samples are provided. In particular, methods for detecting copy number variation in circulating free DNA (cfDNA) that may be used to assay for copy number variations often corresponding to cancerous cells or tumors are provided.05-16-2013
20130122501METHODS AND VECTORS FOR PRODUCING TRANSGENIC PLANTS - Methods of, and compositions for, assembling one or more transcription units in a genome without a linked selectable marker or other unwanted transcription unit are provided. Also provided methods of, and compositions for, assembling one or more transcription units in a genome with a reduced frequency of vector backbone.05-16-2013
20130122502NANOPROBES FOR DETECTION OR MODIFICATION OF MOLECULES - The disclosure provides probes for one or more target molecules. In particular examples, the probes include a molecular linker and first and second functional groups linked and spaced by the molecular linker, wherein the functional groups are capable of interacting with one another or with the target biomolecule in a predetermined reaction, and wherein the molecular linker maintains the first and second functional groups sufficiently spaced from one another such that the functional groups do not substantially interact in an absence of the target biomolecule. In the presence of the target biomolecule the functional groups interact (with each other, with the target biomolecule, or both), and in some examples a detectable signal is produced. In some examples, the functional groups can detect or modify a target molecule. Also provided are methods of using the probes, for example to detect or modify a target molecule.05-16-2013
20120196285Methods for Enriching Microparticles or Nucleic Acids Using Binding Molecules - Methods for enriching specific microparticles, such as fetal microparticles or disease specific microparticles, in a biological sample are disclosed. In certain embodiments, the methods include combining a biological sample with a molecule that binds specific microparticles, and separating fractions of the biological sample, wherein the fraction that contains the binding molecule is enriched for the specific microparticles. Also disclosed are methods for enriching fetal nucleic acids by enriching fetal microparticles in a fraction of the biological sample and isolating nucleic acids from the enriched fraction. Methods for facilitating prenatal diagnosis of fetal chromosomal abnormalities are disclosed. In certain embodiments, the methods include combining a biological sample with a molecule that binds fetal microparticles, separating fractions of the biological sample, isolating nucleic acids from the fraction enriched for fetal microparticles, and analyzing the nucleic acids for the presence of a mutation.08-02-2012
20110129824DOUBLE-STRANDED PROBES FOR THE FLUORESCENT DETECTION OF NUCLEIC ACIDS - The present invention relates to a double-stranded probe intended for the fluorescent detection of at least one single-stranded or double-stranded target nucleic acid, comprising: —a first strand of formula X06-02-2011
20110129831GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.06-02-2011
20110129838USING GENETIC POLYMORPHISMS OF THE BICD1 GENE AS A METHOD FOR DETERMINING A RISK OF DEVELOPING MYOPIA - A method and kit for determining an increased risk of developing myopia in a subject is provided by detecting an SNP in the BICD1 gene. The SNP is selected from a group consisting of rs10844126 (A/C), rs1151029 (A/T), rs2650122 (C/T), rs10771923 (A/G), rs1151009 (T/C), rs2125173 (A/G) and rs161959 (C/G). When the presence of the risk allele associated with myopia is detected at the SNP, the subject is determined in an increased risk of developing myopia.06-02-2011
20120244529MULTIPLEX ANALYSIS OF CELLS, PARTICLES, AND OTHER ANALYTES - In general, the invention features multiplexed devices, systems, methods, and kits for analysis of cells, particles, and other analytes on a porous membrane. Preferred devices detect, identify and quantify low levels of microorganisms in complex biological samples, such as blood. An exemplary device includes a housing having a fluid inlet that is in fluid communication with a plurality of channels, e.g., having substantially the same fluidic resistance. Each of the plurality of channels is in fluid communication with a reservoir containing reagents for analyzing cells, particles, or other analytes bound to particles, one or more substantially planar, porous membranes through which the cells or particles do not pass, and one or more outlets, wherein liquid flowing away from the inlet is divided between the plurality of channels and flows through the one or more membranes towards the outlet, and wherein the reservoir is disposed upstream of the one or more membranes.09-27-2012
20120244535FUNCTIONALIZED 3-ALKYNYL PYRAZOLOPYRIMIDINE ANALOGUES AS UNIVERSAL BASES AND METHODS OF USE - 3-alkynyl inosine analogs and their uses as universal bases are provided. The inosine analogues can be incorporated into nucleic acid primers and probes. They do not significantly destabilize nucleic acid duplexes. As a result, the novel nucleic acid primers and probes incorporating the inosine analogues can be used in a variety of methods. The analogs function unexpectedly well as universal bases. Not only do they stabilize duplexes substantially more than hypoxanthine opposite A, C, T, and G but they are also recognized in primers by polymerases, allowing efficient amplification.09-27-2012
20130189684QUANTIFICATION OF CELL-SPECIFIC NUCLEIC ACID MARKERS - The technology relates in part to selection, quantification and use of particular nucleic acid markers. In some embodiments, such markers are particular epigenetic markers, and sometimes each marker is a particular methylation state of a nucleic acid locus.07-25-2013
20130217011DIAGNOSTIC BIOMARKERS OF DIABETES - Methods are disclosed for the identification of gene sets that are differentially expressed in PBMCs of patients diagnosed with a pre-diabetic disease state and overt type II diabetes. 3 gene and 10 gene signatures are shown to accurately predict a diabetic disease state in a patient. The application also described kits for the rapid diagnosis of diabetic disease states in patients at a point of care facility.08-22-2013
20130217013EXTERNAL FILES FOR DISTRIBUTION OF MOLECULAR DIAGNOSTIC TESTS AND DETERMINATION OF COMPATIBILITY BETWEEN TESTS - Embodiments disclosed herein relate to methods and systems for performing an automated assay, and particularly to performing an assay on a plurality of samples on an automated instrument.08-22-2013
20130217016METHOD FOR DETECTING MUTANT DNA - The present invention relates to a method for detecting of a mutant DNA using a probe, comprising: 08-22-2013
20130217017Detection and Assessment of Cancer Risk Using Telomere Health - Disclosed are compositions and methods related to assessing the risk of cancer, such as breast cancer and lung cancer, through analyzing the length of telomeres, such as chromosome 9p, 15p, and/or Xp telomere, such as the short arm of the 9p, 15p, and/or Xp telomere. For example, if the 9p, 15p, and/or Xp arm is shorter than normal, the risk of cancer is increased.08-22-2013
20130217018METHODS AND SYSTEMS FOR INFERRING BOVINE TRAITS - Methods, compositions, and systems are provided for managing bovine subjects in order to maximize their individual potential performance and edible meat value, and to maximize profits obtained in marketing the bovine subjects. The methods and systems draw an inference of a trait of a bovine subject by determining the nucleotide occurrence of at least one bovine SNP that is identified herein as being associated with the trait. The inference is used in methods of the present invention to establish the economic value of a bovine subject, to improve profits related to selling beef from a bovine subject; to manage bovine subjects, to sort bovine subjects; to improve the genetics of a bovine population by selecting and breeding of bovine subjects, to clone a bovine subject with a specific trait, to track meat or another commercial product of a bovine subject; and to diagnose a health condition of a bovine subject. Methods are also disclosed for identifying additional SNPs associated with a trait, by using the associated SNPs identified herein.08-22-2013
20120129171Genetic Markers for Assessing Risk of Developing Bipolar Disorder - This document provides methods and materials related to genetic markers of Bipolar Disorder (BD) and Schizophrenia (SZ). For example, methods for using such genetic markers to assess risk of developing BD and/or SZ are provided, as are methods for making a differential diagnosis between BD and SZ.05-24-2012
20120196286METHOD AND APPARATUS FOR DIAGNOSING AGE-RELATED MACULAR DEGENERATION - Disclosed is a method for identifying an individual who has an altered risk for developing age-related macular degeneration comprising detecting an insertion/deletion polymorphism in the ARMS2 gene08-02-2012
20120141996CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE MUTATIONS - The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. Also provided are probes for detecting the mutant sequences. Methods of identifying if an individual has a genotype containing one or more mutations in the CFTR gene are further provided.06-07-2012
20120141988METHOD OF CELL-LINE IDENTIFICATION - The present invention discloses a method of cell-line identification comprising one or more of the following steps: (a) analysis of the calmodulin gene; (b) analysis of the Axl receptor tyrosine kinase gene; (c) analysis of an attacin gene; or a combination thereof.06-07-2012
20120141989KIT AND METHOD FOR RAPIDLY DETECTING A TARGET NUCLEIC ACID FRAGMENT - The invention provides a kit for rapidly detecting a target nucleic acid fragment comprising a magnetic bead; an inner primer pair and an outer primer pair suitable for loop-mediated isothermal amplification; and reagents for loop-mediated isothermal amplification. The invention also provides a kit for detecting a pathogen in fish, a method for rapidly detecting a target nucleic acid fragment, and a method for detecting a pathogen in fish.06-07-2012
20120141995Method for the Detection of Multiple Single Nucleotide Variations or Single Nucleotide Polymorphisms in a Single Tube - The present invention discloses a method for detecting multiple single nucleotide variations or polymorphisms in a single reaction tube, and the oligonucleotide, the probe, the set of probes, the kit used, as well as the use thereof. Specifically, it relates to a method for identifying the genotype of multiple single nucleotide variation or SNP sites from the melting temperature of a kind of artificial melting temperature tag sequence (AMTS) and the type of fluorescence labels.06-07-2012
20120141992COMPOSITIONS AND METHODS FOR TRICHOMONAS VAGINALIS DIAGNOSTIC TESTING - The invention provides methods, reagents and kits for determining the presence of 06-07-2012
20120141991METHODS AND PROBES FOR DETECTING ESOPHAGEAL CANCER - Probe sets and methods of using probes and probe sets for selectively detecting high grade dysplasia and esophageal adenocarcinoma or low grade dysplasia from biologic samples are described. Methods of the invention include contacting a biological sample obtained from a subject with a set of chromosomal probes to selectively detect an esophageal carcinoma or precursor lesion in the sample, if any, under conditions for specifically hybridizing the probes to their nucleic targets present in the sample. The presence or absence of high grade dysplasia and esophageal adenocarcinoma or low grade dysplasia is thereafter specifically determined from the hybridization pattern detected for the set of chromosomal probes to the biological sample.06-07-2012
20120141986Multivalent substrate elements for detection of nucleic acid sequences - The invention provides a method of detecting multiple nucleic acid sequences using multiplex substrate elements, each having predetermined sets of independent probes, and using mistures of distinguishably labeled nucleotides.06-07-2012
20120034605METHOD FOR DETECTION OF COLORECTAL TUMOR - Disclosed is a method for determining the presence or absence of a colorectal tumor, specifically colorectal cancer or colorectal adenoma, with high sensitivity and high specificity by employing the methylation of DNA as a measure. Also disclosed is a kit for carrying out the method. Specifically, measurement is made on the degree of methylation of one or more CpG sequences contained in the region lying between positions -477 to -747, more preferably a CGCG sequence contained in the region lying between positions -688 to -691, in TWIST1 gene (02-09-2012
20120034603LIGATION-BASED DETECTION OF GENETIC VARIANTS - The present invention provides assays systems and methods for detection of genetic variants in a sample, including copy number variation and single nucleotide polymorphisms. The invention preferably employs the technique of tandem ligation, i.e. the ligation of two or more fixed sequence oligonucleotides and one or more bridging oligonucleotides complementary to a region between the fixed sequence oligonucleotides.02-09-2012
20120196284Method of Measuring Telomere Length - Disclosed herein is a novel method of measuring telomere length comprising determining the DNA content (Dx) of a sample, determining the telomeric content (T) of a sample, and determining the value of T/Dx.08-02-2012
20110129836Automated Seed Sampler and Methods of Sampling, Testing and Bulking Seeds - An automated seed sampler includes a sampling station; a sampler for removing material from a seed in the sampling station; a seed conveyer for conveying the seed from the sampling station to a compartment in a seed tray; and a conveyor for conveying the material removed from the seed to a corresponding compartment in a sample tray. The method of the present invention comprises feeding seeds individually to a sampling station, removing a sample from the seed in the sampling station; conveying the sample to a compartment in a sample tray, and conveying the seed to a corresponding compartment in a seed tray. The samples can be tested, and the seeds can be sorted according to the results of the testing of their corresponding samples.06-02-2011
20110129830DETERMINATION OF KIR HAPLOTYPES ASSOCIATED WITH DISEASE - Disclosed is a method of determining KIR genotypes for one or more individuals in parallel, the method comprising: for each individual, amplifying the polymorphic exon sequences of the KIR genes, pooling the KIR amplicons, performing emulsion PCR followed by pyrosequencing in parallel to determine all the amplicon sequences present in the individual to determine which KIR alleles are present in the individual.06-02-2011
20110129829METHODS FOR DETECTION OF CORN EVENT DAS-59132 - The invention provides assays for detecting the presence of the maize DAS-59132 event based on the DNA sequence of the recombinant construct inserted into the maize genome and the DNA sequences flanking the insertion site. Kits and conditions useful in conducting the assays are provided.06-02-2011
20130130239Test for Detecting Xanthomonas axonopodis pv. allii - The present invention relates to novel tools for detecting 05-23-2013
20130130258DETECTION, IDENTIFICATION AND DIFFERENTIATION OF EUBACTERIAL TAXA USING A HYBRIDIZATION ASSAY - The present invention relates to a method for the specific detection and/or identification of 05-23-2013
20110129826METHOD FOR DETERMINATION OF INFLAMMATORY DISEASE BY USING SINGLE NUCLEOTIDE POLYMORPHISM IN BRCA1-RELATED PROTEIN (BRAP) GENE - It is an object of the present invention to identify a novel single nucleotide polymorphism (SNP) associated with the development and advancement of inflammatory diseases such as myocardial infarction. The present invention provides a method for judging inflammatory diseases, which comprises detecting at least one gene polymorphism in the BRCA1-associated protein (BRAP) gene.06-02-2011
20110129827METHODS FOR TRANSCRIPT ANALYSIS - The invention takes a unique approach to transcript analysis that provides a novel DGE technology based on single-molecule sequencing. More particularly, the invention relates to methods and compositions for analyzing and identifying genes and gene expression and transcript profiles using a DGE-based technology and single molecule sequencing that does not require amplification or fragmentation.06-02-2011
20110129834SELECTIVE AMPLIFICATION OF POLYNUCLEOTIDE SEQUENCES - The application relates to compositions and methods which may be used for amplifying selected portions of nucleic acid samples. Samples may comprise an entire genome of a bacterium, plant, animal, or other organism. In some instances, methods allow for enrichment of hundred or thousands of target nucleic acids of interest in an efficient and cost effective manner.06-02-2011
20110244455DIGITAL ANALYTE ANALYSIS - The invention generally relates to droplet based digital PCR and methods for analyzing a target nucleic acid using the same. In certain embodiments, methods of the invention involve forming sample droplets containing, on average, a single target nucleic acid, amplifying the target in the droplets, excluding droplets containing amplicon from the target and amplicon from a variant of the target, and analyzing target amplicons.10-06-2011
20110129837DETECTION OF NUCLEIC ACIDS AND PROTEINS - The invention generally relates to methods for detecting a target nucleic acid and a target protein in a single assay.06-02-2011
20110212451RNA DETECTION METHOD - The present invention relates to methods for the detection of target RNA sequences and to RNA amplification methods making use of strand displacement techniques employing RNA-dependent RNA polymerases having RNA-oligonucleotide duplex separation activity and being capable of de novo RNA synthesis in the absence of a primer. The present invention further relates to kits for carrying out such methods.09-01-2011
20110212446FAST PCR FOR STR GENOTYPING - Disclosed is a method of amplifying a nucleic acid sequence, wherein the method comprises subjecting a reaction mixture to at least one amplification cycle, wherein the reaction mixture comprises a double-stranded nucleic acid and at least two primers capable of annealing to complementary strands of the double-stranded nucleic acid and amplifying at least one short tandem repeat (STR) using a Family A DNA polymerase in a Fast PCR protocol having a two-step amplification cycle in 25 seconds or less. Also disclosed are real-time PCR methods using the two-step protocol and kits for STR profiling using the Fast PCR protocol.09-01-2011
20120034607Methods and apparatus for measuring analytes using large scale fet arrays - Methods and apparatus relating to very large scale FET arrays for analyte measurements. ChemFET (e.g., ISFET) arrays may be fabricated using conventional CMOS processing techniques based on improved FET pixel and array designs that increase measurement sensitivity and accuracy, and at the same time facilitate significantly small pixel sizes and dense arrays. Improved array control techniques provide for rapid data acquisition from large and dense arrays. Such arrays may be employed to detect a presence and/or concentration changes of various analyte types in a wide variety of chemical and/or biological processes. In one example, chemFET arrays facilitate DNA sequencing techniques based on monitoring changes in hydrogen ion concentration (pH), changes in other analyte concentration, and/or binding events associated with chemical processes relating to DNA synthesis.02-09-2012
20120034609GENE DETECTION ASSAY FOR IMPROVING THE LIKELIHOOD OF AN EFFECTIVE RESPONSE TO AN EGFR ANTAGONIST CANCER THERAPY - The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing EGFR, as determined by a gene amplification assay, with an EGFR antagonist. Such method comprises administering a cancer-treating dose of the EGFR antagonist, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells erbB1 gene has been found to be amplified e.g., by fluorescent in situ hybridization. EGFR antagonists described include an anti-EGFR antibody.02-09-2012
20110244457IMMUNO-AMPLIFICATION - A high-sensitivity, low-background immuno-amplification assay is provided, which offers a streamlined workflow suitable for high-throughput assays of clinically relevant samples, such as blood and other bodily fluids. The assay comprises the use of two proximity members that each comprise an analyte-specific binding component conjugated to an oligonucleotide. Binding an analyte brings the oligonucleotide moieties of the proximity members in sufficiently close contact that the oligonucleotides form an amplicon. The presence of the analyte then is detected through amplification of the amplicon and detection of the amplified nucleic acids. The sensitivity of the assay of the present invention is improved by preventing spurious or non-specific amplicon formation by proximity members that are not complexed with an analyte.10-06-2011
20110244461METHOD FOR PREPARING STOOL SAMPLE, SOLUTION FOR PREPARING STOOL SAMPLE AND STOOL COLLECTION KIT - The present invention relates to the providing of a method for preparing a stool sample that enables a nucleic acid in a stool to be stably preserved without requiring a complex procedure, a solution for preparing a stool sample, a stool collection kit used in that method, and a method for recovering and analyzing a nucleic acid in a stool using a stool sample prepared using the preparation method of the present invention. A method for preparing a stool sample according to the present invention is a method for preparing a stool sample being used for analyzing a nucleic acid contained in the stool, and is characterized in that a collected stool is mixed with a solution having a protease inhibitor as an active ingredient.10-06-2011
20110244460METHOD FOR DETECTING CONTROLS FOR NUCLEIC ACID AMPLIFICATION AND USE THEREOF - The present invention provides a control detection method for easily detecting a positive control and a negative control simultaneously in one reaction system. An amplification reaction is carried out by adding a control template nucleic acid to a reaction system for detecting controls. The template nucleic acid can be amplified by a primer capable of amplifying an objective target sequence. An amplification region of the control template nucleic acid amplified by the primer can be hybridized with a detection probe capable of hybridizing to the target sequence. A Tm value (Tm10-06-2011
20110244459METHODS FOR IDENTIFYING ERBB2 ALTERATION IN TUMORS - Methods for identifying ERBB2 (also named HER2) alteration in tumors, in particular cancer, based on the analysis of the expression of at least three genes of the ERBB2 amplicon located within less than one megabase on either side of ERBB2, and eventually of the gene corresponding to the Affymetrix probeset 234046_at (SEQ ID NO: 31), as well as a poynucleotide library useful for the molecular characterization of a cancer including polynucleotide sequences for detecting the genes, and a kit including the library.10-06-2011
20110244458Methods and Nucleic Acids for Analyses of Cellular Proliferative Disorders - Aspects of the invention provide methods, nucleic acids and kits for detecting, or for detecting and distinguishing between or among liver cell proliferative disorders or for detecting, or for detecting and distinguishing between or among colorectal cell proliferative disorders. Particular aspects disclose and provide genomic sequences the methylation patterns of which have substantial utility for the improved detection of and differentiation between said class of disorders, thereby enabling the improved diagnosis and treatment of patients.10-06-2011
20110244456HERBICIDE TOLERANT COTTON PLANTS AND METHODS FOR IDENTIFYING SAME - The invention provides specific transgenic cotton plants, plant material and seeds, characterized in that these products harbor a specific transformation event at a specific location in the cotton genome. Tools are also provided which allow rapid and unequivocal identification of the event in biological samples.10-06-2011
20110244454FREEZE-DRIED COMPOSITIONS FOR BIOCHEMICAL REACTIONS - The use of raffinose as a glass-forming agent for freeze-dried compositions intended for use in conducting chemical or biochemical reactions such as the PCR. Thus, for instance, there is provided a composition for carrying out a chemical or biochemical reaction, said composition being in a freeze-dried form and comprising (i) a set of reagents comprising at least some of the chemical or biochemical reagents necessary for conducting said chemical or biochemical reaction, and (ii) raffinose. Kits comprising these compositions and methods of using them form a further aspect of the invention.10-06-2011
20110244451Methods for prenatal diagnosis of chromosomal abnormalities - Chromosomal abnormalities are responsible for a significant number of birth defects, including mental retardation. The present invention is related to methods for non-invasive and rapid, prenatal diagnosis of chromosomal abnormalities based on analysis of a maternal blood sample. The invention exploits the differences in DNA between the mother and fetus, for instance differences in their methylation states, as a means to enrich for fetal DNA in maternal plasma sample. The methods described herein can be used to detect chromosomal DNA deletions and duplications. In a preferred embodiment, the methods are used to diagnose chromosomal aneuploidy and related disorders, such as Down's and Turner's Syndrome.10-06-2011
20110129833Gene Expression Markers for Predicting Response to Chemotherapy - The present invention provides sets of genes the expression of which is important in the prognosis of cancer. In particular, the invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial treatment response to chemotherapy. FHIT; MTA1; ErbB4; FUS; BBC3; IGF1R; CD9; TP53BP1; MUC1; IGFBP5; rhoC; RALBP1; STAT3; ERK1; SGCB; DHPS; MGMT; CRIP2; ErbB3; RAP1GDS1; CCND1; PRKCD; Hepsin; AK055699; ZNF38; SEMA3F; COL1A1; BAG1; AKT1; COL1A2; Wnt.5a; PTPD1; RAB6C; GSTM1, BCL2, ESR1; or the corresponding expression product, is determined, said report includes a prediction that said subject has a decreased likelihood of response to chemotherapy.06-02-2011
20110129832Polynucleotide Primers and Probes - The present invention provides a novel technology that involves improved primer design. These primer pairs have a wide range of applications and provide high sensitivity and specificity.06-02-2011
20110129828SPECIFIC DOUBLE-STRANDED PROBES FOR HOMOGENEOUS DETECTION OF NUCLEIC ACID AND THEIR APPLICATION METHODS - Nucleic acid detection probes that comprise a pair of complementary, fluorophore/quencher labeled oligonucleotides, one of which is shorter than the other, are able to detect single-stranded and double-stranded targets in hybridization reactions and amplification reactions with real-time detection. Double-stranded probes of equal length are useful in PCR amplification reactions with real-time detection.06-02-2011
20110129825COMPOSITIONS, METHODS AND SYSTEMS FOR THE SIMULTANEOUS DETERMINATION OF PARENTAGE, IDENTITY, SEX, GENOTYPE AND/OR PHENOTYPE AND BREED DETERMINATION IN ANIMALS - The invention provides for a universal genetic evaluation system capable of simultaneously determining multiple genetic characteristics in domestic and wild animals. In particular, the invention provides for the use of polymorphisms, such as single nucleotide polymorphisms (SNPs), insertions, deletions, inversions, and/or other mutations within gene sequences, as determinants of genetic characteristics, such as parentage, identity, sex, genotype and/or phenotype. The universal genetic evaluation system is utilized to simultaneously determine multiple genetic characteristics in horses and wild horses, dogs and wild canids, cats, goats and wild goats, sheep and wild sheep, cattle, bison, deer (cervidae), donkeys, mules, swine and wild swine, camelids and wild camelids, other domestic and certain species of wild animals (deer, elk, red deer, antelope, caribou and reindeer, moose and other exotic deer and antelope species), birds (including pet birds and commercial bird species), reptiles, amphibians, fish and rodents, concurrently for each species.06-02-2011
20110212443Method for determining the specific growth rate of distinct microbial populations in a non-homogeneous system - The present invention pertains to a molecular biology-based method and kit for measuring the specific growth rate (or cell doubling time) of distinct microbial populations. The method and kit can be used to analyze mixed culture samples that have been exposed to chloramphenicol or other protein synthesis inhibitors for defined times. In a preferred embodiment, the method of the invention (also referred to herein as FISH-RiboSyn) is an in situ method that utilizes fluorescence in situ hybridization (FISH) with probes that target: (1) the 5′ or 3′ end of precursor 16S rRNA; or (2) the interior region of both precursor 16S rRNA and mature 16S rRNA. Images can be captured for a defined exposure time and the average fluorescent intensity for individual cells can be determined. The rate of increase of the whole cell fluorescent intensity is used to determine the specific growth rate. The method of the invention can be attractive for rapidly measuring the specific growth rate (or cell doubling time) of distinct microbial populations within a mixed culture in industries such as environmental systems (water and wastewater treatment systems), bioremediation (optimization of conditions for microbial growth), public health (identification of rapidly growing infectious microbes), and homeland security (identification of rapidly growing bioterrorism agents).09-01-2011
20110136116DETECTION OF TARGET NUCLEIC ACID SEQUENCES USING FLUORESCENCE RESONANCE ENERGY TRANSFER - A method for identifying a plurality of target nucleic acid molecules in a sample. The method provides a plurality of oligonucleotide probe sets. Each set comprises a first and a second probe, each having a target-specific portion and a tunable portion with an acceptor or a donor group. The first probe further comprises an endcapped hairpin. A reaction comprises a denaturation and hybridization cycle. Under the hybridization, the set of probes hybridize in a base-specific manner to their respective target nucleotide sequences, and ligate to one another to form a ligation product. Under conditions that permit hybridization of the tunable portions of the ligation product to one another, an internally hybridized ligation product formed, which allows the detection of the fluorescence resonance energy transfer (FRET). A method comprising PCR amplification is also disclosed.06-09-2011
20110244452SEQUENCE DATA BY REDUCTION OF NOISE DUE TO CARRY-OVER PRIMER - The present invention provides methods of reducing the background signal of a nucleic acid sequencing reaction. In particular, the invention provides methods of specifically degrading unwanted chain termination reaction products generated by the extension of primers carried over from the amplification step of the sequencing reaction. These methods are amenable for use with both one step and two-step amplification/chain termination reaction sequencing protocols.10-06-2011
20120244538METHOD FOR DETECTING GENE MODIFICATIONS BY MEANS OF ASYMMETRICAL PCR AND BLOCKING AGENTS - A method of detecting at least one gene modification such as a mutation in a gene includes carrying out an asymmetric polymerase chain reaction (PCR) with a combined use of at least one detectable mutation-specific hybridization probe (sensor probe) and at least one wild-type specific blocking agent which inhibits a binding of the at least one detectable mutation-specific hybridization probe (sensor probe) to a wild-type gene so as to provide at least one of a selective intensification and an amplification of a detection of a gene segment of a mutation gene having a gene modification.09-27-2012
20120244536Detection of Bladder Cancer Recurrence - The present invention generally relates to methods of screening for cancer recurrence. Methods of the invention involve identifying a threshold parameter of a protein and of two or more nucleic acids, where the threshold parameters are indicative of the absence of cancer, conducting an assay in a sample to determine a parameter of the two or more nucleic acids and a parameter of the protein, and identifying the sample as positive for cancer recurrence if the parameters of at least one of the nucleic acids and the protein present in the sample are greater than their respective threshold parameters. In certain aspects of the invention, the nucleic acids include FGFR3, Vimentin, and NID2. In certain aspects of the invention, the protein includes MMP2 or MMP9.09-27-2012
20120244534CLOSED-SYSTEM MULTI-STAGE NUCLEIC ACID AMPLIFICATION REACTIONS - The invention is directed to systems, methods, and apparatus for carrying out multi-stage amplification reactions, especially under fluidly closed conditions. In one aspect, methods of the invention are carried out in a fluidly closed reaction system that permits the isolation of a portion of a first (or prior) reaction mixture and its use as a sample or specimen in a second (or subsequent) reaction mixture, thereby substantially avoiding interfering effects that first reaction components may have in the second reaction if both reaction mixtures were simply combined together. In this aspect, systems, methods, and apparatus of the invention may be used with any amplification reaction that permits multiple stages of amplification based on the use of nested primers.09-27-2012
20120244539METHOD FOR SCREENING OF THERAPEUTIC AGENT FOR HYPERLIPEMIA - Disclosed are a highly safe treatment method for hyperlipidemia and a therapeutic agent for hyperlipidemia. Specifically, the invention provides a novel method for screening an agent for treating hyperlipidemia, more specifically, a method for screening a substance that can inhibit the production or function of gangliosides, particularly GM3, or inhibit the activity or expression of GM3 synthase to reduce a blood lipid level. A pharmaceutical composition, which can specifically inhibit the production of gangliosides, particularly GM3, thereby effective for hyperlipidemia treatment, and others are also provided.09-27-2012
20120244530METHODS OF DETECTING LUNG CANCER - Methods of detecting lung cancer, such as non-small cell lung cancer, including squamous cell carcinoma and adenocarcinoma, are provided. Methods of detecting changes in the levels of one or more small RNAs associated with lung cancer are also provided. Compositions and kits are also provided.09-27-2012
20120244527Compositions, Kits and Methods for Synthesis and/or Detection of Nucleic Acids - A composition comprising a thermostable DNA polymerase; and a PCR inhibitor blocking agent, wherein the PCR inhibitor blocking agent is present in an amount effective to enhance tolerance of an assembled PCR to a PCR inhibitor.09-27-2012
20120244533DETECTION OF AAD1 EVENT DAS-40278-9 - This invention relates in part to detecting herbicide tolerant plants—more specifically, an aad-1 transformation event in corn plants. The subject invention also provides assays for detecting the presence of the subject event in a sample (of corn grain, for example). Kits and conditions useful in conducting the assays are also provided. The subject invention also relates in part to plant breeding using the subject methods. In some embodiments, said event/polynucleotide sequence can be “stacked” with other traits. More specifically, the invention relates in part to an endpoint TaqMan PCR assay for AAD-1 corn event 40278-9. Some embodiments are directed to assays that are capable of high throughput zygosity analysis. The subject invention further relates, in part, to the use of a preferred reference gene for use in determining zygosity.09-27-2012
20120244532Device and Methods for Epigenetic Analysis - Provided herein are methods and devices for single object detection. The methods and devices can be used to identify a plurality epigenetic markers on a genetic material, or a chromatin, encompassing fragments thereof. The invention provides for the characterization of the genetic material flowing through a channel in a continuous body of fluid based on detection of one or more properties of the genetic material. The methods and systems provided herein allow genome-wide, high-throughput epigenetic analysis and overcome a variety of limitations common to bulk analysis techniques.09-27-2012
20120244531METHOD FOR PROVIDING INFORMATION FOR DIAGNOSING CANCER USING QUANTITATIVE REAL-TIME PCR AND KIT FOR DIAGNOSING CANCER FOR THE SAME - There is provided a method for providing information for diagnosing cancer using Real-Time RT-PCR, and a kit for diagnosing cancer for the method.09-27-2012
20110177510METHOD AND PROBE SET FOR DETECTING CANCER - Methods for detecting cancer that include hybridizing a set of chromosomal probes to a biological sample obtained from a patient, and identifying if aneusomic cells are present in a selected subset of cells obtained from the biological sample are described. A set of chromosomal probes and kits for detecting cancer that include sets of chromosomal probes, are also described.07-21-2011
20110177504METHODS FOR DETECTING INFLAMMATORY BOWEL DISEASE - The present invention provides for a method of detecting the presence of inflammatory bowel disease in gastrointestinal tissues or cells of a mammal by detecting increased expression of LY6 genes in the tissues or cells of the mammal relative to a control.07-21-2011
20110250601Bisulfite Conversion of DNA - The present invention provides an improved method for the bisulfite conversion of DNA, and facilitates the analysis of cytosine methylation of genomic DNA. Novel combinations of denaturing solvents, new reaction conditions and new purification methods provide surprisingly efficacious methods for bisulfite conversion of DNA relative to prior art methods. The converted DNA may subsequently be analyzed by many different methods.10-13-2011
20110250597DIGITAL ANALYTE ANALYSIS - The invention generally relates to droplet based digital PCR and methods for analyzing a target nucleic acid using the same. In certain embodiments, methods of the invention involve forming sample droplets containing, on average, a single target nucleic acid, amplifying the target in the droplets, excluding droplets containing amplicon from the target and amplicon from a variant of the target, and analyzing target amplicons.10-13-2011
20110250602Methods and Computer Software Products for Identifying Transcribed Regions of a Genome - Methods and computer software products are provided for transcriptional annotation. In one embodiment of the invention, a region of the genome where the intensity of hybridization of all the probes are above a threshold value (usually the level of non-specific hybridization) is identified. The region may be identified by aligning the probes against the genome; walking through the genome to find regions where all consecutive probes have intensities above the threshold value.10-13-2011
20110250598DETERGENT FREE POLYMERASES - The present invention relates to a formulation of a thermostable DNA polymerase which is completely free of detergents and its particular use in real time polymerase chain reaction (PCR). Such a formulation may be obtained if the selected purification method does not require the addition of a detergent at any purification step.10-13-2011
20110250596METHODS, KITS AND COMPOSITIONS PERTAINING TO LINEAR BEACONS - This invention is directed to methods for determining amplified nucleic acid using Linear Beacons10-13-2011
20110151460METHODS AND SYSTEMS OF USING EXOSOMES FOR DETERMINING PHENOTYPES - Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.06-23-2011
20110151457HYPERTHEROMOSTABLE ENDONUCLEASE IV SUBSTRATE PROBE - The present invention relates to a hyperthermostable endonuclease IV substrate probe to be used in nucleic acid assay methods which can be carried out using hyperthermostable enzymes, including detection of target nucleic acids, and detection of nucleic acid polymorphism.06-23-2011
20110151455Fish-ribosyn for antibiotic susceptibility testing - The subject invention concerns materials and methods for evaluating the susceptibility of bacterial cells to an antibiotic or other antimicrobial compound or agent. In one embodiment, a sample comprising a microbial population is exposed to an antibiotic of interest. The sample is then processed using FISH-RiboSyn methods to determine the specific growth rate of the antibiotic-exposed microbes as compared to an untreated control. The subject invention also concerns materials and methods for determining the most suitable and/or effective antibacterial treatment for a person or animal having a bacterial infection.06-23-2011
20110151454Gene expression markers of tumor resistance to HER2 inhibitor treatment - The present invention concerns markers of resistance of HER2 expressing tumors to treatment with HER2 inhibitors, such as HER2 antibodies, including trastuzumab.06-23-2011
20110151451Use of Conjugates with linkers cleavable by photodissociation or fragmentation for mass spectromety analysis of tissue sections - The invention concerns a method for determining at least one target molecule map in a tissue section, using at east one (A-X)n-B conjugate, wherein A is a tag molecule of known molecular weight, X is a linker that is cleaved during sample desorption/ionization, n is an integer of at least 1, and B is a binding molecule that binds specifically to said target molecule. When using MALDI mass spectrometry, said linker molecule X may be cleaved by photodissociation during sample laser irradiation if photocleavable at the wavelength of said MALDI laser. Alternatively, when using UV-MALDI, IR-MALDI, SIMS or DESI mass spectrometry, said linker molecule X may be cleaved by fragmentation during sample desorption/ionization.06-23-2011
20120149019USE OF A BIS-MALEIC ANHYDRIDE CROSS-LINKING AGENT FOR FIXATION OF A CELL OR TISSUE SAMPLE - The present disclosure relates to novel bis-maleic anhydrides and to the surprising discovery that bis-maleic anhydride cross-linking agents can be used for preservation/fixation of a cell or tissue sample. Various bis-maleic anhydride cross-linking agent scan be used in methods requiring fixation of a cell or tissue sample. These reagents and methods are especially useful in procedures that require that the fixation agent be removed in order to facilitate analysis with other reagents. The inventive reagents and methods make it easier to reliably assay for various proteins, a nucleic acid and the like using analytical methods such as like immunohistochemistry, fluorescence in situ hybridization, RT-PCR, and the like.06-14-2012
20120149018Detection of Small Nucleic Acids - The present invention relates to compositions and methods for the detection and characterization of interfering RNAs such as micro RNAs (miRNAs) and small interfering RNAs (siRNAs) and other short nucleic acid molecules. More particularly, the present invention relates to improved methods for the detection and quantitation of interfering RNA expression. The present invention further provides for the detection of variants and types of miRNAs and siRNAs.06-14-2012
20120149017DIAGNOSTIC MARKERS OF HUMAN FEMALE INFERTILITY - The subject invention pertains to methods and reagents for the diagnosis of female infertility, prognostic indicators for female infertility, compounds for the treatment of female infertility, compounds and methods for contraception. Methods and compounds are based on the levels of ebaf in endometrial tissue. Methods for diagnosing endometrial receptivity and bleeding function by screening a biological sample such as an endometrial tissue sample, or bodily fluid for the presence of ebaf. A contraceptive compound containing an effective amount of ebaf and a pharmaceutically acceptable carrier. A diagnostic kit for timing contraception containing reagents for screening a sample for the presence of ebaf. A method of treating endometrial irregularities by down-regulating the expression of ebaf.06-14-2012
20120149016Genetic Variants in the TCF7L2 Gene as Diagnostic Markers for Risk of Type 2 Diabetes Mellitus - Polymorphisms in the gene TCF7L2 are shown by association analysis to be a susceptibility gene for type II diabetes. Methods of diagnosis of susceptibility to diabetes, of decreased susceptibility to diabetes and protection against diabetes, are described, as are methods of treatment for type II diabetes.06-14-2012
20120149015Soybean Plant And Seed Corresponding To Transgenic Event MON87701 And Methods For Detection Thereof - The present invention provides a transgenic soybean event MON87701, and cells, seeds, and plants comprising DNA diagnostic for the soybean event. The invention also provides compositions comprising nucleotide sequences that are diagnostic for said soybean event in a biological sample, probes and primers for use in detecting nucleotide sequences that are diagnostic for the presence of said soybean event in a biological sample, and methods for detecting the presence of said soybean event nucleotide sequences in a biological sample. The invention further provides methods of growing the seeds of such soybean event into soybean plants, and methods of breeding to produce soybean plants comprising DNA diagnostic for the soybean event.06-14-2012
20120149014METHODS FOR OBTAINING FETAL GENETIC MATERIAL - The present invention relates to a method of enriching fetal nuclei from a sample. Enriched fetal nuclei can be used in a variety of procedures including, detection of a trait of interest such as a disease trait, or a genetic predisposition thereto, gender typing and parentage testing.06-14-2012
20120149012DNA Methylation Detection Methods - The present teachings provide DNA methylation quantification methods that avoid bisulfite treatment of DNA. Methylation-specific binding proteins (MeDNA binding proteins) and non-methylation specific binding proteins (non-MeDNA binding proteins) are employed in various embodiments to modulate the accessibility of nucleic acids to primer extension reactions. After selectively removing the target nucleic acids, the extension products can be analyzed and methylation quantitated. In some embodiments, the analysis comprises real-time PCR.06-14-2012
20110212445SWI5 GENE AS A DIAGNOSTIC TARGET FOR THE IDENTIFICATION OF FUNGAL AND YEAST SPECIES - The invention relates to the SWI5 gene, the corresponding RNA, specific probes, primers and oligonucleotides related thereto and their use in diagnostic assays to detect and/or discriminate between fungal and yeast species.09-01-2011
20110212449DISTINGUISHING PCA3 MESSENGER RNA SPECIES IN BENIGN AND MALIGNANT PROSTATE TISSUES - This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.09-01-2011
20110212450Polarization-enhanced detector with gold nanorods for detecting nanoscale rotational motion and method therefor - A nanoscale motion detector attaches a gold nanorod (09-01-2011
20110212444USE OF METHYLATION STATUS OF MINT LOCI AND TUMOR RELATED GENES AS A MARKER FOR MELANOMA AND BREAST CANCER - The invention relates to a method of detecting melanoma or breast cancer using DNA methylation in MINT17, MINT31, or the promoter region of WIF1, TFPI2, RASSF1A, SOCS1, GATA4, or RARβ2 as a biomarker. Also disclosed are methods of using the biomarker for determining the cancer status and predicting the outcome of the cancer.09-01-2011
20120034608MICRORNA AS A BIOMARKER OF PANCREATIC ISLET BETA-CELL ENGAGEMENT - MicroRNAs (miRNAs) are short non-coding RNAs that regulate gene expression and which play important roles in many cell types, including as described herein, the pancreatic β-cell. Glucagon like peptide-1 (GLP-1), a hormone released from intestinal L-cells following meal intake, exerts pleiotropic effects on β-cell function including raising intracellular cAMP levels and now represents an important therapy for type 2 diabetes. Expression of miR-132 and miR212 is upregulated by CREB protein in response increased cAMP levels in the cell; therefore, methods for detecting and evaluating β-cell engagement by GLP-1 receptor agonists by monitoring miR-132 and miR-212 expression in a subject is described. The methods herein are particularly useful in the context of longitudinal clinical trials, such as those designed for testing the durability of any single or combination therapy in type 2 diabetes populations. Because the expression of these miRNAs is not affected by glucose, fatty acid, insulin, or β-cell function, monitoring miR-132 and miR-212 expression can be used to monitor the efficacy of any agent that effects an increase cAMP in β-cells. Such agents include for example, GLP-1, glucagon, GPR-119, and GIP receptor agonists; dipeptidyl peptidase IV (DPP IV) inhibitors; and phosphodiesterase inhibitors.02-09-2012
20120034604USE OF BASIC PROLIN-RICH LACRIMAL GENE PRODUCTS, SUCH AS OPIORPHIN, AS A BIOMARKER - The present invention relates to the use of Basic Prolin-rich Lacrimal protein (BPLP) gene products, such as Opiorphin, for establishing a prognosis, a diagnosis or the monitoring of a pathological state or of treatment efficacy in a subject and the related method of use.02-09-2012
20110151458METHODS AND REAGENTS FOR THE DETECTION OF SALMONELLA SPP - The invention relates to an in vitro method for the detection of bacteria of the 06-23-2011
20110250600MARKER FOR CANCER PROGNOSIS AND METHODS RELATED THERETO - The present invention is related to the novel discovery that HIF-2α, but not HIF-1α, selectively regulates adenosine A10-13-2011
20110250599Methods and Compositions to Detect Nucleic Acids in a Biological Sample - Methods of the invention separate a target nucleic acid from a sample by using at least one capture probe oligonucleotide that contains a target-complementary region and a member of a specific binding pair that attaches the target nucleic acid to an immobilized probe on a capture support, thus forming a capture hybrid that is separated from other sample components before the target nucleic acid is released from the capture support and hybridized to a detection probe to form a detection hybrid that produces a detectable signal that indicates the presence of the target nucleic acid in the sample. Compositions for practicing the methods of the invention include a capture probe oligonucleotide made up a target-complementary region sequence and a covalently linked capture region sequence that includes a member of a specific binding pair.10-13-2011
20110250595ANALYSIS OF SINGLE NUCLEOTIDE POLYMORPHISMS USING END LABELING - A method for analyzing a sequence comprising a SNP site is provide. In general terms, the method comprises: a) contacting a first DNA sample with a first restriction enzyme to provide DNA fragments, wherein: i) the first restriction enzyme cleaves the sequence only if a first allele of a SNP is present at the SNP site; b) end-labeling the DNA fragments to produce an end-labeled sample; c) hybridizing the end-labeled sample to an array comprising a probe sequence; and d) comparing the amount of hybridization between the digested sample and the probe sequence to a reference signal10-13-2011
20110250594METHODS FOR GENETIC ANALYSIS OF TEXTILES MADE OF GOSSYPIUM BARBADENSE AND GOSSYPIUM HIRSUTUM COTTON - Methods for distinguishing between cotton species by analyzing a sample of mature cotton fibers from raw cotton materials or from textile goods are disclosed. DNA is extracted from the mature cotton fiber sample and subjected to PCR techniques which enable the identification of the species of cotton utilized in the textile or cotton material of interest.10-13-2011
20120202205DIAGNOSTIC METHODS - This invention relates to a method of determining the susceptibility of an individual to statin-induced myopathy, comprising detecting the presence or absence of one or more polymorphisms in the SLCO1B1 gene in a biological sample from an individual, whereby the presence of one or more polymorphisms indicates that the individual has altered susceptibility to statin-induced myopathy.08-09-2012
20110151461DETECTION ALGORITHM FOR PCR ASSAY - The application provides methods for improving the detection accuracy of the binding of labeled nucleic acid probes, such as those used in PCR reactions. One such method comprises measuring the label intensity, e.g. fluorescence, at two different temperatures, a higher temperature and a lower temperature, and then calculating the ratio of the label intensity at the lower temperature over the label intensity at the higher temperature. Another method comprises measuring the label intensity at least two points in time post-PCR and calculating the slope of the label intensity as a function of time. Measuring the hybridization kinetics of the probe binding to the target nucleic acid allows an on-rate slope to be calculated which gives this method good specificity of detection.06-23-2011
20110151456TEST METHOD FOR TYPE-2 DIABETES USING GENE POLYMORPHISM - The present invention relates to a method of testing for genetic susceptibility to type-2 diabetes in a subject that comprises detecting one or more polymorphisms present in the KCNQ1 gene and/or EIF2AK4 gene in a DNA-containing sample collected from the subject. The present invention permit a method of accurately, conveniently, and rapidly testing the genetic susceptibility of subjects to type-2 by targeting determinative genetic factors of genetic susceptibility to type-2 diabetes.06-23-2011
20110151459SIMULTANEOUS DETECTION OF MULTIPLE NUCLEIC ACID SEQUENCES IN A REACTION - The present invention relates to a method for simultaneously amplifying and detecting nucleic acid sequences in a reaction comprising the following steps: (i) providing a sample comprising at least one nucleic acid molecule; (ii) providing reagents for performing an amplification reaction, wherein the reagents comprise at least four, preferably at least five, more preferably at least six probes, wherein (a) each of the probes is specific for a nucleic acid sequence; (b) at least two, preferably at least three probes carry the same label; and (c) each of the probes that carry the same label has a melting temperature (Tm) which differs by more than 2° C. from the other probes with the same label when they are dissociated from their target nucleic acid sequence by heating; (iii) amplifying the nucleic acid sequences in the reaction; (iv) detecting the amplified nucleic acids by determining whether the labeled probe has bound its nucleic acid sequence; and (v) detecting the temperature at which each given labeled probe dissociates from the nucleic acid sequence to which it has bound. The invention also relates to kits for the use in such a method.06-23-2011
20120202209CELL IMAGING METHOD FOR VIEWING MICRORNA BIOGENESIS IN THE CELLS - The present invention relates to a method for viewing the biogenesis of at least one microRNA, preferably a microRNA group, in a living cell, characterised in that said method includes the following steps: transforming said cell by an encoding vector for a protein selected among the DGCR8 protein (DiGeorge syndrome critical region gene 8), the Drosha protein and derivatives thereof, said protein being coupled with a marker; expressing said protein coupled with said marker; and detecting said marker.08-09-2012
20120202208NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 193P1E1B USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene 0193P1E1B (also designated 193P1E1B) and its encoded protein, and variants thereof, are described wherein 193P1E1B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 193P1E1B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 193P1E1B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 193P1E1B can be used in active or passive immunization.08-09-2012
20120202207GENETIC ALTERATIONS IN ISOCITRATE DEHYDROGENASE AND OTHER GENES IN MALIGNANT GLIOMA - We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.08-09-2012
20120202206PHARMACEUTICAL COMPOSITIONS AND METHODS USEFUL FOR MODULATING ANGIOGENESIS, INHIBITING METASTASIS AND TUMOR FIBROSIS, AND ASSESSING THE MALIGNANCY OF COLON CANCER TUMORS - Methods and compositions suitable for modulating angiogenesis in a mammalian tissue are provided. Further provided are methods suitable for inhibiting metastasis and fibrosis in a mammalian tissue and for assessing the malignancy of colon cancer tumors.08-09-2012
20120202203SINGLE PROBE, MULTIPLE TEMPERATURE, NUCLEIC ACID DETECTION METHODS, KITS, AND COMPOSITIONS - Provided herein are methods, kits, and compositions related to nucleic acid detection assays that allow discrimination of multiple target sequences with a single probe. In particular, provided herein are methods kits, and compositions that include single-probe target sequence discrimination where different target amplicons may have identical probe hybridization sequences by employing multiple temperature end-point signal probe detection. Also provided herein are methods, kits, and compositions for distinguishing between two or more target amplicons using multiple-temperature end-point probe detection. In certain embodiments, asymmetric PCR amplification methods are employed (e.g., LATE-PCR amplification).08-09-2012
20120202202METHODS FOR DETECTING RARE CIRCULATING CANCER CELLS USING DNA METHYLATION BIOMARKERS - Provided are new and improved methods for detecting circulating tumor cells and tumor cell DNA in patient blood or other biofluid samples. Particular aspects comprise three steps: DNA extraction from patient samples, DNA digestion with multiple selected methylation-sensitive enzymes, and target amplification by a conventional or a real-time PCR with specific probe and/or primers. Also provided are a total of 40 tumor-specific DNA methylation loci as biomarkers having substantial utility and specificity in major types of human malignancies including hematopoietic and solid tumors.08-09-2012
20120202200METHODS FOR DETECTING HUMAN PAPILLOMA VIRUS-ASSOCIATED CANCERS - The present invention provides probes and methods of use thereof in the diagnosis and/or prognosis of certain types of cancers, particularly human papillomavirus (HPV)-associated cancers. The probes are designed for hybridization with genomic material in a manner indicative of one or more aberrations in the genetic material present in the test sample. The identified aberrations are biomarkers of HPV-associated cancer. The methods of the invention comprise contacting a sample to one or more probes, allowing any genetic material in the sample to hybridize to the genomic regions provided in the probes, analyzing the hybridizations, and analyzing the hybridizations to identify detected aberrations as biomarkers indicative of HPV-associated cancer progression.08-09-2012
20120202198PROCESS FOR THE SYNTHESIS OF A CDNA IN A SAMPLE IN AN ENZYMATIC REACTION - This invention relates to a process for synthesis of a cDNA in a sample, in an enzymatic reaction, whereby the process comprises the steps: simultaneous preparation of a first enzyme with polyadenylation activity, a second enzyme with reverse transcriptase activity, a buffer, at least one ribonucleotide, at least one deoxyribonucleotide, an anchor oligonucleotide; addition of a sample that comprises a ribonucleic acid; and incubation of the agents of the previous steps in one or more temperature steps, which are selected such that the first enzyme and the second enzyme show activity. The invention further relates to a reaction mixture that comprises a first enzyme with polyadenylation activity, a second enzyme with reverse transcriptase activity, optionally a buffer, optionally at least one ribonucleotide, optionally at least one deoxyribonucleotide, and optionally an anchor oligonucleotide. Moreover, the invention relates to a kit that comprises a corresponding reaction mixture.08-09-2012
20120202204 Assay for Determining a Molecular Risk Assessment of a Complex Polymicrobial Sample Suspected to Contain an EHEC - The present invention relates to a process to perform a molecular risk assessment (MRA) upon a sample suspected to contain an enterohemorrhagic 08-09-2012
20110256534PREDICTION OF ANTIVIRAL THERAPY RESPONSE - The application relates to methods for determining whether or not antiviral therapies will be effective. In particular, the present application provides a method using miRNA, e.g. miR-122 or miR-296-510-20-2011
20110177509RISK FACTORS AND A THERAPEUTIC TARGET FOR NEURODEGENERATIVE DISORDERS - Compositions and methods for detecting a neurodegenerative disorder, and methods of treating a neurogenerative disorder are disclosed. Biomarkers for a neurodegenerative disorder containing a polymorphism in the nucleotide sequence of PP3R1, GSK3beta, PPP3CA, FYN, WISP1, MGEA5, CTSD, F2, MAPT, OGT or PRKCA are also disclosed. A method for detecting a neurodegenerative disorder by detecting polymorphisms in the above genes is further disclosed.07-21-2011
20110177501BIOSENSOR FOR DETECTION AND VISUALISATION OF SINGLE-STRANDED DNA - A modified protein of the single strand DNA-binding domain, SSB family comprising a detectable label is disclosed. The label has detectable characteristics which alter on binding single stranded DNA. The protein is thus useful in an assay for single stranded DNA.07-21-2011
20110256539Methods for Detecting Tumor Origin Based on MUC1, MUC2, and CK-17 Expression Levels - Methods and compositions for detecting tumor origin are disclosed. In certain embodiments, the origin is determined by detecting expression levels of pan-epithelial membrane mucin (MUC1), intestinal-type secretory mucin (MUC2), cytokeratin 17 (CK17), or a combination thereof. Also disclosed are methods for aiding in the determination of an appropriate course of treatment for a subject with a tumor, or for predicting a therapeutic outcome of a subject, based on the expression levels of MUC1, MUC2, CK17, or a combination thereof. Kits for use in each of these methods are also provided.10-20-2011
20110256537OPTIMIZED OLIGONUCLEOTIDES AND METHODS OF USING SAME FOR THE SCREENING, DETECTION, ISOLATION, QUANTITATION, MONITORING AND SEQUENCING OF PROSTATE CANCER ASSOCIATED VIRUSES AND HOST BIOMARKERS - Described herein are oligonucleotides useful for screening, detecting, isolating, quantitating, monitoring and sequencing of viruses and host biomarkers associated with prostate cancer and methods and kits of using the described oligonucleotides.10-20-2011
20110256533METHODS AND COMPOSITIONS FOR THE IDENTIFICATION OF ANTIBIOTICS THAT ARE NOT SUSCEPTIBLE TO ANTIBIOTIC RESISTANCE - Compositions and methods are provided to identify functional mutant ribosomes that may be used as drug targets. The compositions and methods allow isolation and analysis of mutations that would normally be lethal and allow direct selection of rRNA mutants with predetermined levels of ribosome function. The compositions and methods of the present invention may be used to identify antibiotics to treat a large number of human pathogens through the use of genetically engineered rRNA genes from a variety of species. The invention further provides novel plasmid constructs to be used in the methods of the invention.10-20-2011
20120064527NUCLEIC ACID ANALYSIS DEVICE, NUCLEIC ACID ANALYSIS APPARATUS, AND NUCLEIC ACID ANALYSIS METHOD - The present invention relates to a nucleic acid analysis device in a nucleic acid analysis apparatus, whereby waste of reaction spots on the nucleic acid analysis device is eliminated and leakage of fluorescence excitation light to unobserved nucleic acid measurement regions is minimized. Specifically, the nucleic acid analysis device has a plurality of nucleic acid measurement regions, which are characterized in that one nucleic acid measurement region is disposed at a sufficient distance from the other nucleic acid measurement regions such that the other nucleic acid measurement regions do not enter an irradiation region.03-15-2012
20110165572METHODS AND KITS FOR NUCLEIC ACID SEQUENCING - Various embodiments of the present disclosure generally relate to molecular biological protocols, equipment and reagents for the sequencing of target nucleic acid (DNA, RNA, cDNA, etc) molecules.07-07-2011
20110262913MARKING - The invention provides a marking system, markers and methods of use of such marking systems and markers which enable unique marking of articles and subsequent detection of that marking. In particular the invention provides a marking system, the marking system comprising a plurality of different DNA fragment types, each of the plurality of different DNA fragment types comprising a plurality of different length DNA fragments and a method in which a sample of the DNA fragment type is taken, amplified and analysed to determine the identity of the marker for an article.10-27-2011
20120231458METHOD OF ACQUIRING STANDARD CURVE IN REAL-TIME PCR - A method of acquiring a standard curve for quantifying polynucleotide is provided. The method includes: (a) performing a real-time polynucleotide chain reaction (PCR) for plural samples having different initial polynucleotide concentrations, the PCR being performed with respect to plural amplification cycle numbers using detectable probes providing a signal according to an amount of polynucleotide; (b) acquiring plural amplification profile curves with respect to signal intensity values provided by the probes according to the amplification cycle numbers; (c) selecting one threshold from among the signal intensity values; (d) calculating amplification cycle numbers corresponding to the selected thresholds from the plural amplification profile curves, and determining the calculated amplification cycle numbers as threshold cycle (Ct) values corresponding to each of the initial polynucleotide concentrations; (e) selecting at least two Ct values among the Ct values determined in (d); and (f) acquiring a standard curve from the selected Ct values.09-13-2012
20120122094COMPOSITION AND METHOD FOR STABILIZING FLUORESCENT PARTICLES - Embodiments of a composition for stabilizing fluorescent signal of nanoparticles and methods for its use are disclosed. In some embodiments, the composition has a pH from 7 to 10 and includes borate, protein and/or protein hydrolysate, an amine, a preservative, and a nonionic surfactant. In particular embodiments, the amine is an N-ethanol substituted amine, such as ethanolamine, diethanolamine, triethanolamine, N-methyldiethanolamine, N,N-dimethylethanolamine, or a combination thereof. In some embodiments, a fluorescent particle solution, such as a quantum dot solution or quantum dot conjugate solution, is diluted in the composition and stored at 4° C. In certain embodiments, the fluorescence intensity of the diluted fluorescent particle remains substantially the same when stored at 4° C. for at least one month or at least three months. In particular embodiments, a diluted quantum dot conjugate is used to detect a hybridized probe or a protein antigen.05-17-2012
20120122093METHODS AND KITS FOR MULTIPLEX AMPLIFICATION OF SHORT TANDEM REPEAT LOCI - Compositions, methods and kits are disclosed for use in simultaneously amplifying at least 20 specific STR loci of genomic nucleic acid in a single multiplex reaction, as are methods and materials for use in the analysis of the products of such reactions. Included in the present invention are materials and methods for the simultaneous amplification of 23 and 24 specific loci in a single multiplex reaction, comprising the 13 CODIS loci, the Amelogenin locus, an InDel and at least six to ten additional STR loci, including methods, kits and materials for the analysis of these loci.05-17-2012
20120122090GENE METHYLATION IN CANCER DIAGNOSIS - The present invention provides DNA biomarker sequences that are differentially methylated in samples from normal individuals and individuals with cancer. The invention further provides methods of identifying differentially methylated DNA biomarker sequences and their use the detection and diagnosis of cancer.05-17-2012
20110136121METHOD FOR DETECTING CANCER - The present invention relates to a method for detecting cancer, comprising measuring the expression of a polypeptide having a reactivity of binding to an antibody against a CAPRIN-1 protein having an amino acid sequence shown in any one of the even-numbered SEQ ID NOS: 2-30 in the Sequence Listing via an antigen-antibody reaction in a sample separated from a living organism, and, a reagent for detecting a cancer comprising the CAPRIN-1 protein or a fragment thereof, an antibody against the CAPRIN-1 protein or a fragment thereof, or a polynucleotide encoding the CAPRIN-1 protein or a fragment thereof.06-09-2011
20110136119AIMP2-DX2 Gene and its Uses - The present invention relates to a variant of AIMP2 lacking exon 2 gene, named as AIMP2-DX2 gene, which is specifically expressed in cancer cells. The AIMP2-DX2 gene and siRNA targeting AIMP2-DX2 can be successfully used in the development of diagnosis and treatment of cancer06-09-2011
20110136120Methods of Identification of Methylation of CPG - The present invention relates to the materials and methods for the identification of methylated nucleotides in samples of genomic DNA. The present invention also relates to methods of diagnosis of specific conditions by identification of specific methylated nucleotides.06-09-2011
20110136118REAL TIME POLYMERASE CHAIN REACTION PROCESS USING A UNIVERSAL DETECTION SYSTEM - Provided are methods and kits for detecting amplification of a target nucleic acid during a real time quantitative polymerase chain reaction process using a universal detection system. The detection system uses an unlabeled probe that detects the amplified target nucleic acid and interacts with a universal detection module.06-09-2011
20110136117Method of Detecting Heat-Resistant Fungus - A method of detecting a heat-resistant fungus, which has a step of identifying the heat-resistant fungus using the following nucleic acid (I) or (II):06-09-2011
20110136114NEURAL REGENERATING CELLS WITH ALTERATIONS IN DNA METHYLATION - Disclosed herein are cells, that are descendents of marrow adherent stem cells (MASCs), capable of rescuing and/or reversing various neural disorders after transplantation into sites of central nervous system (CNS) or peripheral nervous system (PNS) injury. The cells contain alterations in the methylation state of certain genes, compared to their methylation state in MASCs. Methods of making cells capable of rescuing and/or reversing various neural disorders after transplantation into sites of CNS or PNS injury, by alteration of the methylation status of certain genes, are also provided.06-09-2011
20120064523Bioagent Detection Systems, Devices, And Methods - The present invention relates to portable systems and devices, and corresponding methods, for detecting bioagents. In particular, the present invention provides systems, devices, and methods that utilize one or more of a sample preparation component, sample analysis component employing broad range primers, and sample detection component.03-15-2012
20110256538EPIGENOMIC DNA MODIFICATIONS FOR TISSUE TYPING, EARLY CANCER DETECTION, AND DISEASE MANAGEMENT - Provided herein is a suitable method for detecting the presence or absence of a cancer in an individual, by determining the level of methylation of the sense strand of a selected regulatory region of a tumor suppressor gene. Also provided herein is a method of detecting the presence or absence a cancer in an individual by determining if there is an apparent 100% methylation by assay of the CpG sites in the anti-sense strand of a selected regulatory region of a tumor suppressor gene. Also provided herein is a method of tissue typing by determining the level of methylation of the anti-sense strand of a selected regulatory region of a tumor suppressor gene indicating an enhanced likelihood that a tissue is liver.10-20-2011
20110151453NUCLEIC ACID SEQUENCES AND COMBINATION THEREOF FOR SENSITIVE AMPLIFICATION AND DETECTION OF BACTERIAL AND FUNGAL SEPSIS PATHOGENS - The present invention relates to methods of detection, as well as assays, reagents and kits for the specific detection of clinically important bacterial and fungal species. The present invention allows for the specific detection of nucleic acids of each of these pathogens in a single assay.06-23-2011
20110256536Two stage nucleic acid amplification using an amplification oligomer - This invention provides methods, compositions and systems to detect a nucleic acid of interest in a two-stage amplification. The two-stage amplification begins with a first non-enzymatic accumulation of an amplification oligomer that is the target substrate for a second nucleic acid amplification or assay. Two or more amplification oligomers can be used to allow multiplexed amplifications of two or more nucleic acids of interest with deconvolution based on unique detection signals or unique signal locations.10-20-2011
20110177511METHOD FOR DETERMINING BREAST CANCER METASTASIS AND METHOD FOR EVALUATING SERUM - It is determined that the breast cancer has metastasized when methylation is detected in the CpG island of at least one selected from the group consisting of GSTP1, RASSF1A and RARb by detecting methylation in CpG island of each of GSTP1, RASSF1A and RARb contained in serum obtained from a patient who has undergone surgery to remove breast cancer.07-21-2011
20110177507OLIGONUCLEOTIDES FOR GENOTYPING THYMIDYLATE SYNTHASE GENE - Oligonucleotides for genotyping the thymidylate synthase gene are provided. The number of tandem repeats in the promoter region of the thymidylate synthase gene can be identified based on the hybridization of an oligonucleotide of the invention to the genomic DNA of a subject. Therefore, the genotype of the thymidylate synthase gene can be identified based on the number of tandem repeats. The genotype relates to the responsiveness of a subject towards an antitumor agent.07-21-2011
20110177505DNA Methylation Analysis of Regulatory T Cells Through DNA-Methylation Analysis of the TSDR Region of the Gene FOXP3 - The present invention relates to a method, in particular an in vitro method for identifying FoxP3-positive CD25+CD4+ regulatory T cells of a mammal, comprising analyzing the methylation status of at least one CpG position in the FOXP3 gene, in particular its “upstream” regulatory regions, and in particular the promoter and the TSDR region of the gene foxp3, wherein a demethylation to at least 90% of at least one CpG in the sample as analyzed is indicative for a FoxP3-positive CD2507-21-2011
20110177500IMMUNOHISTOCHEMISTRY DETECTION METHOD - The invention provides compositions and methods for the detection of targets in a sample; in particular, an immunohistochemistry (IHC) sample. Probes and detectable labels may be provided in multiple layers in order to increase the flexibility of a detection system, and to allow for amplification to enhance the signal from a target. The layers may be created by incorporating probes and detectable labels into larger molecular units that interact through nucleic acids base-pairing, including peptide-nucleic acid (PNA) base-pairing. Optional non-natural bases allow for degenerate base pairing schemes. The compositions and methods are compatible with immunohistochemistry (IHC), but also could be used in immunocytochemistry (ICC), in situ hybridization (ISH), flow cytometry, enzyme immuno-assays (EIA), enzyme linked immuno-assays (ELISA), blotting methods (e.g. Western, Southern, and Northern), labeling inside electrophoresis systems or on surfaces or arrays, and precipitation, among other general detection assay formats. The invention is also compatible with many different types of targets, probes, and detectable labels.07-21-2011
20120034610IDENTIFICATION OF TOXIN-BINDING PROTEIN INVOLVED IN RESISTANCE TO CRY1 TOXINS, AND RELATED SCREENING METHODS - The subject invention relates in part to the surprising and unexpected discovery that insects that are resistant to 02-09-2012
20120178086REDUCTIVE RELEASE PROBES CONTAINING A CHEMOSELECTIVELY CLEAVABLE ALPHA-AZIDOETHER LINKER AND METHODS OF USE THEREOF - Probes comprising one or more selectively cleavable α-azidoether moieties are provided; and linkers comprising the one or more selectively cleavable α-azidoether moieties. The α-azidoether moiety will undergo a Staudinger reaction with a suitable reducing agent, resulting in cleavage. The probes find use in a variety of detection assays, e.g. specific polynucleotide binding assays, polypeptide binding assays, etc. The cleavable linkers are suitable for synthetic reactions, e.g. to prepare probes of the invention; in the synthesis of cleavable peptide conjugates; and the like.07-12-2012
20120208184SYSTEMS AND METHODS FOR IMAGING AND PROCESSING TISSUE - In accordance with preferred embodiments of the present invention, a method for imaging tissue, for example, includes the steps of mounting the tissue on a computer controlled stage of a microscope, determining volumetric imaging parameters, directing at least two photons into a region of interest, scanning the region of interest across a portion of the tissue, imaging layers of the tissue, sectioning a portion of the tissue, capturing the sectioned tissue, and imaging additional layers of the tissue in a second volume of the tissue, and capturing each portion of sectioned tissue, and processing three-dimensional data that is collected to create a three-dimensional image of the region of interest. Further, captured tissue sections can be processed, re-imaged, and indexed to their original location in the three dimensional image.08-16-2012
20120208194Preparation of Templates for Nucleic Acid Sequencing - The invention relates to methods of generating templates for a nucleic acid sequencing reaction which comprise: 08-16-2012
20120208196Probe for Detecting Polymorphism in MPL Gene and Use of the Probe - The present invention provides a probe that can identify a polymorphism in an MPL gene easily and with high reliability and use of the probe. Used as the probe for detecting a polymorphism in the MPL gene is a probe containing any one of oligonucleotides (P1), (P1′), (P2), and (P2′), wherein: 08-16-2012
20120070834Screening Methods for Transfusion Related Acute Lung Injury - The invention relates to the discovery that HNA-3a and HNA-3b are antigens within a polypeptide sequence that is highly similar to the CTL2 amino acid sequence. This invention provides methods and kits for screening for HNA-3a and HNA-3b specific antibodies, HNA-3a and HNA-3b polypeptides and HNA-3a and HNA-3b nucleic acids in a sample of a biological tissue intended for transplantation.03-22-2012
20110189674METHOD FOR QUANTIFYING OR DETECTING DNA - The present invention relates to a method for quantifying or detecting DNA having a target DNA region, and so on.08-04-2011
20110189675Method For Administering Anticoagulation Therapy - The present invention provides a method for use in treating a patient with an anticoagulant to optimize drug therapy and/or to prevent an adverse drug response. More particularly, the present invention relates to a method and system for use in treating a patient with Coumadin® or a substance containing warfarin. Methods of the present invention utilize variables that include the patient's CYP4F2 genotype.08-04-2011
20110189673STOOL SAMPLE PREPARATION METHOD, SOLUTION FOR PREPARING STOOL SAMPLE AND STOOL COLLECTION KIT - The present invention relates to the providing of a method for preparing a stool sample that enables nucleic acids in a stool to be stably preserved without requiring a complex procedure, a stool sample preparation solution and stool collection kit used in that method, and a method for recovering and analyzing nucleic acids in a stool using a stool sample prepared according to the preparation method of the present invention, and a stool sample having superior preservation of nucleic acids contained in the stool sample is prepared by mixing a collected stool with the stool sample preparation solution having for an active ingredient thereof a water-soluble organic solvent containing an organic acid.08-04-2011
20110189672DIAGNOSTIC METHODS INVOLVING DETERMINING GENE COPY NUMBERS AND SNPs IN THE FcyRll/FcyRlll GENE CLUSTER, AND PROBES FOR USE IN SUCH METHODS TO DETECT SUSCEPTIBILITY TO AND TREATMENT EFFICACY IN AUTOIMMUNE DISEASES - The invention relates to diagnostic methods to predict whether a subject is predisposed for acquiring a disease or to predict the therapy responsiveness of an individual patient. Provided is a method for determining whether a subject is predisposed for developing an autoimmune disease, comprising determining in a sample isolated from said subject the amount of intact genes, or gene products thereof, of the FcγRII/FcγRIII gene cluster, said gene cluster comprising the FCGR2C, FCGR3A, FCGR2A and FCGR3B genes encoding an activating FcγR, and FCGR2B encoding an inhibitory FcγR; and correlating said amount to the amount observed in a healthy population. Also provided is a method to predict the responsiveness of a subject to therapy with intravenous immunoglobulin (IVIg) therapy or a monospecific biological, such as a humanized or human monoclonal antibody or a chimeric molecule, comprising the C-terminal Fc-tail of IgG.08-04-2011
20110189671NUCLEOSIDE TRIPHOSPHATE DERIVATIVE, NUCLEIC ACID PROBE, MULTILABELED NUCLEIC ACID PROBE, METHOD FOR PRODUCTION OF MULTILABELED NUCLEIC ACID PROBE, AND METHOD FOR DETECTION OF TARGET NUCLEIC ACID - A novel nucleoside triphosphate derivative, a nucleic acid probe, and a multilabeled nucleic acid probe that can detect a target nucleic acid conveniently and with high sensitivity, as well as a method for producing the multilabeled nucleic acid probe, and a method for detecting a target nucleic acid using the multilabeled nucleic acid probe or the nucleic acid probe. A target nucleic acid can be detected conveniently and with high sensitivity by using a transglutaminase (TGase), and by using a multilabeled nucleic acid probe in which a plurality of labeling portions have been introduced in advance by covalent binding, or by introducing a plurality of labeling portions by covalent binding into a nucleic acid probe that has been hybridized with the target nucleic acid.08-04-2011
20110189668Methods for determining likelihood of longevity and of developing an age-related disease - The present invention provides a method for identifying a subject's likelihood of achieving longevity or of developing an age-related disease, the method for identifying a subject's likelihood of achieving longevity or of developing an age-related disease comprising detecting at least one specified single nucleotide polymorphisms or genotype at a single nucleotide polymorphism or combination of a genotype at a first single nucleotide polymorphism and a genotype at a second single nucleotide polymorphism in a sample of the subject's DNA and, wherein the detection of at least one single nucleotide polymorphisms or genotype at a single nucleotide polymorphism or combination of a genotype at a first single nucleotide polymorphism and a genotype at a second single nucleotide polymorphism identifies the subject's as likely achieving longevity or of developing an age-related disease.08-04-2011
20110189667METHOD OF SCREENING FOR NOVEL EXON 1 MUTATIONS IN MECP2 ASSOCIATED WITH CLASSICAL RETT SYNDROME - Recently, a new MECP2 isoform, which has an alternative N-terminus, transcribed from exon 1, was described. Since the incorporation of exon 1 into standard sequencing protocol for Rett syndrome, few patients with exon 1 mutations have been described and several groups have concluded that exon 1 mutations are a rare cause of Rett syndrome. The present invention provides an improved method of diagnosing Rett Syndrome by identifying two different mutations in exon 1 of the MECP2 gene, the first of which results in a switch from alanine to valine at the beginning of a polyalanine stretch, and the second of which results in a disruption of the ATG initiation codon of exon 1. Patients having either such mutation fit the clinical criteria for classic Rett syndrome, and further support previous reports that exon 1 mutations may be associated with a severe phenotype.08-04-2011
20110189666NUCLEIC ACID PROBE SET AND METHOD OF USING THE SAME - A nucleic acid probe set includes (A) a fluorescent probe and (B) a binding probe. The fluorescent probe (A) is formed of an oligonucleotide including (a) a nucleotide labeled with a fluorescent substance. The binding probe (B) is formed of an oligonucleotide having (b08-04-2011
20110189665METHODS FOR DETECTING DRUG-RESISTANT MICROBES - The present invention provides methods and oligonucleotides for detecting drug-resistant microbes, such as vancomycin resistant 08-04-2011
20110189663ASSESSMENT OF RISK FOR COLORECTAL CANCER - Disclosed is a method for identifying an individual who has an altered risk for developing colorectal cancer comprising detecting a single nucleotide polymorphism (SNP).08-04-2011
20110143343Methods and Kits for Methylation Detection - Ligation-based methods and kits are disclosed for determining the degree of methylation of one or more target nucleotides. In certain embodiments, the methylation status of one or more target nucleotides is determined by generating misligation products. In certain embodiments, at least one target nucleotide is amplified prior to the ligation reaction. In certain embodiments, at least one ligation product, at least one ligation product surrogate, at least one misligation product, at least one misligation product surrogate, or combinations thereof are amplified. In certain embodiments, one or more ligation probes comprise at least one nucleotide analog, at least one Modification, at least one mismatched nucleotide, or combinations thereof.06-16-2011
20120309007PROSTATE CANCER PROGNOSTIC COMPOSITIONS AND KITS - Described herein are method, compositions and kits for prognosis of prostate cancer. The methods comprise: determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. The present invention features a method for prognosing prostate cancer in a sample of a patient comprising: assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.12-06-2012
20120309005KIT AND METHOD FOR IDENTIFICATION OF CAUSATIVE BACTERIUM OF NAIL TINEA - It is an object of the invention to provide a kit and method for identification of causative fungi of tinea unguium, which allows rapid and accurate identification of causative fungi by real-time PCR using primer sets and probes specific for fungal species. An identification kit for identification of causative fungi of tinea unguium using real-time PCR, which comprises a primer set and a probe, wherein the primer set is at least one selected from the group consisting of a primer set consisting of a primer comprising the nucleotide sequence as set forth in SEQ ID NO: 1 and a primer comprising the nucleotide sequence as set forth in SEQ ID NO: 2, and a primer set consisting of a primer comprising the nucleotide sequence as set forth in SEQ ID NO: 3 and a primer comprising the nucleotide sequence as set forth in SEQ ID NO: 4, and wherein the probe is at least one selected from the group consisting of a probe comprising the nucleotide sequence as set forth in SEQ ID NO: 5 and a probe comprising the nucleotide sequence as set forth in SEQ ID NO: 6.12-06-2012
20120309004MICRO-DEVICE AND METHODS FOR DISRUPTING CELLS - A micro-device for disrupting cells includes a first chamber in which the cells are disrupted, a second chamber which is pressurized and depressurized, a flexible membrane which separates the first chamber and the second chamber and is vibrated by pressuring and depressurizing the second chamber, and a micro-unit confined in the first chamber, where the micro-unit disrupts the cells in the first chamber.12-06-2012
20110171643METHOD, PROCESS, AND KIT FOR CANCER DIAGNOSIS, PROGNOSIS, AND AFTERCARE - A method or process for the diagnosis/prognosis/follow-up of cancer in vertebrates, comprising the following steps: 07-14-2011
20110171642Analysing Methylation Specific PCR by Amplicon Melting - The present invention provides a method of evaluating DNA methylation in a sample. The method comprises (i) reacting the DNA with an agent that differentially modifies methylated cytosine and non-methylated cytosine to produce modified DNA, (ii) amplifying the modified DNA by methylation specific PCR to produce amplified DNA, and (iii) subjecting the amplified DNA to melting analysis. In the method the methylation specific primers are selected such that the sequence between the primers includes a region of known sequence variation and/or at least one cytosine nucleotide.07-14-2011
20110189670Circulating Tumor and Tumor Stem Cell Detection Using Genomic Specific Probes - The present invention comprises a method of detecting circular tumor cells and methods of detecting, evaluating, or staging cancer in a patient, as well as a method of monitoring treatment of cancer in a patient using the claimed method. The method comprises contacting a sample with a CD45 binding agent; selecting the cells based on positive or negative CD45 staining; contacting the selected cells with a labeled nucleic acid probe, and detecting hybridized cells by fluorescence in situ hybridization; and analyzing a signal produced by the labels on the hybridized cells to detect the CTCs. In other embodiments, the method provides for directed to a method of determining the level of CTCs in a sample having blood cells from a patient by contacting a sample having blood cells from a patient, wherein the sample has not been pre-sorted into CD45-positive and CD45-negative cells.08-04-2011
20110189669METHODS OF AIDING IN THE DIAGNOSIS OF PROSTATE CANCER - The current invention provides a method for aiding in the assessment of prostate cancer (including metastatic prostate cancer) and/or benign prostate hyperplasia in a patient, wherein the method comprises the step of determining the level of Glycine N-methyltransferase (GNMT) nucleic acid and/or protein in a sample from the patient. The invention also provides compounds that target Glycine N-methyltransferase (GNMT) protein and/or nucleic acid for use in treating prostate cancer. Also provided are screening methods for selecting a compound considered to be useful in treating prostate cancer, comprising the steps of determining the ability of a test compound to reduce GNMT activity and selecting a compound that reduces GNMT activity. The invention also provides methods for aiding in the diagnosis of prostate cancer in a patient comprising obtaining a sample from the patient and assessing said sample for a marker of GNMT activity.08-04-2011
20120040341Method for the Detection and Diagnosis of Cancer Involving Primers and Probes for the Specific Detection of the MAGE-A3-Marker - The present invention relates to MAGE-3 specific primers and probes for use new diagnostic kits and methods. The invention further relates to immunotherapeutic treatment of specific populations of cancer patients, suffering from MAGE-3 expressing tumours.02-16-2012
20120040343Detecting and Sorting Methylated DNA Using a Synthetic Nanopore - Provided are methods for detecting, characterizing or separating DNA based on methylation. Heterogeneous DNA populations are separated based on DNA methylation by providing a membrane having a nanopore through which an electric field is applied. DNA of interest is introduced, and for a given threshold voltage across the nanopore, only DNA having a methylation parameter of interest may transit the pore, thereby facilitating detection, characterization, or separation of DNA based on methylation. The methods are optionally used to detect a disease state that is associated with DNA methylation including, but not limited to, cancer.02-16-2012
20120040344PREDICTIVE USE OF CpG METHYLATION - Determination of the methylation status of individual selected Cp/G dinucleotides/CpG groups 5′ to the coding region of selected genes, preferably in a perinatal tissue sample such as umbilical cord, can be used to predict future development of diverse phenotypic characteristics, such as indices of body composition indicative of for example, obesity or low bone mineral content, indices of impaired cardiovascular structure or function, ability to learn and cognitive function, neurobehavourial problems and allergic disorders such as atopic eczema.02-16-2012
20110306045Method for Confirming a Diagnosis of Rolandic Epilepsy - A strong association between variants in Elongator Protein Complex 4, (ELP4) (specifically single nucleotide polymorphisms, SNPs) at the 11p13 locus on chromosome 11 and the centrotemporal sharp wave trait (CTS) has been discovered, which association has diagnostic significance for rolandic epilepsy. It has further been discovered that the 11p13 locus has a pleiotropic role in the development of speech motor praxis and CTS, which supports a neurodevelopmental origin for classic rolandic epilepsy (RE).12-15-2011
20110306043DEVICES AND METHODS FOR ENRICHMENT AND ALTERATION OF CIRCULATING TUMOR CELLS AND OTHER PARTICLES - The invention features devices and methods for detecting, enriching, and analyzing circulating tumor cells and other particles. The invention further features methods of diagnosing a condition, e.g., cancer, in a subject by analyzing a cellular sample from the subject.12-15-2011
20110306048BOVINE POLYMORPHISMS AND METHODS OF PREDICTING BOVINE TRAITS - Methods of predicting the phenotype of a trait in a bovine subject are provided. The methods include obtaining information about polynucleotide sequences specifically regarding the identity of the nucleotides present at one or more identified single nucleotide polymorphisms and using this information to make predictions regarding the trait in the subject. Also provided are kits for and methods of determining the nucleotide present in a bovine subject at a position in which a single nucleotide polymorphism is correlated with a trait.12-15-2011
20110306047Compositions and Methods for RNA Hybridization Applications - The invention provides methods and compositions for hybridizing at least one molecule to an RNA target. The invention may, for example, eliminate the use of, or reduce the dependence on formamide in RNA hybridization applications. Compositions for use in the invention include an aqueous composition comprising at least one nucleic acid sequence and at least one polar aprotic solvent in an amount effective to enable hybridization to RNA.12-15-2011
20110306046Probes and Primers for Detection of Malaria - The present disclosure gives description of a method used for the detection and quantification of malarial infection caused either by 12-15-2011
20110306044DELTA3, FTHMA-070, TANGO85, TANGO77, SPOIL, NEOKINE, TANGO129, AND INTEGRIN ALPHA SUBUNIT PROTEIN AND NUCLEIC ACID MOLECULES AND USES THEREOF - The invention provides novel Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 proteins, the invention further provides isolated Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 fusion proteins, antigenic peptides and anti-Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 antibodies. The invention also provides Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 or A259 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.12-15-2011
20120040351GENETIC MARKERS OF SCHIZOPHRENIA - The invention includes method of determining if a subject has a genetic predisposition to clinically diagnosed schizophrenia (SZ), schizotypal personality disorder (SPD), and/or schizoaffective disorder (SD).02-16-2012
20120040349METHOD FOR DETECTING NUCLEIC ACIDS - Method for detecting nucleic acids which employs a double-stranded oligonucleotide probe containing i) a first probe including a first label moiety, and ii) a second probe partially complementary with the first probe and including a second label moiety capable of interacting with the first moiety when brought in close proximity with each other, the second moiety being a quencher or acceptor of emission of the first moiety. The first or second probe includes a sequence complementary to that of a target nucleotide, and the second or first probe, respectively, includes a sequence complementary to a complement of the target nucleotide sequence of the nucleic acid to be detected. Oligonucleotides for determining 02-16-2012
201200403452-Nitrobenzyl-Modified Ribonucleotides - This disclosure provides novel reversibly terminated ribonucleotides which can be used as a reagent for DNA sequencing reactions. Methods of sequencing nucleic acids using the disclosed nucleotides are also provided.02-16-2012
20120040342Genetic Indicators Of Weight Loss - Methods for determining resistance to weight loss and susceptibility to binge eating episodes are described. The methods include determination of the presence of a obesity related alleles for a patient at single nucleotide polymorphism sites associated with the genes INSIG2, FTO, MC4R, and PCSK1. The total number of obesity alleles for the patient is indicative of the patient's resistance to weight loss and susceptibility to weight gain following bariatric surgery. The methods also include determining if a patient is homozygous for an obesity related allele at one or more single nucleotide polymorphism sites of the four genes.02-16-2012
20120309003ENTEROHEMORRHAGIC E. COLI O104:H4 ASSAYS - Disclosed are compositions, methods and kits for the specific detection of enterohemorrahagic 12-06-2012
20120040346Method of Determining Chemotherapy of Metastatic Tumor by Assaying DPD Gene Expression in Primary Tumors - The invention relates to a method for determining a chemotherapeutic regimen for an individual, comprising obtaining a mRNA sample from a primary tumor specimen; determining a gene expression level for a tumor gene determinant in the specimen; comparing the gene expression level for the tumor gene determinant with a predetermined threshold value for that gene; and providing a chemotherapeutic regimen comprising a chemotherapeutic agent appropriate for the tumor gene determinant to treat the tumor metastases.02-16-2012
20120040350GENETIC MARKERS OF SCHIZOPHRENIA - The invention includes method of determining if a subject has a genetic predisposition to clinically diagnosed schizophrenia (SZ), schizotypal personality disorder (SPD), and/or schizoaffective disorder (SD).02-16-2012
20120040348METHODS FOR NUCLEIC ACID QUANTIFICATION - The invention relates to a method for quantification of amplified nucleic acids comprising the steps of: calculation of a measure of randomness M of the cycle-to-cycle amplification efficiency Ê(C) for target and comparative nucleic acids, —identification of the cycle numbers C02-16-2012
20120040347Polymorphism in CYP3A4 Gene Affecting Drug Metabolizing and Uses Thereof - A method for predicting a subject's risk factors for CYP3A4-related disorders includes detecting the allelic status of a SNP in a nucleic acid sample of the subject.02-16-2012
20120301886POLYTAG PROBES - The present invention provides probes and probe systems for detection of nucleic acids, and in particular probes and probe systems comprising target nucleic acid probes which comprise a plurality of detection sequences and detection nucleic acid probes which hybridize to the detection sequences of the target nucleic acid probes and which further comprise a plurality of detectable moieties, such as haptens.11-29-2012
20120301885CYTOGENIC ANALYSIS OF METAPHASE CHROMOSOMES - The present invention relates to methods and systems for analyzing chromosomes, and in particular to methods and systems for simultaneously performing banding and in situ hybridization on metaphase chromosomes.11-29-2012
20120301884METHOD AND DEVICE FOR DETECTING THE PRESENCE OF A SINGLE TARGET NUCLEIC ACID IN A SAMPLE - A method comprising subjecting one or more sample portion(s) to a single amplification step, thereby amplifying a single molecule in the sample portion to a detectable level, and, in some embodiments, then determining whether the sample portion contains at least one molecule of the target nucleic acid. In some embodiments, the sample portion is in a porous sample structure, or in a sample chamber which comprises means for minimizing diffusion of the sample portion, or in a sample chamber which is inside a microcapillary device, or in a sample retaining means.11-29-2012
20120301883SHEATH FLOW DEVICES AND METHODS - The invention relates generally to fluid processing and, in particular aspects, processing fluids for detection, selection, trapping and/or sorting of particulate moieties. Sheath flow devices described allow isolation of target species from fluid samples while avoiding non-specific binding of unwanted species to the surfaces of the separation device. Biological fluid processing, detection, sorting or selection of cells, proteins, and nucleic acids is described. The invention finds particular use in diagnostic settings, analyzing a patient's medical condition, monitoring and/or adjusting a therapeutic regimen and producing cell based products.11-29-2012
20120301882METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING POLYMORPHIC GENETIC MARKERS - Processes and methods for creating a database of genomic samples from healthy human donors, methods that use the database to identify and correlate polymorphic genetic markers and other markers with diseases and conditions are provided.11-29-2012
20120301881Compositions, Methods and Related Uses for Cleaving Modified DNA - Compositions, methods and a kit are described relating to a novel family of enzymes which preferentially bind to a hydroxymethylated cytosine or a glucosylated hydroxymethylated cytosine and cleave double-stranded DNA at a defined distance 3′ of the recognition site to produce a cleavage fragment with a 1-3 base overhang.11-29-2012
20120301880ALKYL AMINE COMPOUNDS FOR FLUORESCENT LABELING - Alkyl amine dyes, oligonucleotide probes prepared from the alkyl amine dyes, phosphoramidites and solid supports prepared from the alkyl amine dyes, and methods of labeling biological agents using the alkyl amine dyes.11-29-2012
20120301879NOVEL USE OF CA-125 - Provided is novel use of CA-125. As it is discovered that CA-125 level are positively associated with bone mineral density, thereby CA-125 can be used in biomarker to diagnose osteoporosis or osteopenia, or extent of growth plate development.11-29-2012
20120301878METHODS AND COMPOSITIONS FOR THE DETECTION OF DRUG RESISTANT BRAF ISOFORMS - The present invention provides methods and compositions for the detection of novel BRAF splice variants that mediate resistance to BRAF and/or pan-RAF inhibitors. In particular, the invention provides PCR primer(s) to be used in the disclosed methods of detection. In some embodiments, the compositions and methods of the present invention are used to predict resistance to BRAF and/or pan-RAF inhibitors in a subject suffering from or suspected of having cancer and further provides alternative treatment strategy(ies) for a subject, predicted to be resistant to BRAF and/or pan-RAF inhibitors. In a further embodiment, methods and composition for the identification of novel agents useful to overcome resistance to BRAF and/or pan-RAF inhibitors are disclosed. The present invention also provides isolated polynucleotide sequences of novel 5′ BRAF splice variant(s) and proteins produced from such polynucleotide sequences as well as cell line(s) that endogenously or exogenously express the splice variant(s).11-29-2012
20120301876METHOD TO QUANTIFY SIRNAS, MIRNAS AND POLYMORPHIC MIRNAS - The present teachings provide methods, compositions, and kits for quantifying target polynucleotides. In some embodiments, a reverse stem-loop ligation probe is ligated to the 3′ end of a target polynucleotide, using a ligase that can ligate the 3′ end of RNA to the 5′ end of DNA using a DNA template, such as T4 DNA ligase. Following digestion to form an elongated target polynucleotide with a liberated end, a reverse transcription reaction can be performed, followed by a PCR. In some embodiments, the methods of the present teachings can discriminate between polymorphic polynucleoitides that vary by as little as one nucleotide.11-29-2012
20120301875AMPLICON MELTING ANALYSIS WITH SATURATION DYES - Methods are provided for nucleic acid analysis wherein a target nucleic acid that is at least partially double stranded is mixed with a dsDNA binding dye having a percent saturation of at least 50% to form a mixture. In one embodiment, the nucleic acid is amplified in the presence of the dsDNA binding dye, and in another embodiment a melting curve is generated for the target nucleic acid by measuring fluorescence from the dsDNA binding dye as the mixture is heated. Dyes for use in nucleic acid analysis and methods for making dyes are also provided.11-29-2012
20120301874Compositions and Methods for Detection of Staphylococcus Aureus - The present invention relates to methods for the rapid detection of the presence or absence of 11-29-2012
20120003650MARKER FOR PRENATAL DIAGNOSIS AND MONITORING - The present invention relates to new methods for diagnosing a pregnancy-associated disorder by analyzing fetal DNA present in the mother's blood. More specifically, this invention relies on the discovery that the maspin gene is differentially methylated in fetal DNA and in maternal DNA and provides these new diagnostic methods, which distinguish fetal DNA from maternal DNA and detect prenatal disorders based on abnormalities in fetal DNA level and methylation status.01-05-2012
20120003648Signal Multiplexing and Signal Amplification - Disclosed are methods, compositions and kits for amplifying signals for detecting the presence, quantity and/or sequence of nucleic acids and proteins, as well as methods, compositions and kits for increasing the number of such targets simultaneously detectable in a sample. Detection may be, for instance, in vivo, in cellulo or in situ. Amplification of signal is achieved by way of hybridization of nucleic acid label probe systems and structures. Increase in target multiplex capacity is achieved by way of varying the type of labels utilized in the nucleic acid label probe system.01-05-2012
20120231462ARTIFICIAL BASE PAIR CAPABLE OF FORMING SPECIFIC BASE PAIR - The present invention provides a double-stranded nucleic acid in which at least one nucleic acid strand includes an unnatural base that forms a self-complementary base pair or an unnatural base that forms a base pair with any natural base with substantially the same thermal stability. The present invention also provides a method of hybridizing a first nucleic acid strand with a second nucleic acid strand, wherein the first nucleic acid strand includes an unnatural base that forms a self-complementary base pair or an unnatural base that forms a base pair with any natural base with substantially the same thermal stability, and a method of applying the nucleic acid to SNP detection, a DNA chip, DNA/RNA computing, or an in vitro translation system. The present invention provides a method of introducing an unnatural base into a nucleic acid strand and thereby controlling the thermodynamic stability in hybridization of the nucleic acid strand.09-13-2012
20110318746RAPID OLIGO PROBES - Disclosed are methods, rapid probes, and kits for general purpose nucleic acid detection.12-29-2011
20110318742MICRO RNA MARKERS FOR COLORECTAL CANCER - There are disclosed methods for diagnosing or providing a prognosis for colorectal cancer cells in a biological sample, the method comprising the steps of detecting the presence in the biological sample of an RNA sequence at least about 98% similar over the full sequence length to a sequence selected from the group consisting of SEQ ID NOS:1-7, wherein the presence of the RNA sequence is indicative of the presence of colorectal cancer cells in the sample. Probes for detecting and providing a prognosis for colorectal cancer are also disclosed.12-29-2011
20120231457COMPOSITIONS AND METHODS FOR ASSESSING A GENETIC RISK OF DEVELOPING LATE-ONSET ALZHEIMER'S DISEASE (LOAD) - The described invention provides compositions and methods for assessing a genetic risk of developing late-onset Alzheimer's disease (LOAD) in a subject by analyzing haplotypes of human Apolipoprotein E (APOE) and Translocase of Outer Mitochondrial Membrane 40 homolog (TOMM40) genes using a PCR- and restriction digest-based approach.09-13-2012
20120231456INSTRUMENTS AND METHODS FOR MIXING THE CONTENTS OF A DETECTION CHAMBER - A receptacle having interconnected chambers arranged to permit multiple process steps to be performed independently or simultaneously. The receptacles are manufactured to separate liquid from dried reagents and to maintain the stability of the dried reagents. An immiscible liquid, such as an oil, is included to control loading of process materials, facilitate mixing and reconstitution of dried reagents, limit evaporation, control heating of reaction materials, concentrate solid support materials to prevent clogging of fluid connections, provide minimum volumes for fluid transfers, and to prevent process materials from sticking to chamber surfaces. The receptacles can be adapted for use in systems having a processing instrument that includes an actuator system for selectively moving fluid substances between chambers and a detector. The actuator system can be arranged to concentrate an analyte present in a sample. The detector can be used to detect an optical signal emitted by the contents of the receptacle.09-13-2012
20120309002SAMPLE MULTIPLEXING - The invention generally relates to methods for sample multiplexing. In certain embodiments, methods of the invention obtaining a plurality of different reactant molecules, attaching a unique identifier to the reactant molecules, and forming a droplet including the reactant molecules.12-06-2012
20120309000MYCOBACTERIA-DERIVED DNA MISMATCH REPAIR NUCLEOTIDE SEQUENCES AND USES THEREOF - The present disclosure provides an isolated DNA molecule derived from Mycobacteria having a DNA mismatch repair function represented by a nucleic acid sequence as disclosed in SEQ ID NO: 1 or 2. Also provided is a promoter sequence having SEQ ID NO: 3, and a recombinant vector comprising the isolated DNA of the present disclosure and a promoter operatively linked to the DNA molecule. The isolated DNA molecule of the present disclosure is classified as MutS4A and MutS4 and confers cells with resistance to UV and macrophages when transformed into the cells. Further it increases the frequency of homologous recombination and the genetic stability of a heterologous plasmid in cells.12-06-2012
20120309001METHOD TO DETECT PROSTATE CANCER IN A SAMPLE - The present invention provides methods to detect prostate cancer by detecting the RNA encoded by PCA3. The disclosure provides a method for determining a predisposition, or presence of prostate cancer comprising: (a) contacting a sample with at least one oligonucleotide that hybridizes to a PCA3 polynucleotide; (b) detecting an amount of PCA3 and second prostate-specific polynucleotides; and (c) comparing the amount of PCA3 polynucleotide that hybridizes to the oligonucleotide to a predetermined cut off value, and determining the presence or absence of prostate cancer. Diagnostic kits are provided for detecting prostate cancer or the risk of developing same comprising: (a) at least one container means containing at least one oligonucleotide probe or primer that hybridizes to PCA3 (b) at least one oligonucleotide probe or primer that hybridizes with a second prostate specific nucleic acid; and (c) reagents for detecting PCA3 and the second prostate specific nucleic acid.12-06-2012
20110318738IDENTIFICATION AND REGULATION OF A NOVEL DNA DEMETHYLASE SYSTEM - Disclosed herein are methods and systems directed at detecting, evaluating, ameliorating, preventing and treating an oncogenic event. The disclosed methods and systems can comprise one or more Demethylase System Components or other compositions that can be used alone or in combination to detect, evaluate, treat, ameliorate, or prevent an oncogenic event.12-29-2011
20110318745COMPOSITIONS AND METHODS FOR PERFORMING HYBRIDIZATIONS WITH SEPARATE DENATURATION OF THE SAMPLE AND PROBE - The invention provides methods and compositions for separately denaturing a probe and target in hybridization applications. The invention may, for example, eliminate the use of or reduce the dependence on formamide in hybridization applications. Compositions for use in the invention include an aqueous composition comprising at least one polar aprotic solvent in an amount effective to denature double-stranded nucleotide sequences.12-29-2011
20110318744Method For The Detection And Characterization Of Microorganisms On A Filter - The present invention relates to a method for the specific detection on a filter of one or more microorganisms present in a fluid, characterized in that it comprises the following steps: 12-29-2011
20110318743METHODS, WORKFLOWS, KITS, APPARATUSES, AND COMPUTER PROGRAM MEDIA FOR NUCLEIC ACID SAMPLE PREPARATION FOR NUCLEIC ACID SEQUENCING - A method for preparing a nucleic acid sample for nucleic acid sequencing includes amplifying a nucleic acid target sequence using a primer bound to a first capture substrate; capturing an amplified nucleic acid product by the first capture substrate; generating at least one sequencing ladder from the amplified nucleic acid product using at least one sequencing primer; capturing the at least one sequencing ladder by hybridizing the at least one sequencing ladder to a complementary capture compound on a second capture substrate; and removing the at least one sequencing ladder from the second capture substrate. The first and/or second capture substrate may include a magnetic particle. Other methods, workflows, kits, and computer program media for nucleic acid sample preparation are also disclosed.12-29-2011
20110318741BIOMARKERS FOR THE TREATMENT OF PSORIASIS - Provided herein are the biomarkers for predicting or monitoring the efficacy of a treatment for psoriasis. The use of certain cell markers and mRNA levels as biomarkers to predict whether a psoriasis treatment is likely to be successful is also provided. Further, the expression of these genes or cell markers can be used to monitor progress of treatment effectiveness and patient compliance in psoriasis patients who are receiving treatment.12-29-2011
20110318740Reduced Interference from Single Strand Binding Proteins - Disclosed, for example, are methods for detecting at least one target polynucleotide comprising cleaving a flap from a polynucleotide probe that is hybridized to a complementary target polynucleotide, and hybridizing the cleaved flap to a complementary capture probe immobilized on a surface, wherein said cleaving and/or hybridizing occurs in the presence of a single strand binding protein that is capable of binding single-stranded DNA, but that can bind neither the flap nor the capture probe. The cleaved flap and the complementary capture probe may each comprise PNA, RNA, LNA, L-DNA or other modified nucleotides or chimeras thereof that do not significantly bind to the single strand binding protein.12-29-2011
20110318734DIAGNOSING FETAL CHROMOSOMAL ANEUPLOIDY USING MASSIVELY PARALLEL GENOMIC SEQUENCING - Embodiments of this invention provide methods, systems, and apparatus for determining whether a fetal chromosomal aneuploidy exists from a biological sample obtained from a pregnant female. Nucleic acid molecules of the biological sample are sequenced, such that a fraction of the genome is sequenced. Respective amounts of a clinically-relevant chromosome and of background chromosomes are determined from results of the sequencing. The determination of the relative amounts may count sequences of only certain length. A parameter derived from these amounts (e.g. a ratio) is compared to one or more cutoff values, thereby determining a classification of whether a fetal chromosomal aneuploidy exists. Prior to sequencing, the biological sample may be enriched for DNA fragments of a particular sizes.12-29-2011
20110318739DETERMINATION OF THE DEGREE OF DNA METHYLATION - The present invention provides oligonucleotides and processes for determining the normalized methylation level of DNA, and for determining the relative methylation level of DNA between at least two samples. The invention makes use of the random distribution of transposons in the genome. The disclosed oligonucleotides and processes are of importance, in particular, for clinical diagnostics.12-29-2011
20110318737REAL-TIME POLYMERASE CHAIN REACTION DETECTION OF LEGIONELLA PNEUMOPHILA AND DIFFERENTIATION FROM OTHER LEGIONELLA SPECIES - Materials and processes are provided for the detection of 12-29-2011
20110318735REGULATION OF THE SEROTONIN REUPTAKE TRANSPORTER AND DISEASE - Described herein is a CpG island in the 5′ region of the 5HTT gene that contains an alternative exon 1 and promoter for 5HTT. Methylation at this CpG island is associated with decreased levels of 5HTT mRNA, and this effect is evident when 5HTTLPR genotype is taken into account. Thus, this methylation status indicates 5HTT mRNA production, which serves as an indicator for the expression of the transporter and of a subject's vulnerability to diseases related to serotonergic activity. Accordingly, certain embodiments of the present invention provide diagnostic methods for determining whether a subject has, or is at risk for developing, a disease associated with serotonergic activity.12-29-2011
20110318733TEST SYSTEM AND METHOD FOR THE DETECTION OF ANALYTES - The invention relates to analytical test systems and analytical methods, in which molecular switches are used for the qualitative and quantitative determination of analytes in a sample, which have a broad application by means of a selection of the molecular switch suitable for the analyte. The molecular switch comprises a probe, preferably a nucleic acid or a nucleic acid derivative, coupled to a catalytic component, preferably an enzyme. The analyse induces a conformation change in the probe, which alters the accessibility for a substrate in the probe to catalytic components and the change in substrate turnover, corresponding to the change in catalytic activity, is measured.12-29-2011
20110318747Nonseparation Assay Methods - Assay methods are disclosed involving specific binding reactions which are simplified compared to known methods. A compound capable of producing chemiluminescence is immobilized on a solid support as is a member of a specific binding pair for capturing an analyte from a sample. An activator compound that activates the chemiluminescent compound and is conjugated to a specific binding pair member is added in excess along with the sample to the solid support. Addition of a trigger solution causes a chemiluminescent reaction at the sites where the activator conjugate has been specifically bound. The assay methods are termed non-separation assays because they do not require removal or separation of excess detection label (activator conjugate) prior to the detection step. The methods are applicable to various types of assays including immunoassays, receptor-ligand assays and nucleic acid hybridization assays.12-29-2011
20120208195DISEASE SUSCEPTIBILITY - Provided herein is a method of assessing the susceptibility of a subject to, or aiding the diagnosis of, an anxiety disorder or depression, the method including determining whether the subject has a haplotype including rs3216799, rs6814934, rs7658048, rs2070950 and rs2070951 with respective alleles ‘+CT, ‘C’, ‘T’, ‘C’ and ‘C’. Also provided is a kit of parts or solid substrate for use in assessing the susceptibility of a subject to an anxiety disorder or depression, the kit including or the solid substrate having attached thereto one or more nucleic acid molecules that hybridise selectively to a genomic region encompassing any two or more SNPs selected from the group consisting of rs3216799, rs6814934, rs7658048, rs2070950 and rs2070951, and/or that hybridise selectively to a genomic region encompassing two or more polymorphic sites in linkage disequilibrium with any one or more SNPs selected from rs3216799, rs6814934, rs7658048, rs2070950 and rs2070951.08-16-2012
20120208190LUMINESCENT METAL ION COMPLEXES - The present invention provides luminescent metal ion complexes for use in a wide range of biological and chemical studies. The luminescent metal ion complexes of the invention comprise a metal ion chelating component covalently bound to a carrier molecule. Also provided are methods of making and using the luminescent metal ion complexes.08-16-2012
20120045764METHOD OF EXPANDING HUMAN HEPATOCYTES IN VIVO - Described herein is a method of expanding human hepatocytes in vivo using an immunodeficient mouse which is further deficient in fumarylacetoacetate hydrolase (Fah). The method comprises transplanting human hepatocytes into the immunodeficient and Fah-deficient mice, administering an IL-1R antagonist to the mouse and allowing the hepatocytes to expand. Alternatively, the method includes transplanting human hepatocytes into the immunodeficient and Fah-deficient mice, wherein the mouse is further deficient for IL-1R and allowing the hepatocytes to expand. The method also allows serial transplantation of the human hepatocytes into secondary, tertiary, quaternary or additional mice.02-23-2012
20120045763Antibodies Against Cells of Fetal Origin - This invention relates to antibodies that specific bind to fetal CD36+ cells in preference to binding to maternal CD36+ cells and methods for using these antibodies to detect and separate fetal cells from adult biological fluids including maternal peripheral blood.02-23-2012
20120045762LMNA GENE AND ITS INVOLVEMENT IN HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) AND ARTERIOSCLEROSIS - Disclosed herein are point mutations in the LMNA gene that cause HGPS. These mutations activate a cryptic splice site within the LMNA gene, which leads to deletion of part of exon 11 and generation of a mutant Lamin A protein product that is 50 amino acids shorter than the normal protein. In addition to the novel Lamin A variant protein and nucleic acids encoding this variant, methods of using these molecules in detecting biological conditions associated with a LMNA mutation in a subject (e.g., HGPS, arteriosclerosis, and other age-related diseases), are also described. Oligonucleotides and other compounds for use in examples of the described methods are also provided, as are protein-specific binding agents, such as antibodies, that bind specifically to at least one epitope of a Lamin A variant protein preferentially compared to wildtype Lamin A, and methods of using such antibodies in diagnosis, treatment, and screening.02-23-2012
20120045761PROBES AND PRIMERS FOR DETECTION OF CHIKUNGUNYA - The present disclosure gives a detailed description of methods for determining the presence of Chikungunya viral nucleic acids in blood/serum/plasma samples by employing “Oligonucleotide” probes. The designed “Oligonucleotide” probes can be used for qualitative or quantitative detection of Chikungunya virus in an infected sample by employing Real time PCR.02-23-2012
20120045758IMPRINTING IN VERY SMALL EMBRYONIC-LIKE (VSEL) STEM CELLS - Methods for determining a degree of pluripotency in a first putative stem cell relative to a second putative stem cell are provided. In some embodiments the methods include comparing the imprinting status in the first versus the second putative stem cell of a locus selected from among Igf2-H19, Rasgrf1, lgf2R, Kcnq1, and Peg1/Mest. Also provided are methods for distinguishing very small embryonic like (VSEL) stem cells from hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs), methods for isolating VSELs from sources expected to include VSELs, methods for assessing the purity of a very small embryonic like stem cell (VSEL) preparation, and kits that include oligonucleotide primers that can be employed in the practice of the claimed methods.02-23-2012
20120045757APPARATUS AND METHODS FOR ANALYSING FLUORESCENT PARTICLES - According to an embodiment of the invention, an apparatus to detect fluorescence from a sample is disclosed. The apparatus comprises a sample plane onto which the sample is arranged, an excitation light unit including at least a light source to illuminate the sample, and a detection unit comprising at least a detector having at least 100,000 active detection elements to detect a fluorescence signal from the sample.02-23-2012
20120045756METHODS AND COMPOSITIONS FOR SEQUENCE-SPECIFIC PURIFICATION AND MULTIPLEX ANALYSIS OF NUCLEIC ACIDS - Methods and materials for determining the presence of at least one nucleic acid in a sample are provided, said methods comprising (1) a purification step using sequence specific hybrid capture; (2) an amplification step; and (3) a detection step comprising contacting the target nucleic acid with a plurality of detectably labeled nucleic acid detection probes, wherein each (a) bears a different detectable label from the other detection probes, and/or (b) has a different melting temperature from probes bearing the same detectable label. Also disclosed are compositions and kits for use in such a method.02-23-2012
20120003632 FRET-PROBES AND USE THEREOF - This invention relates to the detection of among others tumor-specific fusion proteins and protein interactions. Provided is a set of at least a first and a second molecular probe, each probe provided with a dye wherein said dyes together allow energy transfer, each probe additionally provided with a reactive group allowing juxtaposing said at least first and second probe, wherein said reactive group is an oligonucleotide and wherein the reactive group of said first probe is not directly reactive with the reactive group of said second probe.01-05-2012
20120045760Single Nucleotide Polymorphism Within An Intronic P53 Binding Motif of the Prkag2 Gene - The present invention relates to single nucleotide polymorphism (SNP). In particular, it relates to a SNP within an intronic p53 binding motif of the PRKAG2. Nucleic acid molecules and methods for aiding assessment of a patient's risk of developing cancer by determining the patient's genotype for a p53 binding motif within the PRKAG2 gene are included in the present invention.02-23-2012
20120045755HER-2 BINDING ANTAGONISTS - There is disclosed a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an isolated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO. 1 or SEQ ID NO:12, wherein the polypeptide binds to the extracellular domain ECD of HER-2 at an affinity of at least 1002-23-2012
20120003649METHODS FOR ASSESSING RISK OF ALZHEIMER'S DISEASE IN A PATIENT - Disclosed are methods for diagnosis or prognosis of Alzheimer's disease in a patient. The methods may include assessing whether a patient has Alzheimer's disease or assessing a patient's risk for developing Alzheimer's disease. The methods typically include determining, either directly or indirectly, whether the patient has mutations, such as single nucleotide polymorphisms, in a plurality of genes that encode gene products that function in steroid biosynthesis.01-05-2012
20120003651TAGGED OLIGONUCLEOTIDES AND THEIR USE IN NUCLEIC ACID AMPLIFICATION METHODS - The present invention provides nucleic acid amplification methods that desirably reduce or eliminate false positive amplification signals resulting from contaminating biological material, e.g., nucleic acid, that may be present in one or more reagents used in an amplification reaction and/or that may be present in the environment in which an amplification reaction is performed. The invention offers the further advantage of requiring less stringent purification and/or sterility efforts than conventionally needed in order to ensure that enzymes and other reagents used in amplification reactions, and the environment in which an amplification reaction is performed, are free of bacterial or other nucleic acid contamination that may yield false positive results.01-05-2012
20120003647GENETIC POLYMORPHISMS IN THE PROSTATE-SPECIFIC ANTIGEN GENE PROMOTER - The present invention includes methods of identifying a subject at risk for increased cellular PSA production and/or prostate cancer by detecting the presence or absence of a genetic polymorphism in the prostate specific antigen gene.01-05-2012
20120003644METHODS AND KITS FOR DETERMINING PREDISPOSITION TO DEVELOP KIDNEY DISEASES - Provided are methods and kits for determining predisposition of a subject to develop a kidney disease, by identifying in a sample of the subject at least one APOL1 polypeptide variant which is characterized by a higher trypanolytic activity on 01-05-2012
20120003645Compositions, Methods and Kits for Nucleic Acid Synthesis and Amplification - The present invention is directed to compositions, methods and kits useful for the synthesis of nucleic acid molecules. More specifically, compositions, methods and kits are provided for the amplification of nucleic acid molecules in a one-step RT-PCR procedure comprising one or more agents used to increase tolerance to PCR inhibitors.01-05-2012
20120003641GENETIC POLYMORPHISMS IN AGE-RELATED MACULAR DEGENERATION - Methods for determining whether a patient is at increased risk of developing wet AMD or whether a patient has an increased likelihood of benefiting from treatment with a high-affinity anti-VEGF antibody.01-05-2012
20120003640mRNA RATIOS IN URINARY SEDIMENTS AND/OR URINE AS A PROGNOSTIC AND/OR THERANOSTIC MARKER FOR PROSTATE CANCER - Described herein are methods and kits for prognosis of prostate cancer in a subject. The methods comprises: (a) determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and (b) correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. Kits for prognosing prostate cancer are also described. More particularly, the present invention features a method for prognosing prostate cancer in a biological sample of a patient comprising: assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the biological sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.01-05-2012
20120003639CANCER BIOMARKERS AND METHODS OF USE THEREOF - Embodiments are provided for characterizing a biological sample. In some embodiments, one can estimate the risk that a subject with ductal carcinoma in situ will have a subsequent DCIS event and/or invasive cancers.01-05-2012
20120003637DIAGNOSING FETAL CHROMOSOMAL ANEUPLOIDY USING MASSIVELY PARALLEL GENOMIC SEQUENCING - Embodiments of this invention provide methods, systems, and apparatus for determining whether a fetal chromosomal aneuploidy exists from a biological sample obtained from a pregnant female. Nucleic acid molecules of the biological sample are sequenced, such that a fraction of the genome is sequenced. Respective amounts of a clinically-relevant chromosome and of background chromosomes are determined from results of the sequencing. The determination of the relative amounts may count sequences of only certain length. A parameter derived from these amounts (e.g. a ratio) is compared to one or more cutoff values, thereby determining a classification of whether a fetal chromosomal aneuploidy exists. Prior to sequencing, the biological sample may be enriched for DNA fragments of a particular sizes.01-05-2012
20120003634IDENTIFICATION OF SOURCE OF DNA SAMPLES - The present disclosure relates to methodology for fast and cost-effective identification of the source of DNA samples. DNA samples obtained from unknown or unrecognized tissues or cell types are analyzed according to the methodology described herein, yielding an identification of the tissue and/or cell type source. Identification is based on sequential biochemical procedures including methylation sensitive/dependent restriction and polymerase chain reaction, followed by analysis of the data. All biochemical steps are performed in a single test tube. The disclosure has immediate applications in forensic science for identification of the tissue source of DNA obtained from biological stains. The disclosure also has immediate applications in cancer diagnosis for identification.01-05-2012
20120003633MEANS AND METHODS FOR INVESTIGATING NUCLEIC ACID SEQUENCES - The invention provides improved methods for investigating nucleic acid sequences, wherein at least one additional probe is used which is specific for a (pseudo)gene variant of a target nucleic acid.01-05-2012
20120003636DIAGNOSING FETAL CHROMOSOMAL ANEUPLOIDY USING MASSIVELY PARALLEL GENOMIC SEQUENCING - Embodiments of this invention provide methods, systems, and apparatus for determining whether a fetal chromosomal aneuploidy exists from a biological sample obtained from a pregnant female. Nucleic acid molecules of the biological sample are sequenced, such that a fraction of the genome is sequenced. Respective amounts of a clinically-relevant chromosome and of background chromosomes are determined from results of the sequencing. The determination of the relative amounts may count sequences of only certain length. A parameter derived from these amounts (e.g. a ratio) is compared to one or more cutoff values, thereby determining a classification of whether a fetal chromosomal aneuploidy exists. Prior to sequencing, the biological sample may be enriched for DNA fragments of a particular sizes.01-05-2012
20120003643ENRICHMENT AND IDENTIFICATION OF FETAL CELLS IN MATERNAL BLOOD AND LIGANDS FOR SUCH USE - The present invention relates to enrichment and/or identification of fetal cells of a maternal blood sample using fetal cell specific ligands and/or fetal cell specific hybridization probes. Enriched or identified fetal cells may be subjected to steps of detection or diagnosis, wherefore the present invention enables non-invasive prenatal diagnostics.01-05-2012
20120003642OLIGONUCLEOTIDES AND METHODS FOR DETERMINING SUSCEPTIBILITY TO SOFT TISSUE INJURIES - A method of determining in a subject a predisposition to, or increased risk for, developing a tendon, ligament, or other soft tissue injury or pathology, the method comprising the step of screening the subject for the presence of at least one poly-morphism in at least one gene family selected from the group consisting of any one or more of: the matrix metallo-protease (MMP) family, the collagen family, including the COL5A1 and COL12A1 genes, the glycoprotein family, including the TNC and COMP genes, and derivatives thereof, which polymorphism is a polymorphism which results in a modified, augmented, or gated interaction with other members of the gene families mentioned herein, when compared to a wild-type interaction.01-05-2012
20120208192NUCLEIC ACID AMPLIFICATION EMPLOYING TEMPERATURE OSCILLATION - A method for carrying out an isothermal nucleic acid amplification reaction at a predetermined temperature, said method comprising changing the temperature of the reaction mixture away from the said predetermined temperature and allowing it to return to the predetermined temperature at least once during the amplification reaction so as to cause a temperature oscillation in particular of up to 15° C., for example of from 2-10° C. Apparatus adapted to carry out the method forms a further aspect of the invention.08-16-2012
20120208188DIAGNOSTIC AND TREATMENT FOR CHRONIC AND ACUTE PHASE MYELOID LEUKEMIA - Disclosed are methods of predicting responsiveness of a cancer cell to a tyrosine kinase inhibitor, and methods of predicting the risk of progression of a cancer cell to a more aggressive form. Also provided are methods of reducing proliferation or promoting differentiation of a cancer cell having reduced level of Numb or increased level of Msi. Further disclosed are methods of treating a mammalian subject having cancer and methods of assessing an agent for chemotherapeutic potential.08-16-2012
20120208185METHOD FOR DETERMINING THE RISK OF DEVELOPING A NEUROLOGICAL DISEASE - Methods and kits are provided for determining whether a subject is at risk of developing a neurological disease such as Alzheimer's disease and multiple sclerosis. The methods and kits are based on the detection of one or more nucleic acid variants in the MBL gene of the subject.08-16-2012
20120009573 Antisense Transcriptomes of Cells - Transcription in mammalian cells can be assessed at a genome-wide level, but it has been difficult to reliably determine whether individual transcripts are derived from the Plus- or Minus-strands of chromosomes. This distinction can be critical for understanding the relationship between known transcripts (sense) and the complementary antisense transcripts that may regulate them. Here we describe a technique that can be used to (i) identify the DNA strand of origin for any particular RNA transcript and (ii) quantify the number of sense and antisense transcripts from expressed genes at a global level. We examined five different human cell types and in each case found evidence for antisense transcripts in 2900 to 6400 human genes. The distribution of antisense transcripts was distinct from that of sense transcripts, was non-random across the genome, and differed among cell types. Anti-sense transcripts thus appear to be a pervasive feature of human cells, suggesting that they are a fundamental component of gene regulation.01-12-2012
20120009580METHODS FOR QUANTITATING SMALL RNA MOLECULES - In one aspect, the present invention provides methods for amplifying a microRNA molecule to produce DNA molecules. The methods each include the steps of: (a) using primer extension to make a DNA molecule that is complementary to a target microRNA molecule; and (b) using a universal forward primer and a reverse primer to amplify the DNA molecule to produce amplified DNA molecules. In some embodiments of the method, at least one of the forward primer and the reverse primer comprise at least one locked nucleic acid molecule.01-12-2012
20120009579MONOCYTE-DERIVED NUCLEIC ACIDS AND RELATED COMPOSITIONS AND METHODS - Nucleic acids encoding various monocyte-derived proteins and related compositions, including purified proteins and specific antibodies are described. Methods of using such composition are also provided.01-12-2012
20120009578Microvesicle-Based Compositions and Methods - Methods and compositions for diagnosis and/or analysis of a condition in a mammal are disclosed in which RNA from microvesicles is enriched and differentiated to so obtain a result that is indicative of the condition of tissue or organ from which the microvesicle originated. In especially preferred embodiments, the condition is a neoplastic disease of a human and can be identified and staged by differential analysis of one or more distinct RNAs, optionally together with identification and analysis of a non-RNA component of the microvesicle.01-12-2012
20120009577Detection of Nucleic Acids Through Amplification of Surrogate Nucleic Acids - Methods for detecting and optionally quantitating one or more target nucleic acids are provided, in which a surrogate nucleic acid is captured to each target nucleic acid, amplified, and detected. Compositions, kit, and systems related to the methods are also described.01-12-2012
20120009576Probe for Detection of Polymorphism in ABL Gene, and Use Thereof - A probe for detecting a polymorphism in ab1 gene, said probe comprising at least one fluorescence-labeled oligonucleotide selected from P1 below: 01-12-2012
20120009574DETECTION OF LISTERIA SPECIES IN FOOD AND ENVIRONMENTAL SAMPLES, METHODS AND COMPOSITIONS THEREOF - Embodiments of the disclosure relate to isolated nucleic acid sequences, methods of use thereof, and workflows for detection of several 01-12-2012
20120009572Novel single nucleotide polymorphisms and community-associated methicillin-resistant staphylococcus aureus - The present invention is based on the discovery of novel polymorphisms (SNPs) in the penicillin binding protein (pbp3) gene in 01-12-2012
20120009571TMPRSS2 FOR THE DIAGNOSIS OF PROSTATE DISEASE - Described herein are methods, compositions and kits directed to the detection the 5′ portion of TMPRSS2 mRNA for the detection and diagnosis of prostate disease including prostate cancer and benign prostatic hyperplasia.01-12-2012
20120009575INDUCIBLE NUCLEIC ACID TARGETS FOR DETECTION OF PATHOGENS, METHODS AND COMPOSITIONS THEREOF - The present application describes compositions, methods and kits for rapid detection and identification of various microorganisms using inducible RNA. Methods for rapidly detecting microorganisms by detecting expression of inducible RNA of target genes following induction of a target gene using an inducer are described. Some embodiments describe methods and workflows for rapidly detecting microbes such as, but not limited to, 01-12-2012
20120009570Restoration of Nucleic Acid From Degraded or Formalin-Fixed and Paraffin-Embedded Tissue and Uses Thereof - This invention provides methods, primers and kits for restoration of nucleic acid from tissue, in particular degraded tissue and formalin-fixed and paraffin-embedded (FFPE) tissue, where the methods involve complementary-template reverse-transcription (CT-RT) where short single-stranded DNA sequences reverse-transcribed from mRNA are used for reverse-transcription of complementary sense-RNA templates. The methods can be used to determine patterns of gene expression and chromosomal alterations in archived tissue samples, and may be used to identify expression of disease-related genes.01-12-2012
20120045759Methods for detecting nucleic acid hybridization - Chemically reactive carbocyanine dyes that are intramolecularly crosslinked between the 1-position and 3′-position, their bioconjugates and their uses are described. 1,3′-crosslinked carbocyanines are superior to those of conjugates of spectrally similar 1,1′-crosslinked or non-crosslinked dyes. The invention includes derivative compounds having one or more benzo nitrogens.02-23-2012
20120129170Methods for Identifying Genomic Deletions - The genomic locus responsible for Van Buchem's disease is narrowed to an approximately 92 kb region of human chromosome 17 at 17q21. Individuals afflicted with or carriers of Van Buchem's disease exhibit a 52 kb deletion within this 92 kb region. Methods are provided that permit the differentiation between individuals homozygous for and therefore afflicted with Van Buchem's disease, individuals heterozygous for and therefore carriers of Van Buchem's disease, and individuals who are normal with respect to Van Buchem's disease. Also provided are general methodologies for the detection of a wide variety of large genomic deletions.05-24-2012
20120129169Two-Step Cold Formalin fixation of organic tissue samples - A method for fixation of organic tissue samples includes immersing a tissue sample in a solution of Formalin at a temperature of between 2° C. and 10° C. for a first time period (A), and immersing the tissue sample in a cold fixation dehydrating agent for a second time period (B) following the first time period. An automated tissue fixation system for fixating organic tissue samples in Formalin is also described.05-24-2012
20120015357PREDICTION OF LIPID-METABOTYPE-RELATED PHYSIOLOGICAL SUSCEPTIBILITIES - The present invention relates to a method for determining a predisposition of a human subject for physiological susceptibilities that result from alterations in lipid metabolism, wherein the physiological susceptibilities are selected from sensitivity to functional food, physical health schemes, identification of non-responsiveness to treatment by diet or physical activity. The present invention further relates to a method for determining a predisposition of a human subject for physiological susceptibilities that result from alterations in lipid metabolism, wherein the physiological susceptibilities are selected from sensitivity to drug treatment or identification of non-responsiveness to treatment by medication. The methods of the present invention comprise determining, in a sample obtained from the human subject, the genotype of that person with respect to at least two genetic polymorphisms selected from the group consisting of a) rs2014355; b) rs11161510; c) rs2286963; d) rs174548; e) rs9393903; f) rs168622; g) rs541503; h) rs2046813; i) rs272889; j) rs2216405; k) rs7156144; l) rs8396; m) rs7094971; and n) rs603424; wherein the presence of one or two copies of the minor allele of at least two genetic polymorphisms is indicative of a predisposition for said physiological susceptibilities. The polymorphisms listed above are located in the following genes: SCAD, MCAD, LCAD, FADS1, ELOVL2, SPTLC3, PHGDH, ACSL1, OCTN1, CPS1, PLEKHH1, ETFDH, SLC16A9 and SCD.01-19-2012
20120015355SIZE STANDARDS FOR USE IN NUCLEIC ACID ANALYSIS - A size standard, kit includes a size standard, method of defining a size standard and method of analysis using a size standard. The size standard is intended to include size standard elements which have a size greater than and/or less than and/or different from the components of a sample which are to be sized. This means that the same characteristic unit, such as a dye, can be used to label the component and the size standard. A further characteristic unit, from amongst a limited number of such characteristic units is liberated from use only on size standards for use on components. The method is therefore particularly useful in multiplex amplification of STRs.01-19-2012
20120208193DETECTING METHYLATION IN A SUBPOPULATION OF GENOMIC DNA - This invention provides methods of determining the biological, pathological, genetic, epigenetic or disease status in a biological sample by determining the methylation status of a subpopulation of genomic DNA in the sample.08-16-2012
20120208189METHODS FOR ISOLATION, IDENTIFICATION, AND QUANTIFICATION OF MIRNAS - Method and compositions and kits for isolation, identification, and quantification of miRNAs and other small RNAs, including but not limited to, siRNAs, mRNAs, and snRNAs are disclosed. Methods of diagnosing a disease or its progression are also disclosed.08-16-2012
20120208187Method and Kit for Determining Severity and Progression of Periodontal Disease - An improved method and kit of determining whether a patient is predisposed to having severe periodontal disease and/or having high risk of progression of periodontal disease, comprising the steps of (i) taking a biological sample from said patient; (ii) genotyping said biological sample for genetic polymorphism pattern comprising IL 1B (rs16944), IL 1B (rs1143623) and IL 1B (rs4848306); and (iii) comparing said genetic polymorphism patterns to a reference composite genotype pattern; wherein the similarity of said genetic polymorphism patterns to said reference pattern indicate said patient's predisposition to having severe periodontal disease and/or having high risk of progression of periodontal disease.08-16-2012
20120208183METHODS FOR DETERMINATION OF HAPLOTYPE DISSECTION - A method for molecular haplotyping of a subject is disclosed. The method comprises: randomly selecting a set of chromosomes in each of a plurality of lyzed diploid cells of the subject, collecting the selected chromosomes from said plurality of cells into a plurality of sample tubes, wherein each sample tube contains chromosomes selected from one or more cells, genotyping genomic DNA in each sample tube, and determining haplotype of the alleles based on allele nucleotide sequence information and corresponding nucleotide signal intensities from genotyping data. Other methods for molecular haplotyping using single cell lysate or single cell microdissection are also disclosed.08-16-2012
20110165571HERBICIDE TOLERANT RICE PLANTS AND METHODS FOR IDENTIFYING SAME - The invention provides specific transgenic rice plants, plant material and seeds, characterized in that these products harbor a specific transformation event at a specific location in the rice genome. Tools are also provided which allow rapid and unequivocal identification of the event in biological samples.07-07-2011
20110165570METHOD OF EFFECTING DE-DIFFERENTIATION OF A CELL - The invention provides a method of effecting de-differentiation of an at least partially differentiated cell or of maintaining pluripotency and/or self-renewing characteristics of an undifferentiated cell. The method comprises increasing the amount or the activity of an Err protein, or a functional fragment thereof, in the cell.07-07-2011
20110165569COMBINATORIAL DNA TAGGANTS AND METHODS OF PREPARATION AND USE THEREOF - DNA taggants in which the nucleotide sequences are defined according to combinatorial mathematical principles. Methods of defining nucleotide sequences of the combinatorial DNA taggants, and using such taggants for authentication and tracking and tracing an object or process are also disclosed.07-07-2011
20110165568SEQUENCES OF E.COLI 055:H7 GENOME - Disclosed is the genomic sequence for 07-07-2011
20110165567ABERRANT METHYLATION OF C6Orf150 DNA SEQUENCES IN HUMAN COLORECTAL CANCER - This application describes methods and compositions for detecting and treating C6Orf150-associated neoplasia. Differential methylation of the C6Orf150 nucleotide sequences has been observed in C6Orf150-associated neoplasia such as colon neoplasia.07-07-2011
20110165566METHODS OF OPTIMIZING TREATMENT OF BREAST CANCER - Breast cancer treatment can be optimized by determining the level of expression of genes in a breast sample from a human to identify a human with an increased likelihood of recurrence of the breast cancer that would potentially benefit from a therapy to decrease the likelihood of recurrence of the breast cancer.07-07-2011
20110165565COMPOSITIONS AND METHODS FOR POLYNUCLEOTIDE EXTRACTION AND METHYLATION DETECTION - The present invention features methods and compositions for methylation detection, as well as a novel method for polynucleotide extraction and sodium bisulfite treatment.07-07-2011
20110165564SEQUENCE-SPECIFIC DETECTION OF METHYLATION IN BIOMOLECULES - A method for detecting sequence specific methylation in a biomolecule, comprising: (a) contacting the biomolecule with an S-adenosyl-07-07-2011
20120058475Detection of Chromosomal Inversions - A method and a kit for the identification of chromosomal inversions is described. Chromosomal inversions are difficult to detect unless they are quite large. The improved ability to detect chromosomal inversions is important to a number of medical applications, such as cancer and birth defects, as examples. Reporter species are attached to oligonucleotide strands designed such that they may hybridize to portions of only one of a pair of single-stranded sister chromatids prepared by the CO-FISH procedure, as an example. If an inversion has occurred, these marker probes will be detected on the sister chromatid at the same location as the inversion on the first chromatid.03-08-2012
20120115140Molecular Diagnosis of Fragile X Syndrome Associated with FMR1 Gene - The present invention includes a rapid, selective, and accurate method of diagnosing a human subject with a triplet repeat genetic disorder of the FMR1 gene that leads to fragile X syndrome. The present invention also includes a rapid, selective, and accurate method of diagnosing a human subject at risk for developing a triplet repeat genetic disorder of the FMR1 gene that leads to fragile X syndrome, or at risk of passing such a disorder on to their progeny.05-10-2012
20120115141ENDPOINT TAQMAN METHODS FOR DETERMINING ZYGOSITY OF COTTON COMPRISING Cry1F EVENT 281-24-236 - A method for zygosity analysis of the cotton Cry1F event 281-24-236 is provided. The method provides 281-24-236 event-specific and cotton endogenous reference gene-specific primers and TaqMan probe combinations for use in an endpoint biplex TaqMan PCR assay capable of determining event zygosity and for assisting in event introgression and breeding.05-10-2012
20120115142ENDPOINT TAQMAN METHODS FOR DETERMINING ZYGOSITY OF COTTON COMPRISING Cry1Ac EVENT 3006-210-23 - A method for zygosity analysis of the cotton Cry1Ac event 3006-210-23 is provided. The method provides 3006-210-23 event-specific and cotton-genome-specific primers and TaqMan probe combinations for use in an endpoint biplex TaqMan PCR assay capable of determining event zygosity and for assisting in event introgression and breeding.05-10-2012
20120058472METHOD AND SYSTEM FOR NUCLEIC ACID DETECTION USING ELECTROCONDUCTIVE OR ELECTROCHEMICALLY ACTIVE LABELS - A method for electrochemically or electrically detecting nucleic acids, utilizes electrochemically active or electrically conductive reporter materials. An electric voltage is applied and electric signals are measured to the electrodes that are suitable for detecting or quantifying the nucleic acid(s) in a sample. This technique is suitable for point-of-use applications, e.g. detecting bioanalytes in remote locations. A microchip, device, kit used adapted to be used for this method is also disclosed.03-08-2012
20120058471IDENTIFICATION OF NUCLEIC ACID SEQUENCES - The invention provides a method for use in the detection of a target nucleic acid comprising the steps of: (i) contacting a single-stranded probe nucleic acid with a sample of interest under conditions effective to generate a probe/target nucleic acid duplex by specific hybridisation of said probe nucleic acid to a target nucleic acid, if said target nucleic acid is present; (ii) contacting any probe/target nucleic acid duplex with an exonuclease to effect digestion of the duplex and release of a label molecule from the duplex; and (iii) detecting the label by Raman spectroscopy.03-08-2012
20120058476Method Of Oligonucleotide Labeling Using Cycloaddition Reaction - The invention provides a novel method of labeling oligonucleotides, with reporter moieties, including but not limited to, quenchers, fluorophores, biotin, digoxigenin, peptides and proteins. In addition, this invention provides a method of detecting hybridization of oligonucleotides. This invention also provides novel azo quenchers having the general formula shown below. The invention further provides compositions comprising labeled oligonucleotides and solid supports. The invention also provides kits comprising at least one composition of the present invention.03-08-2012
20120058474PROBE-ANTIPROBE COMPOSITIONS AND METHODS FOR DNA OR RNA DETECTION - The invention provides novel compositions and methods for detecting unlabeled nucleic acid targets using labeled polynucleotide probes and partially complementary antiprobes. The interaction of probes, antiprobes and targets result in signaling changes that indicate target frequency. This novel detection mechanism is called a DNA detection switch, and it enable end-point detection, microarray detection and real-time PCR detection of a variety of nucleic acid targets including microbial species and subspecies, drug resistant mutants, and pathogenic strains.03-08-2012
20120058473Molecular Adaptors for Dye Conjugates - In various embodiments, the present invention provides fluorescent dyes that are linked to another species through an adaptor moiety. In an exemplary embodiment, the dye is linked to a polyphosphate nucleic acid through an adaptor. An adaptor can be a component of a linker. These conjugates find use in single molecule DNA sequencing and other applications. In various embodiments, the dye moiety is a cyanine dye. Cyanine dyes that are highly charged, such as those including multiple sulfonate, alkylsulfonate, carboxylate and/or alkylcarboxylate moieties are examples of cyanine dyes of use in the compounds of the invention.03-08-2012
20120156676SINGLE NUCLEOTIDE POLYMORPHISMS IN BRCA1 AND CANCER RISK - The invention provides methods for identifying mutations, such as single nucleotide polymorphisms (SNPs), within breast and ovarian cancer associated genes that modify the binding efficacy of microRNAs (miRNAs). In a preferred embodiment, methods of the invention identify a SNP that decreases expression of the BRCA1 gene by increasing or decreasing the binding efficacy of at least one miRNA. Alteration of miRNA binding to BRCA1 by the introduction of SNPs within miRNA binding sites modulates or decreases BRCA1 expression, ultimately leading to the unregulated cell proliferation of a breast or ovarian cancer cells.06-21-2012
20120156677Detection and Quantification of Hydroxymethylated Nucleotides in a Polynucleotide Preparation - Methods and compositions are described for detecting hydroxymethylated nucleotides (hmNs) in a polynucleotide preparation with a view to mapping the location of hmNs in a genome, quantifying the occurrence of hmNs at selected loci and correlating the occurrence of hmNs with gene expression and phenotypic traits. Embodiments describe the use of modifying enzymes together with site-specific endonucleases to detect the hmNs.06-21-2012
20120064525METHOD FOR COLLECTION OF NUCLEIC ACID DERIVED FROM MAMMALIAN CELL, METHOD FOR ANALYSIS OF NUCLEIC ACID, AND KIT FOR COLLECTION OF FECES - A method of recovering a nucleic acid derived from a mammalian cell taken from feces is provided. The nucleic acid is recovered easily even from feces collected in routine health checkups or the like. The nucleic acid of mammalian cell can be recovered more selectively than that from an enterobacterial cell. The method of recovering of the present invention includes the steps of, (A) preparing a fecal sample by placing the feces in a treatment solution with a high salt concentration, immersing the feces in the treatment solution for a predetermined period; (B) recovering a solid component from the fecal sample after the step (A); and (C) recovering a nucleic acid from the solid component recovered in the step (B).03-15-2012
20120208186Methods For The Diagnosis Of Fetal Abnormalities - The present invention relates to methods for detecting, enriching, and analyzing rare cells that are present in the blood, e.g. fetal cells. The invention further features methods of analyzing rare cell(s) to determine the presence of an abnormality, disease or condition in a subject, e.g. a fetus by analyzing a cellular sample from the subject.08-16-2012
20120208182GENETIC TEST FOR LIVER COPPER ACCUMULATION IN DOGS AND LOW COPPER PET DIET - The present invention provides a method of determining the susceptibility of a dog to liver copper accumulation, comprising detecting the presence or absence in the genome of the dog of (a) a polymorphism in the GOLGA5, ATP7a or UBL5 gene that is indicative of susceptibility to liver copper accumulation and/or (b) a polymorphism in linkage disequilibrium with a said polymorphism (a). The invention also provides a method of determining the likelihood that a dog is protected from liver copper accumulation comprising detecting the presence or absence in the genome of the dog of one or more polymorphisms selected from (a) SNP ATP7a_Reg3_F_6 (SEQ ID NO: 142) and (b) one or more polymorphisms in linkage disequilibrium with (a).08-16-2012
20120064526KITS FOR AND METHODS OF DIFFERENTIAL STAINING OF CERVICAL CANCER CELLS AND/OR TISSUES - Provided are methods and kits for staining cervical cell sample by contacting the cervical cell sample with a 03-15-2012
20120064522METHODS FOR DETERMINING GENE-ALPHA TOCOPHEROL INTERACTIONS - Method for predicting the change in the level of at least one pro-inflammatory cytokine in an individual due to alpha tocopherol supplementation are provided, as well as methods for predicting the response of an individual to alpha tocopherol supplementation, and methods of nutrigenetic screening of an individual.03-15-2012
20120064520DIAGNOSIS AND PROGNOSIS OF VARIOUS TYPES OF CANCERS - The present invention provides nucleic acid sequences that are used for identification, classification and diagnosis of specific types of cancers. The nucleic acid sequences can also be used for prognosis evaluation of a subject based on the expression pattern of a biological sample.03-15-2012
20120252014METHOD OF NORMALIZED QUANTIFICATION OF NUCLEIC ACIDS USING ANCHOR OLIGONUCLEOTIDES AND ADAPTER OLIGONUCLEOTIDES - The present invention is related to normalized quantification of nucleic acids and to the normalization of quantities of nucleic acids in samples, e.g. mixtures of nucleic acids. The present invention relates to method for the normalization of the quantity of a nucleic acid to be quantified in a sample to the total quantity of nucleic acid in the sample; or to the total quantity of a specific class of nucleic acid in the sample.10-04-2012
20120252012METHOD FOR DETECTING PROKARYOTIC DNA FROM A FECES SAMPLE - The present invention concerns a method of detection and preferably of quantification of DNA, preferably comprising prokaryotic DNA, extracted from a stool sample of an individual, especially for the molecular determination of the composition of the intestinal flora in the stool. According to the invention, one controls the quality of the DNA extraction by verifying whether one detects a specific DNA of 10-04-2012
20120208191STAPHYLOCOCCUS DETECTION ASSAYS - Provided herein are methods, kits, and compositions related to nucleic acid detection that allow the detection and discrimination of various 08-16-2012
20120070826LAFORA'S DISEASE GENE - A novel gene (EPM2B) that is mutated in humans and dogs with Lafora's disease is described.03-22-2012
20120107818DETECTION OF MULTIPLE NUCLEIC ACID SEQUENCES IN A REACTION CARTRIDGE - The present invention relates to a method for amplifying and detecting nucleic acid sequences in a reaction cartridge comprising the following steps, (i) providing a sample comprising at least one nucleic acid molecule, (ii) in a first reaction chamber of the cartridge providing reagents for an amplification reaction, (iii) mixing the sample with the amplification reagents, (iv) amplifying the at least one nucleic acid in the first reaction chamber of the cartridge, (v) transferring at least parts of the amplification reaction into a second and third reaction chamber of the cartridge each comprising a probe set, wherein (a) each probe set consists of at least three probes, (b) each of the probes is specific for a nucleic acid sequence, (c) there are at least two probes in each set which carry an identical label, (d) each of the probes in a given probe set that carries an identical label has a melting temperature (T05-03-2012
20120070833LATERAL FLOW MICROFLUIDIC ASSAYING DEVICE AND RELATED METHOD - Provided herein is a microfluidic device and related method for controlling flow of different fluid components of a fluid. The microfluidic device comprises an input channel, focusing channel and an assaying channel. The microfluidic device is adapted to separate a fluid into at least two fluid components, and is further adapted to detect a target material comprised within one of the fluid components. The method comprises providing a channel, the channel having a dimension which is a function of a dimension of one of the fluid components and deliver the fluid through the channel at a set flow rate.03-22-2012
20120070831Amplification of Distant Nucleic Acid Targets Using Engineered Primers - The invention is a method of amplifying nucleic acids by synthesizing an engineered amplicon containing the sequence of interest, but omitting intervening sequences present in the template molecule. The method utilizes an “amplicon bridge” incorporated into the amplification primers. The length and content of the desired amplicon can be chosen by the operator and can contain unique regions for probe binding.03-22-2012
20120070828METHODS FOR THE DETECTION AND IDENTIFICATION OF EXTENDED SPECTRUM BETA LACTAMASES - Embodiments disclosed herein relate to compositions for the detection and/or identification of microbes that carry extended spectrum beta-lactamase genes. Specifically, provided herein are oligonucleotides, probes, and kits containing the same, for the detection of bacterial CTX-M sequences. Also provided are methods for the detection and/or amplification of microbes harboring extended spectrum beta-lactamase genes, including CTX-M type extended spectrum beta-lactamase genes.03-22-2012
20120070829SIZE SELECTION OF DNA FOR CHROMATIN ANALYSIS - Methods for analyzing chromosomal DNA, including chromatin, are provided.03-22-2012
20120156678BINDING-INDUCED HAIRPIN DETECTION SYSTEM - This application relates to a binding-induced hairpin detection system comprising: a. a first probe comprising a targeting molecule and an oligonucleotide that has a free end and an end attached to the targeting molecule; and b. a second probe comprising a targeting molecule and an oligonucleotide that has an end attached to the targeting molecule and a free end comprising a nucleotide sequence that is complementary to a nucleotide sequence at or near the free end of the oligonucleotide of the first probe; wherein upon binding of the targeting molecule to a target molecule, the free end of the oligonucleotide of the second probe hybridizes at or near the free end of the oligonucleotide of the first probe forming a hairpin stem, the non-hybridized portions of the first and second probes together with the target molecule bound thereto forming a hairpin loop, thereby providing a binding-induced hairpin.06-21-2012
20120156675PICOWELL CAPTURE DEVICES FOR ANALYSING SINGLE CELLS OR OTHER PARTICLES - A convenient way of isolating individual cells permits individual analysis of their contents. A capture support for individually capturing cells of interest comprises a first surface including at least one well sized to accommodate an individual cell, wherein the support is made of a differentially permeable material which permits transfer of a solvent and any low molecular weight species through the support from a second surface of the support to a well, but which is substantially impermeable to biopolymers. Single cells are captured, their contents are released, and the contents of individual cells are then analysed within a chamber containing suitable analytical components e.g. immobilised nucleic acid probes, immobilised antibodies, etc. Analysis of a single cell's genome, transcriptome, proteome, etc. thus becomes possible.06-21-2012
20120156674METHODS OF DIFFERENTIATING BETWEEN NON-GENOTOXIN AND GENOTOXIN-ASSOCIATED TUMORS - Embodiments of the present disclosure are directed to methods of differentiation of non-genotoxin associated versus genotoxin-associated tumors.06-21-2012
20130011835COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION - The present invention relates to compositions to treat inflammation (LIGHT pathway) related disorders, and specifically liver inflammation or hepatitis. The invention also relates to methods treating LIGHT pathway related disorders. The invention further relates to kits for treating LIGHT pathway related disorders in a subject. The invention further relates to methods of identifying novel treatments for treating LIGHT pathway related disorders in a subject.01-10-2013
20130011834MEAN DNA COPY NUMBER OF CHROMOSOMAL REGIONS IS OF PROGNOSTIC SIGNIFICANCE IN CANCER - Methods for predicting a disease free time interval (DFI) for a cancer patient under consideration for initial or further chemotherapy treatment are disclosed. The methods include obtaining a biological sample from a patient and detecting a copy number of chromosome region A1 and/or C2. The mean copy number per cell is correlated with a DFI for the subject. The chemotherapy can include doxorubicin and/or L-asparaginase treatment. Also provided are kits for predicting DFI in a subject with cancer and computer readable storage media for performing the presently disclosed methods.01-10-2013
20120135407Compositions and Methods for Intramolecular Nucleic Acid Rearrangement - Aspects of the present invention are drawn to processes for moving a region of interest in a polynucleotide from a first position to a second position with regard to a domain within the polynucleotide, also referred to as a “reflex method”. In certain embodiments, the reflex method results in moving a region of interest into functional proximity to specific domain elements present in the polynucleotide (e.g., primer sites and/or MID). Compositions, kits and systems that find use in carrying out the reflex processes described herein are also provided.05-31-2012
20120122092Compositions and methods for detecting Borrelia afzelii - Disclosed are oligonucleotides useful in methods for determining whether a sample contains 05-17-2012
20120122088METHYLATION ASSAY - A method for detecting a methylated genomic locus is provided. In certain embodiments, the method comprises: a) treating a nucleic acid sample that contains both unmethylated and methylated copies of a genomic locus with an agent that modifies cytosine to uracil to produce a treated nucleic acid; b) amplifying a product from the treated nucleic acid using a first primer and a second primer, wherein the first primer hybridizes to a site in the locus that contain methylcytosines and the amplifying preferentially amplifies the methylated copies of the genomic locus, to produce an amplified sample; and c) detecting the presence of amplified methylated copies of the genomic locus in the amplified sample using a flap assay that employs an invasive oligonucleotide having a 3′ terminal G or C nucleotide that corresponds to a site of methylation in the genomic locus.05-17-2012
20120122086METHOD FOR RAPID DETECTION AND IDENTIFICATION OF BIOAGENTS IN EPIDEMIOLOGICAL AND FORENSIC INVESTIGATIONS - The present invention provides methods for rapid forensic investigations by identification of bioagents associated with biowarfare and acts of terrorism or crime. The methods are also useful for epidemiological investigations by genotyping of bioagents.05-17-2012
20120122089Gene Marker For Evaluating Genetic Potential For Marbling In Bovine Individual And Method For Evaluating Genetic Potential For Marbling Using The Same - The present invention provides markers for evaluating a genetic potential for marbling of a bovine individual as well as methods for evaluating genetic potential for marbling using the markers.05-17-2012
20120315635Universal Sample Preparation System And Use In An Integrated Analysis System - The invention provides for devices and methods for interfacing microchips to cartridges and pneumatic manifolds. The cartridges, microchips, and pneumatic manifolds can be integrated with downstream preparation devices, such as thermal regulating devices and separation and analysis devices.12-13-2012
20120315634DISTINGUISHING PCA3 MESSENGER RNA SPECIES IN BENIGN AND MALIGNANT PROSTATE TISSUES - This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.12-13-2012
20120122091BIOLOGICAL SAMPLING DEVICE - A sampling device adapted for transcervical sampling of biological materials from a pregnant patient comprising: an elongate insertion tube (05-17-2012
20120231459CHEMILUMINESCENT PROBES FOR MULTIPLEX MOLECULAR QUANTIFICATION AND USES THEREOF - A novel method is disclosed for simultaneous detection and quantification of two or more nucleic acid targets, without need for amplification. The method depends on spectral-temporal resolution of chemiluminescence emitted from independent hybridization-induced chemiluminescent signal (HICS) probes. The utility of this method has been demonstrated by use of resolvable N-linked acridinium and 2,7-dimethoxyacridinium ester labeled probes in a homogeneous assay for sensitive and simultaneous independent quantification of several bacterial and fungal target sequences. Compositions and kits for practicing the method of the present invention are also disclosed.09-13-2012
20120231461DETECTION OF NUCLEIC ACIDS - The present invention relates to compositions and methods for the detection and characterization of small nucleic acid molecules (e.g., RNA (e.g., small RNAs such as micro RNAs (miRNAs) and small interfering RNAs (siRNAs)) and other short nucleic acid molecules). More particularly, the present invention relates to methods for the detection and quantification of RNA expression. The present invention further provides for the detection of miRNA and siRNA variants.09-13-2012
20120231460Method and Apparatus for Predicting Pharmacological Efficacy of Human Anti-TNFa Antibody Drug against Rheumatoid Arthritis - A method for predicting pharmacological efficacy of a human anti-TNFα antibody drug against rheumatoid arthritis, the method including: measuring a level of at least one of ADAMTS4 and ADAMTS5 in a sample derived from a subject, and determining whether or not the human anti-TNFα antibody drug is efficacious against rheumatoid arthritis of the subject, based on the level of the at least one of ADAMTS4 and ADAMTS5 serving as an index.09-13-2012
20130171633THERMAL REACTION DEVICE AND METHOD FOR USING THE SAME - An M×N matrix microfluidic device for performing a matrix of reactions, the device having a plurality of reaction cells in communication with one of either a sample inlet or a reagent inlet through a via formed within an elastomeric block of the device. Methods provided include a method for forming vias in parallel in an elastomeric layer of an elastomeric block of a microfluidic device, the method comprising using patterned photoresist masks and etching reagents to etch away regions or portions of an elastomeric layer of the elastomeric block.07-04-2013
20130171644COINCIDENCE DETECTION - The invention relates to a method of detecting the coincidence of two biomolecular structures in a solid phase sample, said method comprising: (i) providing a first and a second fusion protein, each fusion protein comprising (a) a detection domain, said detection domain comprising a DNA binding domain; said detection domain capable of binding a cognate specific nucleotide sequence in co-operation with a further detection domain; (b) a recognition domain, said recognition domain capable of binding a target biomolecular structure; and (c) a connector domain; said connector domain being fused at one end to the detection domain and being fused at the other end to the recognition domain; wherein at least two of (a), (b) and (c) are heterologous to one another; wherein the recognition domains of said first and said second fusion proteins are capable of binding to first and second biomolecular structures; (ii) contacting the sample with said first and second fusion proteins; (iii) incubating to allow binding; (iv) removing unbound fusion protein; (v) contacting the sample with nucleic acid comprising said cognate specific nucleotide sequence; (vi) incubating to allow heterotrimeric binding of the nucleic acid; (vii) detecting nucleic acid bound to the sample wherein detection of nucleic acid in step; (vii) indicates that the two biomolecular structures are present coincidentally in said sample.07-04-2013
20120315631TUMOR SUPPRESSOR DESIGNATED TS10Q23.3 - A specific region of chromosome 10 (10q23.3) has been implicated by series of studies to contain a tumor suppressor gene involved in gliomas, as well as a number of other human cancers. One gene within this region was identified, and the corresponding coding region of the gene represents a novel 47 kD protein. A domain of this product has an exact match to the conserved catalytic domain of protein tyrosine phosphatases, indicating a possible functional role in phosphorylation events. Sequence analyses demonstrated the a number of exons of the gene were deleted in tumor cell lines used to define the 10q23.3 region, leading to the classification of this gene as a tumor suppressor. Further analyses have demonstrated the presence of a number of mutations in the gene in both glioma and prostate carcinoma cells. Methods for diagnosing and treating cancers related to this tumor suppressor, designated as TS10q23.3, also are disclosed.12-13-2012
20110183333METHOD FOR PREDICTION OF THE PROGRESSION RISK OF TUMORS - The present invention concerns a method for predicting the potential for aggressive growth and/or the risk to progress to high grade cancer for tumors in cell based detection procedures. In one aspect the invention concerns the detection of overexpression of cyclin-dependent kinase inhibitor gene products as a tool for predicting the progression risk and/or potential for aggressive growth of tumors. In a second aspect the invention concerns predicting the progression risk and/or potential for aggressive growth in tumors on the basis of the simultaneous co-detection of the presence of overexpression of cyclin-dependent kinase inhibitor gene products together with the expression of markers for active cell proliferation. Further the invention concerns preparations of probes for diagnosis namely for predicting the progression risk and/or the potential for aggressive growth of tumors.07-28-2011
20110183335METHODS AND COMPOSITIONS FOR PERIOPERATIVE GENOMIC PROFILING - The present invention relates to methods for perioperative genomic screening of subjects, in particular to perioperative screening for markers indicative of responses to anesthesia and other perioperative or operative treatments and procedures. The present invention also provides compositions for use in screening methods. The methods and compositions of the present invention find use in tailoring a subject's medical or surgical treatment to reflect genetic information that predicts a subject's response to medications or techniques used in the procedure.07-28-2011
20110183334METHOD FOR DETECTION OF CANCER BASED ON SPATIAL GENOME ORGANIZATION - The invention provides methods of detecting abnormal cells in a sample using the radial position of one or more genes within the nucleus of a cell, as well as a kit for detecting abnormal cells using such methods. The invention also provides methods of identifying gene markers for abnormal cells using the radial position of one or more genes within the nucleus of a cell.07-28-2011
20110183328DETECTING NEOPLASM - This document relates to methods and materials for detecting premalignant and malignant neoplasms. For example, methods and materials for determining whether or not a stool sample from a mammal contains nucleic acid markers or polypeptide markers of a neoplasm are provided.07-28-2011
20110183332METHOD FOR RECOVERING NUCLEIC ACID FROM STOOL SAMPLE, NUCLEIC ACID ANALYSIS METHOD AND STOOL SAMPLE PROCESSING APPARATUS - The present invention relates to the a nucleic acid analysis method that uses nucleic acid recovered according to the nucleic acid recovery method, and a stool sample processing apparatus used in that method, wherein the method has steps of: (A) eluting nucleic acid amplification reaction inhibitory substances by preparing a stool sample by adding a collected stool to a solution for removing nucleic acid amplification reaction inhibitory substances that has a water-soluble organic solvent as an active ingredient thereof, and storing the stool sample for a predetermined time, (B) recovering a stool-derived solid fraction by removing the solution for removing nucleic acid amplification reaction inhibitory substances from the stool sample after step (A), and (C) recovering nucleic acid from the stool-derived solid fraction recovered in step (B).07-28-2011
20110183329PROTEIN PHOSPHATASE-1 INHIBITOR-1 POLYMORPHISM AND METHODS OF USE - A method for diagnosing the presence of a G147D polymorphism of human phosphatase-1 inhibitor-1 protein is provided, wherein the method involves determining the presence of the polymorphism in a biological sample from a human subject by means which detect the presence of the polymorphism, wherein the presence of the polymorphism is indicative of a predisposition to impaired functioning of the β-adrenergic signaling pathway.07-28-2011
20110183327Labelled nucleotides - Nucleosides and nucleotides are disclosed that are linked to detectable labels via a cleavable linker group.07-28-2011
20110183326FREE CIRCULATING DNA BIO-MARKERS AND THEIR APPLICATIONS - This invention relates generally to methods for detecting cell damage as a consequence of pathophysiological or traumatic insults such as in a nuclear accident, bioterror attack, tumorigenesis, infections or in individuals with cardiovascular disease.07-28-2011
20120129168TUMOR MARKER AND USE THEREOF - The present invention detects SNX5 in a sample from a subject. The SNX5 is used as a tumor marker specific to papillary thyroid carcinoma, whereby diagnosis of papillary thyroid carcinoma is carried out easily. The present invention provides also a technique of discriminating papillary thyroid carcinoma using the tumor marker.05-24-2012
20120164645MULTIPLEX AMPLIFICATION AND DETECTION - The invention relates to the field of multiplex amplification. In particular, the invention relates to methods for assaying a sample for one or more nucleic acid targets in a single reaction based on the distinct melting temperatures or melting profiles of primers and/or probes. The invention also provides probes and kits for use in such methods.06-28-2012
20120129167TRUNCATED CD20 PROTEIN, DELTACD20 - The present invention relates in particular to a protein from an alternative splicing of the gene encoding CD20, the nucleic acid sequences encoding the protein according to the invention, a mutated form of the CD20 gene as well as drugs, diagnostic tools, diagnostic methods and treatment methods using the protein and the nucleic acid sequences according to the invention.05-24-2012
20120129174Target Sequence Amplification Method, Polymorphism Detection Method, and Reagents for Use in the Methods - An object of the present invention is to provide an amplification method that inhibits amplification caused by erroneous annealing of a primer. Primers X1 and X2 are used in amplification of a target sequence including a target site showing a polymorphism. The primer X1 includes a sequence A1′ and a sequence E1. The sequence A1′ is complementary to a partial sequence A1 in a template nucleic acid, and has, in its 3′ region, a base x1′ complementary to a first base x1 at the target site in a 5′ region of the sequence A1. The sequence E1 is noncomplementary to a partial sequence B1 adjacent to the 3′ end of the partial sequence A1 in the template nucleic acid, and is bound to the 5′ end of the partial sequence A1′. The primer X2 includes a sequence A2′. The sequence A2′ is complementary to a partial sequence A2 in the template nucleic acid, and has, in its 3′ region, a base x2′ complementary to a second base x2 at the target site in a 5′ region of the partial sequence A2. Each of the primers X1 and X2 has a base complementary to the target site in its 3′ region. By these primers, when only a template in which the target site is the first base x1 is present, erroneous amplification of the target sequence having the second base x2 can be prevented. Thus, a false positive for the polymorphism of the second base x2 can be inhibited.05-24-2012
20120129173RECOMBINASE POLYMERASE AMPLIFICATION REAGENTS AND KITS - This disclosure describes kits, reagents and methods for Recombinase Polymerase Amplification (RPA) of a target DNA that exploit the properties of re-combinase and related proteins, to invade double-stranded DNA with single stranded homologous DNA permitting sequence specific priming of DNA polymerase reactions. The disclosed kits, reagents and methods have the advantage of not requiring thermocycling or thermophilic enzymes, thus offering easy and affordable implementation and portability relative to other amplification methods.05-24-2012
20120129172METHOD FOR SELECTING CLONE OF INDUCED PLURIPOTENT STEM CELLS - To efficiently identify and select a clone from clones of induced pluripotent stem cells (iPS cell) having low tumor formation rate in vivo when allowed to differentiate and transplanted in a living body, iPS cells of the clones are induced to differentiate, undifferentiated cells among the cells after the induction of differentiation are detected, and a clone having the content of the undifferentiated cell below a control is selected.05-24-2012
20120129166METHOD OF DETECTING FUNGI BELONG TO GENUS GEOSMITHIA - A method of detecting a fungus belonging to genus 05-24-2012
20120129165IMAGING INDIVIDUAL MRNA MOLECULES USING MULTIPLE SINGLY LABELED PROBES - A method for probing a target sequence of messenger ribonucleic acid molecules (mRNA's) in a fixed, permeabilized cell, said target sequence including at least 30 non-overlapping probe binding regions of 15-100 nucleotides, comprising immersing said cell in an excess of at least 30 nucleic acid hybridization probes, each singly labeled with the same fluorescent label and each containing a nucleic acid sequence that is complementary to a different probe binding region of said target sequence; washing said fixed cell to remove unbound probes; and detecting fluorescence from said probes.05-24-2012
20120164647METHODS FOR ASSESSING THE SUSCEPTIBILITY OF A HUMAN TO DIMINISHED HEALTH AND WELLNESS - The present invention relates to methods for assessing the advisability that a human should employ a compensatory composition comprised of one or more antioxidant ingredients. The methods involve assessing occurrence in the human's genome of a plurality of certain polymorphisms. Methods for determining the composition of preferred compensatory compositions are also disclosed.06-28-2012
20120164646DETECTION OF GENETIC ABNORMALITIES - The present invention provides assay systems and related methods for determining genetic abnormalities in mixed samples comprising cell free DNA from both normal and putative genetically atypical cells. Exemplary mixed samples for analysis using the assay systems of the invention include samples comprising both maternal and fetal cell free DNA and samples that contain DNA from normal cells and circulating cancerous cells.06-28-2012
20120164644NMR SYSTEMS AND METHODS FOR THE RAPID DETECTION OF ANALYTES - This invention features systems and methods for the detection of analytes, and their use in the treatment and diagnosis of disease.06-28-2012
20120164643SET OF OLIGONUCLEOTIDE PROBES AS WELL AS METHODS AND USES THERETO - The present disclosure relates to a set of at least 100 single-stranded oligonucleotide probes directed against (or complementary to) portions of a genomic target sequence of interest. The present disclosure also relates to a method of detecting a genomic target sequence of interest using the set of oligonucleotide probes and a method of generating the set of oligonucleotide probes. Further, the present disclosure relates to a kit comprising the set of oligonucleotide probes and at least one further component.06-28-2012
20120164642METHODS AND MATERIALS FOR IDENTIFYING NODULAR FASCIITIS - This document provides methods and materials involved in detecting gene rearrangements indicative of nodular fasciitis. For example, methods and materials for determining if a mesenchymal neoplasm is nodular fasciitis based at least in part on the detection of a gene rearrangement (e.g. a USP6 or MYH9 rearrangement) are provided.06-28-2012
20120164641Methods and Compositions for Detecting Mutation in the Human Epidermal Growth Factor Receptor Gene - The invention comprises reagents and methods for detecting cancer-causing mutations in the human EGFR gene. Further, a method of detecting the mutations and a method of treatment are disclosed.06-28-2012
20120164640METHODS AND COMPOSITIONS FOR CORRELATING GENETIC MARKERS WITH SUDDEN CARDIAC DEATH RISK - The present invention provides a method of identifying a subject as having an increased risk of sudden cardiac death or cardiac arrhythmia by detecting in the subject the presence of various polymorphisms associated with an increased risk of sudden cardiac death or cardiac arrhythmia.06-28-2012
20120164638Digital Quantification of DNA Methylation - Abnormal DNA methylation can be used as a biomarker in cancer patients. For such purposes, it is important to determine precisely the fraction of methylated molecules in an analyzed sample. A technology we term Methyl-BEAMing achieves this goal. Individual bisulfite-treated DNA molecules can be PCR-amplified within aqueous nanocompartments containing beads, resulting in a population of beads each containing thousands of copies of the template molecule. After hybridization with probes specific for methylated sequences, the beads can be analyzed by flow cytometry. This approach enables detection and enumeration of one methylated molecule in a population of ˜5000 unmethylated molecules. Methyl-BEAMing provides digital quantification of rare methylation events and is generally applicable to the assessment of methylated genes in clinical samples.06-28-2012
20120219953METHOD FOR DETECTING AND QUANTIFYING POLY(A) RNA AND MRNA - The present invention relates to a method for detecting and/or for quantifying poly(A) RNA and/or mRNA, wherein a poly(dT) oligonucleotide which features a fluorescent dye and also a quencher is hybridized to the nucleic acid to be detected. Non-hybridized poly(dT) oligonucleotide is degraded by an added nuclease, and as a result, fluorescently labelled nucleotides are released and the resulting fluorescent signal is measured.08-30-2012
20120214158MUTATIONAL ANALYSIS - A method for analysing genetic mutations, and in particular single nucleotide polymorphisms (SNPs) and/or somatic mutations, is described, as well as methods for preferentially amplifying one allelic form compared with another form. The methods use an oligonucleotide probe which hybridises to a first allele with a lower melting temperature (Tm) than that with which it hybridises to a second allele, together with amplification primers which flank the oligonucleotide probe binding site and which bind to the sample with a higher Tm than that of the probe and the first allele. An amplification reaction may be carried out at a temperature such that the probe is preferentially hybridised to the second allele, thereby amplifying the first allele. The amplified sequences may be detected using the same probe as acted as the blocking probe during amplification.08-23-2012
20120315633METHODS OF ENRICHING AND DETECTING FETAL NUCLEIC ACIDS - The present invention relates to a method of enriching free fetal nucleic acids from a cervical sample. The enriched fetal nucleic acids can be used in a variety of procedures including, detection of a trait of interest such as a disease trait, or a genetic predisposition thereto, gender typing and parentage testing.12-13-2012
20120315630METHODS FOR DIAGNOSING IRRITABLE BOWEL SYNDROME - The invention provides novel biomarkers, kits, and methods of diagnosing, prognosing, and subtyping IBS. Also provided are methods for aiding in the diagnosis of irritable bowel syndrome by detecting the serum level of novel IBS biomarkers identified herein.12-13-2012
20120214166Probe for Detecting Polymorphism in EGFR Gene and Use of the Probe - The present invention provides a polymorphism detection probe that can identify a polymorphism in an EGFR gene easily and with high reliability and a polymorphism detection method using the probe. The probe of the present invention is a probe for detecting a polymorphism in an EGFR gene, including at least one of an oligonucleotide (P1) and an oligonucleotide (P2), wherein: 08-23-2012
20120214165Methods and Compositions for the Diagnosis and Treatment of Thyroid Cancer - Methods for detecting, diagnosing and monitoring thyroid cancer in a subject are described comprising measuring in a sample from the subject markers including Ep-ICD and EpEX. The invention also provides kits and compositions for carrying out the methods of the invention.08-23-2012
20110177508UNIVERSAL METHYLATION PROFILING METHODS - This invention provides methods of derivatizing a double-stranded DNA comprising contacting double-stranded DNA with a CpG methyltransferase and an s-adenosylmethionine analog. This invention also provides methods of sequencing DNA to determine methylation patterns. This invention also provides neobases and methods of sequencing for methylation patterns using neobases.07-21-2011
20110177502IDENTIFICATION OF PEDIATRIC ONSET INFLAMMATORY DISEASE LOCI AND METHODS OF USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF THE SAME - Compositions and methods for detection and treatment of inflammatory bowel disease are provided.07-21-2011
20120135406METHOD FOR DETERMINING LYMPH NODE METASTASIS IN CANCER OR RISK THEREOF AND RAPID DETERMINATION KIT FOR THE SAME - The objective of the present invention is to provide a method and a means of rapidly and reliably detecting lymph node metastasis in cancer or the risk of lymph node metastasis. Specifically, the present invention provides a method and a rapid determination kit for detecting lymph node metastasis in cancer or its risk by identifying a certain genetic polymorphism of the human CRP gene, and it is clinically significant in determining the treatment strategy, because effective prediction/determination can be made regarding lymph node metastasis, which is an important phenomenon in cancer progression.05-31-2012
20120135405INSTRUMENT AND METHOD FOR OPTICAL PARTICLE SENSING - A new device capable of measuring the number of particles present in a colloidal suspension is disclosed, which includes a forward scatter detector, an extinction detector, a laser beam, a cylindrical lens with which to create a plane of light through which particles can pass, and the various pumps and tubing needed to pass the colloidal suspension through the plane of light. The device is particularly designed for measuring particles which have different refractive indices, and which are in the size range of between about 0.7 to 2 microns. The device can determine the presence or absence of biological particles of interest in a given sample, by incubating a sample with a given ratio of active particles and marker particles, and determining whether the ratio of active particles and marker particles has changed. Additional binding and/or non-binding particles can also be present, and kits including the particles are also disclosed.05-31-2012
20120135404OPTOELECTRONIC DETECTION SYSTEM - The invention described herein provides methods for the detection of soluble antigens. In particular, the methods provide for the detection of soluble proteins and chemicals. In addition, the invention provides methods of detecting a nucleic acid sequence in a sample. Also described is an emittor cell comprising an Fc receptor and an emittor molecule for the detection of a target particle in a sample wherein the target particle to be detected is bound by one or more antibodies. Also provided is an optoelectronic sensor device for detecting a target particle in a plurality of samples.05-31-2012
20120135403FIBROSIS SUSCEPTIBILITY GENE AND USES THEREOF - The present invention discloses the identification of a fibrosis susceptibility gene locus, the CTGF gene locus, which can be used for detecting predisposition to, diagnosis and prognosis of fibrosis as well as for the screening of therapeutically active drugs. The invention resides, in particular, in a method which comprises detecting in a sample from the subject the presence of an alteration in the CTGF gene locus, the presence of said alteration being indicative of the presence or predisposition to fibrosis.05-31-2012
20120135402GENE SEQUENCE VARIANCES IN GENES RELATED TO FOLATE METABOLISM HAVING UTILITY IN DETERMINING THE TREATMENT OF DISEASE - The present disclosure describes the use of genetic variance information for folate transport or metabolism genes or pyrimidine transport or metabolism genes in the selection of effective methods of treatment of a disease or condition. The variance information is indicative of the expected response of a patient to a method of treatment. Methods of determining relevant variance information and additional methods of using such variance information are also described.05-31-2012
20120135401Methods and Compounds for the Diagnosis of Inflammatory Disease and Identification of Pharmacological Agents Useful in the Treatment of Inflammatory Disease - Methods for the diagnosis of inflammatory bowel diseases and the identification of agents useful in the treatment of such diseases based upon the agent's effect on reducing Pim-2 expression.05-31-2012
20120219952CARBAPENEMASE AND ANTIBACTERIAL TREATMENT - The present invention relates to a carbapenemase and methods using said carbapenemase such as screening methods, predictive methods and therapeutic uses.08-30-2012
20120219951PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 2 and mutated sequences thereof.08-30-2012
20120219949METHOD OF DETECTING METHYLATED DNA IN SAMPLE - In order to simply obtain a methylated DNA sample, a method including bringing a sample which may include methylated DNA into contact with a protein capable of binding to methylated DNA to bind the methylated DNA in the sample to the protein, bringing the sample obtained into contact with at least one deoxyribonuclease to degrade DNA in the sample; and detecting methylated DNA which is not degraded by the deoxyribonuclease by the binding of the sample obtained to the protein is used. In the method, at least one type of deoxyribonucleases is a deoxyribonuclease different from a methylation-sensitive restriction enzyme capable of degradating a single stranded DNA.08-30-2012
20120219950ASSAY SYSTEMS FOR DETECTION OF ANEUPLOIDY AND SEX DETERMINATION - The present invention utilizes detection of selected nucleic acid regions from pseudoautosomal regions to identify sex chromosomal aneuploidy and to determine fetal sex. Traditional methods of detecting sex chromosomal aneuploidies and performing sex determination typically involves some analysis of the Y chromosome. The assay systems of the present invention utilizing copy number variant detection of pseudoautosomal regions allows quantification of the sex chromosomes in mixed samples using loci that display autosomal inheritance patterns.08-30-2012
20120219946DNA METHYLATION MARKERS ASSOCIATED WITH THE CPG ISLAND METHYLATOR PHENOTYPE (CIMP) IN HUMAN COLORECTAL CANCER - Particular aspects confirm the existence of a CpG island methylator phenotype (CIMP) in colorectal cancer, and provide novel validated DNA methylation markers associated with CIMP. Additional aspects provide novel methods and compositions for: determining CIMP status in colorectal cancers, determining the relationship between CIMP status and other molecular features of the cancers (e.g., BRAF mutation, KRAS mutation and MSI status); determining the relationship between CIMP status and other variables (e.g., age, sex, tumor location, family history, race, country of origin, tumor characteristics (including, tumor type, tumor grade, invasive margin characteristics, lymphocyte infiltration characteristics, direct spread, lymph node spread, venous spread and type of residual adjacent polyp, if present)); and determining, between subgroups defined by CIMP status and BRAF mutations, effects of selected risk factors (e.g., body mass index, smoking history, alcohol intake, dietary folate intake, folate metabolic enzyme polymorphisms and history of hormonal use).08-30-2012
20120219942Methods Employing McrA to Detect 5-Methyl Cytosine - The invention provides methods for using the rMcrA protein, and derivatives thereof, for direct or semi-direct determination of the methylation status of CpG dinucleotides in methyl-CpG island sequences of interest.08-30-2012
20120219944MYH14 AS CAUSATIVE GENE RESPONSIBLE FOR COMPLEX PHENOTYPE OF PERIPHERAL NEUROPATHY, MYOPATHY, HEARING LOSS AND HOARSENESS, AND DIAGNOSTIC METHOD AND KIT FOR THE COMPLEX PHENOTYPE USING THE SAME - The present invention newly identified a missense mutation in the MYH14 gene as a cause responsible for a complex phenotype of peripheral neuropathy, myopathy, hearing loss, and hoarseness. Further, the present invention provides a method for diagnosing inherited neuromuscular disorders showing a complex phenotype of peripheral neuropathy, myopathy, hearing loss, and hoarseness via detection of the mutated MYH14 gene or the protein encoded thereby, and a diagnostic kit therefor. According to the present invention, simple examination of the gene allows early diagnosis of inherited neuromuscular disorders showing the complex phenotype of peripheral neuropathy, myopathy, hearing loss, and hoarseness, which shows high inheritance and is caused by a single gene defect, and accurate diagnosis of the disease makes it possible to tailor therapy.08-30-2012
20120219943METHODS OF PROGNOSIS AND DIAGNOSIS IN CHRONIC HEART FAILURE - The present disclosure provides methods of diagnosing chronic heart failure in patients by detecting the presence and amounts of biomarkers of heart failure in samples from the patients. Such biomarkers may be used to develop a more accurate prognosis for a patient with heart failure, or to accurately diagnose a patient suspected of having heart failure.08-30-2012
20130171646NANOP ARTICLE-OLIGONUCLEOTIDE HYBRID STRUCTURES AND METHODS OF USE THEREOF - The invention relates to hybrid structures comprising an amphiphilic nucleic acid-block co-polymer assembly on the exterior and a nanoparticle core, and methods of use thereof.07-04-2013
20130171642AUTOMATED ANALYSIS OF CIRCULATING TUMOR CELLS - The disclosure provides methods for automated characterization of circulating tumor cells (CTCs), for example using automated tissue strainers. In specific examples, such methods permit characterizing a prostate cancer sample by simultaneously or contemporaneously detecting ERG rearrangements and PTEN deletions in the same CTC. Also provided are kits that can be used with such methods.07-04-2013
20130171634BIOMARKERS FOR CANCERS RESPONSIVE TO MODULATORS OF HEC1 ACTIVITY - Contemplated compositions and methods are drawn to biomarkers and methods related to treatment of neoplastic disease with Hec1 inhibitor. Gene status and/or expression levels of Hec1(HEC), Rb(RB1), and/or p53 (TP53) may be useful as biomarkers for sensitivity to treatment with a Hec1 inhibitor. In addition, Hec 1 inhibitors may show synergistic effects when used in conjunction with cytotoxic drugs.07-04-2013
20120252015METHODS AND COMPOSITIONS FOR DETECTING GENETIC MATERIAL - The present disclosure provides methods and compositions for detecting polynucleotides in a sample and for quantifying polynucleotide load in a sample. The polynucleotides can be associated with a disease, disorder, or condition. In some applications, methylated DNA is quantified, e.g., in order to determine the load of polynucleotides in a sample. The present disclosure also provides methods and compositions for determining the load of fetal polynucleotides in a biological sample, e.g., the load of fetal polynucleotides (e.g., DNA, RNA) in maternal plasma. The present disclosure provides methods and compositions for detecting cellular processes such as cellular viability, growth rates, and infection rates. This disclosure also provides compositions and methods for detecting differences in copy number of a target polynucleotide. In some embodiments, the methods and compositions provided herein are useful for diagnosis of fetal genetic abnormalities, when the starting sample is maternal tissue (e.g., blood, plasma).10-04-2012
20120252019Detection of Bladder Cancers - The present invention generally relates to methods of screening for cancer. Methods of the invention involve identifying a threshold parameter of a protein and of two or more nucleic acids, where the threshold parameters are indicative of the absence of cancer, conducting an assay in a sample to determine a parameter of the two or more nucleic acids and a parameter of the protein, and identifying the sample as positive for cancer if the parameters of at least one of the nucleic acids and the protein present in the sample are greater than their respective threshold parameters. In certain aspects of the invention, the nucleic acids include FGFR3, TWIST1, and NID2. In certain aspects of the invention, the protein includes MMP2 or MMP9.10-04-2012
20120252013METHODS FOR IDENTIFYING MULTIPLE DNA ALTERATION MARKERS IN A LARGE BACKGROUND OF WILD-TYPE DNA - Methods for simultaneously surveying the status of a large number of DNA mutation markers are described. In addition, methods for simultaneously determining the methylation status at multiple sites of a collection of genes, in a single assay, are described.10-04-2012
20120252023Materials and Methods Useful for Affecting Tumor Cell Growth, Migration and Invasion - It is disclosed herein that miR-221 and miR-222 down-regulate PTEN and TIMP3 tumor suppressors, resulting in TRAIL resistance. The present invention provides research, diagnostic, and therapeutic tools and methods related to this discovery. Diagnostics, prognostics and treatments for human hepatocellular cancer and non-small cell lung carcinoma having a TRAIL resistance are particularly described herein.10-04-2012
20120252024Probe for Detection of Polymorphism in C-Kit Gene and Use Thereof - The present invention provides probes that can identify different polymorphisms in a c-kit gene easily with high reliability and use thereof.10-04-2012
20120252022METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF THYROID CANCER - Methods for detecting, diagnosing and monitoring thyroid cancer in a subject are described comprising measuring in a sample from the subject markers including Ep-ICD and β-catenin. The invention also provides kits and compositions for carrying out the methods of the invention.10-04-2012
20120171678APPARATUS FOR THERMAL CYCLING - This invention provides a system for performing PCR, and real time PCR in particular, with great speed and specificity. The system employs a heat block containing a liquid composition to rapidly transfer heat to and from reaction vessels. The system makes use of the reflective properties of the liquid metal to reflect signal from the PCR into the vessel and out the top. In this way, the signal can be measured by an optical assembly in real time without removing the vessels from the heat block.07-05-2012
20120171675METHOD FOR ISOLATING NUCLEIC ACIDS - The invention describes a method of and kits for isolating and/or purifying nucleic acids, more specifically short-chain nucleic acids such as miRNA, from a nucleic acid-containing starting material, characterized by the following method steps of: 07-05-2012
20120171672INFLAMMATORY BOWEL DISEASE PROGNOSTICS - The methods and systems of the present invention are useful in the diagnosis of inflammatory bowel disease (IBD) and in the prognosis of IBD progression and disease complications. With the present invention, it is possible to predict outcome of disease and patients who will have a particular risk of disease complications and/or progression to surgery.07-05-2012
20120171673SAMPLE ANALYSIS METHOD AND ASSAY KIT USED THEREIN - One embodiment is related to a method of analyzing plural samples. The method includes amplifying a plurality of samples using a first primer and second primer, wherein the first primer includes a tag sequence having a sequence different from a sample to one another and wherein a second primer used in pair with the first primer in independent reaction systems for the respective samples to obtain an amplified product in which the tag sequence is introduced, mixing amplified products obtained in the plurality of reaction systems, making the mixed amplified product react with a nucleic acid probe immobilized on a substrate, and detecting the amount of hybridization that has occurred.07-05-2012
20120171670BCR-ABL1 SPLICE VARIANTS AND USES THEREOF - The present invention is based on BCR-ABL1 splice variants which result from insertion and/or truncation of the bcr-abl1 transcript and the finding that these variants provide resistance to kinase domain inhibitors such as imatinib, nilotinib and dasatinib.07-05-2012
20120171669Assay and Compositions for Detection of Bacillus Anthracis Nucleic Acid - The invention includes compositions and methods of detection of 07-05-2012
20120171676HIGHLY SENSITIVE RAPID ISOTHERMAL METHOD FOR THE DETECTION OF POINT MUTATIONS AND SNPs, A SET OF PRIMERS AND A KIT THEREFOR - The present invention refers to a method for detecting a point mutations of a nucleotide sequence by an improve- ment of the LAMP (loop amplification mediated polymerization) amplification method, as well as to a set of primers and kit there- for. As a non limitative embodiment, the invention refers to the G1849T mutation of the JAK2 gene.07-05-2012
20120171674Detection of Cells Expressing T1R2 Taste Receptor - Binding assays for identifying compounds that modulate human T1R2 polypeptide associated taste are disclosed. These assays detect the specific binding of compounds to a human T1R2 polypeptide or the modulation of the specific binding of a compound that specifically binds to a human T1R2 polypeptide. The binding assays may include the use of detectable labels, e.g., radionuclides, enzymes, fluorophases, and the like. Compounds identified in these binding assays have putative application as T1R2 taste modulators, particularly sweet taste, and potentially are useful additives in compositions for human or animal consumption.07-05-2012
20120214163DISEASE-ASSOCIATED GENETIC VARIATIONS AND METHODS FOR OBTAINING AND USING SAME - The invention provides a comprehensive, rapid, unbiased, and accurate method for identifying and/or discovering disease-associated genetic variations, e.g., disease-associated variations. The present invention further provides novel disease-associated genetic variations for use as genetic markers of disease, e.g., cancer. The invention further provides methods for assessing an individual's risk for developing a disease, e.g., cancer, by detecting the presence the novel disease-associated genetic variations of the invention.08-23-2012
20120214164DNA SEQUENCING METHOD - A method for determining the sequence of a polynucleotide, the method relying on the detection of a conformational change in an enzyme that interacts with and processes along the polynucleotide. The detection of a conformational change may be carried out by measuring changes in a fluorophore bound to the enzyme.08-23-2012
20120214162ASSAY METHODS USING DNA BINDING PROTEINS - Assay methods for preparing a biomolecule analyte includes hybridizing a sequence specific oligonucleotide probe to a biomolecule template and reacting the resulting analyte with a binding moiety.08-23-2012
20120214161METHOD OF DETECTING OR QUANTITATING ENDOGENOUS WHEAT DNA AND METHOD OF DETERMINING CONTAMINATION RATE OF GENETICALLY MODIFIED WHEAT IN TEST SAMPLE - An object of the present invention is to discover an endogenous wheat sequence satisfying the conditions of: a) it is universally present in varieties of wheat, b) the amount present (detected amount) is not affected depending on the wheat variety, c) even if other grains are present, only wheat can be detected without cross-reactivity, and d) it is amplified quantitatively by the PCR reaction. A further object of the present invention is to provide a method of accurately detecting and quantitating endogenous wheat DNA in a test sample by the polymerase chain reaction. The present invention provides a kit for detecting or quantitating an endogenous wheat DNA sequence in a test sample by the polymerase chain reaction, the kit comprising at least one primer pair capable of amplifying the endogenous wheat DNA sequence.08-23-2012
20120214159SYSTEMS AND METHODS FOR OBTAINING AND MANAGING SEQUENCING DATA - Systems and methods for biological sample processing are described. A production line extracts genomic DNA from a biological sample, amplifies target components of the sample and produces sequence data for markers from the amplified components. The markers are associated with tests identified in a requisition received with the sample and some markers may be associated with unrequisitioned tests. A sample information management system (SIMS) controls and monitors the production line and subsequent analysis of the results using information in a quality control (QC) database to validate the results. A repository comprising the QC database and a research database receives and aggregates the results without identifying the source of the sample. A portal may be provided to provide access to the research database to a plurality of external contributors. Contributors can selectively provide additional research data and data can be processed using data mining and curation tools.08-23-2012
20110189664DIAGNOSTICS IN A MONOPLEX/MULTIPLEX FORMAT - The present invention relates to a method of detecting and/or quantifying a target molecule from a sample obtained from a subject wherein the method comprises: (i) incubating a fusion protein or conjugate comprising a Ter binding polypeptide fused to at least one anti-target molecule or fragment thereof with a partially double-stranded oligonucleotide for a time and under conditions sufficient to bind to said Ter binding polypeptide thereby producing a complex; (ii) incubating said complex in the presence of said sample comprising said target molecule for a time and under conditions sufficient for said anti-target molecule to bind to said target molecule thereby producing a target-bound complex; (iii) incubating said target-bound complex in the presence of at least one immobilised molecule wherein said immobilised molecule has an affinity to said target molecule; (iv) incubating said immobilised molecule for a time and under conditions sufficient to bind to said target molecule thus immobilising said target molecule; and (v) detecting and/or quantifying said target molecule.08-04-2011
20120252016OPTIMIZED OLIGONUCLEOTIDES AND METHODS OF USING SAME FOR THE DETECTION, ISOLATION, AMPLIFICATION, QUANTITATION, MONITORING, SCREENING, AND SEQUENCING OF GROUP B STREPTOCOCCUS - Described herein are oligonucleotides useful for detecting, isolating, amplifying, quantitating, monitoring, screening and sequencing GBS genes and methods of using the described oligonucleotides.10-04-2012
20120077195Method for Detecting Variations in Nucleic Acid Sequences - The present invention relates to a method and a kit for detecting nucleic acid sequence variation using melting curve analysis, especially relates to a method and a kit for detecting nucleic acid sequence variation by melting curve analysis using self-quenched probe. Said method provides the characteristics of the self-quenched probe employed, as well as the corresponding nucleic acid amplification conditions, so that the probe can bind to the amplified target sequence, and variations of the target sequence can be detected by melting curve analysis. The present invention also encompasses a kit assembled according to the method described.03-29-2012
20120077194APPARATUS AND METHODS FOR PARALLEL PROCESSING OF MICRO-VOLUME LIQUID REACTIONS - Disclosed herein are apparatuses and methods for conducting multiple simultaneous micro-volume chemical and biochemical reactions in an array format. In one embodiment, the format comprises an array of microholes in a substrate. Besides serving as an ordered array of sample chambers allowing the performance of multiple parallel reactions, the arrays can be used for reagent storage and transfer, library display, reagent synthesis, assembly of multiple identical reactions, dilution and desalting. Use of the arrays facilitates optical analysis of reactions, and allows optical analysis to be conducted in real time. Included within the invention are kits comprising a microhole apparatus and a reaction component of the method(s) to be carried out in the apparatus.03-29-2012
20120077193METHOD OF DISTINGUISHING GENOTYPES - The present invention relates to a method of distinguishing genotypes using PCR-PHFA including: a nucleic acid amplification step in which a mutation site-including region of a gene is amplified by a nucleic acid amplification reaction, thereby obtaining an amplification reaction solution; and a distinction step in which the amplification reaction solution obtained from the nucleic acid amplification step is mixed with a reference double-stranded nucleic acid having a specific genotype on the mutation site as well as being labeled with a labeling substance, and the mixture is subjected to a competitive strand displacement reaction, and the level of the occurrence of strand displacement is assessed so as to distinguish the identity; and the competitive strand displacement reaction is performed under a condition to suppress a polymerase extension reaction, and a genotype distinguishing kit for use in the distinct of genotypes by this method.03-29-2012
20120077192Risk Assessment For Adverse Drug Reactions - The present invention provides a method of predicting the risk of a patient for developing adverse drug reactions, particularly SJS or TEN. It was discovered that an HLA-B allele, HLA-B* 1502, is associated with SJS/TEN that is induced by a variety of drugs. The correlation with HLA-B* 1502 is most significant for carbamazepine-induced SJS/TEN, wherein all the patients tested have the HLA-B* 1502 allele. In addition, another HLA-B allele, HLA-B*5801, is particularly associated with SJS/TEN induced by allopurinol. Milder cutaneous reactions, such as maculopapular rash, erythema multiforme (EM), urticaria, and fixed drug eruption, are particularly associated with a third allele, HLA-B *4601. For any of the alleles, genetic markers (e.g., HLA markers, microsatellite, or single nucleotide polymorphism markers) located between DRB1 and HLA-A region of the specific HLA-B haplotype can also be used for the test.03-29-2012
20120077191GENOTYPING DNA - Described herein are compositions and methods useful for the detection of nucleic acid variations. Ligation within a probe or between probes is used to distinguish between probes perfectly complementary to a target and those containing a mismatch. Nucleotide fill-in/extension steps are optionally applied according to the type of assay performed. A circularization and relinearization step can be applied to create a template for further amplification and detection. In certain aspects, portions of a target sequence or its complement are not amplified.03-29-2012
20120214160Methods, compositions, and kits for detecting rare cells - Disclosed herein are methods for identifying rare cells containing particular markers and/or alleles from biological samples that have not been substantially pre-processed (e.g., unprocessed whole blood). The methods described herein provide a system for digital enrichment of target cells from a biological sample and detection of such target cells, thereby allowing accurate and efficient detection and/or enumeration of such cells in the sample.08-23-2012
20120252018METHOD OF DETECTING AN ANALYTE IN A SAMPLE USING SEMICONDUCTOR NANOCRYSTALS AS A DETECTABLE LABEL - The use of semiconductor nanocrystals as detectable labels in various chemical and biological applications is disclosed. The methods find use for detecting a single analyte, as well as multiple analytes by using more than one semiconductor nanocrystal as a detectable label, each of which emits at a distinct wavelength.10-04-2012
20120252020Screening Assay for Bladder Cancer - The present invention generally relates to methods of screening for cancer. Methods of the invention involve identifying a threshold parameter of a protein and of two or more nucleic acids, where the threshold parameters are indicative of the absence of cancer, conducting an assay in a sample to determine a parameter of the two or more nucleic acids and a parameter of the protein, and identifying the sample as positive for cancer if the parameters of at least one of the nucleic acids and the protein present in the sample are greater than their respective threshold parameters. In certain aspects of the invention, the nucleic acids include FGFR3, p53, TWIST1, Vimentin, and NID2. In certain aspects of the invention, the protein includes MMP2 or MMP9.10-04-2012
20120252017DEVICE AND METHOD FOR EXTRACTION AND ANALYSIS OF NUCLEIC ACIDS FROM BIOLOGICAL SAMPLES - Device and methods for extracting and analyzing nucleic acids from biological samples.10-04-2012
20120315629Cloning and Expression of arNOX Protein Transmembrane 9 Superfamily (TM9SF), Methods and Utility - Described are cell surface and circulating markers for aging related disorders (specific isoforms of NADH oxidase (arNOX)). Recombinant age-related NADH oxidase isoforms and their coding sequences and methods for detecting arNOX isoform presence and quantitation in tissues and in blood, sera, urine, saliva, perspiration and in other body fluids, are provided. Recombinant arNOX proteins are useful in preparing antigens for use in the generation of monoclonal and polyclonal antibodies as well as immunogenic compositions for diagnosis and treatment of aging disorders. DNA probes based on the DNA sequence information provide may be used to identify individuals at risk for aging disorders and for development of therapeutic interventions or anti-aging cosmetic or other formulations of benefit in slowing the aging process in mammals.12-13-2012
20120315632DETECTION OF E. COLI STRAINS TY2482 AND LB226692 - The present invention relates generally to strain typing of 12-13-2012
20120219955THD PRIMER TARGET DETECTION - The present invention relates to the detection of a target nucleic acid sequence using a target hybridization and detection primer (THD primer). The present invention allows for both a target amplification and a signal amplification by introducing a label into a primer used in PCR reactions, ensuring a real-time target detection by PCR reaction by no use of complicated oligonucleotides. The present invention could completely be free from the troublesome matters and shortcomings associated with conventional real-time PCR methods. The present invention allows for successful real-time target detection by using only a labeled primer. This feature makes it possible that the present invention exhibits excellent real-time target detection in multiplex manner.08-30-2012
20120219954GENOTYPING - The object of the present invention is to provide a novel method that addresses the problem of differentiating large sets of genomic sequences. The invention relates to a method for genotyping N loci present in a sample in a target nucleic acid molecule, wherein each locus is located in a genotype marker region of the nucleic acid molecule, and corresponds to two or more genotypes. Furthermore the invention relates to a kit for performing said method for genotyping. Also the invention relates to a method for designing and producing selection primers, as well as a method for producing detection primers, all of said primers to be used in the method for genotyping or in the kit for performing the genotyping method. The invention further relates to selection primers adapted for genotyping of loci in a target nucleic acid molecule and a computer program product for designing selection primers.08-30-2012
20120178088THE TUMOR SUPPRESSOR KILLIN - The present invention relates to a new tumor suppressor, designated Killin. Also described are diagnostic and therapeutic uses of the Killin protein and the killin gene, alone or in combination with traditional cancer therapies.07-12-2012
20120178083SPECIFIC MARKER Lmx1a ON DOPAMINERGIC NEURONS - The present invention identified Lmx1a genes, which are expressed in dopaminergic neurons at all differentiation stages, from proliferating dopaminergic neuron progenitor cells before cell cycle exit to cells after cell cycle exit. Lmx1a expression in cells can be used as an indicator when selecting cells suitable for transplantation therapy for neurodegenerative diseases such as Parkinson's disease, and is useful as a marker for screening agents involved in the induction of dopaminergic neuron differentiation.07-12-2012
20120178087Genotyping Assay to Predict Gamma Glutamyl Hydrolase (GGH) Activity - Single nucleotide polymorphisms (SNPs) in the gene encoding gamma glutamyl hydrolase (GGH) associated with reduced GGH activity are disclosed. The primary SNP is a change from a cytosine to a thymine at a position corresponding to nucleotide 511 of Genbank sequence accession no. NM 003878. Methods and kits for detecting these SNPs are provided, along with primers useful in detecting these SNP and for amplifying portions of the GGH gene containing these SNPs.07-12-2012
20120178085METHOD FOR EVALUATION OF CULTURED CELLS, AND METHOD FOR SCREENING OF BIOMARKER - Disclosed are novel means by which evaluation of cultured cells and screening of biomarkers can be attained without consuming the cultured cells. A method for evaluating cultured cells according to the present invention comprises culturing cells in a serum-free medium, and measuring at least one nucleic acid released from the cells into the culture medium. A method for screening of a biomarker according to the present invention comprises culturing cells in a serum-free medium, and measuring a nucleic acid(s) released from the cells into the culture medium. Nucleic acid used as an indicator is e.g. microRNA.07-12-2012
20120178084INTEGRATED ACTIVE FLUX MICROFLUIDIC DEVICES AND METHODS - The invention relates to a microfabricated device for the rapid detection of DNA, proteins or other molecules associated with a particular disease. The devices and methods of the invention can be used for the simultaneous diagnosis of multiple diseases by detecting molecules (e.g. amounts of molecules), such as polynucleotides (e.g., DNA) or proteins (e.g., antibodies), by measuring the signal of a detectable reporter associated with hybridized polynucleotides or antigen/antibody complex. In the microfabricated device according to the invention, detection of the presence of molecules (i.e. Polynucleotides, proteins, or antigen/antibody complexes) are correlated to a hybridization signal from an optically-detectable (e.g. fluorescent) reporter associated with the bound molecules. These hybridization signals can be detected by any suitable means, for example optical, and can be stored for example in a computer as a representation of the presence of a particular gene.07-12-2012
20120178082METHODS AND COMPOSITIONS FOR CORRELATING GENETIC MARKERS WITH RISK OF AGGRESSIVE PROSTATE CANCER - The present invention provides a method of identifying a subject as having an increased risk of having or developing aggressive prostate cancer, comprising detecting in the subject the presence of various polymorphisms associated with an increased risk of having or developing aggressive prostate cancer.07-12-2012
20120178081Methods of Labeling Cells, Labeled Cells, and uses Thereof - Methods of detecting nucleic acids, proteins and cells including methods of detecting two or more nucleic acids, proteins and cells in multiplex bDNA assays, are provided. Assays may be conducted at least in vitro, in vivo, in cellulo, and in situ. Nucleic acids are detected, through cooperative hybridization that results in specific association of a label probe system with target nucleic acids. Embodiments are directed to concurrent detection of one or more nucleic acids and/or one or more proteins. The detected proteins may be intracellular or external markers on the surface of the cell. Detection of protein components is accomplished by use of specific antibodies and a label probe system and/or coated microparticles which bind to the outside surface of specific cells and contain specific probes that can be detected using the same label probe system. Compositions, kits, and systems related to the methods are also described.07-12-2012
20120219948APPLICATION OF QUANTUM DOTS FOR NUCLEAR STAINING - Embodiments of a system, method, and kit for visualizing a nucleus are disclosed. A tissue sample is pretreated with a protease to permeabilize the nucleus, and then incubated with a nanoparticle/DNA-binding moiety conjugate. The DNA-binding moiety includes at least one DNA-binding molecule. The conjugate binds to DNA within the nucleus, and the nanoparticle is visualized, thereby visualizing the nucleus. Computer and image analysis techniques are used to evaluate nuclear features such as chromosomal distribution, ploidy, shape, size, texture features, and/or contextual features. The method may be used in combination with other multiplexed tests on the tissue sample, including fluorescence in situ hybridization. Kits for performing the method include a protease enzyme composition, a nanoparticle/DNA-binding moiety conjugate, and a reaction buffer.08-30-2012
20120219945USE OF SINGLE-STRANDED BINDING PROTEIN IN AMPLIFYING TARGET NUCLEIC ACID - A PCR composition is described that includes a single-stranded nucleic acid binding protein, e.g. the G5p protein, that binds cooperatively to single-stranded nucleic acids such as primers and/or probe or single stranded nucleic acid templates and shields them from nuclease degradation. The single-stranded nucleic acid binding protein complex also prevents the formation of primer dimers or other non-specific PCR products during PCR amplification. The composition promises to improve the specificity and the reliability of high throughput PCR protocols.08-30-2012
20120219947METHODS FOR FORMING MIXED DROPLETS - The invention generally relates to methods for forming mixed droplets. In certain embodiments, methods of the invention involve forming a droplet, and contacting the droplet with a fluid stream, wherein a portion of the fluid stream integrates with the droplet to form a mixed droplet.08-30-2012
20120231454Production of beta-cells - The present invention relates to in vitro and in vivo methods for the generation of pancreatic β-cells, comprising the step of providing at least one pancreatic α-cell or at least one precursor cell with Pax-4 or a nucleic acid encoding Pax-4. Furthermore, the invention relates to a screening method for the screening of a pancreatic-β-cell phenotype-inducing compound, comprising the step of contacting at least one pancreatic α-cell or at least one precursor cell with a given compound, and testing whether said compound is capable of inducing a pancreatic-β-cell phenotype.09-13-2012
20120225428TYPE OF UNIVERSAL PROBE FOR THE DETECTION OF GENOMIC VARIANTS - The present disclosure relates to a composition comprising a first set of probes and a second set of probes, composed of one or more DNA nucleotide(s) and five or more LNA (locked nucleic acid) nucleotides, wherein the base at a discriminating position differs for a first probe of the first set and a first probe of the second set. The present disclosure relates to the composition comprising a plurality of probes in each of the first and second set of probes, wherein the probes in each set differ in one, two, or three LNA random position(s). Further, the present disclosure relates to a method of detecting genomic variants by means of the aforementioned probes.09-06-2012
20120225427sPLA2 IIA Polymorphism Analysis for the Diagnosis/Prognosis of a Cardiovascular Disease/Event - The invention relates to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising determining, in a sample obtained from said subject, the presence or absence of a variant allele of nucleotide polymorphism (SNP) of the sPLA2 type IIA nucleic acid, wherein the SNP is selected from the group consisting of rs11573156 and rs2236771, wherein the presence of the minor allele (G) of SNP rs11573156 indicates an increased risk of having or being at risk of having or developing a cardiovascular disease and/or cardiovascular event, and the presence of the minor allele (C) of SNP rs2236771 indicates a decreased risk of having or being at risk of having or developing a cardiovascular disease and/or cardiovascular event.09-06-2012
20120225426BAALC EXPRESSION AS A DIAGNOSTIC MARKER FOR ACUTE LEUKEMIA - Overexpression of the gene, BAALC, in biological samples from a patient is prognostic for tumor aggressiveness and unfavorable patient outcome. The present invention provides polynucleotide primers and probes for assaying for overexpression of BAALC transcripts. Kits containing the primers and probes are also provided. Also provided are antibodies for assaying for overexpression of BAALC proteins as well as peptide immunogens for producing the anti-BAALC antibodies. The present invention also provides methods for characterizing acute myelogenous leukemia, chronic myelogenous leukemia and prostate cancer in a patient, base on detection of BAALC overexpression.09-06-2012
20120225430METHODS FOR DETECTING HUMAN PAPILLOMA VIRUS-ASSOCIATED CANCERS - The present invention provides probes and methods of use thereof in the diagnosis and/or prognosis of certain types of cancers, particularly human papillomavirus (HPV)-associated cancers. The probes are designed for hybridization with genomic material in a manner indicative of one or more aberrations in the genetic material present in the test sample. The identified aberrations are biomarkers of HPV-associated cancer. The methods of the invention comprise contacting a sample to one or more probes, allowing any genetic material in the sample to hybridize to the genomic regions provided in the probes, analyzing the hybridizations, and analyzing the hybridizations to identify detected aberrations as biomarkers indicative of HPV-associated cancer progression.09-06-2012
20120258454Bisulfite conversion of DNA - The present invention relates to an improved method for the bisulfite conversion of DNA. In certain time-temperature ranges the efficacy of the bisulfite conversion is clearly improved. By combination with denaturating solvents, new reaction conditions and new purification methods the efficacy can be further increased The converted DNA can subsequently be analysed by different methods. The present invention facilitates the analysis of cytosine methylation.10-11-2012
20120190016COMPOSITIONS FOR USE IN IDENTIFICATION OF SALMONELLA - The present invention relates generally to identification of 07-26-2012
20120082983Microbial Reductive Dehalogenation of Vinyl Chloride - Compositions and methods are provided that relate to the bioremediation of chlorinated ethenes, particularly the bioremediation of vinyl chloride by 04-05-2012
20120082982CYSTIC FIBROSIS GENE MUTATIONS - The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. Also provided are probes for detecting the mutant sequences. Methods of identifying if an individual has a genotype containing one or more mutations in the CFTR gene are further provided.04-05-2012
20120082981ENZYME MIXTURE - Polymorphisms are present throughout an organism's genome, and understanding which alleles are present in a particular organism's genome can be advantageous. When probing the identity of these alleles, one must minimize incorrect readings due to inefficiencies in the system. In hydrolysis probe applications, these inefficiencies may be due to over-activity of an exonuclease functionality that excises nucleotides from probes that are only partially, complementary to a region of a target. The present invention provides a mixture that contains a plurality of polymerases including one that has a 5′→3′ exonuclease functionality and one that lacks or substantially lacks it, each in a sufficient relative amount and concentration to increase efficiencies of the system.04-05-2012
20120082980PNA Probes, Probe Sets, Methods and Kits Pertaining to the Detection of Candida - This invention is related to novel PNA probes, probe sets, methods and kits pertaining to the detection of one or more species of 04-05-2012
20120082979COMPOSITIONS, METHODS, AND KITS FOR (MIS)LIGATING OLIGONUCLEOTIDES - Methods, reagents, and kits for (mis)ligating oligonucleotide probes or for identifying at least one target nucleotide are disclosed. One can enhance the generation of misligation product using a ligase under reaction conditions and with reagents where that particular ligase is prone to misligation. Alternatively, one can decrease or avoid generating misligation products using a particular ligase under reaction conditions and using reagents where that ligase is at least less prone to misligation. In certain embodiments, the recombinant ligase from 04-05-2012
20120082978Cell Analysis On Microfluidic Chips - The present invention provides for a method of implementing fluorescent in situ hybridization (FISH) or other cellular analysis processes using intact cells within a microfluidic, chip-based, apparatus. The invention further provides for a method of cellular immobilization within a microfluidic device. Also provided is a method for automated analysis of FISH or other cellular analysis using discrete colormetric probes.04-05-2012
20120258458INTERFERON-LIKE PROTEIN ZCYTO21 - The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-α at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides.10-11-2012
20120258455RNase H-Based Assays Utilizing Modified RNA Monomers - The present invention provides methods of cleaving a nucleic acid strand to initiate, assist, monitor or perform biological assays.10-11-2012
20120258457Methods for Detection of a Single- or Double-Stranded Nucleic Acid Molecule - The present invention is related to a method for the detection of a nucleic acid molecule comprising at least a strand comprising a sequence of nucleotides in a sample, whereby the method comprises the following steps: providing a sample containing the nucleic acid molecule; providing a capture probe, whereby the capture probe is at least partially complementary to a part of the nucleic acid molecule; allowing the capture probe to react with the nucleic acid molecule or a part thereof; and detecting whether or not the capture probe is hybridized to the nucleic acid molecule or part thereof.10-11-2012
20120258456MONITORING RECOMBINASE POLYMERASE AMPLIFICATION MIXTURES - A process includes providing a mixture that includes a recombinase, a single-strand binding protein, and one or more oligonucleotides; and detecting particles in the reaction mixture.10-11-2012
20120258453NUCLEIC ACID PROBE-BASED DIAGNOSTIC ASSAYS TARGETING SSRA GENES OF PROKARYOTIC AND EUKARYOTIC ORGANISMS - Use of the ssrA gene or tmRNA, an RNA transcript of the ssrA gene, or fragments thereof as target regions in a nucleic acid probe assay for the detection and identification of prokaryotic and/or eukaryotic organisms is described. Nucleotide sequence alignment of tmRNA sequences from various organisms can be used to identify regions of homology and non-homology within the sequences which in turn can be used to design both genus specific and species specific oligonucleotide probes. These newly identified regions of homology and non-homology provide the basis of identifying and detecting organisms at the molecular level. Oligonucleotide probes identified in this way can be used to detect tmRNA in samples thereby giving an indication of the viability of non-viral organisms present in various sample types.10-11-2012
20120329054METHOD AND SUBSTANCES FOR ISOLATING MIRNAS - A capture probe suitable for use with a method for isolating miRNAs. A method for isolating an miRNA of interest from a sample comprising the miRNA of interest comprising providing the capture probe. A method for identifying an miRNA of interest.12-27-2012
20120190021DETECTION OF GENETIC ABNORMALITIES - The present invention provides assay systems and related methods for determining genetic abnormalities in mixed samples comprising cell free DNA from both normal and putative genetically atypical cells. Exemplary mixed samples for analysis using the assay systems of the invention include samples comprising both maternal and fetal cell free DNA and samples that contain DNA from normal cells and circulating cancerous cells.07-26-2012
20120264129K-ras Mutations and Anti-EGFr Antibody Therapy - The present application relates to K-ras mutations, to polynucleotides encoding mutant K-ras polypeptides, and to methods of identifying K-ras mutations. The present application also relates to methods of diagnosing cancer; and methods and kits for predicting the usefulness of anti-EGFr specific binding agents in the treatment of tumors.10-18-2012
20120264128METHOD FOR QUALITATIVE AND QUANTITATIVE DETECTION OF COMMON WHEAT - Disclosed are: a method for detecting common wheat among from wheat varieties contained in a sample of interest such as a food raw material or a processed food specifically, with high sensitivity, and in a qualitative and/or quantitative manner; a method for discriminating between common wheat and a wheat variety other than common wheat (e.g., durum wheat) contained in a food raw material or a processed food and detecting the common wheat in a qualitative and/or quantitative manner; and a primer set, a nucleic acid probe, and a detection kit, each of which can be used in the methods employing a PCR method. Specifically disclosed are: a method for detecting the occurrence of common wheat in a sample of interest, which comprises carrying out a PCR method using a nucleic acid extracted from the sample as a template and using a primer comprising the nucleotide sequence represented by SEQ ID NO:5 and a primer comprising the nucleotide sequence represented by SEQ ID NO:6 and detecting the occurrence of a PCR amplification product; and a method for detecting the occurrence of common wheat in a sample of interest, which comprises carrying out a quantitative PCR method using a nucleic acid extracted from the sample as a template and using a primer comprising the nucleotide sequence represented by SEQ ID NO:5, a primer comprising the nucleotide sequence represented by SEQ ID NO:6 and a nucleic acid probe comprising the nucleotide sequence represented by SEQ ID NO:11 and detecting the occurrence of common wheat qualitatively and/or quantitatively.10-18-2012
20120264127SIMULTANEOUS DETECTION OF MUTATIONAL STATUS AND GENE COPY NUMBER - The present invention provides compositions and methods for simultaneously detecting mutational status and gene copy number. In particular, the present invention provides simultaneous measurement of gene copy number and detection of the L858R and Exon 19 del mutations in a tissue sample.10-18-2012
20120264124MICROSATELLITE MARKER COMBINATION AND METHOD FOR IDENTIFYING LANYU PIG BREED - The present invention provides a microsatellite marker combination for identifying Lanyu pig breed, and the identification method thereof. The identification method comprises the following steps: (a) providing a genomic DNA sample obtained from a pig; (b) identifying the polymorphism of microsatellite markers of said genomic DNA sample; and (c) analyzing the results obtained from step (b) to determine the phylogenetic relationship between said pig and Lanyu pig.10-18-2012
20120264121RESOLVING GENOME FRACTIONS USING POLYMORPHISM COUNTS - Methods of reliably estimating genomic fraction (e.g., fetal fraction) from polymorphisms such as small base variations or insertions-deletions are disclosed. Sequenced data from a multigenomic source is used to determine allele counts for one or more of the polymorphisms. For one or more of the polymorphisms, zygosity is assigned, and genomic fraction is determined from the zygosity and allele counts. Certain embodiments employ SNPs as the relevant polymorphism. The disclosed methods can be applied as part of an intentional, pre-designed re-sequencing study targeted against known polymorphisms or can be used in a retrospective analysis of variations found by coincidence in overlapping sequences generated from maternal plasma (or any other setting where a mixture of DNA from several people are present).10-18-2012
20120264125SCREENING METHOD FOR TRINUCLEOTIDE REPEAT SEQUENCES - A method for screening for a trinucleotide repeat sequence in a biological sample is provided. The method comprises the step of contacting a nucleic acid sequence obtained or derived from the biological sample under amplification conditions with i) a first primer having a target sequence in a region 3′ or 5′ of a trinucleotide repeat sequence; ii) a second primer having a target sequence within the trinucleotide repeat sequence and a unique 5′ tail sequence; and iii) a third primer, having a target within the unique 5′ tail sequence of the second primer to generate an amplified product comprising a trinucleotide repeat sequence. Primers, kits of primers together with the use of the primers in methods of screening are also provided.10-18-2012
20120264122METHODS AND COMPOSITIONS FOR NUCLEIC ACID AMPLIFICATION - Compositions that are used in nucleic acid amplification in vitro are disclosed, which include a target specific universal (TSU) promoter primer or promoter provider oligonucleotide that includes a target specific (TS) sequence that hybridizes specifically to a target sequence that is amplified and a universal (U) sequence that is introduced into the sequence that is amplified, by using a primer for the universal sequence. Methods of nucleic acid amplification in vitro are disclosed that use one or more TSU oligonucleotides to attached a U sequence to a target nucleic acid in a target capture step and then use a primer for a U sequence in subsequent amplification steps performed in substantially isothermal conditions to make amplification products that contain a U sequence that indicates the presence of the target nucleic acid in a sample.10-18-2012
20120264126METHODS FOR THE DIAGNOSIS OF BACTERIAL VAGINOSIS - The present invention relates to methods for the diagnosis of bacterial vaginosis based on an analysis of a patient sample. For example, patient test samples are analyzed for the presence or absence of one or more lactobacilli and two or more pathogenic organisms. The presence or absence of one or more lactobacilli and two or more pathogenic organisms may be detected using PCR analysis of nucleic acid segments corresponding to each target organism. The quantity of the target organisms can then be used to determine a score which is indicative of a diagnosis of bacterial vaginosis.10-18-2012
20120264119NEW METHOD FOR DECONTAMINATION AND PROCESSING OF CLINICAL SPECIMENS FROM A PATIENT - The present invention relates to a new method for decontaminating and processing clinical samples suspected of containing 10-18-2012
20120264120SPECIMEN FOR DETECTING INFILTRATIVE LARGE INTESTINE TUMORS - An object of the present invention is to provide a method for non-invasively diagnosing invasiveness or degree of invasion of colorectal tumors.10-18-2012
20110123998Materials and Methods for Treatment of Cancer - Glypican 5 is shown for the first time to have a role in proliferation of cancer cells, including tumours which do not show chromosomal amplification at 13q31. The use of glypican 5 (GPC5) antagonists and binding agents for the treatment of cancer, particularly rhabdomyosarcoma and breast cancer, is disclosed.05-26-2011
20120190028NUCLEIC ACIDS AND METHODS FOR THE DETECTION OF ENTEROBACTER SAKAZAKII (CRONOBACTER SPP.) - Provided are detection means and method specific for the genus 07-26-2012
20120190027LIGATION-BASED METHOD OF NORMALIZED QUANTIFICATION OF NUCLEIC ACIDS - The present invention is related to normalized quantification of nucleic acids and to the normalization of quantities of nucleic acids in samples, e.g. mixtures of nucleic acids. The present invention relates to method for the normalization of the quantity of a nucleic acid to be quantified in a sample to the total quantity of nucleic acid in the sample; or to the total quantity of a specific class of nucleic acid in the sample.07-26-2012
20120190026METHOD OF NORMALIZED QUANTIFICATION OF RNA - The present invention is related to normalized quantification of RNAs and to the normalization of quantities of RNAs in samples, e.g. mixtures of RNAs. The present invention relates to method for the normalization of the quantity of a RNA to be quantified in a sample to the total quantity of RNA in the sample; or to the total quantity of a specific class of RNA in the sample.07-26-2012
20120190023METHODS FOR DISTINGUISHING BETWEEN NATURAL AND ARTIFICIAL DNA SAMPLES - The present invention provides methods for distinguishing between natural and artificial DNA in samples containing nucleic acid molecules. In addition, the present invention provides methods for verifying that DNA profiles obtained from samples represent natural DNA. In various embodiments, the methods employ an array of nucleic acid based procedures for verifying that a DNA sample originates from a natural source. The invention further provides kits for verifying that a DNA sample originates from a natural source employing the methods and reagents described in the disclosure.07-26-2012
20120190020DETECTION OF GENETIC ABNORMALITIES - The present invention provides assay systems and related methods for determining genetic abnormalities in mixed samples comprising cell free DNA from both normal and putative genetically atypical cells. Exemplary mixed samples for analysis using the assay systems of the invention include samples comprising both maternal and fetal cell free DNA and samples that contain DNA from normal cells and circulating cancerous cells.07-26-2012
20120190017POLYMORPHISMS IN THE HUMAN GENE FOR THE MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1 (MRP-1) AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS - The present invention relates to a polymorphic MRP-1 polynucleotide, genes or vectors comprising the polynucleotides and a host cell genetically engineered with the polynucleotide or gene. Also provided are methods for producing molecular variant polypeptides, cells capable of expressing a molecular variant polypeptide and to a polypeptide encoded by the polynucleotide or the gene or obtainable by the method or cells produced herein. Also provided is an antibody to the polypeptide, a transgenic animal, and to a solid support comprising one or a plurality of the provided polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a pro-drug or drug or an inhibitor are also provided. In addition, the invention relates to methods for producing of a pharmaceutical composition, diagnosing a disease and, detection of the polynucleotide. Furthermore, provided herein are uses of the polynucleotides, genes, vectors, polypeptides or antibodies herein.07-26-2012
20120190030Detection of Target Nucleic Acid Sequences by Cyclic Exonucleolytic Reactions - The present invention relates to the detection of a target nucleic acid sequence by a cyclic exonucleolytic reaction. The present method enabling to generate signals by probe digestion with no help of primers and to amplify signals with no help of simultaneous target amplification reactions may enable to detect multiple target sequences without any problems accounted in the conventional real-time PCR methods such as false positive signals and difficulties in oligonucleotides (primer and probe) selection and reaction condition optimization.07-26-2012
20120190029METHODS FOR DETECTING DNA ORIGINATING FROM DIFFERENT INDIVIDUALS - In a first aspect, the present invention features methods for differentiating DNA species originating from different individuals in a biological sample. These methods may be used to differentiate or detect fetal DNA in a maternal sample or to differentiate DNA of an organ donor from DNA of an organ recipient. In preferred embodiments, the DNA species are differentiated by observing epigenetic differences in the DNA species such as differences in DNA methylation. In a second aspect, the present invention features methods of detecting genetic abnormalities in a fetus by detecting fetal DNA in a biological sample obtained from a mother. In a third aspect, the present invention features methods for differentiating DNA species originating from an organ donor from those of an organ recipient. In a fourth aspect, the present invention features kits for differentiating DNA species originating from different individuals in a biological sample.07-26-2012
20120190019CONCATAMERIC LIGATION PRODUCTS: COMPOSITIONS METHODS AND KITS FOR SAME - The present teachings relate to methods, compositions, and kits for detecting one or more target polynucleotide sequences in a sample, and methods compositions and kits for forming concatameric ligation products. In some embodiments of the present teachings, oligonucleotides are hybridized to complementary target polynucleotides and are ligated together to form a concatameric ligation product. In some embodiments of the present teachings, the concatameric ligation product can be amplified, and the identity and quantity of the target polynucleotides determined based on sequence introduced in the ligation reaction. Some embodiments of the present teachings provide methods for removing unligated probes from the reaction mixture. Some embodiments of the present teachings provide for highly multiplexed detection, identification, and quantification of a plurality of target polynucleotides using a variety of analytical procedures.07-26-2012
20120190018ENHANCED RISK PROBABILITIES USING BIOMOLECULE ESTIMATIONS - The present invention provides processes for determining more accurate risk probabilities for medical conditions. The risk probabilities of the presence or absence of a medical condition are calculated using frequency data from selected biomolecules and biomolecule source contribution of at least one source in a mixed sample.07-26-2012
20120276535METHOD FOR THE DIAGNOSIS OF LIMBAL STEM CELL DEFICIENCY - The invention relates to a method for the diagnosis of limbal stem cell deficiency (LSCD) in a subject, based on detecting or quantifying the expression of the MUC5AC gene in a cornea sample from said subject.11-01-2012
20120276540METHOD AND PROBE SET FOR DETECTING CANCER - Methods for detecting cancer that include hybridizing a set of chromosomal probes to a biological sample obtained from a patient, and identifying if aneusomic cells are present in a selected subset of cells obtained from the biological sample are described. A set of chromosomal probes and kits for detecting cancer that include sets of chromosomal probes, are also described.11-01-2012
20120329053MicroRNA Fingerprints During Human Megakaryocytopoiesis - Described herein is a method of decreasing expression of HOXA1 in a subject having a cancer and/or myeloproliferative disorder associated with overexpression of a HOXA1 gene product where an effective amount of at least one miR-10a gene product or an isolated variant or biologically-active fragment thereof is administered to the subject sufficient to decrease expression of the HOXA1 gene product in the subject.12-27-2012
20120329048AUTHENTICATION METHOD OF DAIRY PRODUCTS - The present invention relates to a new method of establishing the authenticity and origin of dairy products, more specifically to the use of lactic acid bacterial strains having strain-specific insertion sequence elements as tools for marking dairy products (such as cheese) and identification thereof. The invention also extends to new lactic acid bacterial strains, their use in the production of dairy products as well as the dairy products containing these bacterial strains.12-27-2012
20120329049BCR-ABL1 SPLICE VARIANTS AND USES THEREOF - The present invention is based on BCR-ABL1 splice variants which result from insertion and/or truncation of the BCR-ABL1 transcript and the finding that these variants provide resistance to kinase domain inhibitors such as imatinib, nilotinib and dasatinib.12-27-2012
20120329046MOLECULAR MARKER FOR EVALUATING PATHOLOGICAL CONDITIONS AND TREATMENT OF MUSCULAR DYSTROPHY - Novel markers associated with the development of muscular dystrophy that elucidate the mechanisms of muscular dystrophy development and provide a means for diagnosis and treatment of muscular dystrophy are presented. The expression level of one or more markers selected from the group consisting of c-Fos, EGR1, IL-6, and IL-8 in a sample obtained from the subject can be compared with a reference value to diagnose muscular dystrophy in the subject.12-27-2012
20120329045RISK ASSESSMENT FOR PHENYTOIN-INDUCED ADVERSE DRUG REACTIONS - A method of predicting the risk of a patient for developing phenytoin-induced adverse drug reactions (ADRs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or drug reactions with eosinophilia and systemic symptoms (DRESS) is disclosed. Genetic polymorphisms of CYP2C genes (including CYP2C9, CYP2C19, CYP2C8 and CYP2C18), HLA alleles (including HLA-A*0207, HLA-A*2402, HLA-B*1301, HLA-B*1502, HLA-B*4001, HLA-B*4609, HLA-B*5101, HLA-DRB1*1001 or HLA-DRB1*1502) and phenytoin concentration in the patient's plasma can all contribute to phenytoin-induced ADRs.12-27-2012
20120329047METHODS AND ASSAYS FOR THE DETECTION OF ALTERNATIVE LENGTHENING OF TELOMERES (ALT) ACTIVITY IN CELLS - The invention relates to methods and assays for the detection of active Alternative Lengthening of Telomeres (ALT) activity in cells. The methods and assays involve detecting or assaying for partially double-stranded telomeric circles wherein the presence of said circles is specific for cells comprising an active ALT mechanism. In some embodiments the methods find application in, inter alia, determining the level of ALT activity in a cell, determining the ALT status of a cancer in a subject, diagnosing and/or treating disease, determining disease status, analysis of treatment efficacy, and the identification of novel therapeutic agents.12-27-2012
20120231455PEPTIDE NUCLEIC ACID PROBES, KIT AND METHOD FOR DETECTING HELICOBACTER PYLORI AND/OR CLARITHROMYCIN RESISTANCE PROFILE AND APPLICATIONS - Four peptide nucleic acid probes (PNA) are for the detection of 09-13-2012
20120231453Brownian Microbarcodes for Bioassays - An encoded microparticle carrying a spatial code is provided; and a set of encoded microparticles are provided with distinguishable spatial codes, wherein the codes comply with a pre-determined coding scheme. Presented are also methods of using the encoded microparticles in various biological assays, such as various multiplex quantitative PCR (real-time PCR) and multiplex chromosomal immunoprecipitation (ChIP) assays.09-13-2012
20120231452ASSAY FOR METHYLATION IN THE GST-PI GENE - A diagnostic or prognostic assay is disclosed for a disease of condition characterized by abnormal methylation of cytosine at side or sites within the glutathione-S-transferase (GST) Pi gene and/or its regulatory flanking sequences (e.g., prostate cancer and liver cancer). The assay comprises: (i) isolating DNA from said subject, and (ii) determining (e.g., by selective PCR amplification) the presence of abnormal methylation of cytosine at a site or sites within the GST-Pi gene and/or its regulatory flanking sequences.09-13-2012
20110124001Compositions For Use In Detection Of Multiple Analytes - Methods, compositions and kits are disclosed. The methods are directed to determining the presence or relative amounts of two or more components in a medium. A combination is provided comprising a medium suspected of containing the components, at least two sensitizer reagents and at least one reactive reagent activatable by singlet oxygen. The sensitizer reagents are capable of generating singlet oxygen and are distinguishable by wavelength of sensitization. The combination of sensitizer reagents and reactive reagents allows differential detection of the components. The sensitizer reagents are differentially activated. The amount of signal generated as a result of the activation of said reactive reagent is determined wherein the amount thereof is related to the amount of each of the components in the medium.05-26-2011
20110124000METHODS AND COMPOSITIONS FOR VITAMIN K EPOXIDE REDUCTASE - The present invention provides a method of identifying a human subject having increased or decreased sensitivity to warfarin, comprising detecting in the subject the presence of a single nucleotide polymorphism in the VKOR gene, wherein the single nucleotide polymorphism is correlated with increased or decreased sensitivity to warfarin, thereby identifying the subject having increased or decreased sensitivity to warfarin.05-26-2011
20110123999Novel Polymorphism in Bovine Prion Protein Gene Sequence - A specific, non-synonymous SNP in the Prnp gene encoding the bovine prion protein affects the susceptibility of bovine animals to bovine spongiform encephalopathy (BSE). Depending on the number of octapeptide repeat units present in the Prnp gene, the position of the SNP is either nucleotide 631 of exon 3 (codon 211) when the Prnp gene comprises six octapeptide repeat region sequences, nucleotide 607 of exon 3 (codon 203) when the Prnp gene comprises five octapeptide repeat region sequences, or nucleotide 655 of exon 3 (codon 219) when the Prnp gene comprises seven octapeptide repeat region sequences. Alleles of the bovine Prnp wherein the SNP at these positions is lysine (K) at the corresponding amino acids (i.e., 211, 203 or 219) in the bovine prion protein are all indicative of increased susceptibility to BSE in comparison to alleles which encode glutamic acid (E) at the same position. This SNP may be used as a marker for selecting bovines susceptible to BSE for disposal and/or removal from breeding, the human food and animal feed supplies.05-26-2011
20110123997MOLECULAR DIAGNOSIS AND CLASSIFICATION OF MALIGNANT MELANOMA - The present invention provides methods for diagnosing and providing a prognosis of melanoma using molecular markers that are overexpressed in melanoma cells. The invention provides kits for diagnosis and prognosis. Also provided are methods to identify compounds that are useful for the treatment or prevention of melanoma and melanoma progression.05-26-2011
20110123996METHODS AND COMPOSITIONS TO EVALUATE ANTIBODY TREATMENT RESPONSE - The present invention relates to methods and compositions to evaluate or assess the response of a subject to particular therapeutic treatment. More particularly, the invention provides methods to determine the response of subjects, or to adapt the treatment protocol of subjects treated with therapeutic antibodies. The invention is based on a determination of the FCGR3A genotype of a subject. The invention can be used for patients with malignancies, particularly lymphoma, and is suited to select best responders and/or adjust treatment condition or protocol for low responders.05-26-2011
20130171645GENETIC MAKE-UP MODIFIES CANCER OUTCOME - A frequent SNP A259G (K87E) genotype switch in the MMP8 gene in has been found to modify the clinical behavior of cancers. The modification varies based on the patient's genotype for the SNP, and whether homozygous or heterozygous. One particular genotype for this SNP leads to more aggressive tumor behavior and worst clinical outcome than the others.07-04-2013
20120264123Extracellular Serine Protease - The present invention provides a DNA encoding a novel extracellular serine protease termed Tumor Antigen Derived Gene-14 (TADG-14) which is overexpressed in ovarian, breast and colon carcinoma samples. Also provided are vector and host cells capable of expressing the DNA of the present invention, as well as the uses of the DNA and protein of the present invention. Also provided is a TADG-14 protein variant that has a potential role for detecting and targeting of ovarian carcinomas.10-18-2012
20120322070CRYOGENIC BIOPSY SYSTEM AND METHOD - A cryogenic biopsy device is configured to provide thin, frozen tissue samples, which may be viewed under a microscope and selected for biomarker analysis. The device is configured to provide slices which are less than 50 micrometers in thickness, while snap-freezing the tissue and maintaining the sample in a deep-frozen state until it reaches the pathology lab for further processing. Alternatively, thicker slices can be harvested by the device and additional sectioning can be done in the pathology lab by using cryomicrotome. The device of the present invention may be used in rigid instruments and in flexible devices, such as endoscopes, for example, and may be suitable for single use or multiple use.12-20-2012
20120322069Diagnositic Methods of Tumor Susceptibility With Nucleotide Polymorphisms Inside MicroRNA Target Sites - Methods of diagnosing tumor susceptibility or cancer including the step of determining whether a patient has one or more SNP-miRNA expression pattern combinations described herein. Each SNP-miRNA expression pattern combination is supported by data that shows that the SNP is associated with tumor susceptibility because of its ability to affect miRNA binding sites and/or miRNA:mRNA gene regulation.12-20-2012
20120322065Methods for Use with Nanoreactors - The invention relates to methods of using nanoreactor technology for sample analysis in microfluidic systems.12-20-2012
20120322064HYBRIDIZATION PROBES AND METHODS OF THEIR USE - Hybridization probes for hybridizing to the same target nucleic acid are disclosed, the hybridization probes comprising an electrically-active magnetic nanoparticle-labeled detector probe and a capture probe including a conjugating moiety for immobilization. Also disclosed is a biodetection method including the steps of: providing hybridization probes for hybridizing to the same target nucleic acid, the hybridization probes comprising an electrically-active magnetic nanoparticle-labeled detector probe and a capture probe; hybridizing the target nucleic acid with each of the electrically-active magnetic nanoparticle-labeled detector probe and a capture probe in a sample including the target nucleic acid; magnetically separating the hybridized target nucleic acid from the sample; capturing the hybridized target nucleic acid on a substrate through the capture probe; and measuring the oxidation-reduction signal of the electrically-active magnetic nanoparticle-labeled detector probe.12-20-2012
20120322059MUTATION WITHIN THE CONNEXIN 26 GENE RESPONSIBLE FOR PRELINGUAL NON-SYNDROMIC DEAFNESS AND METHOD OF DETECTION - A purified polynucleotide having a chain of nucleotides corresponding to a mutated sequence, which in a wild form encodes a polypeptide implicated in hereditary sensory defect, wherein said mutated purified polynucleotide presents a mutation responsible for prelingual non-syndromic deafness selected from the group consisting of a specific deletion of at least one nucleotide.12-20-2012
20120322060DIAGNOSIS AND MONITORING TREATMENT OF PSYCHIATRIC DISEASES WITH SPADIN AND RELATED METHODS - A method of diagnosing depression in a subject, comprising analyzing a biological sample from a subject in need of diagnosis of depression for the expression of spadin, detecting and measuring the amount of spadin in the sample, and diagnosing depression in the subject if an increase or a decrease in spadin expression in the biological sample is detected compared to a control, is described as are methods for monitoring treatment, remission and the course of the disease. Related kits are also described. Also described is a method for identifying candidate compounds for treating depression.12-20-2012
20120322063METHODS FOR QUANTIFYING MICRORNA PRECURSORS - The present invention is directed to methods, reagents, kits and compositions for identifying and quantifying microRNA (miRNA) precursor expression in a biological sample. The method uses gene-specific primers and reverse transcriptase to convert the primary miRNA precursors (pri-miRNA) and pre-miRNA precursors (pre-miRNAs) to cDNA. The method also uses amplification reactions using gene specific forward and reverse primers that are targeted to the hairpin sequence of pri- and pre-microRNA precursors to detect the expression levels of both the pri- and the pre-micoRNAs. In one embodiment, the amplification reaction is a real-time PCR wherein the level of PCR amplification products produced is related to the levels of the microRNA precursors in the biological sample. In another embodiment, a probe is used to distinguish between similar isoforms of microRNA precursors. In another embodiment, the expression levels of a pre-miRNA precursor is calculated by using primers and amplification reactions that detect the pri-miRNA together with amplification reactions and primers that detect both pri- and pre-miRNAs, and calculating the difference.12-20-2012
20120322061MACROMOLECULAR COMPOUND FOR DETECTING TARGET MATERIAL AND METHOD OF DETECTING TARGET MATERIAL BY USING THE SAME - Macromolecular compound for detecting a target material in a biological sample, and a method of using same.12-20-2012
20120322062Methods And Compositions For Detection Of Cowden Syndrome (CS) and CS-Like Syndrome - The invention is directed to methods of detecting Cowden syndrome (CS) or CS-like syndrome in an individual or determining whether an individual is at risk for developing Cowden syndrome (CS) or CS-like syndrome comprising detecting the presence of a mutated succinate dehydrogenase B (SDHB), mutated succinate dehydrogenase D (SDHD) or combination thereof in the individual, wherein detection of a mutated SDHB, SDHD or a combination thereof indicates that the individual is positive for, or at risk of developing, CS or CS-like syndrome. The invention is also directed to an article of manufacture for detecting Cowden syndrome (CS) or Cowden-like syndrome in an individual, comprising one or more agents that detects mutated succinate dehydrogenase B (SDHB), mutated succinate dehydrogenase D (SDHD) or combination thereof in the individual, and instructions for use.12-20-2012
20120322058Analysis of nucleic acids - Provided herein are improved methods, compositions, and kits for analysis of nucleic acids. The improved methods, compositions, and kits can enable copy number estimation of a nucleic acid in a sample. Also provided herein are methods, compositions, and kits for determining the linkage of two or more copies of a target nucleic acid in a sample (e.g., whether the two or more copies are on the same chromosome or different chromosomes) or for phasing alleles.12-20-2012
20120149013METHODS OF EVALUATING CELLS AND CELL CULTURES - Methods of evaluating the composition of a cell culture (e.g., to distinguish chondrocytes from fibroblasts) and methods for evaluating the phenotype of an individual cell (e.g., as a chondrocyte) are disclosed. The methods may be used, for example, for assessing chondrocyte cultures used for treatment of cartilage defects. In some embodiments, the invention involves identifying cell culture composition or the identity of a cell based on expression level of a fibroblast marker. In other embodiments, the invention involves comparing expression levels of at least one chondrocyte marker and at least one fibroblast marker in a cell culture sample or in an individual cell. In illustrative embodiments, the chondrocyte marker is hyaluronan and proteoglycan link protein 1 (HAPLN1), and the fibroblast marker is microfibrillar associated protein 5 (MFAP5).06-14-2012
20120270213SCREENING METHOD FOR CELL AGING - The present invention relates to a method for increasing the chronological lifespan of a cell comprising disrupting the function of at least one of the SAGA1 SLIK and/or SALSA complexes in said cell.10-25-2012
20120322068METHOD FOR IDENTIFYING INCREASED RISK OF ANXIETY DISORDERS - The present invention is for methods for identifying a human having an increased risk for anxiety disorders. The method involves genotyping the human for a specific brain-derived neurotrophic factor (BDNF) single nucleotide polymorphism (SNP), and/or administering a fear conditioning procedure while measuring fear, and administering an extinction procedure while measuring fear. The method can also involve comparing/MRI images of the amygdala of the human acquired during conditioning and extinction and determining if the human is unresponsive to extinction therapy by noting heightened and non-declining activity in the amygdala during extinction.12-20-2012
20120322067ASSAY METHOD FOR TARGET NUCLEIC ACID BY SIGNAL AMPLIFICATION USING PROBE HYBRIDIZATION AND RESTRICTION - Oligonucleotides for detection of nucleic acid in a sample that provide for an amplified signal by recycling probes and probe fragments.12-20-2012
20120270218Method for analyzing cervical lymph node metastasis, and tumor marker for head and neck cancer - Provided are a method for analyzing metastasis of head and neck cancer to a cervical lymph node, and a tumor marker for head and neck cancer used therein. Specifically, provided is a method for analyzing metastasis of head and neck cancer to a cervical lymph node, involving: measuring an expression level of at least one gene selected from the group consisting of genes represented by SEQ ID NOS: 1 to 36 in the sequence listing in a cervical lymph node sample; and comparing the aforementioned expression level with a reference value. Also provided is a tumor marker for head and neck cancer used in the aforementioned method for analyzing cervical lymph node metastasis, including at least one gene selected from the group consisting of genes represented by SEQ ID NOS: 1 to 36 in the sequence listing, and/or an expression product of the aforementioned gene and/or an expression level thereof.10-25-2012
20120270215PROBE FOR DETECTING POLYMORPHISM IN CYP3A GENE, METHOD OF DETECTING POLYMORPHISM, METHOD OF EVALUATING DRUG EFFICACY, AND REAGENT KIT FOR DETECTING POLYMORPHISM - Provided in the present disclosure is a probe for detecting polymorphism that enables a simple detection of polymorphism in the CYP3A gene with high sensitivity.10-25-2012
20120270212Methods for Non-Invasive Prenatal Ploidy Calling - The present disclosure provides methods for determining the ploidy status of a chromosome in a gestating fetus from genotypic data measured from a mixed sample of DNA comprising DNA from both the mother of the fetus and from the fetus, and optionally from genotypic data from the mother and father. The ploidy state is determined by using a joint distribution model to create a plurality of expected allele distributions for different possible fetal ploidy states given the parental genotypic data, and comparing the expected allelic distributions to the pattern of measured allelic distributions measured in the mixed sample, and choosing the ploidy state whose expected allelic distribution pattern most closely matches the observed allelic distribution pattern. The mixed sample of DNA may be preferentially enriched at a plurality of polymorphic loci in a way that minimizes the allelic bias, for example using massively multiplexed targeted PCR.10-25-2012
20120270219NOVEL GENES ENCODING PROTEINS HAVING PROGNOSTIC, DIAGNOSTIC, PREVENTIVE, THERAPEUTIC, AND OTHER USES - The invention provides isolated TANGO 509 nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.10-25-2012
20120270216COMPOSITIONS AND METHODS FOR DETECTING AND IDENTIFYING SALMONELLA ENTERICA STRAINS - The present specification describes several novel SNPs of 10-25-2012
20120270214METHODS FOR LOCALIZED IN SITU DETECTION OF mRNA - The present invention relates to the detection of RNA in a sample of cells. More particularly, the present invention relates to the localized detection of RNA in situ. The method relies on the conversion of RNA to complementary DNA prior to the targeting of the cDNA with a padlock probe(s). The hybridization of the padlock probe(s) relies on the nucleotide sequence of the cDNA which is derived from the corresponding nucleotide sequence of the target RNA. Rolling circle amplification of the subsequently circularized padlock probe produces a rolling circle product which may be detected. Advantageously, this allows the RNA to be detected in situ.10-25-2012
20110217702METHODS FOR DIAGNOSIS OF AND PREDICTING TREATMENT EFFICACY OF HORMONE RECEPTOR EXPRESSING TUMORS, CANCERS AND NEOPLASIAS - The invention relates to diagnosis, detection, screening, identifying and predicting methods. In various embodiments, methods of the invention include diagnosis, detection, or screening for a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in the subject; identifying a subject that will or is likely to respond to a therapy for a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia); and predicting therapeutic efficacy of a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) treatment in a subject.09-08-2011
20110236896RGS2 GENOTYPES ASSOCIATED WITH EXTRAPYRAMIDAL SYMPTOMS INDUCED BY ANTIPSYCHOTIC MEDICATION - The present invention identifies genotypes associated with resistance to extrapyramidal symptoms induced by antipsychotic drugs. The present invention further identifies genotypes associated with predisposition to the onset or aggravation of extrapyramidal symptoms induced by antipsychotic drugs and use thereof for assessment of patient populations. Specifically, the present invention relates to particular polymorphisms in the RGS2 gene that are associated with resistance or susceptibility to drug-induced extrapyramidal symptoms.09-29-2011
20110236895METHOD FOR PREPARING SAMPLE, SOLUTION FOR PREPARING SAMPLE AND STOOL COLLECTION KIT METHOD FOR ANALYZING A NUCLEIC ACID - The present invention relates to the providing of a method for preparing a sample from a nucleic acid-containing sample such as biological samples, where inhibitory substance's action against a enzyme reaction using a nucleic acid as substrate are decreased, a solution for preparing a sample used for the method, a stool collection kit used in that method, and a method for recovering and analyzing a nucleic acid in a nucleic acid-containing sample using a sample prepared using the preparation method of the present invention. A method for preparing a sample according to the present invention is a method for preparing a sample being used for analyzing a nucleic acid, and is characterized in that a nucleic acid-containing sample is mixed with a solution having one or more members selected from the group consisting of a polycation and a chelating agent as an active ingredient.09-29-2011
20110236894SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS - The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.09-29-2011
20110236893LGR5 MODULATORS IN THE TREATMENT OF ALOPECIA - An in vitro method of screening for candidate compounds for the preventive or curative treatment of alopecia, which comprises determining the ability of a compound to modulate the expression or the activity of the LGR5 receptor is described. The use of modulators of the expression or of the activity of this receptor for treating alopecia is also described. In addition, methods for the diagnosis or prognosis, in vitro, of this disease are described.09-29-2011
20110236891NUCLEIC ACID TEMPLATE PREPARATION FOR REAL-TIME PCR - The invention teaches a novel reagent formulation for the efficient preparation of a nucleic acid template from cells for high throughput real-time PCR analysis. The reagent permits rapid cell lysis and template preparation without the need for template purification and isolation. The reagent therefore dramatically improves throughput of real-time PCR analysis while at the same time permitting the rapid and sensitive real-time Catacleave PCR detection of a single molecule of nucleic acid template in as little as about 35 cycles of PCR amplification.09-29-2011
20110236890METHOD OF SCREENING FOR CANCER BY DETECTING MUTATIONS IN THE DELTA-CATENIN GENE PROMOTER AND 5'-UNTRANSLATED REGION - A method for screening for risk of cancer in a subject is carried out by detecting the presence or absence of at least one mutation in the delta-catenin gene promoter or 5′ untranslated region in a biological sample from said subject, the presence of such mutation or an increased frequency of mutation indicating said subject is afflicted with or at least at risk of developing cancer.09-29-2011
20120276529MUTATED SUMO ISOFORMS AND USES THEREOF - Disclosed herein are substantially pure nucleic acids encoding mutated SUMO isoforms, polypeptides, vectors, cells and methods of their use to identify and quantify protein SUMOylation in mammalian cells. Also disclosed is a dual affinity method for detecting a mutated SUMOylated protein substrate fragment.11-01-2012
20120276532SAMPLE PROCESSING DEVICE FOR PRETREATMENT AND THERMAL CYCLING - A sample processing device may include an opening, a sample pretreatment unit, a thermal cycling reaction unit, and a detection unit.11-01-2012
20120276534Probe for Detecting Polymorphism in Exon 12 of NPM1 Gene and Use Thereof - The present invention relates to probes which detect a polymorphism(s) in exon 12 of the NPM1 gene, a kit therefor, and the method of detecting the polymorphism(s) thereof.11-01-2012
20120276533Method for Simultaneously Detecting Polymorphisms of Acetaldehyde Dehydrogenase 2 and Alcohol Dehydrogenase 2 - A probe for detection of at least 1 type of genetic polymorphism of the ALDH2 gene rs671 and the ADH2 gene rs1229984, a kit therefore, and methods of detecting the polymorphism(s).11-01-2012
20120276538SEQUENCE-SPECIFIC METHODS FOR HOMOGENEOUS, REAL-TIME DETECTION OF LAMP PRODUCTS - Presented herein are methods and compositions for generating sequence-specific, secondary amplification products during Loop-mediated Isothermal Amplification (LAMP). Conventional LAMP produces a preponderance of high molecular weight DNA structures concatenated into self-complementary hairpins, which are not amenable to detection by routine probe-based hybridization methods, making multiplex detection of two or more targets or sequence variants in closed-tube formats extremely difficult. Provided herein, for example, are methods for generating secondary LAMP products bearing a fragment of the original target sequence embedded within low-molecular weight products that are devoid of competitive hairpin structures, the lack of which enhances probe-based detection of target sequences. These secondary products can, for example, be produced in real-time, during the LAMP process, and can provide the option of detecting multiple target sequences within a single tube using, e.g., a homogenous, real-time fluorescence format.11-01-2012
20120276531GENES FOR PROGNOSIS OF CANCER - To provide a novel method for determining the risk of lymph node metastasis of breast cancer uses as an index the difference in the expression levels of marker genes in at least one material selected from the group consisting of a breast tissue and a breast cell of a patient. The method includes measuring an expression level of a marker gene in at least one material selected from the group consisting of a breast tissue and a breast cell of a patient with breast cancer, and determining the risk of lymph node metastasis of breast cancer in the patient using the expression level of the marker gene as an index.11-01-2012
20120276530LABEL-FREE SENSING OF PNA-DNA COMPLEXES USING NANOPORES - Embodiments disclosed herein relate to a method of detecting specific DNA sequences and the application of this method in the detection of pathogens, viruses, drug-resistant pathogens, genomic variations associated with disease/disorder susceptibility etc. based on specific signature sequences unique to the pathogens, viruses, drug-resistant pathogens or genomic variations. The method can also be used to distinguish a pool of same-sized dsDNA on the basis of sequence differences. The method uses non-optically labeled bis-PNA and/or gamma-PNA probes to tag specific target sequences for identification by solid-state nanopores.11-01-2012
201301836723-D GENOMIC REGION OF INTEREST SEQUENCING STRATEGIES - The invention relates to methods for determining the sequence of a genomic region of interest comprising a target nucleotide sequence comprising, fragmenting a crosslinked DNA, ligating the fragmented cross linked DNA, reversing the crosslinking and determining at least part of the sequences of ligated DNA fragments which comprise a target nucleotide sequence.07-18-2013
20110262914METHODS AND COMPOSITIONS FOR DIAGNOSING OR MONITORING AUTOIMMUNE AND CHRONIC INFLAMMATORY DISEASES - Methods of diagnosing or monitoring an autoimmune or chronic inflammatory disease, particularly SLE in a patient by detecting the expression level of one or more genes or surrogates derived therefrom in the patient are described. Diagnostic oligonucleotides for diagnosing or monitoring chronic inflammatory disease, particularly SLE infection and kits or systems containing the same are also described.10-27-2011
20120088242ASSAY FOR MYCOBACTERIUM AVIUM/INTRACELLULARE NUCLEIC ACID - Disclosed is a method for determining the presence of 04-12-2012
20120088241Bioreactive Agents - This invention relates to agents and conjugates to detect and isolate target components from complex mixtures such as nucleic acids from biological samples, cells from bodily fluids, and nascent proteins from translation reactions. Agents comprise a detectable moiety bound to a photoreactive moiety. Conjugates comprise agents coupled to substrates by covalent bounds which can be selectively cleaved with the administration of electromagnetic radiation. Targets substances labeled with detectable molecules can be easily identified and separated from a heterologous mixture of substances. Exposure of the conjugate to radiation releases the target in a functional form and completely unaltered. Using photocleavable molecular precursors as the conjugates, label can be incorporated into macromolecules, the nascent macromolecules isolated and the label completely removed. The invention also relates to targets isolated with these conjugates which may be useful as pharmaceutical agents or compositions that can be administered to humans and other mammals.04-12-2012
20120088240FUNCTIONALIZED POLYMER BIOSENSOR - One aspect of the present disclosure relates to a novel sensor mechanism based on the aggregation of nanoparticles for target molecule detection and quantification. The nanoparticles that can be used include non-conducting polymers and conducting polymers such as polyaniline, polypyrrole and polythiophene derived nanofibers. Embodiments can include covalently functionalized nanoparticles with probes for target molecules, a biosensor where functionalized nanoparticles bind to one another upon presence of target to generate a visible conjugate induced aggregation, a biosensor wherein nanoparticles bind spontaneously in the presence of target molecules such as biological molecules, cells and biological markers.04-12-2012
20120088238CONVERSION OF ALPHA-HYDROXYALKYLATED RESIDUES IN BIOMOLECULES USING METHYLTRANSFERASES - The present invention relates to targeted conversion of alpha-hydroxyalkylated residues in biomolecules in the presence of a directing methyltransferase, namely to targeted removal of the alpha-hydroxyalkyl moieties to give unmodified residues, or targeted derivatization of the alpha-hydroxyalkyl groups by covalent coupling of non-cofactor compounds represented by formula HQ-LX1 wherein X represents a functional group or a reporter group attached via a linker moiety L, and QH is selected from HS—, HSe—, HO—H04-12-2012
20120088237Engineering a Novel Methylation-Specific Restriction Endonuclease - A restriction endonuclease is provided that has been engineered to have a cleavage specificity for a DNA recognition sequence containing a modified nucleotide. Methods for engineering enzymes to cleave DNA containing modified nucleotides at specific sequences are provided.04-12-2012
20120088236Methods and Systems for Sequential Determination of Genetic Mutations and/or Varients - The present invention relates to methods and systems for genome scanning using high resolution melting analysis for identifying mutations and/or variants in genes of interest.04-12-2012
20120088235HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION AND RELATED METHODS - Nucleic acid sequencing methods and related products and methods for detection and presentation of the same are disclosed. Methods for sequencing a target nucleic acid comprise providing a daughter strand produced by a template-directed synthesis, the daughter strand comprising a plurality of subunits coupled in a sequence corresponding to a contiguous nucleotide sequence of all or a portion of the target nucleic acid.04-12-2012
20120088234DEVICE FOR PERFORMING PCRS - A device is described to perform reactions, in which the device includes at least one test cell with a cavity to receive the test sample and at least a first, a second and a third spatially discrete regulatable temperature units. The three temperature units thus define three spatially discrete temperature areas. At least one means is provided to perform a rotary movement of the test cell. The cavity provided to receive the test sample can be moved across the three spatially discrete temperature areas, in which the cavity in one position of the test cell, remains in contact with a least two of the temperature areas.04-12-2012
20110281264METHOD FOR DIAGNOSING AND PREDICTING CEREBELLAR ATAXIA - The present invention relates to an in vitro method for diagnosing and/or predicting hereditary cerebellar ataxia in a dog, and/or identifying a dog which is healthy carrier of hereditary cerebellar ataxia, comprising determining the presence or absence of an homozygous or heterozygous genetic variation in the arylsulfatase G gene sequence in a biological sample from said dog, as compared with the arylsulfatase G gene sequence of a healthy non-carrier dog, wherein the presence of said homozygous genetic variation indicates that said dog is or will be affected by hereditary cerebellar ataxia, and the presence of said heterozygous genetic variation indicates that said dog is healthy carrier of hereditary cerebellar ataxia, said dog being of a breed selected in the group consisting of American Staffordshire Terrier, American Pit Bull Terrier and Pit Bull type.11-17-2011
20110287417Predicting a response to risperidone - The invention relates generally to the relative effect of specific genetic polymorphisms in predicting the clinical outcome of risperidone therapy in patients suffering from a psychiatric disease such as schizophrenia.11-24-2011
20110294127ELITE EVENT A2704-12 AND METHODS AND KITS FOR IDENTIFYING SUCH EVENT IN BIOLOGICAL SAMPLES - Tools are provided which allow rapid and unequivocal identification elite event A207-12 in biological samples.12-01-2011
20110294118WATER SOLUBLE FLUORESCENT COMPOUNDS - The invention provides a novel class of fluorescent compounds. Also provided are conjugates of the fluorescent compounds, methods of using the fluorescent compounds and their conjugates as well as kits including the fluorescent compounds and their conjugates.12-01-2011
20110294117NUCLEIC ACID SEQUENCING DEVICE AND METHOD OF DETERMINING NUCLEOTIDE SEQUENCE OF TARGET NUCLEIC ACID USING THE SAME - A nucleic acid sequencing device includes at least one nanochannel, a first electrode and a second electrode disposed at opposite ends of the nanochannel for applying a voltage in the lengthwise direction of the nanochannel, and a first detector that detects a location signal of a target nucleic acid passing through the nanochannel and a second detector that detects a signal from a detectable label bound to the target nucleic acid.12-01-2011
20120329052IDENTIFICATION OF A DNA VARIANT ASSOCIATED WITH ADULT TYPE HYPOLACTASIA - The present invention relates to a nucleic acid molecule comprising a 5′ portion of an intestinal lactase-phlorizine hydrolase (LPH) gene contributing to or indicative of the adult-type hypolactasia. The present invention further relates to methods for testing for the presence of or predisposition to adult-type hypolactasia that are based on the analysis of an SNP contained in the above recited nucleic acid molecule. Additionally, the present invention relates to diagnostic composition and kit useful in the detection of the presence of or predisposition to adult-type hypolactasia.12-27-2012
20120329051METHODS OF EVALUATING CELLS AND CELL CULTURES - Methods of evaluating the composition of a cell culture (e.g., to distinguish chondrocytes from fibroblasts) and methods for evaluating the phenotype of an individual cell (e.g., as a chondrocyte) are disclosed. The methods may be used, for example, for assessing chondrocyte cultures used for treatment of cartilage defects. In some embodiments, the invention involves identifying cell culture composition or the identity of a cell based on expression level of a fibroblast marker. In other embodiments, the invention involves comparing expression levels of at least one chondrocyte marker and at least one fibroblast marker in a cell culture sample or in an individual cell. In illustrative embodiments, the chondrocyte marker is hyaluronan and proteoglycan link protein 1 (HAPLN1), and the fibroblast marker is microfibrillar associated protein 5 (MFAP5).12-27-2012
20120329050METHODS FOR THE DETECTION OF MICROORGANISMS - Presented herein are methods for the detection of the presence or absence of one or more microorganisms in a sample. The method deploys a plurality of probe sets to detect a plurality of microorganisms. The probes in the probe set are detectably labeled. At least one probe set has probes labeled with a combination of detectable labels. The number of detectable labels used in the plurality of probe sets numbers less than the number of microorganisms being detected by the probe set.12-27-2012
20120100545METHOD AND/OR PRIMERS FOR THE DETECTION OF MYCOBACTERIUM TUBERCULOSIS - The invention provides oligonucleotide(s) for simple, specific and/or sensitive test(s) for the presence of 04-26-2012
20120100544METHOD FOR QUANTIFYING DNA IN A BIOLOGICAL SAMPLE - Improved methods of quantifying nucleic acids that are unique to a transgenic corn event designated Bt11 in a biological sample and compositions thereof are disclosed. The invention further relates to primer pairs used in the method that are unique to event Bt11.04-26-2012
20120100543COMPOSITIONS FOR THE USE IN IDENTIFICATION OF FUNGI - The present invention provides compositions, kits and methods for rapid identification and quantification of fungi by molecular mass and base composition analysis.04-26-2012
20120100542METHOD FOR DETECTION OF TARGET NUCLEIC ACID, AND METHOD FOR TESTING FOR COLON CANCER - The present invention provides: a method for easily and simply obtaining highly reliable results of the detection of a target nucleic acid from nucleic acids that are directly recovered from feces; and a method for testing for diseases, particularly colon cancer, by using this method. Specifically, the present invention is a method for detecting an animal-derived target nucleic acid, comprising: (a) a step of collecting a fixed quantity of feces; (b) a step of recovering nucleic acids from the feces that has been collected in the step (a), and preparing a fixed volume of a nucleic acid solution; and (c) a step of dispensing a fixed volume of an aliquot from the nucleic acid solution that has been prepared in the step (b), and detecting the target nucleic acid in the dispensed solution.04-26-2012
20120100541GENE METHYLATION IN CANCER DIAGNOSIS - The present invention provides DNA biomarker sequences that are differentially methylated in samples from normal individuals and individuals with cancer. The invention further provides methods of identifying differentially methylated DNA biomarker sequences and their use in detecting and diagnosing cancer.04-26-2012
20120100540ULTRA SENSITIVE METHOD FOR IN SITU DETECTION OF NUCLEIC ACIDS - Disclosed is a method for in situ detection of one or more target nucleic acids based on a combination of RNAscope® method and a general ISH signal amplification method. This new method produces high signal intensity and while keeps low background noise of signal amplification. The result can be consistently reproduced and the method can be easily adopted for routine clinic diagnostic use. Further, the invention relates to a kit, comprising the components of RNAscope® assay and a general ISH signal amplification assay, for sensitive detection of one or more target nucleic acids.04-26-2012
20120100539METHOD FOR DETERMINING RISK FOR KIDNEY STONES DEVELOPING OR RECURRING AND METHOD FOR USING SINGLE-NUCLEOTIDE POLYMORPHISM RS12313273 AS BIOMARKER FOR DETERMINING DEVELOPMENT OR RECURRENCE OF KIDNEY STONE - The invention provides a method for determining a risk for kidney stones to develop in a subject, including: obtaining a biosample of the subject; detecting the presence of the single-nucleotide polymorphism rs12313273 (C/T) at position 30881 of the ORAI1 gene (SEQ ID No.: 1) in the biosample; and determining a risk for kidney stones to develop in the subject, wherein if the presence of a C allele of the single-nucleotide polymorphism rs12313273 (C/T) is detected, it indicates that the subject has an increased risk for kidney stones to develop.04-26-2012
20120100538Devices and methods of cell capture and analysis - The present invention provides a device for isolating target biomolecules or cells from samples, particularly biological samples. In particular, the device comprises a loading mixture, which contains the biological sample and a first binding entity that specifically binds to the target biomolecule or target cell; and a micro-channel coated with a second binding entity that binds directly or indirectly to the first binding entity. Methods of capturing, detecting, and/or evaluating target biomolecules or target cells (e.g. cancer cells) in biological samples are also disclosed.04-26-2012
20120100537Method of Prenatal Molecular Diagnosis of Down Syndrome and Other Trisomic Disorders - The present invention encompasses a method of diagnosing chromosomal trisomy in a human subject. In one embodiment, the method comprises pyrosequencing at least one single nucleotide polymorphism on a chromosome being assessed for trisomy, where the SNP comprises two alleles.04-26-2012
20120100536ASSOCIATION OF HTRA1 MUTATIONS AND FAMILIAL ISCHEMIC CEREBRAL SMALL-VESSEL DISEASE - The present invention provides a method of diagnosing a cerebrovascular disease in a human comprising the steps of: (a) measuring a mutation of HTRA1 gene in a test sample from said human; and (b) determining if the mutation of HTRA1 gene in said test sample correlates with a cerebrovascular disease in said human.04-26-2012
20120100535METHODS FOR QUANTITATIVE DETERMINATION OF METHYLATION DENSITY IN A DNA LOCUS - The present invention is a novel method of determining the average DNA methylation density of a locus of interest within a population of DNA fragments.04-26-2012
20120100534EFFICIENT BASE DETERMINATION IN SEQUENCING REACTIONS - The present invention is directed to compositions and methods for nucleic acid identification and detection. Compositions and methods of the present invention include extracting and fragmenting target nucleic acids from a sample, using the fragmented target nucleic acids to produce target nucleic acid templates and subjecting those target nucleic acid templates to amplification methods to form nucleic acid nanoballs. The invention also includes methods of detecting and identifying sequences using various sequencing applications, including sequencing by ligation methods.04-26-2012
20120288856MOLECULAR SEXING OF AVIAN SUBJECTS - The present invention provides oligonucleotides including amplification primers and probes as well as pairs of said oligonucleotides that are useful in methods and uses for the determination of the sex of an avian subject. Similarly, these oligonucleotides can be used for the preparation of a kit for the determination of the sex of an avian subject. Also, the present invention provides a method for the identification of a pair of oligonucleotides for sexing of an avian subject and a kit comprising such oligonucleotides.11-15-2012
20130011838Kits And Methods For Assessing Oxidative Stress - The invention relates to kits and methods for assessing the susceptibility of a human to oxidative stress or damage. The methods involve assessing occurrence in the human's genome of one or more polymorphisms (e.g., single nucleotide polymorphisms) that occur in one or more genes associated with oxidative stress and that are associated with a disorder in humans. Preferred assessment and scoring methods are disclosed, as are kit for performing the methods.01-10-2013
20130011836KIT FOR THE DETECTION OF BED BUGS - A kit and method for the detection of bed bugs is discussed. The kit comprises at least one pair of polymerase chain reaction (“PCR”) amplification primers capable of forming a Cimicidae-DNA-amplification-product for a family of organisms of a Cimicidae. Additionally, the kit provides a specimen collection device for collecting a DNA sample from an area suspected of harboring one or more members of the Cimicidae family. The kit also provides a DNA probe having fluorescent primer chemistry. In a preferred embodiment, the nucleic acid amplification detection kit utilized a pair of PCR primers. The probe utilizes fluorescent primer chemistry and contains chemistry similar to TaqMan Probes, Molecular Beacons, Hybridization Probes; or Eclipse Probes. Additionally, the kit contains a positive-control-Cimicidae DNA template for confirming Cimicidae-DNA-amplification-product.01-10-2013
20130011839Methods for the Reduction of Stutter in Microsatellite Amplification - The invention provides a method for reducing stutter in the amplification of a microsatellite comprising the steps of providing a sample comprising a microsatellite having a G+C content of 50% or less; contacting the sample with at least one enzyme having nucleic acid polymerase activity; and incubating the sample with the enzyme for a sufficient amount of time and under conditions sufficient to amplify the microsatellite; wherein the incubation is performed in the presence of an amount of betaine, sorbitol or mixtures thereof, effective to reduce stutter relative to the amount of stutter observed in the absence of betaine and/or sorbitol. The invention also provides compositions containing betaine and/or sorbitol, kits for amplifying microsatellites having a G+C content of 50% or less, and methods of using all of the foregoing.01-10-2013
20130011842DNA Sequencing System - An apparatus for detecting labeled beads is provided. The apparatus can include: one or more irradiation sources disposed for irradiating the one or more detection zones with radiation; at least one detector disposed for collecting charges corresponding to light signals emitted from labeled beads in the one or more detection zones, which have been excited by the radiation; and a system coupled to the at least one detector for effecting time delay integration of the charges by accumulating the charges before reading the charges at the output of the at least one detector.01-10-2013
20130011843TISSUE SEPARATION METHOD - The invention relates to a method for non-destructively sampling individual seeds in a population of seeds. In one embodiment, the invention relates to an efficient, high throughput method for removing contaminating tissue from the other seed material. The methods of the invention are useful for determining the genotype of a seed and the detection of a genetic marker or genetic trait. The methods of the invention comprise removing maternal tissue, such as seed coat or pericarp from the seed, and analyzing the remainder of the seed. The methods of the invention reduce the degree of ambiguity in the genetic tests because complicating maternal tissue has been removed.01-10-2013
20130011841Genetic Association of Polymorphisms in Perilipin (PLIN) Gene With Resistance to Weight Loss - Diagnostics and therapeutics for resistance to weight-loss, which are based upon the identification of a subject's PLIN polymorphisms, haplotype and genotype pattern, are described in this invention.01-10-2013
20130011840Methods, Compositions, and Kits Comprising Linker Probes for Quantifying Polynucleotides - The present invention is directed to methods, reagents, kits, and compositions for identifying and quantifying target polynucleotide sequences. A linker probe comprising a 3′ target specific portion, a loop, and a stem is hybridized to a target polynucleotide and extended to form a reaction product that includes a reverse primer portion and the stem nucleotides. A detector probe, a specific forward primer, and a reverse primer can be employed in an amplification reaction wherein the detector probe can detect the amplified target polynucleotide based on the stem nucleotides introduced by the linker probe. In some embodiments a plurality of short miRNAs are queried with a plurality of linker probes, wherein the linker probes all comprise a universal reverse primer portion a different 3′ target specific portion and different stems. The plurality of queried miRNAs can then be decoded in a plurality of amplification reactions.01-10-2013
20130011837Assays for Affinity Profiling of Nucleic Acid Binding Proteins - Methods, compositions and kits are disclosed for assays to determine the binding affinity of DNA-binding proteins or RNA-binding proteins for their corresponding recognition site(s). In particular, assays are disclosed for measuring binding affinities when either the binding protein, or the recognition sequence of the recognition site, or cofactor proteins, contain one or more mutations. The disclosed assays can thus be utilized to measure the effect on transcription factor binding caused by mutations within the recognition site, or mutations within the binding domain of the protein, and to provide binding affinity information that can be correlated with altered gene regulation and expression. The disclosed assays can be personalized to a specific person or organism, with the measured binding affinities based upon an individual's specific binding proteins and recognition sites. Furthermore, embodiments are capable of measuring binding affinities between multiple binding proteins and multiple recognition sites through an entirely in vitro process.01-10-2013
20130011833METHOD FOR IDENTIFYING NUCLEIC ACIDS BOUND TO AN ANALYTE - A method for identifying a target nucleic acid bound by an analyte in a sample comprising: (a) contacting said sample with a first probe comprising a first nucleic acid and a first analyte binding domain and a second probe comprising a second nucleic acid and second analyte binding domain, wherein said first and second probes can bind to said analyte, such that said first and second nucleic acid are in spatial proximity to form a complex with said target nucleic acid if said target nucleic acid is bound by said analyte in said sample; (b) incubating said sample with a ligase that can ligate said complex to form a ligated target nucleic acid template; (c) amplifying said target nucleic acid template if present in said sample, and (d) detecting the presence or absence of an amplified target nucleic acid template.01-10-2013
20130011831Compositions And Methods For The Rapid Detection Of Legionella pneumophila - The present application describes compositions and methods useful for the rapid detection of 01-10-2013
20130011832Dual-mode microfluidic genetics testing platforms and methods of dual-mode genetics testing using same - Dual mode genetics testing systems are devised about a single element testing platform. A microfluidic network and system of interconnected receiving cells and reaction vessels supports at the same time genotyping and copy number analysis where the platform may be subject to a common thermal cycle schedule to cause the proper reactions (DNA replication) necessary in both test types. Further, the microfluidic platform which includes reaction vessels for genotyping which are spatially removed from reaction vessels for copy number analysis, is coupled to optical scanner and detection systems specifically arranged to apply test specific detection routines on each of these distinct regions or portions of the dual mode test platform.01-10-2013
20130017544High Resolution Melting Analysis on a Droplet Actuator - An integrated droplet actuator device and methods are provided for performing PCR amplification and high-resolution melting (HRM) analysis on a single droplet actuator. HRM analysis can be used in combination with PCR amplification for detection of sequence variations (e.g., single-nucleotide polymorphisms, nucleotide-repeat polymorphisms, mutation scanning and assessment of DNA methylation) within one or more genes of interest. The PCR amplicons can be fluorescently labeled during amplification using a saturating DNA intercalating fluorescent dye, a 5′-labeled primer, or labeled probes. Also provided are a droplet actuator device and methods for sample preparation using the droplet actuator and detection of sequence variations on the same droplet actuator.01-17-2013
20130017539METHODS AND COMPOSITIONS FOR CHLAMYDIA TRACHOMATIS DIAGNOSTIC TESTING - The invention provides methods, reagent, and kits for detecting the presence of 01-17-2013
20130017540IDENTIFICATION OF MUTATION TYPES ASSOCIATED WITH ACQUIRED RESISTANCE AND METHODS FOR USING SAME - Methods for identifying or classifying a gene mutation type associated with acquired drug resistance of cancer is provided. Said methods may include determining a total copy number (N) of a susceptible gene in a cancer cell, identifying a mutant copy number of the susceptible gene, determining a mutant copy number sufficient to cause acquired drug resistance (M); and comparing N with M to identify or classify the mutation type in the cancer cell.01-17-2013
20130017543Method and Kit for Amplifying and Detecting PolynucleotideAANM Hosomi; ToshiyaAACI Kyoto-shiAACO JPAAGP Hosomi; Toshiya Kyoto-shi JPAANM Hirai; MitsuharuAACI Kyoto-shiAACO JPAAGP Hirai; Mitsuharu Kyoto-shi JP - Disclosed is a method of amplifying a polynucleotide, comprising: 01-17-2013
20130017538DEVICES, SYSTEMS, AND METHODS FOR MAGNETIC SEPARATIONAANM Ionescu-Zanetti; CristianAACI BerkeleyAAST CAAACO USAAGP Ionescu-Zanetti; Cristian Berkeley CA USAANM Nevill; Joshua TannerAACI El CerritoAAST CAAACO USAAGP Nevill; Joshua Tanner El Cerrito CA USAANM Schwartz; MichaelAACI OaklandAAST CAAACO USAAGP Schwartz; Michael Oakland CA USAANM Conant; Carolyn G.AACI San FranciscoAAST CAAACO USAAGP Conant; Carolyn G. San Francisco CA USAANM Rudoff; RogerAACI CupertinoAAST CAAACO USAAGP Rudoff; Roger Cupertino CA US - Methods, microfluidic devices, and instruments for magnetic separation of particles from a fluid are described. Examples include microfluidic devices having a removable portion. Examples include microfluidic devices having one or more regions of reduced fluid velocity. Examples further including instruments having pneumatic interfaces. Examples further includes instruments having controllable magnets, imaging components, or combinations thereof.01-17-2013
20130017542Method and Kit for Amplifying and Detecting PolynucleotideAANM Hosomi; ToshiyaAACI Kyoto-shiAACO JPAAGP Hosomi; Toshiya Kyoto-shi JPAANM Hirai; MitsuharuAACI Kyoto-shiAACO JPAAGP Hirai; Mitsuharu Kyoto-shi JP - Disclosed is a method of amplifying a polynucleotide, comprising: 01-17-2013
20110159495METHOD FOR THE QUANTITATIVE DETECTION OF AN ORGANIC SUBSTANCE IN A SAMPLE - A method for the quantitative detection of an organic substance containing a nucleic acid to be detected in a sample based on a given threshold value for that organic substance in the sample, the use of this method, as well as a kit for practicing this method.06-30-2011
20110159494Analyzing the FMR1 Gene - A method of predicting a degree of risk of autoimmunity in a human female is disclosed. The method may include analyzing the female's FMR1 gene, wherein the FMR1 gene has a first allele and a second allele, determining the number of triple CGG repeats on each of the first and second alleles; defining a normal range of triple CGG repeats; and comparing the number of triple CGG repeats on each of the first and second alleles to the normal range. If the triple CGG repeat number for one of the first and second alleles is in the normal range and the triple CGG repeat number for the other one of the first and second alleles is less than the lower boundary of the normal range, then the female is at increased risk of autoimmunity. Additionally, a method of predicting pregnancy chances for a human female is disclosed. The method may include analyzing the female's FMR1 gene, wherein the FMR1 gene has a first allele and a second allele; determining the number of triple CGG repeats on each of the first and second alleles; defining a normal range of triple CGG repeats; and comparing the number of triple CGG repeats on each of the first and second alleles to the normal range. If the triple CGG repeat number for one of the first and second alleles is in the normal range and the triple CGG repeat number for the other one of the first and second alleles is less than the lower boundary of the normal range, then the female has decreased chances of pregnancy.06-30-2011
20110159492Diffuse Large B-Cell Lymphoma Markers and Uses Therefore - The present invention provides methods and compositions for prognosing treatment outcome in DLBCL patients, diagnosing DLBCL and monitoring efficacy of DLBCL treatment.06-30-2011
20110159491Method for detecting cytosine methylation in DNA samples - Described is a method for detecting 5-methylcytosine in genomic DNA samples. First, a genomic DNA from a DNA sample is chemically converted with a reagent, 5-methylcytosine and cytosine reacting differently, and the pretreated DNA is subsequently amplified using a polymerase and at least one primer. In the next step, the amplified genomic DNA is hybridized to at least one oligonucleotide, forming a duplex, and said oligonucleotide is elongated by at least one nucleotide, the nucleotide carrying a detectable label, and the elongation depending on the methylation status of the specific cytosine in the genomic DNA sample. In the next step, the elongated oligonucleotides are analyzed for the presence of the label.06-30-2011
20110159490USE OF THE COMBING PROCESS FOR THE IDENTIFICATION OF DNA ORIGINS OF REPLICATION - Eukaryotic genomes are duplicated by the activation of multiple bidirectional origins of replication. The replication programs of these cells depend on the temporal and spatial organisation of replication origins throughout the genome. To investigate the replication program in a higher eukaryote, we employed a technique called molecular combing. This technique allows for a quantitative analysis of DNA replication on a genome wide basis. As a model system, 06-30-2011
20110159489SINGLE NUCLEOTIDE POLYMORPHISMS ASSOCIATED WITH DIETARY WEIGHT LOSS - The present invention relates to genetic polymorphisms associated with obesity and obesity-related phenotypes and their use in predicting if an individual successfully completes a dietary weight loss intervention program.06-30-2011
20110159488Primers for Amplification and Sequencing of Eubacterial 16S rDNA for Identification - The invention relates to oligonucleotides for the qualitative and/or quantitative amplification and/or the sequencing of 16S rDNA-genes, as well as of fragments thereof and RNA derived thereof. It relates to their use as primers in amplification reactions and in sequencing, in particular in combination for the identification of the genus/species/strain of the bacterial sample or clinical isolate.06-30-2011
20130022978Measurement of Brain CDP-Diacylglycerol Synthase 1 Enzyme and Uses Thereof - Provided herein are methods of diagnosing depressive disorders in a subject by comparing a CDP-diacylglycerol synthase 1 enzyme activity or expression level to enzyme activity or expression level of CDP-diacylglycerol synthase 1 in a control subject. Also herein are methods of predicting therapeutic efficacy of an antidepressant drug in a subject with depressive disorders by monitoring enzyme activity or expression level of CDP-diacylglycerol synthase 1 in the subject. Further provided herein are methods of identifying a compound effective to treat or alleviate the symptoms of depression by monitoring enzyme activity or expression level of CDP-diacylglycerol synthase 1 in a tissue. Further provided are kits for diagnosing depressive disorders.01-24-2013
20130171630METHODS OF USING TELOMERES AS MARKERS FOR AGING - The invention relates to a simple, reproducible, fast, and accurate method of quantifying and measuring telomeres in a clinical sample. The invention further relates to kits comprising premixed and optimized buffers, DNA polymerase, primers, and instructions for the detection of telomere length and quantities. Also envisioned are complete kits further including instrumentalities for the detection of telomere length and quantities.07-04-2013
20130171631CONJUGATES OF NUCLEOTIDES AND METHOD FOR THE APPLICATION THEREOF - The invention relates to a novel method for enzymatically marking nucleic acid chains (target sequences) by using nucleotide conjugates. Said nucleotide conjugates are capable of binding specifically to the target sequence under reaction conditions and of being incorporated in the complementary growing strand by means of a polymerase. The nucleic acid chains marked with such conjugates can be bound to the solid phase. The marking can be carried out in parallel with the enzymatic amplification of target sequences.07-04-2013
20130171632METHODS AND COMPOSITIONS FOR DETECTION AND ANALYSIS OF POLYNUCLEOTIDES USING LIGHT HARVESTING MULTICHROMOPHORES - Methods, compositions and articles of manufacture for assaying a sample for a target polynucleotide are provided. A sample suspected of containing the target polynucleotide is contacted with a polycationic multichromophore and a sensor polynucleotide complementary to the target polynucleotide. The sensor polynucleotide comprises a signaling chromophore to receive energy from the excited multichromophore and increase emission in the presence of the target polynucleotide. The methods can be used in multiplex form. Kits comprising reagents for performing such methods are also provided.07-04-2013
20130171635DUAL OLIGONUCLEOTIDE METHOD OF NUCLEIC ACID DETECTION - Methods for amplifying and detecting nucleic acids are described, as well as sets of 5′ labeled oligonucleotides.07-04-2013
20130171637MATERIALS AND METHODS FOR DIAGNOSIS OF BLADDER CANCER AND MONITORING RECURRENCE THEREOF - A method of diagnosing bladder cancer in a patient comprising contacting a sample of urothelial cells obtained from the patient with a set of detectably labeled probes comprising locus-specific probes for c-myc and AURKA and centromeric probes for chromosomes 7 and 17 under hybridization conditions, and determining the presence of chromosomal abnormalities, wherein the presence of chromosomal abnormalities involving at least two of the detectably labeled probes indicates that the patient has bladder cancer; a method of monitoring recurrence of bladder cancer in a patient; a set of probes comprising locus-specific probes for c-myc and AURKA and centromeric probes for chromosomes 7 and 17; and a kit comprising (a) the set of probes and (b) instructions for diagnosing bladder cancer, or monitoring the recurrence thereof, in a patient.07-04-2013
20130171638MATERIALS AND METHODS FOR DIAGNOSIS, PROGNOSIS AND ASSESSMENT OF THERAPEUTIC/PROPHYLACTIC TREATMENT OF PROSTATE CANCER - A method to detect prostate cancer comprising contacting a sample of prostate cells from the patient with a set of detectably labeled probes under hybridization conditions and determining the presence of chromosomal abnormalities in prostate tumor tissue, PIN (intra-epithelial neoplasia), histologically benign tissue and benign prostatic hyperplasia (BPH); a method to combine immunofluorescence and FISH (IF-FISH) to facilitate the assessment of chromosomal abnormalities; a set of probes; and a kit comprising the set of probes and instructions for diagnosing prostate cancer in a patient.07-04-2013
20130171639MATERIALS AND METHODS FOR DIAGNOSIS, PROGNOSIS, MONITORING OF RECURRENCE, AND ASSESSMENT OF THERAPEUTIC/PROPHYLACTIC TREATMENT OF PANCREATOBILIARY CANCER - A method of detecting high-grade dysplasia, pancreatobiliary cancer, or metastatic cancer to the pancreatobiliary tract or inferring an increased risk thereof, comprising obtaining a sample of pancreatobiliary cells from a patient with a set of detectably labeled probes comprising a locus-specific probe for MCL1 (myeloid cell leukemia sequence 1), a locus-specific probe for EGFR (epidermal growth factor receptor), a locus-specific probe for MYC, and a locus-specific probe for P16 under hybridization conditions and determining the presence of chromosomal abnormalities; a set of probes comprising a locus-specific probe for MCL1, a locus-specific probe for EGFR, a locus-specific probe for MYC, and a locus-specific probe for P16; and a kit comprising the set of probes and instructions for detecting high-grade dysplasia, pancreatobiliary cancer, or metastatic cancer to the pancreatobiliary tract, or inferring an increased risk thereof, in a patient.07-04-2013
20130171640SOLID REAGENT DISSOLVING DEVICE AND METHOD OF DISSOLVING SOLID REAGENT BY USING THE SAME - A solid reagent dissolving device including a flexible layer; an upper plate disposed on the flexible layer; and a lower plate disposed under the flexible layer, wherein the upper plate comprises a plurality of minute channels, a dissolution chamber connected with the plurality of minute channels, and a protrusion for limiting a flow of a fluid flowing through one of the plurality of minute channels, the lower plate comprises a plurality of penetration holes that correspond to the protrusion and the dissolution chamber, respectively, and one side of each of the plurality of penetration holes, the plurality of minute channels, and the dissolution chamber are covered with the flexible layer, and method of using same.07-04-2013
20130171641METHOD AND COMPOSITIONS FOR DETECTING EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT FORMS IN CANCER CELLS - Method and compositions for screening for the presence of Epidermal Growth Factor Receptor variant 3 (EGFR(v3)) in a sample are described. The method comprises obtaining a sample containing a plurality of cells; hybridizing a set of chromosomal probes to the sample, wherein the set comprises an EGFR(v3)-probe and a probe to chromosome 7 different from an EGFR(v3)-probe; and visualizing the hybridization pattern of the set of chromosomal probes in the plurality of cells of the sample, wherein the presence of at least one copy of chromosome 7 lacking a hybridization signal of the EGFR(v3)-probe in at least one cell is indicative of the presence of the EGFR(v3) in the sample. The method and compositions are suitable for diagnosing the therapeutic outcome for treating a patient having a cancer with an anti-EGFR therapeutic agent and for screening a sample for a predisposition for forming an EGFR-associated cancer.07-04-2013
20130171643Sequence Specific Real-Time Monitoring of Loop-Mediated Isothermal Amplification (LAMP) - Gene-based diagnostics capable of rapidly discriminating selected strains of a selected pathogen from other populations within the same species are disclosed. Sequence-specific, real-time monitoring of LAMP of DNA may be accomplished through the use of oglionucleotide probes, referred to as “assimilating probes.” The assimilating probes include two oglionucleotide strands, one which includes a quencher (referred to as the quenching probe) and another which includes a fluorophore (referred to as the fluorescent probe). A fluorescent signal results when the two strands are displaced from one another during the LAMP reaction. By monitoring the emitted fluorescence, sequence specific amplification may be detected.07-04-2013
20110262916NON-INVASIVE FETAL RHD GENOTYPING FROM MATERNAL WHOLE BLOOD - The present invention discloses methods of determining the RhD genotype of subject. In particular, the invention provides a non-invasive method of determining fetal RhD genotype from a maternal biological sample containing fetal cells. The invention also provides novel probes and primers useful in the described methods. Kits and mixtures comprising the novel probes and primers are also disclosed.10-27-2011
20110262915METHOD FOR PREDICTING THE ATHLETIC PERFORMANCE POTENTIAL OF A SUBJECT - A method for predicting the athletic performance potential of a subject comprising the step of assaying a biological sample from a subject for a genetic variant in linkage disequilibrium with MSTN-66493737 (T/C) SNP. The invention also provides an assay for determining the athletic performance potential of a subject.10-27-2011
20110262912METHOD FOR MEASURING DNA METHYLATION - The present invention relates to a method of measuring the content of methylated DNA in a DNA region of interest in a genomic DNA contained in a biological specimen, and so on.10-27-2011
20110262911CORRECTING AN ASSAY IMAGE OF AN ARRAY OF SIGNALS GENERATED FROM A MULTIPLEXED HYBRIDIZATION-MEDIATED ASSAY - Described are methods of assay design and assay image correction, useful for multiplexed genetic screening for mutations and polymorphisms, including CF-related mutants and polymorphs, using an array of probe pairs (in one aspect, where one member is complementary to a particular mutant or polymorphic allele and the other member is complementary to a corresponding wild type allele), with probes bound to encoded particles (e.g., beads) wherein the encoding allows identification of the attached probe. The methods relate to avoiding cross-hybridization by selection of probes and amplicons, as well as separation of reactions of certain probes and amplicons where a homology threshold is exceeded. Methods of correcting a fluorescent image using a background map, where the particles also contain an optical encoding system, are also disclosed.10-27-2011
20110262909Genetic Markers for Horned and Polled Cattle and Related Methods - Embodiments of the present invention provide methods for improving desirable animal traits including the horned/polled phenotype in bovine animals. Also provided are methods for determining a dairy animal's genotype with respect to multiple markers associated with polled, fitness and/or productivity traits. The invention also provides methods for selecting or allocating animals for predetermined uses such as progeny testing or nucleus herd breeding, for picking potential parent animals for breeding, and for producing improved progeny animals. Also provided are methods for identifying genetic markers associated with polled, fitness and/or productivity traits that are in allelic association with the SNPs disclosed herein.10-27-2011
20130143207METHODS AND COMPOSITIONS FOR IDENTIFYING BIOMARKERS USEFUL IN CHARACTERIZING BIOLOGICAL STATES - The present invention relates to methods, compositions, and kits for identifying biomarkers useful in characterizing biological states. In particular, the invention relates to methods and compositions for molecular characterization of biological states by gene expression profiling. The invention also relates to assessing effects of DNA polymorphisms on regulation of transcription. The biomarkers and polymorphisms identified find use in diagnostic and treatment approaches, e.g., some embodiments of the invention provide methods and kits for detecting bronchogenic carcinoma and risks thereof.06-06-2013
20130143213DETECTION OF GENETIC ABNORMALITIES - The present invention provides assay systems and related methods for determining genetic abnormalities in mixed samples comprising cell free DNA from both normal and putative genetically atypical cells. Exemplary mixed samples for analysis using the assay systems of the invention include samples comprising both maternal and fetal cell free DNA and samples that contain DNA from normal cells and circulating cancerous cells.06-06-2013
20130177904ARNT ISOFORM 3 AS A PREDICTOR OF AMINOFLAVONE RESPONSIVENESS IN CANCER CELLS - The present invention is directed to methods for determining whether a selected cancer is susceptible to an activity of an arylhydrocarbon receptor agonist, such as aminoflavone, via screening the cancer for expression of isoform 3 of aryl hydrocarbon nuclear translocator.07-11-2013
20130177905SAMPLE PREPARATION FOR IN SITU NUCLEIC ACID ANALYSIS, METHODS AND COMPOSITIONS THEREFOR - Sample preparation processes for in situ RNA or DNA analysis, methods and compositions therefor are provided. Processes provided herein allow DNA or RNA analysis to be carried out in the same tube or on an aliquot of the prepared sample without centrifugation or extraction. The preparation process can be carried out at room temperature in as little as seven minutes and is amenable to high throughput processing using manual or robotic platforms.07-11-2013
20130177906ENHANCED AMPLIFICATION OF TARGET NUCLEIC ACID - Described herein are a composition for an improved amplification of a target nucleic material, a kit containing the composition and a method for an improved amplification. The composition contains a primer sequence which has a ribonucleic acid segment which can be cleaved by a RNase activity. The method using such primer improves probe cleavage kinetics is to increase availability or duration of a single strand template for probe binding.07-11-2013
20130177907GRAY LEAF SPOT TOLERANT MAIZE AND METHODS OF PRODUCTION - The invention relates to methods and compositions for identifying maize plants that have newly conferred tolerance or enhanced tolerance to, or are susceptible to, Gray Leaf Spot (GLS). The methods use molecular genetic markers to identify, select and/or construct tolerant plants or identify and counter-select susceptible plants. Maize plants that display newly conferred tolerance or enhanced tolerance to GLS that are generated by the methods of the invention are also a feature of the invention.07-11-2013
20130177908Probes for Detecting Paraoxonase 1 Gene Polymorphism (Q192R) and Methods of Use Thereof - The present disclosure provides probes for detecting a polymorphism in the PON1 gene.07-11-2013
20130177909METHOD FOR CONTROLLING THE AMOUNT OF GENE PRODUCT, AND AGENT FOR CONTROLLING THE AMOUNT OF GENE PRODUCT - The invention relates to a method of intracellularly controlling amounts of gene products, which can increase an amount of gene product intracellularly, comprising a step of introducing into the cell a substance having a sequence complementary to the base sequence of mRNA corresponding to the gene product, its precursor or another substance which can have equivalent action in the cell.07-11-2013
20130177910DETECTION, IDENTIFICATION AND DIFFERENTIATION OF SERRATIA SPECIES USING THE SPACER REGION - The present invention relates to new nucleic acid sequences derived from the ITS (Internal Transcribed Spacer) region, between the 16S and 23S rRNA genes, to be used for the specific detection and/or identification of 07-11-2013
20130177911NOVEL SINGLE NUCLEOTIDE POLYMORPHISMS AND COMBINATIONS OF NOVEL AND KNOWN POLYMORPHISMS FOR DETERMINING THE ALLELE-SPECIFIC EXPRESSION OF THE IGF2 GENE - Single nucleotide polymorphisms and uses for determining the imprinting status of the Insulin Growth Factor-2 gene in a clinical specimen are described.07-11-2013
20130177912SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS - The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.07-11-2013
20130143214PROSTATE CANCER ASSOCIATED CIRCULATING NUCLEIC ACID BIOMARKERS - The invention provides methods and reagents for diagnosing prostate cancer that are based on the detection of biomarkers in the circulating nucleic acids from a patient to be evaluated.06-06-2013
20130143215Methods of Predicting Methotrexate Efficacy and Toxicity - The present invention provides methods for analyzing genetic and/or metabolite biomarkers to individualize methotrexate (MTX) therapy. For example, the assay methods of the present invention are useful for predicting whether a patient will respond to MTX and/or has a risk of developing toxicity to MTX based upon the genotype of one or more folate pathway genes. The assay methods of the present invention are also useful for optimizing the dose of MTX in a patient already receiving the drug to achieve therapeutic efficacy and/or reduce toxic side-effects based upon the genotype of one or more folate pathway genes. In addition, the assay methods of the present invention are useful for predicting or optimizing the therapeutic response to MTX in a patient based upon the methotrexate polyglutamate and/or folate polyglutamate levels in a sample from the patient.06-06-2013
20130143212Method of Determining the Abundance of a Target Nucleotide Sequence of a Gene of Interest - The disclosure relates to a method of measuring gene abundance, including obtaining at least two types of amplification product, each of which contains a single additional base sequence and corresponds to each of at least two genes, by amplifying, in one reaction solution, nucleic acids encoding the at least two genes, whose abundances in nucleic acids contained in a subject sample may be different, using a first primer set, which includes at least two types of first primer, each of which is capable of introducing the single additional base sequence to a resulting amplification product and corresponds to each of the at least two genes, and a second primer for amplifying a nucleic acid containing the single additional base sequence; and determining the abundances of the at least two genes based on detected signals corresponding to the abundances of the at least two types of amplification product.06-06-2013
20130143216Real Time Cleavage Assay - A cleavage-based real-time PCR assay method is provided. In general terms, the assay method includes subjecting a reaction mixture comprising a) PCR reagents for amplifying a nucleic acid target, and b) flap cleavage reagents for performing a flap cleavage assay on the amplified nucleic acid target to two sets of thermocycling conditions. No additional reagents are added to the reaction between said first and second sets of cycles and, in each cycle of the second set of cycles, cleavage of a flap probe is measured.06-06-2013
20130143218DEVICE FOR AMPLIFYING TARGET NUCLEIC ACID - A device for amplifying a target nucleic acid in a sample containing one or more target nucleic acids may include a substrate assembly comprising a flow channel and an inlet, wherein the inlet is in flow communication with the flow channel and is configured to introduce sample containing one or more target nucleic acids into the flow channel. The device may further include a plurality of moieties disposed at inner surface regions of the flow channel along at least a portion of a length of the flow channel, each of the plurality of moieties being sufficient to respectively hybridize to the one or more target nucleic acids in the sample to facilitate amplification of the one or more target nucleic acids when hybridized. The device is further configured to retain amplified product of the one or more hybridized target nucleic acids at discrete locations proximate the inner surface regions after amplification.06-06-2013
20130171636METHOD OF DNA SEQUENCING BY POLYMERISATION - Described herein is a method for determining a nucleic acid sequence, said method comprising: a) denaturing a double-stranded nucleic acid molecule corresponding to the said nucleic acid sequence; b) hybridizing a single-stranded nucleic acid molecule, the primer, with the said denatured double-stranded nucleic acid molecule; c) applying a tension to the hybridized primer/double-stranded nucleic acid molecule obtained in b); d) incubating the hybridized primer/double-stranded nucleic acid molecule obtained in b) with a polymerase in conditions which will lead to at least one pause in replication; and e) determining a position of the said pause in replication with respect to one end of the double-stranded nucleic acid.07-04-2013
20130171647PREDICTING RESPONSES TO ANDROGEN DEPRIVATION THERAPY - This document provides methods and materials for identifying prostate cancer patients likely to respond to an androgen deprivation therapy. For example, methods and materials for identifying a prostate cancer patient likely to respond to an androgen deprivation therapy based at least in part on the presence of a genetic variation in a TMRT11 nucleic acid are provided. This document also provides methods and materials for identifying prostate cancer patients likely to survive prostate cancer related death for a short or long period of time. For example, methods and materials for identifying a prostate cancer patient likely to survive prostate cancer related death for a short or long period of time based at least in part on the presence of a genetic variation in a UGT1A3 nucleic acid, a UGT1A7 nucleic acid, and/or a UGT1A10 nucleic acid are provided.07-04-2013
20130143217KITS FOR COMPARATIVE TRANSCRIPT ANALYSIS AND MUTANT SEQUENCE ENRICHMENT - A kit to execute a method of simultaneously performing comparative transcript analysis in a multitude of samples. The kit includes a blocking adapter. The blocking adapter includes an inert 3′ end.06-06-2013
20120252021DOPAMINERGIC NEURON PROGENITOR CELL MARKER 187A5 - An object of the present invention is to provide a probe, a primer, a primer set and an antibody for use in the detection or selection of a dopaminergic neuron progenitor cell. The present invention provides a probe, a primer and a primer set for use in the detection or selection of a mesencephalon dopaminergic neuron progenitor cell, and preferably a dopaminergic neuron proliferative progenitor cell, which can hybridize with a nucleotide sequence of a 187A5 gene, or a complementary sequence thereto, and an antibody for use in the detection or selection of a mesencephalon dopaminergic neuron progenitor cell, and preferably a dopaminergic neuron progenitor cell, which is capable of binding to a 187A5 protein.10-04-2012
20130137101Methods of Modifying Eukaryotic Cells - A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.05-30-2013
20130137102Methods and kits for modulating tumor invasiveness and metastatic potential - Methods and kits for evaluating invasive potential and metastatic potential of cancers by assessing Tiam1 expression levels in fibroblasts in the microenvironments surrounding tumors are provided.05-30-2013
20110269131SUBSTRATE FOR MANUFACTURING DISPOSABLE MICROFLUIDIC DEVICES - Embodiments of the present invention relate to a UV-curable polyurethane-methacrylate (PUMA) substrate for manufacturing microfluidic devices. PUMA is optically transparent, biocompatible, and has stable surface properties. Embodiments include two production processes that are compatible with the existing methods of rapid prototyping, and characterizations of the resultant PUMA microfluidic devices are presented. Embodiments of the present invention also relate to strategies to improve the production yield of chips manufactured from PUMA resin, especially for microfluidic systems that contain dense and high-aspect-ratio features. Described is a mold-releasing procedure that minimizes motion in the shear plane of the microstructures. Also presented are simple yet scalable able methods for forming seals between PUMA substrates, which avoids excessive compressive force that may crush delicate structures. Two methods for forming interconnects with PUMA microfluidic devices are detailed. These improvements produce a microfiltration device containing closely spaced and high-aspect-ratio fins, suitable for retaining and concentrating cells or beads from a highly diluted suspension.11-03-2011
20110269129BINARY PROBE SYSTEM FOR SENSITIVE DETECTION OF TARGET ANALYTES - The present disclosure encompasses systems, and their methods of use, for detecting a target analyte, the systems comprising: (a) a first oligonucleotide probe comprising a reporter oligonucleotide-binding arm complementary to the nucleotide sequence of a first region of a reporter oligonucleotide and an analyte-binding arm selectively binding to a first region of a target analyte, a second oligonucleotide probe comprising a reporter oligonucleotide-binding arm having a nucleotide sequence complementary to the nucleotide sequence of a second region of a reporter oligonucleotide, and an analyte-binding arm having a nucleotide sequence characterized as selectively binding to a second region of a target analyte; and a reporter oligonucleotide comprising a region complementary to the reporter oligonucleotide-binding arm of the first oligonucleotide probe, a second region complementary to the reporter oligonucleotide-binding arm of the second oligonucleotide probe, a fluorophore and a quencher disposed on the reporter oligonucleotide and a cleavable site disposed between the fluorescent label and the quencher. The cleavable site of the reporter oligonucleotide when in the presence of a target analyte can be cleaved by an enzyme such as a restriction endonuclease, an RNase H, a Flap-endonuclease-1 (FEN-1), and a DNA glycosylase.11-03-2011
20110269125METHODS AND COMPOSITIONS FOR PREDICTING DEVELOPMENT OF ATOPIC DISEASES - The present invention relates to methods of testing for allergic diseases and methods for screening candidate compounds as therapeutic agents for allergic diseases. In particular the present invention provides genetic markers useful for the prediction of an individual's susceptibility to and/or the molecular diagnosis of atopic diseases such as bronchial asthma and allergic rhinitis.11-03-2011
20110269124Methods, Primers, Probes and Kits Useful for the Detection of BRAF Mutations - The present invention relates to methods, primers and probes useful for detecting the presence of mutant BRAF sequences in a sample, specifically for detecting the presence of the BRAF V600E, V600D, V600K, and V600M mutations.11-03-2011
20130137095METHOD FOR IDENTIFYING TARGET BASE SEQUENCE - A method for identifying a base sequence accompanying competitive hybridization that includes a thermal denaturation subjecting a sample double-stranded nucleic acid and a reference double-stranded nucleic acid containing the same base sequence as a target base sequence to thermal denaturation treatment in a single reaction solution, a temperature lowering carrying out competitive hybridization between the sample double-stranded nucleic acid and the reference double-stranded nucleic acid by lowering the temperature of the reaction solution after the thermal denaturation, a measurement measuring a double-stranded nucleic acid formed by a nucleic acid strand that composed the reference double-stranded nucleic acid and a nucleic acid strand that composed the sample double-stranded nucleic acid, and an identification identifying identity between the reference double-stranded nucleic acid and the sample double-stranded nucleic acid based on measurement results obtained from the measurement, the temperature lowering being carried out in the presence of a cationic comb-type polymer.05-30-2013
20130137098METHOD OF DNA SEQUENCING BY HYBRIDISATION - Described herein is a method for determining a nucleic acid sequence, said method comprising: a) denaturing a double-stranded nucleic acid molecule corresponding to the said nucleic acid sequence by applying a physical force to the said molecule; b) providing a single-stranded nucleic acid molecule; c) renaturing the said double stranded nucleic acid molecule in the presence of the said single-stranded nucleic acid molecule; and d) detecting a blockage of the renaturation of the double-stranded nucleic acid.05-30-2013
20130137094One-Step Cell and Tissue Preservative for Morphologic and Molecular Analysis - The invention relates to a one-step chemical composition that preserves animal tissue, cells, and biomolecules, such as human tissue, human cells, and biomolecules therein. It improves the fidelity and morphologic structure of cells, organelles, and nuclear chromatin, and maintains and enhances the cellular antigenicity for immunohistochemistry and flow cytometry, while preserving proteins, post-translational modifications of proteins, and nucleic acids. In one embodiment, the composition comprises a) a non-aldehyde precipitating fixative at a concentration below 25% (volume/volume), b) a reversible/cleavable protein cross-linker that targets lipid-associated molecules, and c) a c reversible/cleavable protein cross-linker that targets water soluble molecules. In another embodiment, the composition further includes a kinase inhibitor, a phosphatase inhibitor, and a permeation enhancer. In still another embodiment, the compositions further include lactic acid at a concentration sufficient to maintain cellular nuclear volume at a level equivalent to aldehyde fixation of the same type of cell. In a further embodiment, the composition comprises: a) a precipitating fixative, b) a reversible/cleavable cross-linker, c) a permeation enhancer, d) a kinase inhibitor, e) a phosphatase inhibitor, and f) a carboxylic acid. In a still further embodiment, the invention comprises method for preserving a biological sample by contacting the sample with the composition of the invention under conditions effective for the preservation of the sample.05-30-2013
20130095487Interferon-Gamma Response as a Diagnostic Test for Persistent Chlamydial Infections - The present invention provides a non-invasive, sensitive, and convenient diagnostic test for persistent Chlamydial infection and diseases arising from persistent Chlamydial infection. The present invention also provides kits for diagnosis of persistent Chlamydial infection.04-18-2013
20130095486Materials and Methods for Detecting the Aryloxyalkanoate Dioxygenase Gene (AAD-12) in Plants - This application provides materials and methods for the detection of aad-12 gene events in biological samples derived from recombinant plants and a materials and methods for the detection of contaminating events in samples derived from recombinant plants.04-18-2013
20130095485Materials and Methods for Detecting the Aryloxyalkanoate Dioxygenase Gene (AAD-12) Containing Event pDAB4472-1606 in Plants - This application provides materials and methods for the detection of the aad-12 gene and event pDAB4472-1606 in biological samples derived from plants.04-18-2013
20130095484Systems And Methods For Predicting Response To Anti-Androgen Therapy For The Treatment Of Androgenetic Alopecia - Methods, processes, systems, and apparatuses are disclosed for predicting anti-androgen therapy response in the treatment of androgenetic alopecia based on a fluorometric assay and proteomics.04-18-2013
20130095483PREDICTIVE BIOMARKERS FOR BREAST CANCER - The invention relates to compositions and methods for detecting, screening, diagnosing or determining the progression of, regression of and/or survival from a proliferative disease or condition, specifically breast cancer. The invention also provides new assays and kits for the staging or stratifying breast cancer patients or patients suspected of having breast cancer.04-18-2013
20130095481METHODS FOR PREDICTING LIKELIHOOD OF RESPONDING TO TREATMENT - The disclosure provides materials and methods related to using biomarkers for prediction of duration of response to prostate cancer treatment and for treating prostate cancer.04-18-2013
20130095477Non-Invasive Method for the Early Detection of Stomach Cancer - The invention relates to a non-invasive method for the early detection of stomach cancer, based on the identification of a biomarker. The biomarker corresponds to the methylated promoter region of the Reprimo gene.04-18-2013
20130095478HtSNPs FOR DETERMINING A GENOTYPE OF CYTOCHROME P450 1A2, 2A6 AND 2D6, PXR AND UDP-GLUCURONOSYLTRANSFERASE 1A GENE AND MULTIPLEX GENOTYPING METHODS USING THEREOF - The present invention relates to htSNPs for determining a genotype of cytochrome P450 1A2 (CYP1A2), 2A6 (CYP2A6) and 2D6 (CYP2D6), PXR and UDP-glucuronosyltransferase 1a (UGT1A) genes and a gene chip using the same, and more particularly, to a selection method of htSNPs for determining a haplotype of human CYP1A2, CYP2A6, CYP2D6, PXR and UGT1A genes, a method of determining a genotype of the genes by using the htSNPs and a gene chip therefor.04-18-2013
20130095475GENES FROM THE 20Q13 AMPLICON AND THEIR USES - The present invention relates to cDNA sequences from a region of amplification on chromosome 20 associated with disease. The sequences can be used in hybridization methods for the identification of chromosomal abnormalities associated with various diseases. The sequences can also be used for treatment of diseases.04-18-2013
20130095474DESIGN OF STEM-LOOP PROBES AND UTILIZATION IN SNP GENOTYPING - Stem-loop probe for single nucleotide polymorphism (SNP) genotyping of individual SNP nucleic acid target sequences has first, second, and third single stranded nucleic acid portions. Second portion is between the first and third portions. First and third portions build a double stranded, intramolecular stem. Second portion forms a single stranded oligonucleotide loop with a nucleotide sequence, complementary to individual SNP nucleic acid target sequences. The nucleotide sequence of probe is matches probe/target hybrids have a melting point T04-18-2013
20130115594HIGH SPECIFICITY AND HIGH SENSITIVITY DETECTION BASED ON STERIC HINDRANCE & ENZYME-RELATED SIGNAL AMPLIFICATION - The present invention relates to a molecular probe capable of high sensitivity and high specificity detection of a target nucleic acid in a sample. Also disclosed is a detection method using this probe.05-09-2013
20130115602ENDOGENETIC RETROVIRAL SEQUENCES, ASSOCIATED WITH AUTOIMMUNE DISEASES OR WITH PREGNANCY DISORDERS - A genomic retroviral nucleic material, in an isolated or purified state, at least partially functional or non-functional, wherein the genome comprises a reference nucleotide sequence selected from the group including sequences of SEQ ID NOs: 1-15, their complementary sequences, and their equivalent sequences, in particular, nucleotide sequences having, for every series of 100 contiguous monomers, at least 70% and preferably at least 90% homology with the sequences of SEQ ID NOs: 1-15.05-09-2013
20130115601TISSUE TYPING ASSAYS AND KITS - The present invention relates generally to compositions of lyophilised reagents suitable for nucleic acid amplification use in in-vitro diagnostics. More particularly, the invention relates to lyophilised PCR reagent compositions and methods for genotyping including HLA and/or ABO and/or HFE typing.05-09-2013
20130115600SEQUENCES AND THEIR USE FOR DETECTION OF SALMONELLA - This invention relates to a rapid method for detection of 05-09-2013
20130115599INCREASED CIP2A EXPRESSION AND BLADDER CANCER IN HUMANS - The present invention provides a method of detecting CIP2A protein in a bladder tissue. Methods and compositions are provided herein for detecting and diagnosing bladder cancer by obtaining a bladder tissue from a human subject suspected of bladder cancer, followed by detecting CIP2A protein or mRNA levels in the bladder tissue using Western blot analysis or ELISA to specifically detect CIP2A protein or qRT-PCR to specifically detect CIP2A mRNA. The present method permits specific detection of CIP2A protein or mRNA in bladder tissue as a biomarker for bladder cancer in humans.05-09-2013
20130115596DNA POLYMORPHISMS AS MOLECULAR MARKERS IN CATTLE - A method of predicting the phenotype of cattle through the analysis of one or more single nucleotide polymorphisms (SNPs) is described. More particularly, a method for predicting cattle temperament and behavior through the analysis of one or more single nucleotide polymorphisms (SNPs) mapped at specific regions of the bovine genome is described.05-09-2013
20130102002METHOD TO DETERMINE ZYGOSITY OF THE FAD3 GENE IN CANOLA USING END-POINT TAQMAN.RTM. PCR - The subject disclosure relates in part to endpoint TaqMan® PCR assays for the detection and high throughput zygosity analysis of the fad-3c gene in canola. The subject disclosure further relates, in part, to the use of wild type DNA as a reference for use in determining zygosity. These and other related procedures can be used to uniquely identify the zygosity and variety of canola lines comprising the subject gene. The subject disclosure also provides related kits for determining zygosity from a sample of a canola plant or seed, for example.04-25-2013
20130102001METHOD TO DETERMINE ZYGOSITY OF THE FAD2 GENE IN CANOLA USING END-POINT TAQMAN PCR - The subject disclosure relates in part to endpoint TaqMan® PCR assays for the detection and high throughput zygosity analysis of the fad-2 gene in canola. The subject disclosure further relates, in part, to the use of wild type DNA as a reference for use in determining zygosity. These and other related procedures can be used to uniquely identify the zygosity and variety of canola lines comprising the subject gene. The subject disclosure also provides related kits for determining zygosity from a sample of a canola plant or seed, for example.04-25-2013
20130102000PEPTIDE NUCLEIC ACID PROBE, KIT AND METHOD FOR DETECTION AND/OR QUANTIFICATION OF SALMONELLA SPP. AND APPLICATIONS THEREOF - The present invention refers to the development of a Peptide Nucleic acid (PNA) probe for the detection of the 04-25-2013
20130101999MULTI-LEG LUMINESCENT NANOPARTICLES, MULTI-LEG LUMINESCENT NANOPARTICLE COMPOUNDS AND VARIOUS APPLICATIONS - Multi-leg luminescent nanoparticles (“MLN's”) that can be paired to other MLN's as well s biological molecules to film branched multi-leg luminescent nanoparticles (“BMLN's) that can be used in biological multiplexing applications, imaging applications, biological detection applications and other biological applications.04-25-2013
20130102004Endometrial Phase or Endometrial Cancer Biomarkers - Methods for detecting endometrial diseases or an endometrium phase in a subject are described comprising measuring endometrial markers or polynucleotides encoding the markers in a sample from the subject. The invention also provides localization or imaging methods for endometrial diseases, and kits for carrying out the methods of the invention. The invention also contemplates therapeutic applications for endometrial diseases employing endometrial markers, polynucleotides encoding the markers, and/or binding agents for the markers.04-25-2013
20130101997GENETIC MARKER FOR THE DIAGNOSIS OF DEMENTIA WITH LEWY BODIES - Specific alterations in BChE gene have been found which allow determining whether a patient suffers from dementia with Lewy bodies (DLB), and allow distinguishing it from Alzheimer's disease. The invention provides an in vitro method for the diagnosis of DLB comprising determining in a biological sample from a subject, the genotype of the following alterations in butyrylcholinesterase (BChE) gene: the polymorphic sites at position 68974 in NCBI Accession Number NG_009031 (i.e. position 934 in SEQ ID NO: 28), and the polymorphic sites 3687, 4206, 4443, and the poly-thymine region at positions 4780 to 4786, said positions with reference to NCBI Accession Number NG_009031 (i.e. positions 3687, 4206 and 4443 respectively in SEQ ID NO: 1), which corresponds to the nucleotide sequence of human BChE gene.04-25-2013
20130101998METHOD FOR DIAGNOSING KIDNEY DISEASE COMPRISING DETECTING THE LEVEL OF ANNEXIN A2 OR S100A6 - The present invention provides biomarkers for detecting kidney disease, selected from the oligonucleotide sequence, complementary sequence or derivatives, amino acid sequence or derivatives, fragment, variants, antibody of annexin A2 or S100A6 or combinations thereof. Moreover, the present invention also provides an assay kit and a method for kidney disease detecting, practically for the kidney disease resulting from acute tubular necrosis.04-25-2013
20130102003Point-of-Care Immunoassay for Quantitative Small Analyte Detection - Point-of-care assays for quantitatively measuring the amount of small analytes, such as opioids, tetrahydrocannibinol (“THC”), or hormones, in a biological sample are disclosed. The assays are capable of non-competitive detection of a small analyte using binding agents that selectively bind the analyte and capture agents that selectively bind a complex of the binding agent and analyte but do not bind either free binding agent or free analyte. The assay is capable of simultaneous diction of multiple analytes for multiplex analysis and quantitative control. Quantitative measurements are obtained by plotting results against a response surface calculated from a plurality of analyte standards and adjusted using internal controls.04-25-2013
20130115598OLIGONUCLEOTIDE PROBE RETRIEVAL ASSAY FOR DNA TRANSACTIONS IN MAMMALIAN CELLS - Methods to measure a variety of DNA synthetic processes in live human cells by introducing and retrieving exogenous DNA probes are provided herein. Using fragments of bacterial plasmid or phage DNA, a wide array of DNA constructs may be assembled to mimic the intermediates of DNA transactions, including replication, translation synthesis, and end-joining. These DNA probes may be transfected into human cells and retrieved for mutational analysis using a modified Random Mutation Capture assay or NextGen DNA sequencing. These assays require only a small number of cells, such as might be available from biopsy material. Thus, the methods described herein may be applied to the early detection of cancer, predicting the responsiveness of individual cancers to chemotherapy, and measuring the DNA repair capacity of individuals to environmental DNA damaging agents. This approach may be automated and used for screening human populations for variations in DNA synthetic and repair activities.05-09-2013
20130115597METHOD FOR DETECTING SPECIFIC NUCLEIC ACID SEQUENCES - The present invention relates to a method and test kit for detecting specific nucleic acid sequences, comprising the steps of: 1. matrix-dependent new synthesis of the target nucleic acid; 2. target-specific probe hybridization; and 3. detection of the hybridization event. The invention is characterized in that, in the first step, an oligonucleotide 1, which is marked by a marker 1 and is entirely or partially complementary to the target sequence, acts as a primer in the matrix-dependent new synthesis of the target nucleic acid and, in the second step, an oligonucleotide 2, which is marked by a marker 2 and, owing to its melting temperature being lower than that of the oligonucleotide 1, is not involved in the first step, partially or completely hybridizes with the DNA new synthesis product of oligonucleotide 1.The detection of the hybridization reaction can take place both fluorometrically in the form of a homogeneous assay and, for verification of the result, subsequently immunologically. The detection reaction always takes place in time after the matrix-dependent new synthesis has been carried out.05-09-2013
20130115595METHOD TO DETECT REPEAT SEQUENCE MOTIFS IN NUCLEIC ACID - Methods for determining the presence or absence of expansion of CGG repeat sequence in the FMR1 gene presence or absence of expansion of CCG repeat sequence in the FMR2 gene are provided. The methods are useful in identifying an individual with normal/intermediate, versus premutation or full mutation allele of FMR1 gene and FMR2 gene due to the expansion of CGG repeats and CCG repeats in the 5′-untranslated region respectively. The methods are also useful for screening newborns for fragile X syndrome or for screening women to determine heterozygosity status with full premutation of the CCG repeat tract. The methods are also useful in estimating the premutation and full mutation carrier frequency and estimating the prevalence of FXTAS AND FXPOI in a population. The methods are simple, rapid and require small amount of sample.05-09-2013
20130122493DETECTION OF NEIGHBORING VARIANTS - The present invention relates to methods, kits, probes, and systems for distinguishing between nucleotide variants that are close in proximity on a gene. The methods, kits, probes, and systems can include the use of a small amplicon assay in combination with two unlabeled probes in a high resolution thermal melting analysis of a biological sample containing a locus of interest in order to discern between disease-causing and benign variants that are close in proximity on a gene within the biological sample. The present invention also relates to method of detecting a disease in a patient based on the patient's genotype by determining whether the patient has a disease-causing variant at a locus of interest. The signature melt curves produced by the unlabeled probe tests can be analyzed using HRMA software to distinguish between disease-causing and benign variants that are close in proximity on a gene within the biological sample.05-16-2013
20130130241ANDROGEN RECEPTOR ISOFORMS AND METHODS - The invention relates to exploiting differences in androgen receptor gene amplification and expression of androgen receptor isoforms in various cell types such as, for example, prostate tumor cells. In one aspect, the invention provides a method for detecting unbalanced amplification of androgen receptor isoforms. Generally, the method includes receiving a biological sample obtained from a subject, the biological sample comprising cells expressing a plurality of non-wild-type androgen receptors, measuring the copy number of at least a polynucleotide encoding a first non-wild-type androgen receptor and a polynucleotide encoding a second non-wild-type androgen receptor, thereby producing an expression ratio, and identifying the sample as exhibiting unbalanced amplification of androgen receptor if the expression ratio is no less than a predetermined expression ratio. In another aspect, the invention provides a method of analyzing a biological sample from a subject. Generally, the method includes receiving the biological sample, the biological sample comprising cells expressing a plurality of androgen receptor isoforms, measuring expression of at least one androgen receptor isoform, and identifying the sample as exhibiting a predetermined pattern of androgen receptor isoform expression if at least one predetermined pattern of androgen receptor expression is detected.05-23-2013
20130130255OPTICAL MAPPING OF GENOMIC DNA - A method for single-molecule optical DNA profiling using an exceptionally dense, yet sequence-specific coverage of DNA with a fluorescent probe, using a DNA methyltransferase enzyme to direct the DNA labeling, followed by molecular combing of the DNA onto a polymer-coated surface and subsequent sub-diffraction limit localization of the fluorophores. The result is a ‘DNA fluorocode’; a simple description of the DNA sequence, with a maximum achievable resolution of less than 20 bases, which can be read and analyzed like a barcode. The method generates a fluorocode for genomic DNA from the lambda bacteriophage using a DNA methyltransferase to direct fluorescent labels to four-base sequences reading 5′-GCGC-3′. A consensus fluorocode is constructed that allows the study of the DNA sequence at the level of an individual labeling site and is generated from a handful of molecules and entirely independently of any reference sequence.05-23-2013
20130130251IDENTIFICATION OF SNARE YKT6 SEQUENCES - Provided are isolated genomic polynucleotide fragments that encode human SNARE YKT6, human glucokinase, human adipocyte enhancer binding protein (AEBP1) and DNA directed 50 kD regulatory subunit (POLD2), vectors and hosts containing these fragments and fragments hybridizing to noncoding regions as well as antisense oligonucleotides to these fragments. The invention is further directed to methods of using these fragments to obtain SNARE YKT6, human glucokinase, AEBP1 protein and POLD2 and to diagnose, treat, prevent and/or ameliorate a pathological disorder.05-23-2013
20130130260Methods to Fix and Detect Nucleic Acids - In one aspect, the invention relates to a method for fixing a short nucleic acid in a biological sample. In another aspect, the invention relates to a method for detecting a target short nucleic acid in a biological sample. The method includes contacting the biological sample with an aldehyde-containing fixative, and subsequently contacting the sample with a water-soluble carbodiimide. In a further aspect, the invention relates to a kit for fixing a short nucleic acid in a biological sample. The kit includes a support substrate for holding the sample; an aldehyde-containing fixative; and a water-soluble carbodiimide.05-23-2013
20130130249NUCLEIC ACID PRODUCTION AND SEQUENCE ANALYSIS - A method for producing a nucleic acid molecule from a template nucleic acid sequence and a linking unit attached to a primer, which method comprises a step of contacting the template nucleic acid sequence with a nucleic acid polymerase under conditions which allow the nucleic acid polymerase to produce the nucleic acid molecule from the primer based on the template nucleic acid sequence, wherein the linking unit is attached to a target site in the template nucleic acid sequence with a covalent linkage.05-23-2013
20130130247Kits and Methods for Assessing Skin Health - The invention relates to kits and methods for assessing skin health for a human and the human's susceptibility to skin disorders. The methods involve assessing occurrence in the human's genome of one or more polymorphisms (e.g., single nucleotide polymorphisms) that occur in one or more genes associated disclosed herein and that are associated with a disorder in humans. Preferred assessment and scoring methods are disclosed, as are kits for performing the methods.05-23-2013
20130130248ENDORIBONUCLEASE COMPOSITIONS AND METHODS OF USE THEREOF - The present disclosure provides variant Csy4 endoribonucleases, nucleic acids encoding the variant Csy4 endoribonucleases, and host cells genetically modified with the nucleic acids. The variant Csy4 endoribonucleases find use in a variety of applications, which are also provided. The present disclosure also provides methods of detecting a specific sequence in a target polyribonucleotide; and methods of regulating production of a target RNA in a eukaryotic cell.05-23-2013
20130130244P53 ASSAY FOR A URINE TEST FOR HCC SCREENING - A rapid and sensitive assay to detect p53 mutations in urine has been developed for use in screening cancer patients. The method uses a locked nucleic acid (LNA) clamp mediated one-step PCR-based assay with a sensitivity of up to a single copy and can be used not only in urine, but also other biological samples. The assay is particularly useful for hepatocellular carcinoma, colon cancer, breast cancer, lung cancer, prostate cancer, ovarian cancer, bladder cancer, lymphoma, and stomach cancer.05-23-2013
20130130245METHOD OF PLANT GENOME DESIGN, METHOD OF CREATING NEW CULTIVAR AND NEW CULTIVAR - Plant genome design method defines DNA markers M1 to M5, for each target region, DNA marker M2 is at an upstream side of a target region, or upstream thereof, DNA marker M1 is upstream of DNA marker M2, DNA marker M4 is at a downstream side of the target region, or downstream thereof, DNA marker M5 is downstream of DNA marker M4, and DNA marker M3 is in the target region; and designs a genome so that a substitution region, containing the target region, in a chromosome of the original cultivar to be substituted with a chromosome fragment derived from the foreign cultivar has an end on an upstream side between DNA marker M1 and DNA marker M2, and an end on a downstream side of the substitution region between DNA marker M4 and DNA marker M5.05-23-2013
20130130243METHOD AND DEVICE FOR DETECTING AND QUANTIFYING AN ANALYTE WITH RECYCLING OF THE REAGENTS - The present invention relates to a method for detecting and quantifying an analyte present in a liquid of interest using a solid support, the surface of which comprises at least one active area on which at least one probe capable of binding said analyte is immobilized and a solution containing at least one secondary reagent capable of binding to the analyte, said method comprising a step consisting of recycling said solution in order to put it back into contact with the surface and notably with the active area at least one additional time. The present invention also relates to a device which may be applied within the scope of such a method.05-23-2013
20130130240METHODS FOR IDENTIFYING DRUG RESISTANT MYCOBACTERIUM - Presented herein are methods for determining the presence of a non-mutated 05-23-2013
20130130254OPTICAL RESONATOR DIAGNOSTIC DEVICE AND METHODS OF USE - An implantable diagnostic device in accordance with the present disclosure provides various benefits such as a compact size thereby allowing implanting of the device inside animate objects; low cost due to incorporation of inexpensive detection circuitry and the use of conventional IC fabrication techniques; re-usability by heating thereby allowing multiple diagnostic tests to be performed without discarding the device; and a configuration that allows performing of simultaneous and/or sequential diagnostic tests for detecting one or more similar or dissimilar target molecules concurrently or at different times.05-23-2013
20130130250ISOLATED GLUCOKINASE GENOMIC POLYNUCLEOTIDE FRAGMENTS FROM CHROMOSOME 7 - Provided are isolated genomic polynucleotide fragments that encode human SNARE YKT6, human glucokinase, human adipocyte enhancer binding protein (AEBP1) and DNA directed 50 kD regulatory subunit (POLD2), vectors and hosts containing these fragments and fragments hybridizing to noncoding regions as well as antisense oligonucleotides to these fragments. The invention is further directed to methods of using these fragments to obtain SNARE YKT6, human glucokinase, AEBP1 protein and POLD2 and to diagnose, treat, prevent and/or ameliorate a pathological disorder.05-23-2013
20130130252IDENTIFICATION OF POLD2 SEQUENCES - Provided are isolated genomic polynucleotide fragments that encode human SNARE YKT6, human glucokinase, human adipocyte enhancer binding protein (AEBP1) and DNA directed 50kD regulatory subunit (POLD2), vectors and hosts containing these fragments and fragments hybridizing to noncoding regions as well as antisense oligonucleotides to these fragments. The invention is further directed to methods of using these fragments to obtain SNARE YKT6, human glucokinase, AEBP1 protein and POLD2 and to diagnose, treat, prevent and/or ameliorate a pathological disorder.05-23-2013
20130130261CHEMICAL SENSOR - A sensor comprising a memory device having a first electrode and a first chemical-sensing layer coupled to the first electrode. The chemical-sensing layer, in the presence of an analyte, is arranged to change a property of the Memristive device. The sensor can detect an analyte by providing a sample to be detected proximate the chemical sensing layer, observing the state of the memory element; and determining a property of the sample by comparing the observed state of the memory element with a previous state. The sensor is manufactured by depositing a second electrode on a surface, depositing an active layer or layers onto said second electrode, depositing a first electrode onto said active layer(s), and coupling a chemically sensitive layer to the first electrode.05-23-2013
20130130257MOBILE RAPID TEST SYSTEM FOR NUCLEIC ACID ANALYSIS - A mobile rapid test system for nucleic acid analysis. A method comprising the steps of amplification of the nucleic acids by means of rapid-PCR technology, conversion of a double-stranded amplification product into a single-stranded DNA fragment, hybridization with a labeled probe and detection of the nucleic acids on a lateral-flow test strip. A device comprising a reaction cavity which preferably consists of a thin film, inlet and outlet openings for the reaction cavity, one or more heatable sample blocks which are connected to miniaturized cooling bodies and a window for reading off the result. The lateral-flow test strip is a component of the mobile rapid test system. Operation of the instrument system requires no external power source, but only batteries or a rechargeable battery.05-23-2013
20130130259Methods for evaluating the methylation status of a polynucleotide - The invention provides methods related to evaluating the methylation status of a polynucleotide that includes an internal control.05-23-2013
20130130256ACF DETECTION METHOD - The present invention provides a method for detecting ACF by analyzing a test region of large intestine tissue at the molecular level. Namely, the present invention relates to a method for detecting aberrant crypt foci (ACF) that comprises detecting one or more types of molecules for which ACF-specific expression increases selected from the group consisting of GSTp, iNOS, CD44, EGFR, COX2 and Fzd1 present in a test region of large intestine tissue; the aforementioned ACF detection method wherein the diameter of the test region is 0.5 mm or less; a an ACF detection marker that is GSTp, iNOS, CD44, EGFR, COX2 or Fzd1; and, a method for evaluating risk of colorectal cancer and colorectal adenoma in subjects based on the results of detecting ACF in a test region of large intestine tissue of the subjects using the aforementioned ACF detection method.05-23-2013
20130130246METHODS FOR THE DETECTION, VISUALIZATION AND HIGH RESOLUTION PHYSICAL MAPPING OF GENOMIC REARRANGEMENTS IN BREAST AND OVARIAN CANCER GENES AND LOCI BRCA1 AND BRCA2 USING GENOMIC MORSE CODE IN CONJUNCTION WITH MOLECULAR COMBING - Methods for detecting genomic rearrangements in BRCA1 and BRCA2 genes at high resolution using Molecular Combing and for determining a predisposition to a disease or disorder associated with these rearrangements including predisposition to ovarian cancer or breast cancer. Primers useful for producing probes for this method and kits for practicing the methods.05-23-2013
20130130253METRONIDAZOLE RESISTANCE IN TRICHOMONAS VAGINALIS AND SINGLE NUCLEOTIDE POLYMORPHISMS - The present invention is directed to the discovery of single nucleotide polymorphisms (SNPs) in the presence of metronidazole-resistant 05-23-2013
20130130242METHOD FOR DETERMINING PRESENCE OR ABSENCE OF CANCER CELL IN BIOLOGICAL SAMPLE, AND MOLECULAR MARKER AND KIT FOR DETERMINATION - The present invention relates to a method for determining presence or absence of a cancer cell in a biological sample based on the analysis result obtained by analyzing methylation status of DNA extracted from the biological sample with a novel molecular marker allowing a determination of presence or absence of the cancer cell.05-23-2013
20130143208Oligonucleotide Trapping - Novel methods and compositions for identifying one or more factors associated with a nucleic acid sequence (e.g., DNA and/or RNA) of interest are provided.06-06-2013
20130143209PROCESSING OF ANALYTE SUPPORTS WITH OSCILLATING FLUID BY INTERRUPTED ROTATION - Analyte supports such as Western blots, gels, and the like is processed for purposes of detection and analysis, by placing the blot or gel on a plate and causing process fluids to oscillate across the blot or gel by intermittently rotating the plate. The plate can be inclined or flat, divided into sectors to accommodate multiple sheets, and multiple plates can be mounted to a single rotating shaft to process a large number of blots or gels simultaneously under the same protocol.06-06-2013
20130143210METHOD FOR THE PROGNOSIS OF OVARIAN CARCINOMA - The invention relates to a method for determining prognosis of subjects with ovarian carcinoma using a biological sample comprising genomic tumor DNA isolated from the subject. According to the invention, the method comprises the steps of: determining the methylation status of a CpG dinucleotide in a target sequence that is selected from the group consisting of the target sequences as referred to by name in Table 1 in a biological sample isolated from a subject; and deducing from the determined methylation status of the target sequence the prognosis of subject with ovarian carcinoma. The improved prognosis determination of the subject with ovarian carcinoma enables the improved treatment of the said patient.06-06-2013
20130143211PROCESSES AND COMPOSITIONS FOR METHYLATION-BASED ENRICHMENT OF FETAL NUCLEIC ACID FROM A MATERNAL SAMPLE USEFUL FOR NON-INVASIVE PRENATAL DIAGNOSES - Provided are compositions and processes that utilize genomic regions differentially methylated between a mother and her fetus to separate, isolate or enrich fetal nucleic acid from a maternal sample. The compositions and processes described herein are useful for non-invasive prenatal diagnostics, including the detection of chromosomal aneuploidies.06-06-2013
20130078624Systems and methods for multi-purpose analysis - Systems and methods are provided for sample processing. A device may be provided, capable of receiving the sample, and performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing multiple assays. The device may comprise one or more modules that may be capable of performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing the steps using a small volume of sample.03-28-2013
20130095480Chondroitin Sulfate Sulfotransferases and Proteoglycans as Cancer Biomarkers: Use of Expression and Methalytion Status - A method of determining a prognosis of a cancer in a human comprising: determining expression level of CHST11 in a cancer tissue sample or determining methylation status of CHST11 gene in a cancer tissue sample. CHST11 is Carbohydrate (Chondroitin 4) Sulfotransferase 11.04-18-2013
20110217709DETECTION OF CHROMSOMAL REGION COPY NUMBER CHANGES TO DIAGNOSE MELANOMA - This invention provides methods of detecting melanoma. The methods comprises detecting a gain or loss of certain chromosomal regions that undergo copy number changes in melanoma.09-08-2011
20130157270Marker of Diagnosis and Prognosis in Multiple Sclerosis - The present invention provides a method for determining whether an individual with relapsing-remitting multiple sclerosis will suffer a relapse. In the method, measuring the level of Response Gene to Complement (RGC)-32 is measured in the individual, where a significantly lower level of RGC-32 therein indicates that the individual will have or is having a relapse of multiple sclerosis.06-20-2013
20110212448GAMMACARBOXYGLUTAMATE-RICH PROTEIN, METHODS AND ASSAYS FOR ITS DETECTION, PURIFICATION AND QUANTIFICATION AND USES THEREOF - The presently disclosed subject matter refers to a gammacarboxyglutamate-rich protein that shows in vivo a high capacity to bind calcium through specific gamma carboxylated glutamic acid residues (Gla). It includes a description of the referred protein, purification procedures, protein detection and quantification tools and methods. A kit for the detection and quantification of said protein in samples is contemplated. This kit can include the use of one or more antibodies produced against the homologous sequence of the target species to be analyzed, and thus, methods for the production of such antibodies are disclosed as well. In another aspect, the methods and tools described hereby can be used as biomarkers for evaluation of presence or risk to develop certain diseases. In another aspect of the disclosed subject matter, available complete GRP cDNA and gene sequences obtained from several species also enable the in vitro production of antigens, the quantification of GRP expression, the screening of GRP polymorphisms to access the predisposition for certain diseases and the screening for GRP mutations.09-01-2011
20110212447Method of Using FOXO3A Polymorphisms and Haplotypes to Predict and Promote Healthy Aging and Longevity - The invention provides methods and compositions relating to identification and use of genetic information from the FOXO3A gene that can be used for determining and increasing an individual's likelihood of longevity and of retaining physical and cognitive function during aging, and for determining and decreasing an individual's likelihood of developing a cardiovascular-, metabolic- or age-related disease, including coronary artery (heart) disease, stroke, cancer, chronic pulmonary disease, diabetes, Parkinson's disease and dementia.09-01-2011
20110212441Methods and Systems for Inferring Bovine Traits - Methods, compositions, and systems are provided for managing bovine subjects in order to maximize their individual potential performance and edible meat value, and to maximize profits obtained in marketing the bovine subjects. The methods and systems draw an inference of a trait of a bovine subject by determining the nucleotide occurrence of at least one bovine SNP that is identified herein as being associated with the trait. The inference is used in methods of the present invention to establish the economic value of a bovine subject, to improve profits related to selling beef from a bovine subject; to manage bovine subjects, to sort bovine subjects; to improve the genetics of a bovine population by selecting and breeding of bovine subjects, to clone a bovine subject with a specific trait, to track meat or another commercial product of a bovine subject; and to diagnose a health condition of a bovine subject. Methods are also disclosed for identifying additional SNPs associated with a trait, by using the associated SNPs identified herein.09-01-2011
20110223602Systems and Methods for Multiplex Analysis of PCR in Real Time - The present invention provides methods and systems for real-time measurements of PCR with multiplexing capability. Certain embodiments relate to methods and systems that use fluorescently encoded superparamagnetic microspheres for the immobilization of amplification products during the PCR process, and an imaging chamber of a measurement device that is also capable of controllable thermal cycling for assisting the PCR process.09-15-2011
20110223592Multiple fluorophore detector system - A detector oligonucleotide comprises multiple pairs of a donor fluorophore and a quencher molecule, which donor fluorophores and quencher molecules are separated by a site that is capable of being cleaved when in double-stranded form. The detector oligonucleotide may be made double-stranded in a manner that depends on the presence of a target nucleic acid, allowing the cleavage sites to be cleaved. Separation of the donor fluorophores and the quencher molecules decreases fluorescence quenching and generates a detectable change in a fluorescence parameter of the fluorophores of the detector oligonucleotide. By using multiple donor/quencher pairs, the present detector oligonucleotide advantageously generates a high signal to noise ratio and high efficiency in detection of a target nucleic acid.09-15-2011
20130203056Detection of methicillin-resistant Staphylococcus aureus - The present invention provides improved tests for the detection of methicillin-resistant 08-08-2013
20130203057STEP-WISE DETECTION OF MULTIPLE TARGET SEQUENCES IN ISOTHERMAL NUCLEIC ACID AMPLIFICATION REACTIONS - Compositions and methods useful in nucleic acid assays are provided. The invention permits detection of multiple target sequences and control nucleic acids using isothermal nucleic acid amplification methods and subsequent detection of amplification products at different temperature steps by at least two probes with different annealing temperatures. This method can be used in isothermal nucleic acid amplification reactions to detect multiple targets of interest. In a particular example, cycling hybridization probes with different spectral and hybridization temperatures are used to detect different target sequences. Probes become fluorescent when they are cleaved by a thermostable ribonuclease, which only acts when the probes are hybridized to their respective templates.08-08-2013
20130203060MAMMALIAN GENES; RELATED REAGENTS - Nucleic acids encoding a new family of small cysteine rich soluble proteins, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.08-08-2013
20130203051Methods for prenatal diagnosis of chromosomal abnormalities - Chromosomal abnormalities are responsible for a significant number of birth defects, including mental retardation. The present invention is related to methods for non-invasive and rapid, prenatal diagnosis of chromosomal abnormalities based on analysis of a maternal blood sample. The invention exploits the differences in DNA between the mother and fetus, for instance differences in their methylation states, as a means to enrich for fetal DNA in maternal plasma sample. The methods described herein can be used to detect chromosomal DNA deletions and duplications. In a preferred embodiment, the methods are used to diagnose chromosomal aneuploidy and related disorders, such as Down's and Turner's Syndrome.08-08-2013
20130203052FREE CIRCULATING DNA BIO-MARKERS AND THEIR APPLICATIONS - This invention relates generally to methods for detecting cell damage as a consequence of pathophysiological or traumatic insults such as in a nuclear accident, bioterror attack, tumorigenesis, infections or in individuals with cardiovascular disease.08-08-2013
20130203054ANTIVIRAL TREATMENT SUSCEPTIBILITY GENE AND USES THEREOF - The present invention relates to an in vitro method for determining the likelyhood for a patient affected with a viral infection to respond to a treatment with an antiviral agent and/or an interferon, which method comprises determining alteration in CTGF gene locus or in CTGF expression or in CTGF activity in a biological sample of the patient.08-08-2013
20130203055METHODS AND KITS FOR IN SITU DETECTION OF NUCLEOTIDE SEQUENCES - The present invention relates to in situ hybridization methods comprising a room temperature hybridization step for detecting a target nucleic acid in a biological sample. The invention further relates to kits for performing such methods.08-08-2013
20110229890EGFR MUTATIONS - The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.09-22-2011
20110229887DETECTION OF NUCLEIC ACID AMPLIFICATION PRODUCTS IN THE PRESENCE OF AN INTERNAL CONTROL SEQUENCE ON AN IMMUNOCHROMATOGRAPHIC STRIP - Compositions and methods useful in nucleic acid assays are provided. The invention permits detection of test and control nucleic acids. Test nucleic acids can be immobilized at multiple locations, such that amplification of either a test nucleic acid or a control nucleic acid provides a captured nucleic acid in a control capture zone.09-22-2011
20110229886Methods for detecting aneuploidy using microparticle multiplex detection - The present invention provides a method for the detection and sorting of microparticles in a mixture of microparticles. The method of the present invention allows for the detection and sorting of many distinct microparticle classes. Detection and sorting is on the basis of microparticle size, the fluorescence spectrum of any attached reporter molecule, the fluorescence intensity of the reporter molecule, and the number of particles in each classification bin. These microparticle classes have particular applications in many genetic or biochemical multiplexing studies and especially as binding agents for the detection of aneuploidy in an organism or embryo of the organism. In humans, the detection and sorting of at least 24 classes of microparticles would be sufficient for a single tube method for the simultaneous detection of aneuploidy in all chromosomes, wherein each distinct microparticle class comprises a polynucleotide sequence complementary to, and specific for, a polynucleotide sequence that is unique to a particular human chromosome. Furthermore, using currently available technology, the present method has application for the simultaneous detection of aneuploidy in all chromosomes for an organism that has 216 or fewer pairs of chromosomes. Kits for the simultaneous detection of aneuploidy in one or more human chromosomes are also provided.09-22-2011
20110229883Biochemical Markers for Disease States and Genes for Identification of Biochemical Defects - The present invention relates to a system utilizing biochemical markers and genetic markers to diagnose, predict, and/or monitor intervention of a number of diseases and conditions that have unresolved oxidative stress as an important component. The present invention relates generally to markers and assays for diagnosing, predicting, and monitoring disease, particularly disease-relevant oxidative stress and lipid metabolites and mediators. The oxidative stress, lipid metabolite and lipid mediator biochemical and genetic markers may be further combined with other disease associated or disease relevant markers in methods and assays for diagnosis, monitoring, and assessment of disease, particularly of complex diseases with multi-component factors. The system, methods and assays are applicable to various diseases, including autism, asthma, and Alzheimer's disease.09-22-2011
20130137100GENETICALLY MODIFIED BACTERIUM OF THE SPECIES LISTERIA MONOCYTOGENES - The present invention relates to a genetically modified bacterium of the species 05-30-2013
20130137097HIGH THROUGHPUT SINGLE NUCLEOTIDE POLYMORPHISM ASSAY - A method consisting of a homogeneous assay detection system for a PCR process using FRET for detection and zygosity analysis of the HaAHASL1-A122(At)T single nucleotide polymorphism in sunflower is provided. The method provides specific sunflower-genome primers that can be used to detect the presence or absence of the HaAHASL1-A122(At)T single nucleotide polymorphism. The primer combinations for use in an endpoint PCR assay capable of determining zygosity and for assisting in breeding introgression are described.05-30-2013
20130137096Diagnosis of Hereditary Spastic Paraplegias (HSP) by Identification of a Mutation in the ZFVYE26 Gene or Protein - The Invention relates to an ex vivo method of diagnosing or predicting a hereditary spastic paraplegias (HSP), in a subject, which method comprises detecting a mutation in the ZFYVE26 gene or protein (spastizin), wherein said mutation is indicative of a hereditary spastic paraplegias (HSP).05-30-2013
20110244453SALMONELLA DETECTION ASSAY - There is provided a method and reagents for detecting 10-06-2011
20130149705METHODS AND KITS FOR ROOM TEMPERATURE IN SITU DETECTION OF A TARGET NUCLEIC ACID IN A BIOLOGICAL SAMPLE - The present invention relates to in situ hybridization methods for detecting a target nucleic acid in a biological sample comprising performing one or more method steps (e.g., pretreatment, denaturation, hybridization, washes) at room temperature. The invention further relates to kits for performing such methods.06-13-2013
20130149702PRIMER SET, METHOD AND KIT FOR DETECTING PATHOGEN IN FISH - The invention provides a method for rapidly detecting a pathogen in fish comprising conducting loop-mediated isothermal amplification with a specific primer set and a nucleic acid in a test sample. If at least one amplification is carried out, the test sample comprises the pathogen in fish. The invention also provides a primer set, probe and kit for detecting a pathogen in fish.06-13-2013
20130149703"MARKERS FOR PROSTATE CANCER PROGRESSION" - Purpose. The relationship between inherited genetic variations in 5α-reductase type 1 (SRD5A1) and type 2 (SRD5A2) genes and the risk of biochemical recurrence after radical prostatectomy (RP) in prostate cancer (PCa) remains a fairly unexplored area of research. Patients and Methods. We studied 526 men with organ-confined and locally advanced PCa with a median follow-up time of 7.4 years. We investigated the effects of allelic variants of SRD5A1 and SRD5A2 genes and haplotype-tagging single nucleotide polymorphisms (htSNPs; n=19) on recurrence-free survival after RP using Kaplan-Meier plots, the log-rank test, and Cox proportional hazard models. Results. Upon adjusting for known prognostic clinical and pathological factors, eight htSNPs were shown to be independent predictors of recurrence. The SRD5A1 rs166050 polymorphism was associated with an increased recurrence risk of HR=1.83 (95% CI, 1.04-3.21; P=0.035), while the rs518673 in SRD5A1 was associated with a decreased risk (HR=0.59, 95% CI, 0.41-0.85; P=0.004). The SRD5A2 gene was strongly associated with the risk of relapse with six polymorphisms being positively associated with recurrence including the known SRD5A2 V89L (rs523349) (HR=2.14, 95% CI, 1.23-3.70; P=0.007) and a protective htSNP rs12470143 with a HR of 0.66, (95% CI, 0.46-0.95; P=0.023). By combining SRD5A1 (rs518673T) and SRD5A2 (rs12470143 A), the protective effect was shown to be additive with the maximum protection conferred by 3 or 4 alleles (HR=0.33, 95% CL 0.17-0.63; P=0.001). Conclusion. Germline polymorphisms in 5α-reductase genes are independent prognostic genetic biomarkers that predict PCa biochemical recurrence after radical prostatectomy and may represent useful molecular tools for a genotype-tailored clinical approach.06-13-2013
20130149704MATERIALS AND METHODS FOR DIAGNOSIS OF MALIGNANT MELANOMA AND PROGNOSIS OF METASTASIS OF MALIGNANT MELANOMA - Methods, probes and kits for diagnosing malignant melanoma and prognosing metastasis thereof in a patient.06-13-2013
20130137099TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN MAMMALIAN ORGANISMS - An object of the present invention is to develop a new alternative splicing reporter system and to provide a method for detecting alternative splicing patterns in a mammalian multicellular organism more precisely, a method for identifying efficiently substances and gene regions that affect alternative splicing in a mammalian multicellular organism, and the like by utilizing the alternative splicing reporter system. Specifically, the present invention relates to a method for detecting alternative splicing in a mammalian multicellular organism, and a method for identifying substances and gene regions that affect alternative splicing in a mammalian multicellular organism, which use a DNA construct in which at least two different reporter genes are inserted into a specific gene that undergoes alternative splicing, or a combination of DNA constructs (a combination of at least two different DNA constructs) in which DNA construct a reporter gene is inserted into a specific gene that undergoes alternative splicing.05-30-2013
20110236892METHOD FOR LOWERING THE DEPENDENCY TOWARDS SEQUENCE VARIATION OF A NUCLEIC ACID TARGET IN A DIAGNOSTIC HYBRIDIZATION ASSAY - A primer or/and probe for a target sequence containing at least one variation, defined as either one non-conserved nucleotide, called genotype variation, or one nucleotide variation within one and the same genotype, wherein the primer or/and probe has a nucleic acid sequence that is complementary to said target sequence except for the at least complementary base of the variation(s), which is not present in the primer or/and probe.09-29-2011
20120276539USE OF METASTASIS PROGRESSOR S100A4 TRANSCRIPTS IN BODY FLUIDS OF COLORECTAL AND GASTRIC CANCER PATIENTS - Transcript quantification of the metastasis progressor S100A4 is performed in body fluids. Methods, assays and kits relying on this quantification are disclosed that have diagnostic and/or prognostic applications in colorectal and gastric cancer patients.11-01-2012
20120276537HOMOLOGOUS RECOMBINATION IN THE OOCYTE - The present invention relates to a method of modifying a target sequence in the genome of a mammalian or avian oocyte by homologous recombination with a donor nucleic acid sequence, the method comprising the steps (a) introducing into the oocyte a zinc finger nuclease or a nucleic acid molecule encoding the zinc finger nuclease in expressible form, wherein the zinc finger nuclease specifically binds within the target sequence and introduces a double strand break within the target sequence; and (b) introducing a nucleic acid molecule into the oocyte, wherein the nucleic acid molecule comprises the donor nucleic acid sequence and regions homologous to the target sequence. The present invention further relates to a method of producing a non-human mammal or an avian carrying a modified target sequence in its genome.11-01-2012
20120276536Hair Shape Susceptibility Gene - A genetic polymorphism and a hair shape susceptibility gene that are related to hair shape, and a method for determining the genetic susceptibility to hair shape in individual test subjects are provided. Disclosed is a hair shape susceptibility gene, which overlaps with a haplotype block in in the 11q12.2 to 11q13.2 region (D11S4191 and D11S987) of human chromosome 11 and comprises a portion or the entirety of the base sequence of the haplotype block, wherein the haplotype block is determined by a linkage disequilibrium analysis conducted on a single nucleotide polymorphism (SNP) marker whose allele frequency differs statistically significantly between a group having a curly hair trait and a group having a non-curly hair trait, and consists of a base sequence set forth in any one of SEQ ID NO: 1 to NO: 5.11-01-2012
20120276528GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.11-01-2012
20110256535OPTIMIZED OLIGONUCLEOTIDES AND METHODS OF USING SAME FOR THE DETECTION, ISOLATION, AMPLIFICATION, QUANTIFICATION, MONITORING, SCREENING AND SEQUENCING OF CLOSTRIDIUM DIFFICILE GENES ENCODING TOXIN B, AND/OR TOXIN A AND/OR BINARY TOXIN - Described herein are oligonucleotides useful for detecting, isolating, amplifying, quantitating, monitoring, screening and sequencing the 10-20-2011
20130149706OPTICAL REPORTER COMPOSITIONS - This invention provides compositions that have a light emitting reporter linked to biomolecules, preferably, nucleotide oligomers. The light reporter particles are silylated and functionalized to produce a coated light reporter particle, prior to covalently linking the biomolecules to the light reporter particle. The light reporter particles of the invention can be excited by a light excitation source such as UV or IR light, and when the biomolecule is DNA, the attached DNA molecule(s) are detectable by amplification techniques such as PCR.06-13-2013
20110275078RNA-Containing Microvesicles and Methods Thereof - Contemplated compositions and methods are directed to the use of microvesicles from an optionally recombinant donor cell to impart a desirable effect to a recipient cell. In certain preferred aspects, RNA of the microvesicles is employed to achieve the desirable effect. For example, microvesicles are used in vitro to increase the number of passages of a cell growing in a medium, reduce serum and/or growth factor requirements of a cell growing in a medium, and/or delay differentiation of a cell growing in a medium. Further preferred aspects include use of the microvesicles as therapeutic agents in which RNA, a membrane protein, and/or a cytosolic protein encapsulated in or coupled to the microvesicle provide a therapeutic effect. Additionally, diagnostic methods are contemplated in which RNA of a microvesicle isolated from a mammal is associated with a condition of the mammal.11-10-2011
20110275077Oligonucleotide-Coated Affinity Membranes and Uses Thereof - A method of analyzing tissue sections in a manner that provides information about the presence and expression levels of multiple biomarkers at each location within the tissue section. The method comprises the preparation of membranes having covalently bound oligonucleotides and the use of those membranes for evaluation of various markers in the sample. The membranes may be arranged in stacks, wherein each layer has a different oligonucleotide capture strand. Transfer oligonucleotides complementary to the capture strands are attached through a cleavable bond to antibodies that recognize and bind to specific biomarkers present in the tissue sample. The tissue sample is exposed to the antibody-transfer strand conjugate and then treated with a cleaving reagent. Upon cleavage, the transfer strand migrates through the stack and binds to the capture strand. The level of expression of the biomarker may be determined by measuring expression of a reporter on the transfer strand.11-10-2011
20110275076BULKED MUTANT ANALYSIS (BMA) - The current invention relates to a new strategy for identification, and optional isolation, of a nucleic acid sequence that is expressed in an organism and that is related to a particular phenotype (trait of a character) of said organism. With the method of the current invention it has become possible to, in contrast to known methods in the art, efficiently identify, isolate or clone genes in, for example, organism like (crop) plants for which no or only limited information with respect to the genome is available.11-10-2011
20110275075SOX MODULATORS IN THE TREATMENT OF ALOPECIA - An in vitro method for screening candidate compounds for the preventive or curative treatment of alopecia is described. The method can include determining the capacity of a compound to modulate the expression or the activity of a SOX transcription factor. The use of modulators of the expression or the activity of the transcription factor for the treatment of alopecia is also described. Methods for the in vitro diagnosis or prognosis of the pathology are also described herein.11-10-2011
20110275074METHOD AND APPARATUS FOR CHROMOSOME PROFILING - A method and apparatus for generating an Interphase chromosome profile. The method comprises obtaining a sample containing cells having chromosomes for profiling; obtaining species specific DNA probes, wherein the DNA probes are capable of marking at least one chromosome at substantially equidistant locations on said chromosome; hybridizing the sample with the DNA probes with plurality of fluorescent labels; and using visual analysis for determining the profile of the chromosome.11-10-2011
20110275073Method for detecting tumor-associated DNA in blood or blood fractions - This invention relates to detection of specific extracellular nucleic acid in plasma or serum fractions of human or animal blood associated with neoplastic or proliferative disease. Specifically, the invention relates to detection of nucleic acid derived from mutant oncogenes or other tumor-associated DNA, and to those methods of detecting and monitoring extracellular mutant oncogenes or tumor-associated DNA found in the plasma or serum fraction of blood by using rapid DNA extraction followed by nucleic acid amplification with or without enrichment for mutant DNA. In particular, the invention relates to the detection, identification, or monitoring of the existence, progression or clinical status of benign, premalignant, or malignant neoplasms in humans or other animals that contain a mutation that is associated with the neoplasm through detection of the mutated nucleic acid of the neoplasm in plasma or serum fractions. The invention permits the detection of extracellular, tumor-associated nucleic acid in the serum or plasma of humans or other animals recognized as having a neoplastic or proliferative disease or in individuals without any prior history or diagnosis of neoplastic or proliferative disease. The invention provides the ability to detect extracellular nucleic acid derived from genetic sequences known to be associated with neoplasia, such as oncogenes, as well as genetic sequences previously unrecognized as being associated with neoplastic or proliferative disease. The invention thereby provides methods for early identification of colorectal, pancreatic, lung, breast, bladder, ovarian, lymphoma and all other malignancies carrying tumor-related mutations of DNA and methods for monitoring cancer and other neoplastic disorders in humans and other animals.11-10-2011
20110275072EGFR MUTATIONS - The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.11-10-2011
20110275071Methods and Reagents for Combined PCR Amplification - An oligonucleotide probe is disclosed, the probe including an oligonucleotide, a fluorescer molecule attached to a first end of the oligonucleotide and a quencher molecule attached to the opposite end of the oligonucleotide. The probe is rendered impervious to digestion by the 5′→3′ exonuclease activity of a polymerase and the 5′→3′ extension of by a polymerase. The invention also includes methods for performing combined PCR amplification and hybridization probing, one such method including the steps of contacting a target nucleic acid sequence with PCR reagents and an oligonucleotide probe as described above, and subjecting these reagents to thermal cycling. One preferred refinement of the above method further includes the addition of a strand displacer to facilitate amplification. Additional similar combined PCR hybridization methods are disclosed, such methods not requiring probes having their 5′ ends protected, wherein (i) the polymerase lacks 5′→3′ exonuclease activity, (ii) a 5′→3′ exonuclease inhibitor is included, and (iii) an exonuclease deactivation step is performed.11-10-2011
20110275070HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS - Conjugates between a minor groove binding molecule, such as the trimer of 1,2-dihydro-(3H)-pyrrolo[3,2-11-10-2011
20110275069Method for the detection of gene transcripts in blood and uses thereof - The present invention is directed to detection and measurement of gene transcripts ad their equivalent nucleic acid products in blood. Specifically provided is analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using gene-specific and/or tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.11-10-2011
20110275068METHOD - The present invention relates to a combination method for A) measuring the copy number frequency of one or more nucleic acid sequences in a sample; and B) analysing the sequence of at least part of the nucleic acid sequence(s), wherein method A) comprises the steps of: 11-10-2011
20120258459SYSTEM AND METHOD FOR PARTICLE FILTRATION - Embodiments of the present disclosure feature a filtration system comprising a filtration module for particle filtration and methods of using the device for the isolation of particles (e.g., viable cells). Advantageously, embodiments of the device provide for the high throughput filtration of large volumes of sample while preserving cell viability and. providing high yields.10-11-2012
20130122496STORAGE OF NUCLEIC ACID - Processes are disclosed for storing nucleic acid in a stable form. A solution comprising nucleic acid is applied to an unmodified, silica-based substrate whereby at least a portion of the nucleic acid binds to a surface of the substrate, the bound nucleic acid is washed and dried, and the resulting dried nucleic acid on the substrate is stored at from 5° C. to 60° C. for a period of at least one week.05-16-2013
20130157265COMPOSITION, METHOD AND KIT FOR DETECTING BACTERIA BY MEANS OF SEQUENCING - The present invention describes a method for detecting the presence and type of a microorganism present in a sample by means of stabilization and sequencing techniques and subsequent analysis of microsequences in genes encoding the ribosomal RNA most conserved, and on specific areas of the 16-S region with taxonomic value.06-20-2013
20130157266ABSCRIPTION BASED MOLECULAR DETECTION OF DNA METHYLATION - The present invention provides methods for detecting biomarkers based on Abscription®, abortive transcription technology. Particularly, the present invention provides bisulfate free methods for detecting methylation of CpG islands from small samples containing DNA, including formalin fixed, paraffin embedded samples. The methods are suitable for multiplexing and can be used to analyze multiple CpG islands from a single sample in a short time.06-20-2013
20130157267Marker for Cancer Prognosis and Methods Related Thereto - The present invention is related to the novel discovery that HIF-2α, but not HIF-1 a, selectively regulates adenosine A06-20-2013
20130157268PHOSPHATIDYLINOSITOL PHOSPHATE KINASE TYPE 1 GAMMA SPLICE VARIANTS AS BIOMARKERS AND DRUG TARGETS FOR EPITHELIAL CANCERS - The present invention relates generally to the field of phosphatidylinositol based signaling pathways, and more specifically to the use of novel members of these pathways for disease prognosis and treatment. In some aspects, the present invention relates to the use of novel splice variants of type I phosphatidylinositol phosphate kinase γ, named PIPKIγ 700 and PIPKIγ 707, to determine breast cancer and breast cancer prognosis.06-20-2013
20130157269METHOD OF DETERMINING A RATIO OF RNA SPECIES IN A SAMPLE - A method of amplifying DNA from RNA in a sample by using circular RNA is provided.06-20-2013
20120282613METHODS AND COMPOSITIONS FOR NONINVASIVE PRENATAL DIAGNOSIS OF FETAL ANEUPLOIDIES - The invention provides methods and compositions for noninvasive prenatal diagnosis of fetal aneuploidies. A large panel of differentially methylated regions (DMRs) have been identified. Certain of these DMRs are hypomethylated in adult female blood DNA and hypermethylated in fetal DNA, whereas others are hypermethylated in adult female blood DNA and hypomethylated in fetal DNA. Moreover, DMRs that are hypomethylated in adult female blood DNA and hypermethylated in fetal DNA have been shown to accurately predict a fetal aneuploidy in fetal DNA present in a maternal blood sample during pregnancy. In the methods of the invention, hypermethylated DNA is physically separated from hypomethylated DNA, preferably by methylated DNA immunoprecipitation.11-08-2012
20120282612METHOD FOR ANALYZING PSA, AND A METHOD FOR DISTINGUISHING PROSTATE CANCER FROM PROSTATIC HYPERTROPHY USING THAT METHOD FOR ANALYZING PSA - A method for distinguishing prostate cancer from prostatic hypertrophy using the method for analyzing PSA and an analysis kit of PSA are provided.11-08-2012
20120282611METHODS, KITS AND REACTION MIXTURES FOR ANALYZING SINGLE-STRANDED NUCLEIC ACID SEQUENCES - Provided herein are fluorescence detection methods for nucleic acid sequences and to kits for performing such methods.11-08-2012
20120282610Oligonucleotides for Detection Test of Polymorphism of EGFR Exon 19 and Use Thereof - An oligonucleotide for a detection test of a polymorphism of EGFR exon 19, the oligonucleotide being at least one selected from the group consisting of a P1 oligonucleotide and a P1′ oligonucleotide, the P1 oligonucleotide having a 3′ end subjected to an extension inhibition treatment, which has an identity of at least 80% with respect to a base sequence including at least the 115th to the 123rd bases of the base sequence indicated in SEQ ID NO: 1 and has a length of from 9 to 80 bases; and the P1′ oligonucleotide having a 3′ end subjected to an extension inhibition treatment, which hybridizes under stringent conditions with a complementary strand of a base sequence including at least the 115th to the 123rd bases of the base sequence indicated in SEQ ID NO: 1 and having a length of from 9 to 80 bases.11-08-2012
20120282609Gene Mutation Detection Probe - A gene mutation detection probe for detection of a target gene mutation in a base sequence encoding a gene of interest that includes the target gene mutation and a non-target gene mutation, the probe including at least one oligonucleotide selected from the group consisting of oligonucleotides P1, P1-1, P1′, and P 1′-1. For example, the P1 oligonucleotide is an oligonucleotide that has, at a base position corresponding to the target gene mutation, a base complementary to either a wild-type base or a mutant base of the target gene mutation, and has, at a base position corresponding to the non-target gene mutation, a base complementary to neither a wild-type base nor a mutant base of the non-target gene mutation, and has an identity of at least 80% with a base sequence complementary to a part or an entirety of the base sequence encoding the gene of interest11-08-2012
20120282608Probe, Polymorphism Detection Method, Method of Evaluating Drug Efficacy or Tolerance, and Reagent Kit - A probe for detecting polymorphism in the ABCC2 gene is constituted by including, for example, an oligonucleotide which is complementary to a base sequence including the 207th to the 217th bases of the base sequence indicated in SEQ ID NO:1 and having a length of from 11 bases to 60 bases, and has an identity of at least 80%, and in which a base corresponding to the 217th base has been labeled with a fluorescent dye.11-08-2012
20120282615METHODS OF SCREENING FOR COMPOUNDS FOR USE AS MODULATORS OF LEFT-RIGHT ASYMMETRY IN SCOLIOTIC SUBJECTS AND FOR MONITORING EFFICACY OF AN ORTHOPAEDIC DEVICE - A method of screening for a compound for treating or preventing adolescent idiopathic scoliosis (AIS), said method comprising: (a) contacting a test compound with a paraspinal skin fibroblast or a paraspinal muscle cell sample from the right and/or left side of the spine of a subject; and (b) determining at least one of Nodal, Notch1, Pitx2, Lefty1 and Lefty2's expression and/or activity in the cell sample; wherein the test compound is selected as potentially useful in treating or preventing AIS if at least one of Nodal, Notch1, Pitx2, Lefty1 and Lefty2's expression and/or activity in the cell sample is different in the presence of the test compound as compared to in the absence thereof.11-08-2012
20120282614METHODS AND NUCLEIC ACIDS FOR THE DETECTION OF METASTASIS OF COLON CELL PROLIFERATIVE DISORDERS - The invention provides methods, nucleic acids and kits for detecting metastasis of colon cell proliferative disorders. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of metastasis of colon cell proliferative disorders, thereby enabling the improved diagnosis and treatment of patients.11-08-2012
20120282607Probe, Polymorphism Detection Method, Method of Evaluating Drug Efficacy or Tolerance, Disease Prediction Method and Reagent Kit - A probe for detecting polymorphism in the ABCG2 gene is constituted by including, for example, an oligonucleotide which is complementary to a base sequence including the 301st to the 311th bases of the base sequence indicated in SEQ ID NO:1 and having a length of from 11 bases to 50 bases, and has an identity of at least 80%, and in which a base corresponding to the 311th base has been labeled with a fluorescent dye.11-08-2012
20120282606METHOD, KITS AND REACTION MIXTURES FOR HIGH RESOLUTION MELT GENOTYPING - Various methods are described that provide for high resolution melt (HRM) genotyping. Some embodiments comprise providing a locus specific primer, and two allele specific primers each comprising at least one single nucleotide polymorphism (SNP) allele-hybridizable sequence, wherein at least one of the allele specific primers also comprises at least one nucleotide alteration. In some embodiments, a nucleic acid is provided comprising a SNP base located within 1-20 bases of its 3′ end. Some embodiments comprise hybridizing the locus specific primer and at least one of the allele specific primers to the nucleic acid, amplifying the hybridized nucleic acid using pyrophosphorolysis activated polymerization (PAP) PCR, and determining the melting temperature (Tm) of the resulting amplicons, for example, using HRM. In some embodiments, reaction mixtures and kits for HRM genotyping are provided.11-08-2012
20120282605PROCESS CONTROLS FOR MOLECULAR ASSAY - A full process control for use with a molecular assay and a method of determine the efficacy of the molecular assay. A full process control can include a fixed cell, and specifically can include a fixed vegetative cell. A method of determining the efficacy of a molecular assay can include providing an internal control, mixing the internal control with a sample, lysing the internal control and the sample, and detecting the lysis product. The full process control and/or the internal control can be 11-08-2012
20120282604Copy Number Variation Determination, Methods and Systems - The present invention methods and systems for determining copy number variation of a target polynucleotide in a genome of a subject including amplification based techniques. Methods can include pre-amplification of the sample followed by distribution of sample and a plurality of reaction volumes, quantitative detection of a target polynucleotide and a reference polynucleotide, and analysis so as to determine the relative copy number of the target polynucleotide sequence in the genome of the subject.11-08-2012
20130183673NEW MARKERS FOR THE EPITHELIAL AND PROLIFERATIVE OR MESENCHYMAL INVASIVE PHENOTYPE OF HUMAN NEOPLASIAS - The present invention relates to a new Ena/VASP protein isoform, uses thereof, diagnostic methods and kits comprising the same.07-18-2013
20130183671ALLELIC DISORDERS CAUSED BY MUTATIONS IN TRPV4 - The present invention provides methods, kits, and compositions for detecting mutations in transient receptor potential cation channel, subfamily V, member 4 (TRPV4). In particular, mutations are detected in TRPV4 to detect diseases such as scapuloperoneal spinal muscular atrophy (SPSMA) and hereditary motor and sensory neuropathy type IIC (HMSN IIC) or Charcot-Marie-Tooth disease type 2C (CMT2C).07-18-2013
20130183670METHOD FOR PRODUCING NUCLEIC ACID PROBES - The present disclosure provides nucleic acid probes, as well as kits that include such probes. Methods for producing and using (for example in chromosomal in situ hybridization) the probes are also provided. Such probes in some examples are used to detect chromosomal abnormalities or the presence of a pathogen.07-18-2013
20130183669COMPOSITIONS AND METHODS FOR DIAGNOSING AUTISM - Mutations located within the gene encoding the homeobox transcription factor, ENGRAILED 2 (EN2), have now been identified as molecular markers associated with susceptibility for autism and related disorders. Thus, the present invention relates to compositions in the form of diagnostic kits, primers and target sequences, for use in methods for determining the predisposition, the onset or the presence of autism spectrum disorder in a mammal. Moreover, therapeutic methods for treating a person inflicted with, or predisposed to, an autism spectrum disorder based upon modulating the level or activity of EN2 are also provided.07-18-2013
20130183668METHODS RELATING TO IDENTIFICATION OF SUSCEPTIBILITY TO LIVER INJURY - The present invention relates to methods for identifying susceptibility of impaired hepatic wound healing in a patient, most particularly by identifying modifications of the of PPAR-γ and TGFβ1 genes. It further relates to stratifying populations of patients to determine susceptibility to impaired hepatic wound healing and direct appropriate healthcare resources. More specifically methods can be used to stratify liver disease patient populations to identify those most likely to progress to cirrhosis, or to identify the likelihood that a patient with liver disease will progress to having cirrhosis.07-18-2013
20130183667METHODS FOR CANCER SCREENING IN LATIN AMERICAN/HISPANIC POPULATIONS - Provided herein are novel methods for diagnosing ovarian and breast cancer risk in a Latin American/Hispanic population based on the presence of specific BRCA1 and/or BRCA2 mutations.07-18-2013
20130183666PARTIAL GENOTYPING BY DIFFERENTIAL HYBRIDIZATION - In a method of detecting the number of repeat units in a selected short tandem repeat (STR) in a genomic sample, the genomic sample is amplified by PCR and a single stranded target DNA is selected and separated for use in differential hybridization experiments. Subsequent partial genotyping comprises the steps of admixing to the target DNA at least one fluorescent labeled STR probe oligonucleotide and one different fluorescent labeled reference probe oligonucleotide allowing hybridization to the single stranded target DNA in a hybridization experiment. Measurement of the fluorescence intensities of the probes that are bound to the repeat units of the selected STR and normalizing the fluorescence intensity of the STR probes on the base of the reference probe intensity reveals a relative fluorescence signal representing the result of the differential hybridization experiment. Also disclosed are kits for carrying out partial genotyping by differential hybridization.07-18-2013
20110287415IN-SITU HYBRIDIZATION TO DETECT RNA AND DNA MARKERS - The present invention provides probes, kits and methods for specifically binding mRNA of target cells, e.g., fetal cells, that allows visualization of the target cells, under conditions that allows a second probe to specifically bind the target cell's chromosomal DNA.11-24-2011
20130122503METHOD FOR PRODUCING RNA-CONTAINING PROBE FOR DETECTING A TARGET NUCLEOTIDE - An object of the present invention is to provide a simple and useful method for producing an RNA-containing probe for detecting a target nucleotide, a simple and useful method, device, and system for processing nucleotide sequence information, and a simple and useful method for detecting a target nucleotide. The present invention provides a method for processing nucleotide sequence information, the method comprising the step of generating partial nucleotide sequences which has 7 to 14 nucleotides and a Tm value of 25 to 40° C. and in which a target nucleotide or a nucleotide adjacent to the target nucleotide is located at a position between 3 and 5 nucleotides from the 3′ or 5′ end. The method according to the present invention is useful for simply and efficiently producing an RNA-containing probe for detecting a target nucleic acid, without the basis of researchers' experiences or guess, and are extremely useful not only in the field of genetic engineering, but also in the field of medical research.05-16-2013
20130122494DETECTION OF CANCER - Assays for detecting and grading disease by assessing amounts of GSTP1 nucleic acid and ADAM protein in a sample, and methods of using the assays. In some embodiments, the assays use single molecule sequencing to simultaneously assay both GSTP1 nucleic acid and ADAM protein. The methods are especially useful for detecting and grading cancers, for example, prostate cancer.05-16-2013
20130122498NUCLEIC ACID PROBES AND METHODS FOR DETECTING PLASMODIUM PARASITES - This invention relates to novel nucleic acid-based probes and methods for detecting 05-16-2013
20130122497THERAPEUTIC TARGETS FOR ADRENOCORTICAL CARCINOMA - This invention identifies and provides a recurrent translocation t(4;8) (p16.2; p23.1) associated with Adrenocortical Carcinoma, and diagnostic methods using the translocation by FISH hybridization or PCR based assays.05-16-2013
20130122500ASSAY SYSTEMS FOR GENETIC ANALYSIS - The present invention provides assay systems and methods for detection of copy number variation at one or more loci and polymorphism detection at one or more loci in a mixed sample from an individual.05-16-2013
20130122492DETECTION, ISOLATION AND ANALYSIS OF RARE CELLS IN BIOLOGICAL FLUIDS - The invention provides a method for isolating or enriching a rare cell from a biological fluid of a mammal employing an antibody that binds a cell-surface antigen of the rare cell. The immobilized antibody is incubated with a sample of biological fluid that includes the rare cells and a plurality of other cells so as to form an antibody-rare cell complex. The complex can be detected or isolated and subsequently analyzed by any of a variety of physical, chemical and genetic techniques.05-16-2013
20110294122Synthesis of 2', 3'-Dideoxynucleosides for Automated DNA Synthesis and Pyrophosphorolysis Activated Polymerization - Methods for preparation of 2′,3′-dideoxynucleotides support structures, such as 2′,3′-dideoxyguanosine, 2′,3′-dideoxyadenosine, and 3′-deoxythymidine support structures are disclosed. Various methods of using such structures are also provided, such as their use for automated DNA synthesis and pyrophosphorolysis activated polymerization.12-01-2011
20110311975GENOMIC SELECTION AND SEQUENCING USING ENCODED MICROCARRIERS - The present invention relates to a method for determining the sequence of a nucleic molecule. Herein a capture oligonucleotide probe is attached to an encoded microcarrier, wherein the code of said microcarrier identifies the sequence of said oligonucleotide probe. The capture oligonucleotide probe is hybridized with a sample comprising nucleic acids molecules, wherein said DNA fragment comprises a sequence which is complementary to the sequence of the capture oligonucleotide probe. The sequence of the DNA molecule is determined, wherein the capture oligonucleotide probe serves as a primer for a DNA polymerase, in the case of single molecule sequencing this is a sequencing primer. After the sequence determination, the nucleotide sequence of the capture oligonucleotide probe is identified by determining the code on the microcarrier, which corresponds with the capture oligonucleotide probe. This sequence information directly identifies the location of the sequenced DNA fragment on the genome, allowing direct comparison.12-22-2011
20110311974COMPOSITIONS AND METHODS FOR PERFORMING A STRINGENT WASH STEP IN HYBRIDIZATION APPLICATIONS - The invention provides methods and compositions for performing a stringent wash step in a hybridization assay between at least one molecule and a target. The invention may, for example, eliminate the use of, or reduce the dependence on formamide in the stringent wash step. Compositions for use in the invention include an aqueous composition comprising at least one polar aprotic solvent in an amount effective to denature non-complementary sequences in a hybridization product.12-22-2011
20110311973COMPOSITIONS FOR DETECTING HUMAN INTERFERON-ALPHA SUBTYPES AND METHODS OF USE - The invention provides highly sensitive, specific and efficient quantitative real-time PCR compositions, methods and assay kits to detect at least one IFN subtype and/or IFN subtype allotypic variants. Primer/probe sets complementary to the coding sequence of an IFN subtype of interest avoid spurious detection of degraded mRNA and enhances the correlation between the IFN subtype that is measured by the assays of the invention and the protein that is actually expressed. The invention also provides methods for designing primers and methods of using the compositions and assay kits. The compositions, kits, and methods of the invention may be used, for example, to monitor vaccine efficacy, autoimmune disease, chronic infections, or tumor therapy.12-22-2011
20110311972DPYD GENE VARIANTS AND USE THEREOF - Variants in DPYD gene are disclosed which can result in abnormal synthesis of DPD proteins and alteration of DPD activities. The invention provides methods for detecting the newly discovered genetic variants. The DPD genetic variants of the invention can be used as biomarkers in predicting toxicity to 5-FU and other drugs metabolized by the DPD enzyme.12-22-2011
20110311971RT-LATE-PCR - An assay comprising more than one primer pair and more than one detection probe, a low copy number synthetic amplicon corresponding to each of the primer pairs. The assay can detect and distinguish between various sub-types and strains of an influenza virus using any suitable nucleic acid amplification technique. Related kits and methods are also described.12-22-2011
20110311970COMPOSITIONS AND METHODS FOR INTRACELLULAR ANALYTE ANALYSIS - Compositions and methods for multiplex immunodetection of analytes in single cells or cell populations are described. The invention utilizes analytical nanotags (ANTs) each specific for a different target analyte (TA) species. Analytical nanotags typically comprise biocompatible composite organic-inorganic nanoparticles (bCOINs) that include probe molecules specific for a particular TA species. A plurality of ANTs each specific for a different TA species can be used in a single multiplex assay, including assays for analyzing intracellular analytes in living cells.12-22-2011
20110311969Diagnostic Kit for Aspergillus Fumigatus Species - The use of the Ayg1 gene or an RNA transcript of the Ayg1 gene or fragments thereof as target regions in a diagnostic assay for the eukaryotic organism 12-22-2011
20110311968Allele-Specific Amplification of Nucleic Acids - The present invention includes a method of allele-specific amplification, utilizing an allele-specific oligonucleotide, at least partially complementary to more than one variant of the target sequence, having an internally-placed selective nucleotide complementary to only one variant of the target sequence wherein the allele-specific oligonucleotide is extended by a nucleic acid polymerase predominantly or exclusively when hybridized to the variant of the target sequence for which it has said complementary selective nucleotide.12-22-2011
20110311967Novel Single Nucleotide Polymorphisms and Combinations of Novel and Known Polymorphisms for Determining the Allele-Specific Expression of the IGF2 Gene - Single nucleotide polymorphisms and uses for determining the imprinting status of the Insulin Growth Factor-2 gene in a clinical specimen are described.12-22-2011
20130189688RARE CELL ANALYSIS USING SAMPLE SPLITTING AND DNA TAGS - The present invention provides systems, apparatuses, and methods to detect the presence of fetal cells when mixed with a population of maternal cells in a sample and to test fetal abnormalities, e.g. aneuploidy. The present invention involves labeling regions of genomic DNA in each cell in said mixed sample with different labels wherein each label is specific to each cell and quantifying the labeled regions of genomic DNA from each cell in the mixed sample. More particularly the invention involves quantifying labeled DNA polymorphisms from each cell in the mixed sample.07-25-2013
20130189689RARE CELL ANALYSIS USING SAMPLE SPLITTING AND DNA TAGS - The present invention provides systems, apparatuses, and methods to detect the presence of fetal cells when mixed with a population of maternal cells in a sample and to test fetal abnormalities, e.g. aneuploidy. The present invention involves labeling regions of genomic DNA in each cell in said mixed sample with different labels wherein each label is specific to each cell and quantifying the labeled regions of genomic DNA from each cell in the mixed sample. More particularly the invention involves quantifying labeled DNA polymorphisms from each cell in the mixed sample.07-25-2013
20130189690SCN5A Splice Variants for Use in Methods Relating to Sudden Cardiac Death and Need for Implanted Cardiac Defibrillators - Provided herein are methods of determining a subject's need for an implanted cardiac defibrillator, methods of determining a subject's risk for sudden cardiac death (SCD), arrhythmias, or heart failure, methods of determining a subject's need for an anti-arrhythmic agent, e.g., a sodium channel blocker, and methods of reducing risk of SCD in a subject. In exemplary embodiments, each of the methods comprise the step of determining a ratio, R07-25-2013
20130189691IDENTIFICATION OF ISOLATED GENOMIC NUCLEOTIDE FRAGMENTS FROM THE p15 REGION OF CHROMOSOME 11 ENCODING HUMAN CLUSTER OF DIFFERENTIATION ANTIGEN 81 AND VARIANTS THEREOF - Provided herein are isolated genomic polynucleotide fragments from the p15 arm of chromosome 11 and methods of use.07-25-2013
20130189679PSEUDOGENES AND USES THEREOF - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to pseudogenes as diagnostic markers and clinical targets for prostate cancer.07-25-2013
20130189699IONIC SIGNAL ENHANCEMENT - Provided is a method of identifying an unknown nucleic acid comprising the steps of combining the unknown polynucleic acid with known nucleic acid reagents in a reaction chamber; producing a first quantity of protons from a polymerisation reaction when bases of one or more of the unknown nucleic acids are complementary to the bases of one or more known nucleic acids comprised within the known reagents; producing a second quantity of protons from a hydrolysis reaction of by-products of the polymerisation reaction with one or more enzymes; monitoring an electrical output signal derived from an ISFET exposed to the reaction chamber; and correlating changes in an output signal with said reactions between the unknown polynucleic acid and said known reagents to thereby identify the unknown nucleic acid.07-25-2013
20130189680POLYMER STABILIZATION OF CHROMOGEN SOLUTIONS - Disclosed embodiments concern a composition comprising DAB chromogen, and/or derivative thereof, a stabilizer, and polymer capable of preventing or reducing DAB precipitation relative to a composition that does not comprise the polymer. Also disclosed herein is a method for using the disclosed composition and embodiments of a kit.07-25-2013
20130189681COTTON EVENT pDAB4468.19.10.3 DETECTION METHOD - Cotton event pDAB4468.19.10.3 comprises gene expression cassettes which contain genes encoding aad-12 and pat, affording herbicide tolerance to cotton crops containing the event, and enabling methods for crop protection. Embodiments of the subject invention provide polynucleotide-related event detection methods.07-25-2013
20130189676USE OF GENETIC MODIFICATIONS IN HUMAN GENE CHK1 WHICH CODES FOR CHECKPOINT KINASE 1 - The invention relates to an in vitro method for predicting disease risks, progression of diseases, drug risks, success of treatment and for finding drug targets by looking for one or more genetic modifications in the promoter region of the CHK1 (CHEK1) gene on human chromosome 11q23, the genetic modifications being a substitution thymine for guanine in position −1143 in the promoter of CHK1, of thymine for cytosine in position −1400, a substitution of cytosine for thymine in position −1453 or an insertion of one cytosine in position −1454 and the genetic modifications being detected individually or in any combinations by way of known methods.07-25-2013
20130189678MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) PROMOTER POLYMORPHISM IN INFLAMMATORY DISEASE - Describe herein is a novel CATT-tetranucleotide repeat polymorphism at position −817 of the human Mif that functionally affects the activity of the Macrophage Inhibitory Factor (MIF) promoter in gene reporter assays. Four genotypes are described which comprise 5, 6, 7, or 8-CATT repeat units. Of these, the 5-CATT allele has the lowest level of basal and stimulated MIF promoter activity in vitro. The presence of the low expressing, 5-CATT repeat allele correlated with low disease severity in a cohort of rheumatoid arthritis patients. Methods, compositions and apparatus for detecting this CATT-tetranucleotide repeat polymorphism at position −817 of the human Mif gene, and for using same for assessing predisposition to severe inflammatory disease, are also disclosed.07-25-2013
20130189695IDENTIFICATION OF ISOLATED GENOMIC NUCLEOTIDE FRAGMENTS FROM THE p15 REGION OF CHROMOSOME 11 ENCODING HUMAN RIBOSOMAL PROTEIN L26 (RIBO26) AND VARIANTS THEREOF - Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human ribosomal protein L26 (RIBO26) and methods of use.07-25-2013
20130189675Assay to Capture and Detect Circulating Multiple Myeloma Cells from Blood - The invention includes methods for isolating circulating multiple myeloma cells as well as method of treating patients suspected of having diseases of abnormal plasma cells.07-25-2013
20130189682COTTON EVENT pDAB4468.18.07.1 DETECTION METHOD - Cotton event pDAB4468.18.07.1 comprises gene expression cassettes which contain genes encoding aad-12 and pat, affording herbicide tolerance to cotton crops containing the event, and enabling methods for crop protection. Embodiments of the subject invention provide polynucleotide-related event detection methods.07-25-2013
20130189683IDENTIFICATION OF A JAK2 MUTATION INVOLVED IN VAQUEZ POLYGLOBULIA - The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.07-25-2013
20130189692Single Nucleotide Polymorphisms (SNPs) in Genes Associated With Inflammatory Diseases - The present disclosure describes the identification of single nucleotide polymorphisms (SNPs) in inflammatory diseases and uses thereof, and methods of screening for, diagnosing, identifying susceptibility to or detecting a risk of developing an inflammatory disease comprising detecting the presence or absence of at least one SNP identified in a gene associated with inflammatory disease.07-25-2013
20130189693IDENTIFICATION OF ISOLATED GENOMIC NUCLEOTIDE FRAGMENTS FROM THE p15 REGION OF CHROMOSOME 11 ENCODING HUMAN SMS3 AND VARIANTS THEREOF - Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human SMS3 (SMS3) and methods of use.07-25-2013
20130189696Screening Methods for Transfusion Related Acute Lung Injury (TRALI) - The invention relates to the discovery that HNA-3a and HNA-3b are antigens within a polypeptide sequence that is highly similar to the CTL2 amino acid sequence. This invention provides methods and kits for screening for HNA-3a and HNA-3b specific antibodies, HNA-3a and HNA-3b polypeptides and HNA-3a and HNA-3b nucleic acids in a sample of a biological tissue intended for transplantation07-25-2013
20130189697IDENTIFICATION OF ISOLATED GENOMIC NUCLEOTIDE FRAGMENTS FROM THE p15 REGION OF CHROMOSOME 11 ENCODING HUMAN TUMOR SUPPRESSING SUBTRANSFERABLE CANDIDATE 4 (TSSC4) AND VARIANTS THEREOF - Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human and tumor suppressing subtransferable candidate 4 (TSSC4) and methods of use.07-25-2013
20130189698In Situ Cloning From Pathological Tissue Specimens - The present invention pertains to methods related to cloning nucleic acids from biological samples, particularly pathological tissue samples. This method includes hybridizing a population of oligonucleotide sequence probes comprising degenerate sequence tags to a fixed tissue, isolating the hybridized oligonucleotide sequence probes and amplifying the sequence tags in the hybridized oligonucleotide sequence probes. This method can be utilized to identify genes associated with disease and to quantitate the expression of disease-related transcripts. The method can also be used to identify truncated mRNAs.07-25-2013
20130189677ABC terpenoid transporters and methods of using the same - Provided are ATP-binding cassette transporters (ABC transporters). More specifically, the present disclosure relates to ABC terpenoid transporters, nucleic acid sequences, amino acids, proteins, vectors, cells, transgenic organisms, uses, compositions, methods, processes, and kits thereof.07-25-2013
20130189694IDENTIFICATION OF ISOLATED GENOMIC NUCLEOTIDE FRAGMENTS FROM THE p15 REGION OF CHROMOSOME 11 ENCODING HUMAN TUMOR SUPPRESSING SUBTRANSFERABLE CANDIDATE 6 (TSSC6) AND VARIANTS THEREOF - Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human tumor suppressing subtransferable candidate 6 and methods of use.07-25-2013
20110318736Allele Amplification Bias - Methods are provided for nucleic acid analysis. In an illustrative method, allele amplification bias is used to amplify preferentially a target nucleic acid that is present in a low allele fraction.12-29-2011
20120003638KIT FOR HIGH THROUGHPUT MUTATION SCREENING METHODS - One example embodiment includes a kit to execute a method of simultaneously screening for genetic mutations in different genes in a multitude of samples. The kit includes an antisense deoxyribonucleic acid (DNA) probe, where the antisense DNA probe will be mixed with a strand of a ribonucleic acid (RNA) to be tested to form a heteroduplex molecule within a sample. The kit also includes a ribonuclease enzyme, an RNA-primed DNA polymerase, a single strand-specific nuclease, DNA-dependent DNA polymerase, a blocking adapter and a tagged reporter adapter. Through ribonuclease digestion, differential sequence fill-in (DSF) and full-length sequence extension, tagged mutant-dual adapter hybrids are formed for detection, quantification or amplification. The sequence ubiquity of said mutant-dual adapter hybrids enables the use of universalized primers for sequence amplification regardless of the numbers or the origins of the mutations involved.01-05-2012
20120015359METHODS FOR MOLECULAR DETECTION - This invention relates to methods for molecular detection, particularly to methods utilizing target-specific molecular probes. In exemplary embodiments, target-specific molecular probes include single-stranded deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) aptamers. In general, the molecular probe may bind with relatively high specificity to a given target. In one aspect, a method for molecular detection comprises a molecular probe paired to a reporter molecule wherein the molecular probe impairs the amplification of the reporter molecule in the absence of the target molecule.01-19-2012
20120015358ORTHOGONAL NUCLEIC ACID AFFINITY PAIRS - The invention provides methods to identify pRNA- and pDNA oligomer affinity pairs. Affinity pairs comprised of nucleic acid oligomers which demonstrate no cross-reactivity (“orthogonal”) are designed using software and empirically verified by thermodynamic study and lateral flow testing. The design software uses a semi-random algorithm to build such sequences of nucleic acid oligomers based on user-input parameters for affinity strength and orthogonal stringency. These pairs can be applied for use in multi-analyte solid support and lateral flow diagnostic tests.01-19-2012
20120015356CONNEXIN MUTATION DETECTION FOR LYMPHATIC VARIATION AND DISEASE - Methods are provided for identifying risk of developing lymphedema, including primary and secondary edema. The methods comprise identifying the presence in a biological sample of a polymorphism in one or more of GJA4, GJA5 and GJC2, resulting in a functional mutation of one or more of connixin 37 (Cx37), Cx40 or Cx47.01-19-2012
20120021417DOPAMINERGIC NEURON PROLIFERATIVE PROGENITOR CELL MARKER Nato3 - The present invention is a probe, a primer, and an antibody, for detecting a dopaminergic neuron proliferative progenitor cell. According to the present invention, there is provided a polynucleotide probe and a polynucleotide primer for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell, which can hybridize with a polynucleotide consisting of a nucleotide sequence of a Nato3 gene, or a complementary sequence thereto, and an antibody against a Nato3 protein, or a part thereof for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell.01-26-2012
20120021416BIOLAYER INTERFEROMETRY MEASUREMENT OF BIOLOGICAL TARGETS - Disclosed are methods and compositions for the ultrasensitive detection of oligonucleotides, proteins, protein complexes, biomolecules, and infectious agents using a peroxidase driven deposition of substrates onto interferometry capable biosensors, coupled to the specific recognition of the target molecules. More specifically, methods are disclosed to specifically immobilize biological target molecules onto the surface of interferometry capable biosensors and to associate the target molecules with peroxidase enzymes. Through the peroxidase driven deposition of substrates onto the interferometry capable biosensors there is the ability to achieve ultrasensitive detection and quantification of specific target molecules.01-26-2012
20120021415Methods for Determining Response to Neoadjuvant Therapy and Survival Using MicroRNA-10b - The present invention provides methods for determining response to neoadjuvant therapy and metastasis-free survival in pancreatic ductal adenocarcinoma based upon the level of microRNA expression and optionally the presence of a protein cancer cell marker in biological samples such as formalin-fixed paraffin-embedded specimens using in situ hybridization and optionally an immunohistochemical assay.01-26-2012
20120021414DIAGNOSTIC MARKERS OF IMMUNOSENESCENCE AND METHODS OF USE THEREOF - Embodiments of the present invention provide diagnostic markers of immunosenescence and methods of identifying individuals with impaired immune function based on a combination of such markers obtained from various analyses, primarily from blood, testing immune function including the analysis of immune cell subset frequencies, gene expression, cytokine and chemokine levels, and signaling responses to stimulation with cytokines (‘cytokine response’). Particular combinations of markers can predict with high accuracy whether an individual will respond to active vaccination and become protected against recurring diseases.01-26-2012
20120021413Method for Detecting Mutation in Exon 12 of JAK2 Gene, and Nucleic Acid Probe and Kit Therefor - A probe for detecting a polymorphism in exon 12 of the JAK2 gene, the probe comprising at least one of the oligonucleotides in (a) to (c) below: 01-26-2012
20120021412Compositions and Methods for Detecting Pathogen Specific Nucleic Acids in Urine - The invention is based upon the discovery that small nucleic acids from non-viral pathogens are able to cross the kidney and are present in urine of a subject when the subject is infected with the non-viral pathogen. These transrenal DNAs are especially prevalent at smaller sizes under about 300 bp. Thus the invention provides compositions and methods for the diagnosis of infection of a subject with non-viral pathogens through the detection of transrenal nucleic acids from those pathogens in the urine of the subject.01-26-2012
20120028256METHOD FOR PROVIDING INFORMATION ON ANTIDEPRESSANT THERAPEUTIC EFFECT USING SINGLE NUCLEOTIDE POLYMORPHISM - Disclosed is a method for providing information on the therapeutic effect of an SSRI antidepressant by identifying TPH2 gene polymorphism rs4760815, SLC6A4 gene polymorphism 5-HTTLPR, SLC6A4 gene polymorphism rs2066713, GAD1 gene polymorphism rs3828275, and GRIK2 gene polymorphism rs543196. Through the disclosed method, it is possible to select an antidepressant based on genetic information, to prevent the worsening or relapse of depression, and to establish customized depression treatment models which are effective in the development of customized new drugs, and appropriate for Korean people. Therefore, the base of domestic clinical trials can be expanded, which will enhance competitive power in the pharmaceutical market and preoccupy technology of drug prediction.02-02-2012
20120028255HIGH YIELDING SOYBEAN PLANTS WITH LOW LINOLENIC ACID - The invention overcomes the deficiencies of the prior art by providing methods for marker assisted selection to create plants of a soybean variety that exhibit a mid/low linolenic acid content with a commercially significant yield and an agronomically elite phenotype. The invention also provides derivatives and plant parts of these plants. Further provided by the invention are methods for the use of these plants. The invention is significant in that oil with decreased linolenic acid exhibits numerous beneficial characteristics yet prior art varieties with decreased linolenic acid also exhibited decreased yield and poor agronomic quality.02-02-2012
20120028254SNP Marker of Breast and Ovarian Cancer Risk - The invention provides methods for predicting an increased risk or probability of developing breast or ovarian cancer in a patient based upon the patient's KRAS-Variant and BRCA status.02-02-2012
20120028253METHOD FOR AMPLIFYING OLIGONUCLEOTIDE AND SMALL RNA BY USING POLYMERASE-ENDONUCLEASE CHAIN REACTION - A method for amplifying oligonucleotide in vitro by polymerase-endonuclease chain reaction (PECR) which utilizes a single-stranded DNA probe containing repeat sequences, extends a target oligonucleotide by a thermostable DNA polymerase, cleaves extended products with a thermostable endonuclease, and amplifies target oligonucleotide by thermocycling. In PECR, a specific oligonucleotide is exponentially amplified using one single probe instead of a pair of primers, and the reaction is precisely controlled by thermal cycles whose parameters are flexibly adjustable according to length, sequence, melting temperature and initial amount of the target oligonucleotide. Amplification speed depends totally on initial amount of target oligonucleotide present in the reaction system. The method can be used to amplify specific small nucleic acids, such as oligonucleotides and microRNAs, and further conduct quantitative analysis. PECR is easy to conduct with high efficiency, specificity and stability, and thus can be widely used in molecular biology studies.02-02-2012
20120028252HUMAN MENA ISOFORMS SERVE AS MARKERS OF EPITHELIAL TO MESENCHYMAL TRANSITION AND SENSITIVITY TO EGFR INHIBITION IN HUMAN CANCER CELLS - The present invention discloses a method for discriminating between sensitive and resistant tumours to a treatment with EGFR inhibitor drugs comprising: in vitro testing whether tumour material expresses the hMena02-02-2012
20130196315DEVICE FOR CELL CULTURE AND ANALYSIS - The present invention relates to a device for cell culture and analysis, comprising a first containing element, a second containing element sealingly couplable to one another to define a culture chamber and a flexible film housable in said culture chamber and available alternatively on one of said first element or second element. The flexible film can be made of a transparent material selected from the group consisting of polycarbonate, polystyrene and polyethylene. A method for cell analysis is also provided.08-01-2013
20130196322MODIFICATION OF DNA ON MAGNETIC BEADS - Provided herein is technology related to the chemical modification and purification of DNA. Specifically, the technology provides methods for performing a bisulfate conversion reaction on small amounts of single-stranded, fragmented DNA and performing the subsequent desulfonation and purification steps on magnetic beads.08-01-2013
20130196324DIGITAL ANALYTE ANALYSIS - The invention generally relates to droplet based digital PCR and methods for analyzing a target nucleic acid using the same. In certain embodiments, methods of the invention involve forming sample droplets containing, on average, a single target nucleic acid, amplifying the target in the droplets, excluding droplets containing amplicon from the target and amplicon from a variant of the target, and analyzing target amplicons.08-01-2013
20130196328RARE CLONOTYPES AND USES THEREOF - The invention is directed to a method of selecting disease-correlated clonotypes that have a reduced likelihood of producing a false positive signal of relapse when, used to monitor minimal residual disease. In accordance with the invention, candidate correlating clonotype are obtained from a patient, the rarity of each is determined either by comparison with a clonotype database or a clonotype model, and one or more of the rarest of such clonotypes are used to monitor the minimal residual disease.08-01-2013
20130196313Pharmacogenetic Method for Prediction of the Efficacy of Methotrexate Monotherapy in Recent-Onset Arthritis - Pharmacogenetic methods for determining a predicting responsiveness to antifolate therapy for subjects that present with recent-onset undifferentiated arthritis. The methods are based on the determination of a set of clinical parameter values and determining a predicted responsiveness to antifolate therapy by correlating the parameter values with predefined responsiveness values associated with ranges of parameter values. Parameters values that are decisive for responsiveness to antifolate therapy may include polymorphisms in the methylenetetrahydrofolate dehydrogenase (MTHFD1) gene as well as in three genes involved in the adenosine release pathway, the presence or absence of Rheumatoid factors, gender, pre- or postmenopausal status and/or smoking status.08-01-2013
20130196314Genes Differentially Expressed in Breast Cancer - A polynucleotide sequence as shown in SEQ ID NO:1 is associated with metastatic potential of cancer cells, especially breast cancer cells. Methods are provided for determining the risk of metastasis of a tumor, by determining whether a tissue sample from a tumor expresses a polypeptide or mRNA encoded by a polynucleotide as shown in SEQ ID NO:1. Also provided are therapeutic methods and compositions.08-01-2013
20130196316DETECTION OF SINGLE AND MULTIMODAL ANALYTES - A method for detecting analyte in a sample comprises: 08-01-2013
20130196317METHODS FOR DETECTING FETAL NUCLEIC ACIDS AND DIAGNOSING FETAL ABNORMALITIES - The invention generally relates to methods for detecting fetal nucleic acids and methods for diagnosing fetal abnormalities. In certain embodiments, the invention provides methods for determining whether fetal nucleic acid is present in a maternal sample including obtaining a maternal sample suspected to include fetal nucleic acids, and performing a sequencing reaction on the sample to determine presence of at least a portion of a Y chromosome in the sample, thereby determining that fetal nucleic acid is present in the sample. In other embodiments, the invention provides methods for quantitative or qualitative analysis to detect fetal nucleic acid in a maternal sample, regardless of the ability to detect the Y chromosome, particularly for samples including normal nucleic acids from a female fetus.08-01-2013
20130196318METHODS FOR MEASURING ENZYME ACTIVITY USEFUL IN DETERMINING CELL VIABILITY IN NON-PURIFIED SAMPLES - The present invention relates generally to the field of detection of microorganisms, in particular detection of bacteria, to methods for measuring enzyme activity, such as DNA polymerase activity, and particularly relates to such methods performed on microbial crude lysates, useful for determining microbial enzyme activities which can be linked to amplification signal generators such as real-time Polymerase Chain Reaction (PCR) techniques, thereby enabling determination of microbial pathogens in samples such as unpurified blood and other body fluids. This invention also relates to reagents for use in such methods, and to test kits comprising such reagents for carrying out the methods.08-01-2013
20130196319SERIAL QUANTITATIVE PCR ASSAY FOR DETECTION, SPECIES-DISCRIMINATION AND QUANTIFICATION OF LEISHMANIA SPP. IN HUMAN SAMPLES - The invention provides a method for determining the presence, species, and/or quantity of 08-01-2013
20130196320METHOD FOR IMPROVING CLEAVAGE OF DNA BY ENDONUCLEASE SENSITIVE TO METHYLATION - The present invention concerns novel methods for improving cleavage of DNA by rare-cutting endonucleases, overcoming DNA modification constraints, particularly DNA methylation, thereby giving new tools for genome engineering, particularly to increase the integration efficiency of a transgene into a genome at a predetermined location, including therapeutic applications and cell line engineering.08-01-2013
20130196321Gene Expression Profile Algorithm and Test for Determining Prognosis of Prostate Cancer - The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.08-01-2013
20130196326METHOD FOR THE ISOLATION OF PROTEINS BINDING TO ANY KIND NUCLEIC ACID SEQUENCE OF INTEREST - The invention is to supply a novel way for the isolation and identification of proteins bound to any kind of interesting nucleic acid sequence (Sequence-of-Interest: SoI), advantageously to any kind of interesting DNA sequence, particularly in the context of chromosomal DNA or RNA or episomal DNA in living cells or in test tubes.08-01-2013
20130196327DNA Polymerase Variants with Reduced Exonuclease Activity and Uses Thereof - Compositions and methods are described to modify Family B DNA polymerases that contain residual exonuclease activity that interferes with sequencing techniques and with detection of single nucleotide polymorphisms. The compositions are mutant proteins with reduced exonuclease activity compared with presently available “exo08-01-2013
20130196329IDENTIFICATION OF ISOLATED GENOMIC NUCLEOTIDE FRAGMENTS FROM THE p15 REGION OF CHROMOSOME 11 ENCODING HUMAN ACHAETE-SCUTE HOMOLOG 2 (HASH2) AND VARIANTS THEREOF - Provided herein are isolated genomic polynucleotide fragments from the p15 arm of chromosome 11 encoding HASH2 and methods of use.08-01-2013
20130196325In Situ Chemiluminescent Substrates and Assays - Methods for generating a chemiluminescent enzyme substrate in situ, in aqueous or other assay conditions. Also disclosed are methods to use the substrates to generate light, detect and/or quantify enzymes, antigens, and/or nucleic acids. Kits relating to these methods are also disclosed.08-01-2013
20130196323Methods Of Nucleic Acid Analysis - In one aspect, methods of nucleic acid analysis are described herein. In some embodiments, a method of nucleic acid analysis comprises providing a mixture of differing single-strand nucleic acid segments, including unamplified single-strand nucleic acid segments, combining the mixture of differing single-strand nucleic acid segments with a single-strand nucleic acid probe, contacting the mixture with a membrane comprising at least one nanopore, applying an electric field across the nanopore, and measuring change in current through the nanopore during one or more nucleic acid translocation events.08-01-2013
20130196312GENOMIC LANDSCAPES OF HUMAN BREAST AND COLORECTAL CANCERS - Human cancer is caused by the accumulation of mutations in oncogenes and tumor suppressor genes. To catalogue the genetic changes that occur during tumorigenesis, we isolated DNA from 11 breast and 11 colorectal tumors and determined the sequences of the genes in the Reference Sequence database in these samples. Based on analysis of exons representing 20,857 transcripts from 18,191 genes, we conclude that the genomic landscapes of breast and colorectal cancers are composed of a handful of commonly mutated gene “mountains” and a much larger number of gene “hills” that are mutated at low frequency. We describe statistical and bioinformatic tools that may help identify mutations with a role in tumorigenesis. These results have implications for understanding the nature and heterogeneity of human cancers and for using personal genomics for tumor diagnosis and therapy.08-01-2013
20120034606DETECTION OF SALMONELLA ENTERICA SUBSPECIES ENTERICA SEROVAR ENTERITIDIS IN FOOD AND ENVIRONMENTAL SAMPLES, METHODS AND COMPOSITIONS THEREFOR - Embodiments of the disclosure relate to compositions of isolated nucleic acid sequences, methods, workflows and kits of use thereof for detection of 02-09-2012
20120295264METHOD FOR DETECTING ULCERATIVE COLITIS - An object of the present invention is to provide a method of detecting an inflammatory bowel disease, and particularly ulcerative colitis, by using a component contained in fecal matter as an indicator. Namely, the present invention provides a method for detecting ulcerative colitis comprising: (A) a step of extracting RNA contained in fecal matter collected from a subject, (B) a step of measuring the amount of RNA derived from a marker gene in the RNA obtained in step (A), and (C) a step of comparing the amount of the RNA derived from the marker gene measured in step (B) with a preset threshold value, wherein the marker gene is one or more types of genes selected from the group consisting of COX-2 gene, B2M gene, MMP-7 gene, Snail gene, CD45 gene and CEA gene.11-22-2012
20120295260METHODS FOR ACCURATE SEQUENCE DATA AND MODIFIED BASE POSITION DETERMINATION - Disclosed herein are methods of determining the sequence and/or positions of modified bases in a nucleic acid sample present in a circular molecule with a nucleic acid insert of known sequence comprising obtaining sequence data of at least two insert-sample units. In some embodiments, the methods comprise obtaining sequence data using circular pair-locked molecules. In some embodiments, the methods comprise calculating scores of sequences of the nucleic acid inserts by comparing the sequences to the known sequence of the nucleic acid insert, and accepting or rejecting repeats of the sequence of the nucleic acid sample according to the scores of one or both of the sequences of the inserts immediately upstream or downstream of the repeats of the sequence of the nucleic acid sample.11-22-2012
20130203050HYBRID NANOPORE DEVICE WITH OPTICAL DETECTION AND METHODS OF USING SAME - The invention is directed to a device comprising a protein nanopore immobilized in a lipid layer within an aperture of a solid phase substrate, which provides a stable platform for using first and second members of one or more FRET pairs to generate optical signals as a labeled analyte translocates through the bore of the protein nanopore. In another aspect, the invention is directed to the use of the device to determine the nucleotide sequence of a polynucleotide analyte.08-08-2013
20130203049METHOD AND APPARATUS FOR CONDUCTING AN ASSAY - The present invention relates to methods and apparatus for conducting nucleic acid sequencing. The method comprises the steps of providing a platform having at least one well for containing at least one support surface, and providing at least one support surface within each well, wherein the support surface is adapted to immobilise a first binding partner or selectively immobilise a second binding partner. The method further comprises the steps of binding or immobilising the first or second binding partner to the support surface and dispensing into each well from a point external of said platform a reagent, wherein after the dispensing step the platform is rotated sufficiently such that any residual or unreacted said reagent is substantially centrifugally removed from each well and/or each support surface, wherein during rotation each support surface is held within each well. The invention also relates to kits and uses of the kits for conducting nucleic acid sequencing. In particular, the invention has been developed primarily for use in sequencing nucleic acid by pyrosequencing, however the invention is not limited to this field.08-08-2013
20130203059Method for Diagnosis of Bladder Cancer and Related Kits - The invention refers to a novel molecular biomarker, namely PTPD1, that is markedly increased in human bladder cancers. PTPD1 expression positively correlated with the grading and invasiveness potential of these tumors. PTPD1 can be detected at high levels in exfoliated bladder cells isolated from urine of bladder cancer patients, while no PTPD1 signal was evident in normal exfoliated bladder cells. Thus, PTPD1 detection in urine samples may represent a novel and reliable marker for non-invasive diagnosis of aggressive bladder cancer.08-08-2013
20130203058COMPOSITE ASSAY FOR DETECTING A CLINICAL CONDITION - The invention generally relates to methods for screening patients for one or more clinical conditions using a composite assay. According to certain aspects, methods of the invention involve isolating at least one nucleic acid from a biological sample obtained from the subject, detecting at least one sequence mutation and a chromosomal abnormality in the at least one nucleic acid in a single assay format, and identifying a clinical condition in said subject when both the sequence mutation and the chromosomal abnormality are present.08-08-2013
20130203053METHODS FOR IMPROVING INFLAMMATORY BOWEL DISEASE DIAGNOSIS - The present invention provides methods and systems to diagnose the ulcerative colitis (UC) subtype of inflammatory bowel disease (IBD) by detecting the presence or absence of one or more variant alleles in the GLI1, MDR1, and/or ATG16L1 genes. Advantageously, with the present invention, it is possible to provide a diagnosis of UC and to differentiate between UC and Crohn's disease (CD) with increased accuracy.08-08-2013
20120064524TUMOR SUPPRESSOR GENE, P47ING3 - The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods of diagnosing and treating tumors with such nucleic acids and proteins.03-15-2012
20120070830STABILIZATION OF OZONE-LABILE FLUORESCENT DYES BY THIOUREA - The present invention provides compositions and methods for stabilization of fluorescent dyes. In particular, the present invention provides buffer systems comprising thiourea to protect against degradation of ozone-labile fluorescent dyes.03-22-2012
20120301877Use of Phenanthridium Derivatives for Distinguishing Between Intact and Membrane Comprised Cells Using Molecular Nucleic Acid-Based Techniques - The present invention provides novel chemicals and methods for selectively excluding DNA of dead cells from a mixture containing live and dead cells from molecular detection.11-29-2012
20130095482METHODS OF DETECTING PREGNANCY-ASSOCIATED PLASMA PROTEIN-A2 (PAPP-A2) - The present invention provides pregnancy associated plasma protein A2 (PAPP-A2), its nucleotide and amino acid sequences, antisense molecules to the nucleotide sequences which encode PAPP-A2, expression vectors for the production of purified PAPP-A2, antibodies capable of binding specifically to PAPP-A2, hybridization probes or oligonucleotides for the detection of PAPP-A2-encoding nucleotide sequences, genetically engineered host cells for the expression of PAPP-A2, and methods for screening for pathologies in pregnant and non-pregnant patients. Methods for screening for altered focal proliferation states in pregnant and/or non-pregnant patients, which include detecting levels of PAPP-A2, are also described.04-18-2013
20130095479PRIMERS, PROBES AND METHODS FOR NUCLEIC ACID AMPLIFICATION - Homogenous detection during or following PCR amplification, preferably LATE-PCR, utilizing fluorescent DNA dye and indirectly excitable labeled primers and probes, improves reproducibility and quantification. Low-temperature homogeneous detection during or following non-symmetric PCR amplification, preferably LATE-PCR, utilizing fluorescent DNA dye and indirectly excitable labeled mismatch-tolerant probes permits analysis of complex targets. Sequencing sample preparation methods following LATE-PCR amplifications reduce complexity and permit “single-tube” processing.04-18-2013
20130095488Nucleotide Sequences Encoding Insecticidal Proteins - The present invention provides nucleotide sequences encoding an insecticidal protein exhibiting lepidopteran inhibitory activity, as well as a novel insecticidal protein referred to herein as a Cry1A.105 insecticide, transgenic plants expressing the insecticide, and methods for detecting the presence of the nucleotide sequences or the insecticide in a biological sample.04-18-2013
20130095489PROCESS FOR DETECTION OF MULTIDRUG RESISTANT TUBERCULOSIS USING REAL-TIME PCR AND HIGH RESOLUTION MELT ANALYSIS - Compositions and process are provided for the rapid and specific detection of drug resistant forms of 04-18-2013
20130095476DETECTION OF QUANTITATIVE GENETIC DIFFERENCES - A method for detection of a quantitative difference between the amount of a first target region of nucleic acid and a second target region of nucleic acid in a sample, comprising the steps of: providing the sample comprising the nucleic acid; amplifying the first and second target regions of the nucleic acid to obtain multiple copies of a first and a second sequence of nucleic acid; associating the amplified first sequence with the amplified second sequence to form associated nucleic acid complexes which comprise the first sequence and the second sequence in a 1:1 ratio, wherein any excess of either the first sequence or the second sequence remain un-associated; detecting any un-associated sequences, wherein detection of any un-associated sequences is indicative of a quantitative difference between the amount of the first and second target regions of nucleic acid in the sample.04-18-2013
20120082984NUCLEIC ACIDS FOR DETECTION AND DISCRIMINATION OF GENOTYPES OF CHLAMYDOPHILA PSITTACI - Methods of detecting 04-05-2012
20120094293PGC-1 , A NOVEL PGC-1 HOMOLOGUE AND USES THEREFOR - The invention provides isolated nucleic acid molecules, designated PGC-1β nucleic acid molecules, which encode novel PGC-1 related coactivator molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1β nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1β gene has been introduced or disrupted. The invention still further provides isolated PGC-1β proteins, fusion proteins, antigenic peptides and anti-PGC-1β antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.04-19-2012
20120094292FORENSIC IDENTIFICATION - The invention provides allelic ladder mixtures and individual alleles suitable for use in such mixtures. The allelic ladder mixtures give improved identification and distinguishing capabilities, particularly suitable in forensic investigations.04-19-2012
20120094291FCgamma POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOME - The invention provides compositions and methods for determining the likelihood of successful treatment with Cetuximab or other equivalent. The methods comprise determining the genomic polymorphism present in a predetermined region of the FcγRIIa gene at amino acid position 131 and/or alternatively the FcγRIIIa gene at amino acid position 158.04-19-2012
20120094290Epigenetic Marker for the Identification of Natural Killer Cells - The present invention relates to a method, in particular an in vitro method for identifying natural killer cells of a mammal, which often express the surface proteins CD 16 and/or CD56, comprising analysing the methylation status of at least one CpG position in the CX3CR1 and/or FGR and/or NKG7 and/or GNLY genes, in particular their upstream regulatory regions, and in particular the promoter and other conserved regions of the genes CX3CR1 and/or FGR and/or NKG7 and/or GNLY, wherein a demethylation of at least one CpG in the analyzed sample to at least 70% is indicative for CD56 expressing NK cells, which might also be CD8+ or CD8−, CD56 dim or bright, CD 16+ or CD 16− NK cells. The methods of the present invention are useful for the detection and quality assurance and control of NK cells. Furthermore, the present invention relates to a kit for performing the above methods as well as respective uses of the inventive methods or kits. The present invention furthermore provides an improved method for analysing the methylation status of at least one CpG position in the gene CX3CR1 and/or FGR and/or NKG7 and/or GNLY genes that allows for a precise analysis even from sub-optimal quality samples, such as non-freshly obtained blood, tissue or serum samples.04-19-2012
20120094289MATERIALS AND METHODS FOR DETERMINING CANCER RISK - This document relates to materials and methods involved in assessing inflammatory bowel disease patients at risk for developing cancer. For example, materials and methods for monitoring colorectal cancer risk in ulcerative colitis patients are provided.04-19-2012
20120094288ASSAY FOR DETERMINING EPIGENETIC PROFILES OF MARKERS OF FRAGILE X ALLELES - The present invention relates generally to an assay for the determination of epigenetic profiles, particularly epigenetic profiles associated with a pathological condition. Even more particularly, the present invention provides an assay to detect epigenetic profiles within the Fragile X Mental Retardation (FMR) genetic locus indicative of a pathoneurological condition such as pathoneurodevelopmental and pathoneurodegenerative conditions. The epigenetic profiles can also identify potential non-neurological conditions. Kits and assays for medicaments also form part of the present invention as do computer programs to monitor changes in epigenetic patterns and methods for screening for agents which modulate epigenetic modification.04-19-2012
20120094287METHODS AND COMPOSITIONS FOR DETECTING GASTROINTESTINAL AND OTHER CANCERS - This application describes methods and compositions for detecting and treating vimentin-associated neoplasia. Differential methylation of the vimentin nucleotide sequences has been observed in vimentin-associated neoplasia such as neoplasia of the upper or lower gastrointestinal tract, pancreas, and/or bladder.04-19-2012
20120094286GENE DOSAGE ANALYSIS - The present invention relates to methods of detecting the presence of a genetic polymorphism within two or more closely linked, homologous genes, for example α-thalassemia, in a sample using RT-PCR by subjecting the sample to separate amplification reactions using (a) a pair of forward and reverse primers specific for the head region of each of said two or more closely linked, homologous genes and (b) a pair of forward and reverse primers specific for the tail region of each of said two or more closely linked, homologous genes; and detecting and quantitating the amplification products relative to a control product.04-19-2012
20120094285Ratiometric Pre-rRNA Analysis - Disclosed are compositions and methods for detecting the presence of viable cells in a sample. Included are compositions and methods for increasing the sensitivity of a nucleic acid amplification test for determining the presence of at least one target microorganism in a sample. Also disclosed are compositions and methods for detecting ribosomal RNA precursors (pre-rRNA) as dynamic indicators of viable microorganisms in a sample.04-19-2012
20120094284Prediction of Early Virological Response in HCV Treatment - The present invention is based on the discovery of associations that exist between single nucleotide polymorphisms (SNPs) on chromosome 19 and virological outcomes in a diverse population of patients with hepatitis C virus (HCV) who received interferon-based treatment.04-19-2012
20120094283ACE2 AS A TARGET GENE FOR THE MOLECULAR IDENTIFICATION OF YEAST AND FUNGAL SPECIES - The present invention relates to nucleic acid primers and probes for use in the identification of one or more yeast species. More specifically the invention relates to the Ace2 gene, the corresponding RNA, specific probes, primers and oligonucleotides related thereto and their use in diagnostic assays to detect and/or discriminate between yeast species.04-19-2012
20130209998Microbial Assay - A method of detecting genetic material deriving from 08-15-2013
20130210008METHOD FOR AMPLIFYING NUCLEIC ACIDS - The present invention describes methods for amplifying a target nucleic acid wherein target nucleic acids hybridise to capture probe nucleic acids which are immobilized to a support via their 5′ end. The hybridization product is further extended with a polymerase to form a double stranded nucleic acid. To this double stranded nucleic acid, a hairpin nucleic acid is ligated. This ligation product is further amplified and sequenced.08-15-2013
20130209999SQSTM1 MUTATIONS IN AMYOTROPHIC LATERAL SCLEROSIS - Provided herein is technology relating to diagnosing, monitoring, and treating disease and particularly, but not exclusively, to methods, compositions, and kits for diagnosing, monitoring, and treating amyotrophic lateral sclerosis by detecting and identifying mutations in the gene SQSTM1 and providing therapies by targeting aberrant biological functions related to mutant forms of SQSTM1.08-15-2013
20130210000NEUROGENIC AND GLIOGENIC FACTORS AND ASSAYS THEREFOR - Disclosed herein are quantitative assays for measuring the potential of a substance, or a source of a substance, to promote neurogenesis and gliogenesis. Substances that promote neurogenesis and gliogenesis are also disclosed.08-15-2013
20130210001SEQUENCE DETECTION ASSAY - There is provided a method of detecting the presence in a sample of a first target sequence and a second target sequence within a test region of a nucleic acid sequence comprising conducting a nucleic acid amplification reaction, to form a forward amplicon strand and a reverse amplicon strand of the test region, contacting the forward amplicon strand with a first probe labelled with a first FRET label and capable of hybridising to the first target sequence of complement thereof in the forward amplicon strand, and contacting the reverse amplicon strand with a second probe labelled with a second FRET label and capable of hybridising to the second target sequence or complement thereof in the reverse amplicon strand; wherein the nucleic acid amplification reaction is conducted using a forward amplification primer labelled with a third FRET label and a reverse amplification primer labelled with a fourth FRET label, the forward primer being incorporated into the forward amplicon strand and the second primer being incorporated into the reverse amplicon strand during the amplification reaction; and further wherein the first and third FRET labels form a FRET pair and the second and fourth FRET labels form a different FRET pair, each FRET pair comprising a donor label; the method further comprising the steps of exposing the sample to an excitation source having a wavelength which excites the donor label in the first FRET pair and the donor label in the second FRET pair, detecting fluorescence from the sample and relating this to the presence or absence of the first and second target sequences.08-15-2013
20130210002METHOD OF ANALYZING CELLULAR CHROMOSOMES - The present invention involves an analysis method of cellular chromosomes, particularly involves a method of analyzing whether a difference exists in the chromosome number between amniotic cells and standard cells by a sequencing method.08-15-2013
20130210003COMPOSITIONS FOR USE IN DETECTION OF MULTIPLE ANALYTES - Methods, compositions and kits are disclosed. The methods are directed to determining the presence or relative amounts of two or more components in a medium. A combination is provided comprising a medium suspected of containing the components, at least two sensitizer reagents and at least one reactive reagent activatable by singlet oxygen. The sensitizer reagents are capable of generating singlet oxygen and are distinguishable by wavelength of sensitization. The combination of sensitizer reagents and reactive reagents allows differential detection of the components. The sensitizer reagents are differentially activated. The amount of signal generated as a result of the activation of said reactive reagent is determined wherein the amount thereof is related to the amount of each of the components in the medium.08-15-2013
20130210004EGFR-RELATED POLYPEPTIDES AND METHODS OF USE - Described herein are truncated EGF receptor polypeptides, nucleic acids encoding them, and methods of using them to help select a method of treatment for an EGFR-related cancer, to predict clinical outcome, and to detect micrometastases or minimal residual disease. High EGFR expression and phosphorylated EGFR predicts poor survival in head and neck cancer patients, but does not correlate with advanced stage disease. In our studies, we determined that clinical biological correlates are likely to be more accurate when different aspects of EGFR are evaluated in combination. We analyzed EGFR phosphorylation, expression and mutations in 60 primary head and neck tumors. We not only found that head and neck tumors with either truncated or activated EGFR tend to have higher tumor and nodal stage, but also discovered three EGFR truncations.08-15-2013
20130210005METHOD FOR DETECTING MYCOBACTERIUM TUBERCULOSIS AND NONTUBERCULOUS MYCOBACTERIA BY USING DUAL REAL-TIME POLYMERASE CHAIN REACTION - Disclosed are a primer set and/or a probe capable of detecting specific nucleotide sequences of MTC and NTM, a kit for the detection of MTC and NTM, comprising the same, and a method for detecting MTC and NTM by duplex real-time PCR using the same. Useful in detecting genes characteristic of MTC and NTM, the primer sets and/or probes, detection kits, and detection methods can be applied as the clinical diagnosis of diseases caused by MTC and NTM, and therefore find applications in the medical fields including hospitals, research institutes, etc.08-15-2013
20130210006PERICARP DNA EXTRACTION AND MATRILINEAGE DETERMINATION - This disclosure concerns the separation of pericarp tissue from surrounding tissues in grain. Some embodiments concern the isolation of high-purity pericarp DNA from a grain plant that reflects the genotype of the maternal parent of the grain plant, such that the isolated DNA may be used in a PCR-based genotyping assay.08-15-2013
20130210010RAPID SALMONELLA SEROTYPING ASSAY - Processes for the serotype specific detection and identification of one or more 08-15-2013
20130210011METHODS AND BIOMARKERS FOR DETECTION OF BLADDER CANCER - The invention relates to methods and biomarkers (e.g., epigenetic biomarkers) for detection of bladder cancer in biological samples (e.g., tissue samples, urine samples, urine sediments). In some embodiments, methods and biomarkers of the present invention find use in discriminating between bladder cancer, prostate cancer and renal epithelial tumors.08-15-2013
20130210007TREATMENT AND DIAGNOSIS OF EPIGENETIC DISORDERS AND CONDITIONS - The present disclosure relates generally to the field of epigenetics and in particular epigenetic profiles associated with a pathological condition. The present specification teaches screening of individuals and populations for epigenetic profiles associated with a pathological condition. The epigenetic profiles can be from an intron, an intron/exon boundary or a splicing region. Epigenetic profiles are disclosed from the following sites in the FMR locus: FREES, intron 2 of FMR1, the genomic FREE2 region as a whole or specific FREE2 fragments including FREE2 (D) or FREE2 (E). Kits and diagnostic assays are also taught herein as are computer programs to monitor changes in epigenetic patterns and profiles. Further enabled herein is a method for screening for agents which can reduce or mask the adverse effects of epigenetic modification and the use of these agents in therapy and prophylaxis.08-15-2013